



IASLC



**2025 World Conference
on Lung Cancer**

SEPTEMBER 6-9, 2025 | BARCELONA, SPAIN

PROGRAM BOOK

wclc.iaslc.org



#WCLC25



COMMITTED TO TRANSFORMING CANCER CARE

Accord is a fast-growing pharmaceutical company that is:

Established in oncology

>60 cancer related therapies available across Europe

Driven by innovation

>15 pipeline medicines aiming to reach patients within 5 years

Focused on patient-centred care

Addressing unmet needs and improving availability of essential treatments



Scan to learn
more about our
work in oncology

Date of preparation: June 2025 EUR-Non-P--01419

TABLE OF CONTENTS

05 OVERVIEW

Important Information
Welcome Messages
IASLC Staff and WCLC Committees
IASLC and Conference Awards
Program at a Glance

37 SCIENTIFIC PROGRAM SATURDAY, SEPTEMBER 6

53 SCIENTIFIC PROGRAM SUNDAY, SEPTEMBER 7

79 SCIENTIFIC PROGRAM MONDAY, SEPTEMBER 8

105 SCIENTIFIC PROGRAM TUESDAY, SEPTEMBER 9

123 POSTERS

Posters - Sunday, September 7
Posters - Monday, September 8
Posters - Tuesday, September 9
ePosters

211 GENERAL INFORMATION

Exhibit and Supporter Information
Satellite CME Symposia, Industry Sponsored Symposia
Non-Profit Presentation
Conference Information
Venue Floor Plans



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER

The IASLC's headquarters are located at:

**1775 N. Sherman Street, Suite 1600,
Denver, CO 80203-4317**

Phone: +1 855 464 2752 | Website: www.iaslc.org

CONFERENCE SECRETARIAT

International Conference Services Ltd. (ICS)
555 Burrard Street (Bentall Center 2), Vancouver, BC, Canada, V7X 1M8
+1 604 681 2153 | www.icsevents.com



IVONESCIMAB

NSCLC & BEYOND

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China's NMPA.



IVONESCIMAB PIPELINE

36 Ivonescimab Clinical Trials
Ongoing or Completed in
Multiple Tumor Types¹

Phase 3

Planned and Ongoing Studies Sponsored by Summit Therapeutics

HARMONI	2L+ NSCLC EGFR+ Enrollment Complete
HARMONI ₃	1L NSCLC
HARMONI ₇	1L NSCLC

Phase 3

Conducted in China, Fully Sponsored and Managed by Akeso

HARMONI _A	2L+ NSCLC EGFR+
HARMONI ₂	1L NSCLC
HARMONI ₆	1L NSCLC
HARMONI _{8A}	2L+ NSCLC
HARMONI ₉	SCLC
HARMONI _{BC1}	1L TNBC
HARMONI _{HN1}	1L HNSCC
HARMONI _{GI1}	1L Biliary Tract
HARMONI _{GI2}	1L Pancreatic
HARMONI _{GI6}	1L Colorectal

Phase 1-2

NSCLC	G/GEJ	Colorectal	Breast
Ovarian	Hepatocellular	SCLC	

First-in-Class*
PD-1/VEGF Bispecific
Antibody in Clinical Development

Cooperative Binding²
Increased:
Avidity in TME, Activity of T Cells

**Globally, 2,300+
Patients Treated**
with Ivonescimab Across
All Summit & Akeso Trials to Date³

13 Phase 3 Trials Announced
Ongoing or Completed¹

For More Information
Visit Us at Booth #204
MedInfo@smmttx.com

THE COMMENCEMENT OF A NEW ERA

*There are no known PD-1-based bispecific antibodies approved by the U.S. Food and Drug Administration or the European Medicines Agency.
References: 1. Ivonescimab Clinical Trials. Available at: <https://clinicaltrials.gov/search?term=ivonescimab%20OR%20AK112>. Accessed on: May 19, 2025; 2. Zhong T. iScience. 2024;28(3):111722; 3. Data on file. 38. Summit Therapeutics Inc.
Abbreviations: 1L=first-line; 2L=second-line; EGFR=epidermal growth factor receptor positive; G/GEJ=gastric/gastroesophageal junction; HNSCC=head and neck squamous cell carcinoma; NMPA=National Medical Products Administration; NSCLC=non-small cell lung cancer; PD-1=programmed cell death protein 1; SCLC=small cell lung cancer; TME=tumor microenvironment; TNBC=triple-negative breast cancer;



By use of this QR code you agree to Summit's privacy notice located at smmttx.com
MAT-SMT12-0223



01

CONFERENCE OVERVIEW

IASLC 2025 WORLD CONFERENCE ON LUNG CANCER
CONQUERING LUNG AND OTHER THORACIC CANCERS WORLDWIDE IN THE 21ST CENTURY.

Dear Colleagues and Friends,

We are honored to welcome you to the IASLC 2025 World Conference on Lung Cancer (WCLC 2025) in Barcelona.

You are now part of one of the world's largest gatherings dedicated to thoracic oncology - a community of researchers, clinicians, nurses, patients, survivors, advocates, industry representatives, and thought leaders from across the globe. Your presence here matters. Together, we are united by one extraordinary goal: to conquer thoracic cancers worldwide in the 21st century.

This Conference reflects the heart of the IASLC's mission and the power of its people. Our shared work lives in three core objectives that guide everything we do:

DRIVING DISCOVERY

By advancing research and exploring bold new frontiers.

CONNECTING CHANGEMAKERS

By building collaborations that break silos and spark progress.

ELEVATING EXPERTISE

By sharing knowledge, skills, and ideas that improve care and save lives.

Over the next four days, we encourage you to be part of that mission in action. Share your science. Ask questions. Make new connections. Challenge yourself. Learn something unexpected. Mentor someone. Let this experience expand your perspective, fuel your purpose, and inspire your next steps.

The program you will experience has been thoughtfully curated to reflect the progress we have made together and the momentum we continue to build. It spans disciplines, geographies, and career stages—with something meaningful for everyone who is committed to advancing thoracic cancer care.

Thank you for being here. Thank you for being part of this global movement.

Welcome to Barcelona. Welcome to WCLC 2025.

WCLC 2025 Conference Chairs,



Umberto Malapelle
Italy



Jarushka Naidoo
Ireland



Isabelle Opitz
Switzerland



Noemi Reguart
Spain

Greetings WCLC Delegates,

As the President and the CEO of the IASLC, we are delighted to welcome you to the IASLC 2025 World Conference on Lung Cancer (WCLC 2025) in beautiful Barcelona, Spain. We are honored that you have chosen to join us for what is sure to be a rigorous, fascinating, and collaborative meeting.

Over the last 51 years, we have witnessed extraordinary progress in every facet of thoracic malignancies from epidemiology, biology, diagnosis, and treatment. Throughout its long history, the WCLC has played a strong role in facilitating that progress. Providing a platform for sharing cutting-edge research, creating space for new collaborations and partnerships, connecting established researchers with young investigators, and serving as a foundational meeting for healthcare professionals (representing the full spectrum of the multidisciplinary team), patients, and advocates who have dedicated their lives to conquering these challenging diseases.

This enduring importance is illustrated by the remarkable growth of the WCLC, which has evolved from a small gathering to the world's largest meeting dedicated to thoracic oncology, now attracting over 7,000 international participants each year.

While the story of the WCLC is well-established, we recognize that we must continually look to the future if we are to continue making progress in the treatment of thoracic cancers. That is why, for WCLC 2025, we are proud to announce that the Conference Chairs, along with the WCLC 2025 Program Committee, have assembled an incredible educational and scientific program that highlights emerging talent, multidisciplinary expertise, and international perspectives to foster richer dialogue and innovation. We are confident you will find WCLC 2025 to be an exceptional educational experience. We want to thank the Program Committee for their hard work and are especially grateful for the dedication and leadership of our Conference Chairs: Drs. Umberto Malapelle, Jarushka Naidoo, Isabelle Opitz, and Noemi Reguart.

Thank you for attending WCLC 2025, and thank you for your engagement with the IASLC. We hope you enjoy the Conference, explore Barcelona, find opportunities to develop new relationships and collaborations, and gain novel skills and insights that you can apply to improve the lives of thoracic cancer patients in your local communities and worldwide. Like so much of what the IASLC does, the success of the WCLC hinges on the passion, commitment, and engagement of those who participate. In short, your participation is one of the main reasons why the event has remained the world's leading thoracic cancer conference for 51 years. We appreciate you being a part of our ongoing story.




Paul Van Schil
IASLC President,
Belgium



Karen Kelly
IASLC CEO,
USA

SINGULA™ Lung



The first molecular test to predict individual response to targeted therapy and chemo-immunotherapy in NSCLC.

Avoid ineffective regimens and unnecessary toxicity.

One Test. Current Workflow. Personalized Therapy.

Cellworks

www.cellworks.life

*A **Meet the Expert** session at WCLC on*

**Challenging conventional thinking:
Understanding activating
HER2 (ERBB2) mutations
in NSCLC**

Location & Time:

Bayer Medical
Booth (#203)
September 7, 2025
14:00–14:30 (CET)

with:

Bruna Pellini, MD
Moffitt Cancer Center
and Research Institute
Tampa, FL, USA




**Bayer sponsored 'Meet the Expert' session at the
2025 IASLC World Conference on Lung Cancer (WCLC)**

© 2025 Bayer. Bayer and the Bayer Cross are registered trademarks of Bayer.
MA-BY-ES-0013-1 08/25



Precise innovation in lung cancer research

Guided by **chemistry**
and driven by **purpose**,
we are committed to
advancing lung cancer
research that puts
patients first.



Nuvalent's therapies are
investigational candidates
and have not been
approved by the FDA or any
other regulatory authority.

© 2025 Nuvalent, Inc.
All rights reserved.

MC-2500012

Visit us at **booth #413**
or **nuvalent.com**



Get Connected **FREE WIFI**

Stay connected throughout the Conference with complimentary WiFi. Simply select the network WCLC2025 and follow the login instructions.

Network Name: **WCLC2025**
Password: **WCLC2025**

Complimentary Public Transportation Pass

WCLC 2025 is pleased to offer delegates a complimentary 4-day public transportation pass, valid on Barcelona's buses, metro, trams, and trains. Passes are available for pickup at the Material Pick Up Desk during the Conference. Travel easily and explore the city while attending WCLC 2025!

For more information scan the QR code or visit:
wclc.iaslc.org/complimentary-public-transport-pass



Let's Get **SOCIAL!**

Stay connected with the IASLC community and get the latest updates on the IASLC World Conference on Lung Cancer (#WCLC25) through our social media channels! Follow us to engage with fellow attendees, access exclusive content, and be the first to know about important announcements and highlights from the Conference.



Join The Conversation:
#WCLC25

Share Your
WCLC 2025 Experience!

Tag @IASLC and use #WCLC25



DISCLAIMER

The organizers have made every attempt to ensure that all the information in this publication is correct. The organizers take no responsibility for changes to the program or any loss that may occur due to changes to the program. Some of the information provided in this publication has been provided by external sources. Although every effort has been made to ensure the accuracy, currency, and reliability of the content, the organizers accept no responsibility in that regard.

The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies. Since its founding in 1974, the association's membership has grown to more than 8,000 lung and thoracic cancer specialists from all disciplines and more than 100 countries.

By hosting global conferences, funding cutting-edge research, and educating the health care community and the public about thoracic cancers, the IASLC works to alleviate the burden lung cancer places on patients, families, and communities.

THE IASLC'S MISSION

Be the multidisciplinary world authority on lung and other thoracic cancers through collaborative science, education, and advocacy in order to ensure optimal prevention and patient care.

THE IASLC'S VISION

Conquering Lung and Other Thoracic Cancers Worldwide in the 21st Century.



IASLC Staff

Karen Kelly, Chief Executive Officer
Elizabeth Donahue, Chief Financial Officer
J. Michael Hoehn, Chief Operating Officer
Jennifer C. King, Chief Science Officer
Matt Yeingst, Chief Development Officer
Andrea Alarcon, Scientific Program Manager
Ruth Barratt, Senior Scientific Program Manager
Tessa Baxter, Development Program Manager
Bernina Bijou, Executive Assistant & Board Liaison
Becky Bunn, Director, Strategic Initiatives
Carey Burgess, Education Coordinator
Bailey Creamer, Editorial Coordinator
Kathy Doherty, Director, Human Resources
Gena Erwin, Associate Director, Conferences
Sierra Esparza, Grants Coordinator
Thalia Giraldo, Data Analyst
Rory Graham, Web Content Administrator
Debbie Hadala, Marketing & Communications Coordinator
Kelsey Hecker, Conference Manager
Kelly Heemsbergen, Conference Manager
O'Ryan Jackson, Development Specialist

Lauren Karls, Senior Accountant
Maggie Lilac, Sponsorship & Exhibits Coordinator
Sara Lindsey Patton, Patient Advocacy Manager
Sunhee Malinowski, Contoller
Katie Maher, Membership Manager
Courtland Matthews, Marketing & Communications Manager
Beanie Montoya, Associate Director, Marketing & Communications
Uli Neitzel, Accountant
Kahri Nestingen, Corporate Development Specialist
Kelly Nevins, Director, Education
Alan Nguyen, Education Coordinator
Kelsey Petri, Membership Specialist
William Sanders, Scientific Affairs Coordinator
Savannah Spakes, Membership Coordinator
Alexander Watson, Office Administrator
Cayla Williby, Conference Coordinator
Kelsey Wood, Director, Membership
Laura Woodruff, Education Manager
Murry Wynes, Senior Advisor, Scientific Affairs
Keelan Zius, Scientific Program Manager

IASLC Board of Directors 2023 - 2025

President: Paul Van Schil, Belgium
Past President: Heather Wakelee, USA
President-Elect: Caicun Zhou, China
Secretary: Ming-Sound Tsao, Canada
Treasurer: Joachim Aerts, Netherlands
Chief Executive Officer: Karen Kelly, USA

Board Members

Joe Chang, USA
Carlos Gil Moreira Ferreira, Brazil
Jhanelle Gray, USA
Young Tae Kim, Republic of Korea
Natasha Leighl, Canada
Morten Quist, Denmark
Antoni Rosell, Spain
Lecia Sequist, USA
Benjamin Solomon, Australia
Paula Ugalde, USA
Ignacio Wistuba, USA
Wen-Zhao Zhong, China

IASLC Board of Directors 2025 - 2027

President: Caicun Zhou, China
Past President: Paul Van Schil, Belgium
President-Elect: Alex A. Adjei, USA
Secretary: Benjamin Solomon, Australia
Treasurer: Ignacio Wistuba, USA
Chief Executive Officer: Karen Kelly, USA

Board Members

Fredrick Chite Asirwa, Kenya
Clarissa Baldotto, Brazil
Joe Chang, USA
Narjust Florez, USA
Hidehito Horinouchi, Japan
Natasha Leighl, Canada
Isabelle Opitz, Switzerland
Mary Pasquinelli, USA
Helmut Prosch, Austria
Antoni Rosell, Spain
Triparna Sen, USA
Motoko Tachihara, Japan
Jie Wang, China
Wen-Zhao Zhong, China

WCLC 2025 PROGRAM COMMITTEE

RISK FACTORS, RISK REDUCTION & TOBACCO CONTROL

Co-Chair: Silvia Novello, Italy
Co-Chair: Abhishek Shankar, India
Marcelo Corassa, Brazil
Angeline Low, Australia
Laura Mezquita, Spain
Ugo Pastorino, Italy
Biagio Ricciuti, USA
Conor E Steuer, USA
Randi Williams, USA

TUMOR BIOLOGY - PRECLINICAL BIOLOGY

Co-Chair: Montse Sanchez-Cespedes, Spain
Co-Chair: Triparna Sen, USA
Roberto Bianco, Italy
David Paul Carbone, USA
Diego de Miguel Perez, USA
Carminia Maria Della Corte, Italy
Mervat El Deftar, Egypt
Aya El Helali, Ireland
Mariam Jamal-Hanjani, UK
Hongbing Ji, China

WCLC 2025 PROGRAM COMMITTEE

TUMOR BIOLOGY - TRANSLATIONAL BIOLOGY

Co-Chair: Caroline Dive, UK
Co-Chair: Deepali Jain, India
 Chiara Ambrogio, Italy
 Fiona Blackhall, UK
 Milena Cavic, Serbia
 Yuchen Han, China
 Cheryl Ho, Canada
 George Oblitas, Peru
 Christian Diego Rolfo, USA
 Jon Zugazagoitia, Spain

PULMONOLOGY & STAGING

Co-Chair: James Huang, USA
Co-Chair: Jeremy John Erasmus, USA
 Fredrick Chite Asirwa, Kenya
 Zeno Gouw, Netherlands
 Anna Rita Larici, Italy
 Tracey Leong, Australia
 Carole Ridge, UK
 Valerie Rusch, USA
 Jacob Sands, USA

EARLY-STAGE NON-SMALL CELL LUNG CANCER

Co-Chair: Tina Cascione, USA
Co-Chair: Eric Lim, UK
Co-Chair: Ricardo Terra, Brazil
 Antonio Calles, Spain
 Kristen Marrone, USA
 Yuko Oya, Japan
 Martin Reck, Germany
 Hisashi Saji, Japan
 Pamela Samson, USA
 Jonathan Spicer, Canada
 Agathe Seguin, France

SCREENING & EARLY DETECTION

Co-Chair: Long Jiang, China
Co-Chair: David Baldwin, UK
 Ricardo Sales dos Santos, Brazil
 Thomas Frauenfelder, Switzerland
 Anita McGrath, Australia
 Rachael Murray, UK
 Coral Olazagasti, USA
 Betty Tong, USA
 Doug Wood, USA
 Chi-Fu Yang, USA

PATHOLOGY & BIOMARKERS

Co-Chair: Beatriz Bellosillo, Spain
Co-Chair: Jia Luo, USA
Co-Chair: Luisella Righi, Italy
 Lukas Bubendorf, Switzerland
 Guilherme Harada, Brazil
 Rosalyn Juergens, Canada
 Herbert Loong, Hong Kong
 Fernando Lopez Rios, Spain
 Ellen Caroline Nascimento, Brazil
 Cristina Teixeira, Spain

LOCAL-REGIONAL NON-SMALL CELL LUNG CANCER

Co-Chair: Nasser Altorki, USA
Co-Chair: Ernest Nadal, Spain
Co-Chair: Luisella Righi, Italy
 Monica Castro, Argentina
 Kevin Chua, Singapore
 Dusty Donaldson, USA
 Jessica Donington, USA
 Corinne Faivre-Finn, USA
 Salma Jabbour, USA
 Francesco Passiglia, Italy
 Juan Carlos Trujillo Reyes, Spain

WCLC 2025 PROGRAM COMMITTEE

METASTATIC NON-SMALL CELL LUNG CANCER - LOCAL THERAPIES

Co-Chair: Matthias Guckenberger, Switzerland
Co-Chair: Myung-Ju Ahn, Republic of Korea
 Pablo Munoz Schuffenegger, Chile
 Anne-Marie Dingemans, Netherlands
 Shanker Siva, Australia
 Mara Antonoff, USA
 Lilian Faroni, Brazil
 Patricia Mondragon, Mexico
 Gabriela Antelo, Spain
 Vanessa Costa Menezes, Brazil

METASTATIC NON-SMALL CELL LUNG CANCER - IMMUNOTHERAPY

Co-Chair: Misako Nagasaka, USA
Co-Chair: Delvys Rodriguez-Abreu, Spain
Co-Chair: Giannis Mountzios, Greece
 Andres Cardona, Colombia
 Seamus Cotter, Ireland
 Enriqueta Felip, Spain
 Lizza Hendriks, Netherlands
 Jin-Hyoung Kang, Republic of Korea
 Ola Khorshid, Egypt
 Luis Raez, USA
 Vamsidhar Velcheti, USA

SMALL CELL LUNG CANCER AND NEUROENDOCRINE TUMORS

Co-Chair: Luis Paz-Ares, Spain
Co-Chair: Motoko Tachihara, Japan
 Noura Choudhury, USA
 Julie George, Germany
 Antonin Levy, France
 Tatiane Montella, Brazil
 Alejandro Navarro, Spain
 Taofeek K Owonikoko, USA
 Angus Pratt, Canada
 Junko Tanizaki, Japan

METASTATIC NON-SMALL CELL LUNG CANCER - ANTIBODY-DRUG CONJUGATE AND CYTOTOXIC THERAPY

Co-Chair: Mauricio Cuello Toledo, Uruguay
Co-Chair: Fiona McDonald, UK
 Benjamin Levy, USA
 Alfredo Addeo, Switzerland
 Riyaz Shah, UK
 Sally Lau, USA
 Gerard Walls, UK
 Deborah Doherty, Ireland
 Li Zhang, China

METASTATIC NON-SMALL CELL LUNG CANCER - TARGETED THERAPY

Co-Chair: Sewanti Limaye, India
Co-Chair: Jordi Remon, France
 Christina Baik, USA
 Prunella Blinman, Australia
 Laura Book, USA
 Charo Campelo, Spain
 Luis Corrales, Costa Rica
 Alessandra Curioni-Fontecedro, Switzerland
 Jianchun Duan, China
 Koichi Goto, Japan
 Victor Marcondes Lopes dos Santos, Brazil

MESOTHELIOMA, THYMOMA, AND OTHER THORACIC TUMORS

Co-Chair: Nicolas Girard, France
Co-Chair: Joshua Reuss, USA
Co-Chair: Melissa Culligan, USA
 Prasad Adusumilli, USA
 John Cho, Canada
 Marc de Perrot, Canada
 Federica Grosso, Italy
 Samina Park, Republic of Korea
 Ross Soo, Singapore

WCLC 2025 PROGRAM COMMITTEE

MULTIDISCIPLINARY CARE: NURSING, ALLIED HEALTH & PALLIATIVE CARE

Co-Chair: Lucia Viola, Colombia

Co-Chair: Santiago Viteri, Spain

Cristiane Bergerot, Brazil

Caitlin Broderick, Australia

Elizabeth Castronovo, USA

Rafal Dziadziuszko, Poland

Juan Carlos Laguna, Spain

Stephanie McDonald, USA

Beth Sandy, USA

GLOBAL HEALTH, HEALTH SERVICES, & HEALTH ECONOMICS

Co-Chair: Clarissa Mathias, Brazil

Co-Chair: Navneet Singh, India

Sze Wai Chan, South Africa

Verna Vanderpuye, Ghana

Annie Wong, New Zealand

Drew Moghanaki, USA

Matthew Evison, UK

Tomohito Saito, Japan

Emmet O'Brien, Ireland

Samuel Kareff, USA

PATIENT ADVOCACY

Co-Chair: Luciana Holtz, Brazil

Co-Chair: Cecilia Pompili, UK

Sydney Barned, USA

Daniel Black, Switzerland

Lauren Pretorius, South Africa

Maria Clara Rodriguez, Uruguay

Eric Singhi, USA

Antoinette Wozniak, USA

WCLC 2025 INTERNATIONAL ABSTRACT REVIEW COMMITTEE

Alfredo Addeo, Switzerland

Prasad Adusumilli, USA

Myung-Ju Ahn, Republic of Korea

Nasser Khaled Altorki, USA

Chiara Ambrogio, Italy

Mihaela Angelova, UK

Gabriela Antelo, Spain

Mara Antonoff, USA

Marisol Arroyo Hernández, Mexico

Fredrick Asirwa, Kenya

Lekan Ayo-Yusuf, South Africa

Christina Baik, USA

Amanjit Bal, India

Clarissa Baldotto, Brazil

David Baldwin, UK

Sydney Barned, USA

Upal Basu Roy, USA

Beatriz Bellosillo, Spain

Cristiane Bergerot, Brazil

Roberto Bianco, Italy

Andrea Billè, UK

Fiona Blackhall, UK

Caitlin Broderick, Australia

Lukas Bubendorf, Switzerland

Antonio Calles, Spain

Maria Rosario Campelo, Spain

David Carbone, USA

Andrés F. Cardona, Colombia

Tina Cascone, USA

Mónica Castro, Argentina

Milena Cavic, Serbia

Fabiana Cecere, Italy

Jamie Chaff, USA

Sze Wai Chan, South Africa

Veronica Cheung, Australia

John Cho, Canada

Noura Choudhury, USA

Kevin Chua, Singapore

Esther Conde, Spain

Terri Conneran, USA

Marcelo Corassa, Brazil

Luis Corrales, Costa Rica

Francesco Cortiula, Netherlands

Mauricio Cuello, Uruguay

Melissa Culligan, USA

Gianluigi De Gennaro, Italy

Diego de Miguel Perez, USA

Fabio de Moraes, Canada

Marc de Perrot, Canada

Carminia Maria Della Corte, Italy

Jules Derks, Netherlands

Anne-Marie Dingemans, Netherlands

Caroline Dive, UK

Dusty Donaldson, USA

Victor dos Santos, Brazil

Jian Chun Duan, China

Mary Duffy, Australia

Jazmin Eckhaus, Australia

Aya El Helali, China

Lawson Eng, Canada

Jeremy Erasmus, USA

Matthew Evison, USA

Lilian Faroni, Brazil

Enriqueta Felip, Spain

Thomas Frauenfelder, Switzerland

Naoki Furuya, Japan

Thomas Gaisl, Switzerland

Julie George, Germany

Ritu Gill, USA

Nicolas Girard, France

Koichi Goto, Japan

Zeno Gouw, Netherlands

Dario Gregori, Italy

Federica Grosso, Italy

Matthias Guckenberger, Switzerland

Balazs Halmos, USA

Yuchen Han, China

Guilherme Harada, Brazil

Lizza Hendriks, Netherlands

Merel Hennink, Netherlands

Cheryl Ho, Canada

Luciana Holtz, Brazil

WCLC 2025 INTERNATIONAL ABSTRACT REVIEW COMMITTEE

Hidehito Horinouchi, Japan
James Huang, USA
Salma Jabbour, USA
Deepali Jain, India
Hongbin Ji, China
Long Jiang, China
Tom John, Australia
Melissa Johnson, USA
Rosalyn Juergens, Canada
Jin Hyoung Kang, Republic of Korea
Ryohei Katayama, Japan
Ola Khorsid, Egypt
Aki Kobayashi, Japan
Juan Carlos Laguna, Spain
Anna Rita Larici, Italy
Sally Lau, USA
Chee Khoon Lee, Australia
Jay Lee, USA
Tracy Leong, Australia
Antonin Levy, France
Benjamin Levy, USA
Sun Min Lim, Republic of Korea
Herbert Loong, China
Gilberto Lopes, USA
Fernando Lopez-Rios, Spain
Angeline Low, Australia
Jia Luo, USA
Margherita Majem, Spain
Alessandro Mariani, Brazil
Kristen Marrone, USA
Celine Mascaux, France
Clarissa Mathias, Brazil
Julien Mazieres, France
Stephanie McDonald, USA
Anita McGrath, Australia
Vanessa Costa Menezes, Brazil
Jessica Menis, Italy
Laura Mezquita, Spain
Satoru Miura, Japan
Drew Moghanaki, USA
Tatiane Montella, Brazil
Giannis Mountzios, Greece
Pablo Munoz Schuffenegger, Chile
Rachael Murray, UK
Ernest Nadal, Spain
Misako Nagasaka, USA
Ellen Nascimento, Brazil
Alejandro Navarro, Spain
Calvin Ng, Hong Kong

Silvia Novello, Italy
Emmet O'Brien, Ireland
Mary O'Brien, UK
Deborah O'Doherty, Ireland
George Oblitas, Peru
Coral Olazagasti, USA
Yuko Oya, Japan
Giovanni Pappagallo, Italy
Kaushal Parikh, USA
Samina Park, Republic of Korea
Sehhoon Park, Republic of Korea
Francesco Passiglia, Italy
Ugo Pastorino, Italy
Luis Paz-Ares, Spain
Giuseppe Pelosi, Italy
Cecilia Pompili, UK
Angus Pratt, Canada
Arsela Prelaj, Italy
Lauren Pretorius, South Africa
Morten Quist, Denmark
Luis Raez, USA
Sara Ramella, Italy
Meredith Ray, USA
Martin Reck, Germany
Jordi Remon, France
Joshua Reuss, USA
Biagio Ricciuti, USA
Carole A Ridge, UK
Luisella Righi, Italy
Maria Clara Rodriguez, Uruguay
Rafael Rosell, Spain
Rossana Ruiz, Peru
Valerie Rusch, USA
Tomohito Saito, Japan
Hisashi Saji, Japan
Pamela Samson, USA
Montse Sanchez, Spain
Jacob Sands, USA
Yoshitaka Sekido, Japan
Triparna Sen, USA
Riyaz Shah, UK
Abhishek Shankar, India
Mahdi Sheikh, France
Lynette Sholl, USA
Navneet Singh, India
Pawan Kumar Singh, India
Eric Singhi, USA
Shankar Siva, Australia
Matthew Smeltzer, USA

WCLC 2025 INTERNATIONAL ABSTRACT REVIEW COMMITTEE

Ross Andrew Soo Lai Kit, Singapore
Conor Steuer, USA
Motoko Tachihara, Japan
Junko Tanizaki, Japan
Cristina Teixido, Spain
Anish Thomas, USA
Juan Carlos Trujillo, Spain
Mylene Truong, USA
Lucia Viola, Colombia
Santiago Viteri, Spain
Rozemarijn Vliegthart, Netherlands
Gerard Walls, UK
Randi Williams, USA
Annie Wong, New Zealand
Douglas Wood, USA
Antoinette Wozniak, USA
Chi-Fu Yang, USA
Soo-Ryum Yang, USA
Li Zhang, China
Wen-Zhao Zhong, China
Qing Zhou, China
Jon Zugazagoitia, Spain

Congratulations **2025 DISTINGUISHED SERVICE AWARD WINNERS**

The IASLC Distinguished Service Awards will be presented during the Opening Plenary Session on **Saturday, September 6, 16:15 – 17:45.**

The Adi F. Gazdar IASLC Merit Award proudly recognizes Dr. Gazdar and honors his lifelong dedication to lung cancer research and his pioneering work in molecular pathology.



ADI F. GAZDAR IASLC MERIT AWARD

Pasi A. Jänne

USA

Dr. Pasi Jänne is Senior Vice President for Translational Medicine at Dana-Farber Cancer Institute, Professor of Medicine at Harvard Medical School, and holds the David M. Livingston, MD Chair at Dana-Farber. He also directs the Belfer Center for Applied Cancer Science and the Chen-Huang Center for EGFR Mutant Lung Cancers. Dr. Jänne received his MD and PhD from the University of Pennsylvania School of Medicine, completed his internship and residency at Brigham and Women's Hospital, along with a fellowship in medical oncology through the combined Dana-Farber Cancer Institute/Massachusetts General Hospital program. In 2002, he earned a Master's Degree in Clinical Investigation from Harvard University.

Dr. Jänne is internationally recognized for his contributions to the understanding and treatment of lung cancer, particularly for co-discovering EGFR mutations. His research combines laboratory science with translational research and clinical trials, focusing on the therapeutic importance of oncogenic alterations in lung cancer. His work has led to numerous seminal discoveries and the development of multiple clinical trials. He has received honors from the American Association for Cancer Research, the European Society for Medical Oncology, the American Society of Clinical Oncology, and the American Cancer Society, which awarded him the Medal of Honor.

Dr. Jänne has been actively involved with the IASLC, contributing to its mission through scientific presentations, participation on the Education Committee (2011-2015), and serving on the Board of Directors (2013-2017).

Congratulations **2025 DISTINGUISHED SERVICE AWARD WINNERS**

The IASLC Distinguished Service Awards will be presented during the Opening Plenary Session on **Saturday, September 6, 16:15 – 17:45.**

The Joseph W. Cullen Prevention/Early Detection Award recognizes an IASLC scientist for a lifetime achievement in the prevention of thoracic malignancies. Dr. Cullen served as the Deputy Director of the National Cancer Institute, Division of Cancer Prevention and Control. He created the Smoking, Tobacco and Cancer Program at the NCI in 1982.



JOSEPH W. CULLEN PREVENTION /
 EARLY DETECTION AWARD

Witold Rzyman

POLAND

Prof. Witold Rzyman is Chief Surgeon of the Department of Thoracic Surgery at the Medical University of Gdańsk and the Provincial Hospital for Lung Diseases in Prabuty, Poland. He began his medical career in 1986 as a general and vascular surgeon and transitioned to thoracic surgery in 1993. He has served as Poland's National Consultant in Thoracic Surgery and is a board member of the Polish Society of Cardiothoracic Surgery.

Prof. Rzyman has authored over 122 scientific publications and is recognized for his work in minimally invasive surgery and multimodality treatment of thoracic malignancies. He co-leads the Gdańsk Lung Cancer Research Group and oversees biobanking initiatives. He is also a leader in lung cancer screening, having authored Poland's national LCS consensus statement and served on the Steering Committee for the national pilot program (2020–2023). He has led four major grants supporting LDCT-based screening and molecular diagnostics, collectively screening over 18,000 individuals.

Prof. Rzyman has been thoroughly engaged with the IASLC through his service on the Early Detection and Screening Committee (2017-2027) and as Associate Editor of International Lung Cancer News. In 2024, he received the IASLC Regional Cancer Care Team Award.

Congratulations

2025 DISTINGUISHED SERVICE AWARD WINNERS

The IASLC Distinguished Service Awards will be presented during the Opening Plenary Session on **Saturday, September 6, 16:15 – 17:45.**

The Mary J. Matthews Pathology/Translational Award recognizes an IASLC scientist for lifetime achievement in pathology and translational research of thoracic malignancies. Mary J. Matthews served as a senior investigator and pathologist at the National Cancer Institute. She was a pioneer in defining the histologic subtypes of lung cancer.



MARY J. MATTHEWS PATHOLOGY /
TRANSLATIONAL RESEARCH AWARD

Sanja Dacic

USA

Dr. Sanja Dacic is Professor of Pathology, Vice Chair and Director of Anatomic Pathology, and Director of Thoracic Pathology at Yale School of Medicine. She earned her MD and PhD from the University of Zagreb in Croatia. Dr. Dacic completed her residency in anatomic and clinical pathology at the University of Pittsburgh, along with a fellowship in surgical thoracic pathology. Immediately following, she joined as faculty, serving as Professor of Pathology at the University of Pittsburgh, Director of Anatomic Pathology at UPMC Presbyterian Hospital, Director of Thoracic Pathology Center of Excellence and Interim Director of the Molecular Anatomic Pathology.

Dr. Dacic's research focuses on diagnostic pulmonary and molecular pathology, with extensive work in lung cancer and pleural mesotheliomas. She has authored over 200 peer-reviewed publications, book chapters, and guidelines. She was a co-author for the 4th edition and an editorial board member for the 5th edition of the WHO Classification of Thoracic Tumors. She currently serves as a Deputy Editor-in-Chief of Archives of Pathology & Laboratory Medicine and as an editorial board member of several high-impact journals.

Dr. Dacic has been a dedicated member of the IASLC, serving on the Pathology Committee (2011-2027) and chairing the group (2023-2025). She has contributed to WCLC as invited faculty, abstract reviewer, and program committee member since 2011. In 2020, she received the IASLC Fred R. Hirsch Lectureship Award for Translational Research.

Congratulations

2025 DISTINGUISHED SERVICE AWARD WINNERS

The IASLC Distinguished Service Awards will be presented during the Opening Plenary Session on **Saturday, September 6, 16:15 – 17:45.**

The Paul A. Bunn, Jr. Scientific Award recognizes an IASLC scientist for a lifetime achievement of scientific contributions to thoracic cancer research. The award is named after IASLC's longtime CEO, Paul A. Bunn, Jr., whose studies set worldwide standards for the treatment of lung cancer.



PAUL A. BUNN, JR. SCIENTIFIC AWARD

Solange Peters

SWITZERLAND

Prof. Solange Peters is a Full Professor and Director of Medical Oncology, along with the Thoracic Malignancies Program within the Department of Oncology at the University Hospital of Lausanne in Switzerland. She earned her MD and PhD at the University Hospital of Lausanne and completed clinical training in medical oncology and molecular biology in Switzerland and Italy.

Prof. Peters' research interests span new biomarkers discovery and validation in preclinical and clinical settings, multimodality strategies for locally advanced non-small cell lung cancer (NSCLC), as well as cancer immunotherapy. She has authored over 500 peer-reviewed manuscripts and book chapters and serves as Associate Editor for Annals of Oncology and ESMO Open. She is the former Editor-in-Chief of Lung Cancer and continues to serve on several editorial boards. She holds prominent leadership roles, including President of Oncosuisse, President of the Swiss Academy of Multidisciplinary Oncology, Vice Director of the Swiss National Cancer League, and Strategic Advisory Board President for the Paris Saclay Cancer Cluster.

Prof. Peters has been a long-time supporter of the IASLC, acting as past Deputy Editor of the Journal of Thoracic Oncology (JTO), serving to enhance the collaborative educational programs of the IASLC and ESMO, participating on the Publications Committee (2011-2017), and serving on the Board of Directors (2013-2017).

Congratulations IASLC 2025 LECTURESHIP AWARD WINNERS



SUNDAY, SEPTEMBER 7, 2025

The following IASLC Lectureship Awards will be presented during the Presidential Symposium 1 on **Sunday, September 7, 08:15 - 10:30**.

Robert J. Ginsberg Lectureship Award for Surgery

Andrea Wolf, USA

James D. Cox Lectureship Award for Radiation Oncology

Suresh Senan, Netherlands

IASLC Lectureship Award for Tobacco Control and Smoking Cessation

Lawson Eng, Canada



MONDAY, SEPTEMBER 8, 2025

The following IASLC Lectureship Awards will be presented during the Presidential Symposium 2 on **Monday, September 8, 08:15 - 10:30**.

Tsuguo Naruke Lectureship Award for Surgery

Kazuhiro Asufuku, Canada

Heine H. Hansen Lectureship Award for Small Cell Lung Cancer

Ying Cheng, China **IN MEMORIAM**



TUESDAY, SEPTEMBER 9, 2025

The following IASLC Lectureship Awards will be presented during the morning Plenary Session on **Tuesday, September 9, 08:30 - 10:30**.

Clifton F. Mountain Lectureship Award for Staging

Jin Mo Goo, Republic of Korea

Fred R. Hirsch Lectureship Award for Translational Research

Mary Beth Beasley, USA

Daniel C. Ihde Lectureship Award for Medical Oncology

Lizza Hendriks, Netherlands

Congratulations WCLC 2025 EDUCATION AWARD WINNERS

All WCLC 2025 Education Award Winners will be presented with their award during the IASLC Award Luncheon on **Saturday, September 6, 11:30 - 13:00**.

EARLY CAREER EDUCATION AWARDS

Hanie Abolfathi, Canada

Abstract #: MA07.04

Abstract Title: Integration of a Molecular Prognostic Classifier Enhances Conventional Staging of Lung Adenocarcinoma

Alessandro Leonetti, Italy

Abstract #: MA02.05

Abstract Title: Liquid Biopsy in BRAF V600E NSCLC Treated with Dabrafenib Plus Trametinib: Final Analysis of LIBRA Study (GOIRC-03-2020)

Yin Li, China

Abstract #: P2.02.01

Abstract Title: Characterizing UPPI Expression in Non-Tumor Cells of Lung Cancer and Its Clinical Implications

Elham Khodayari Moez, Canada

Abstract #: MA05.06

Abstract Title: Integrating Circulating Protein Biomarkers in Nodule Malignancy Prediction Model Based on Five International Lung Cancer Screening Cohorts

Ezekiel Olumuyide, USA

Abstract #: P3.03.13

Abstract Title: HLA II Genetics Shapes Lung Cancer Immunosurveillance

Masahiro Torasawa, Japan

Abstract #: P3.03.36

Abstract Title: Whole Genome Doubling Drives Genomic Instability and Poor Postoperative Outcomes in Stage I Driver-Negative Lung Adenocarcinoma

Sarah Waliany, USA

Abstract #: MA02.01

Abstract Title: Contemporary Landscape of Acquired Resistance to Next-Generation ALK Inhibitors: Paired Pre-/Post-Treatment Biopsy Analysis

Runchen Wang, China

Abstract #: P1.07.01

Abstract Title: Wearable-Based Evaluation of Tubeless Thoracic Surgery for Early-Stage Lung Cancer

Xiao Wang, USA

Abstract #: MA06.01

Abstract Title: Real-World Outcomes of First-Line Immunotherapy Intensification of Patients with Advanced Non-small Cell Lung Cancer (aNSCLC)



Discover the many individuals advancing IASLC's mission by visiting the **IASLC Awards Alley**, located at the **entrance to the Exhibit Hall**. Explore overviews of IASLC award winners, grant recipients, and program participants, and learn about IASLC committees and their ongoing projects.

Congratulations WCLC 2025 EDUCATION AWARD WINNERS

DEVELOPING COUNTRIES EDUCATION AWARDS

Ayah Al-Bzour, Jordan

Abstract #: P3.03.31

Abstract Title: Transcriptomic Profiling Identifies a Prognostic and Predictive Inflammatory Signature in Patients with Lung Adenocarcinoma

Gabriela Carmona De Souza, Brazil

Abstract #: OA18.02

Abstract Title: Emerging Disparities in Lung Cancer Burden in the Americas: A GLOBOCAN-Based Projection to 2050

Yanan Cui, China

Abstract #: MA11.10

Abstract Title: IFITM3 Enhances Immunotherapy Sensitivity Through MHC-I Regulation in Small Cell Lung Cancer

Maria Raquel Gomes

Fernandes, Brazil

Abstract #: PT1.03.03

Abstract Title: Drug Repurposing for Metastatic Lung Adenocarcinoma Therapy Using AI-Guided Single-Cell Gene Expression Profiles

Zixuan Hu, China

Abstract #: P3.03.43

Abstract Title: Gut Klebsiella Pneumoniae Drives Lung Cancer Progression by Modulating Macrophage Hpgds and Suppressing the PGJ2-PPAR γ Signaling Pathway

Guang-Ling Jie, China

Abstract #: P3.03.14

Abstract Title: PCSK9-Mediated Immune Escape as a Mechanism of Acquired Resistance to PD-1/PD-L1 Blockade

Shangbiao Li, China

Abstract #: OA14.02

Abstract Title: DCBLD2high Tumor-Derived Retinoic Acid Orchestrates Macrophages to Drive Vascular Immunosuppression and Immunotherapy Resistance

Shencheng Ren, China

Abstract #: P2.02.30

Abstract Title: Targeting MTA2 Lactylation as a Therapeutic Strategy to Overcome Chemoresistance in Lung Adenocarcinoma

Haojie Si, China

Abstract #: OA11.04

Abstract Title: Validation and Refinement Proposal of the Ninth Edition n Descriptor for Non-small Cell Lung Cancer Receiving Neoadjuvant Therapy

Osama Younis, Jordan

Abstract #: P2.10.11

Abstract Title: Single-Cell RNA Sequencing Identifies ALCAM and Gpnmb as Therapeutic Targets for ADC Development in Squamous Cell Carcinoma of the Lung

Abstract #: P2.10.09

Abstract Title: Single-Cell RNA Sequencing Reveals Subtype-Specific Resistance Mechanisms to TROP2-Targeted ADCs in Non-small Cell Lung Cancer

Abstract #: P2.06.62

Abstract Title: Integrin- β 6 Modulates the Tumor Microenvironment and Serves as a Prognostic Marker in Lung Squamous Cell Carcinoma

Congratulations WCLC 2025 EDUCATION AWARD WINNERS

NURSE OR ALLIED HEALTH PROFESSIONAL AWARDS

Aline Barreto, Brazil

Abstract #: EP15.01

Abstract Title: Anorexia, an Underreported Adverse Event, Predicts Mortality in Lung Cancer Patients

Jaimini Patoliya, India

Abstract #: P3.01.14

Abstract Title: The Rising Toll: Global Burden and Future Projections of Tracheal, Bronchus, and Lung Cancer in Women, 1990-2050

Feifei Huang, China

Abstract #: P2.15.07

Abstract Title: Effect of Message Framing in a Digital Lung Cancer Screening Decision Navigation Intervention: A Three-Arm Randomized Controlled Trial

TOBACCO CONTROL AND SMOKING CESSATION AWARDS

EARLY CAREER

Lawson Eng, Canada

Abstract #: OA11.01

Abstract Title: Impact of Smoking Status on the Prognosis of Lung Cancer in the IASLC Ninth Edition TNM Classification Database

DEVELOPING COUNTRIES

Durre Aden, India

Abstract #: EP01.27

Abstract Title: Gender and Tobacco Use Status Shape Support for Endgame Strategies in India

PATIENT ADVOCACY EDUCATION AWARDS

Anne Fidler, Australia

Bernard Gaspar, Spain

Micki Goldfain, Israel

Mami Hanada, Japan

Virginia Harrison, UK

Vendi Jukic Buca, France

Wee-Hau Lee, Singapore

Omogbemi Ojole, Nigeria

Urvashi Prasad, India

Sanjeev Sharma, India

Ashley Vassallo, USA

Suzanne Vincze, USA

Congratulations IASLC INTERNATIONAL MENTORSHIP PROGRAM PARTICIPANTS

Oussama Aazzane, Morocco

Abstract #: P2.10.07

Abstract Title: Combined Immunoscore for Predictive Stratification of Unresectable Non-small Cell Lung Cancer

Huizhao Hong, China

Abstract #: OA03.01

Abstract Title: Multiomic Single Cell Profiling Reveals Novel Evolutionary Trajectories in Lung Carcinogenesis

Zi-Xuan Rong, China

Abstract #: OA03.04

Abstract Title: TNFSF8-Targeting CpG Peptide Vaccine Reduces ICB Pneumonitis While Boosting Cancer Immunotherapy Efficacy

Nattanit Suriyaphan, Thailand

Abstract #: P3.12.28

Abstract Title: Association of PD-L1 Expression with Clinical Outcome in Advanced NSCLC with ALK Rearrangement

Weng-Fang Tang, China

Abstract #: OA03.02

Abstract Title: Deciphering Genomic Evolution of Metastatic Organotropism with Large-Scale Paired Primary Lung Cancers and Metastases

Pragadeesh Thamaraiselvan, India

Abstract #: P3.01.21

Abstract Title: Lifting the Smoke Screen: A Real-World Comparative Study of Lung Cancer in Never-Smokers Versus Ever-Smokers

Rogelio Velasco Jr., Philippines

Abstract #: P1.11.79

Abstract Title: A Meta-Analysis on Anti-PD-1/L1 With or Without Anti-VEGF Plus Chemotherapy in EGFR-Mutant or ALK-Rearranged NSCLC Progressing on TKIs

Yanpei Zhang, China

Abstract #: P2.02.33

Abstract Title: Radiotherapy Induces Ferroptosis and Activates STING Pathway to Reverse Immunotherapy Resistance in LKB1-Mutant Lung Cancer

Abstract #: P2.08.59

Abstract Title: SCGB1A1 Enhances Radioimmunotherapy Efficacy and Mitigates Pulmonary Toxicity via Dendritic Cell Functional Reprogramming

International Mentorship Program supported by

Johnson & Johnson



RACING TOWARD IMPACT

Explore a series of compelling, real-world thoracic oncology cases featured in the Amazing Case Race. Displayed throughout the conference venue, each case showcases clinical decision-making at its finest. Review the cases, consider the challenges, and vote for the one you think stands out.

SCAN THE QR CODE TO CHECK WHO'S LEADING THE RACE AND CAST YOUR VOTE FOR YOUR FAVORITE CASE!



WHERE TO FIND THE CASES?
FIND THE COMPETING CASES ON DISPLAY BOARDS THROUGHOUT THE WCLC 2025 VENUE.

LET THE BEST CASE WIN!

PROGRAM AT A GLANCE

Saturday, September 6, 2025

08:30						
09:00	Early Career Investigator Workshop	Joint IASLC-CSCO-CAALC Session 08:30 - 11:30	IASLC/ iMig Workshop 08:30 - 11:30	2025 IASLC CT Screening Symposium (Ticketed Event)	Crowd-Sourced Workshops* 08:15 - 09:45	Industry Symposia 09:00 - 10:00
09:30						
10:00	Morning Session 08:30 - 11:30			Morning Session 08:30 - 11:30	Crowd-Sourced Workshops* 10:00 - 11:30	Industry Symposia 10:30 - 11:30
10:30						
11:00						
11:30						
12:00	Awards Luncheon <i>All are Welcome to Join</i> 11:30 - 13:00					Industry Symposia 12:00 - 13:00
12:30						
13:00	Early Career Investigator Workshop	Nurse & AHP + ITONF Workshop 13:00 - 16:00	Social Media & Communications Workshop 13:00 - 14:15	2025 IASLC CT Screening Symposium (Ticketed Event)	Crowd-Sourced Workshops* 13:00 - 15:00	Industry Symposia 13:30 - 14:30
13:30						
14:00	Afternoon Session 13:00 - 16:00		LATAM Workshop 14:30 - 16:00	Afternoon Session 13:00 - 16:00	Crowd-Sourced Workshops* 14:30 - 16:00	Industry Symposia 15:00 - 16:00
14:30						
15:00						
15:30						
16:00	Opening Plenary with Distinguished Service Award Presentations 16:15 - 17:45					
16:30						
17:00	Welcome Reception 17:45 - 19:15					Press Conference 17:45 - 18:45
17:30						
18:00						
18:30						
19:00						

*Please find crowd-sourced workshop titles below:

- 08:15 - 09:45:** Humans Helping Humans: Overcoming Compassion Fatigue and Building Resilience in Oncology Care
- 08:15 - 09:45:** Personalizing Approaches to SCLC: Translating New Understandings of SCLC Heterogeneity into Biomarker-driven Small Cell Lung Cancer Therapies
- 10:00 - 11:30:** Implication of the New TNM on the Management of Thymic Malignancies
- 10:00 - 11:30:** Practical Application of Gene-Editing for the Verification of Novel Lung Cancer Biomarkers: From Gene Discovery to Pre-clinical and Beyond
- 13:00 - 15:00:** AI Usage for Radiation Oncology: Where Are We and Where Will We Go?
- 13:00 - 15:00:** GGO Management and Treatment - Intraoperative Electromagnetic Navigation Bronchoscopy (ENB) Guided Marking and Minimally Invasive Resection
- 14:30 - 16:00:** From Guidelines to Implementation in NSCLC: Pertinent Considerations of Adherence to Consensus Standards of Care in Clinical Practice

PROGRAM AT A GLANCE

Sunday, September 7, 2025

08:30	Presidential Symposium 1 Lecture Award Presentations 08:15 - 10:30				
09:00					
09:30					
10:00					
10:30	Poster Viewing Break with PI Presenters in Attendance 10:30 - 12:00	Non-Profit Presentation 10:45 - 11:45	Announcing the IASLC-Lancet Commission: A Transformative Global Approach to Lung Cancer 10:45 - 11:45	Press Conference 10:45 - 11:45	
11:00					
11:30					
12:00	Concurrent Abstract & Education Sessions 12:00 - 13:15	Radiation Oncology Contouring Workshop - Locally Advanced NSCLC (pre-signup and laptop required) 12:00 - 13:15			
12:30					
13:00					
13:30	Lunch Break & Poster Tours 13:15 - 15:15	Work-Life Harmony: Redefining Balance in the Demanding Field of Oncology 13:45 - 14:45	Industry Symposia 13:45 - 14:45		
14:00					
14:30					
15:00					
15:30	Concurrent Abstract & Education Sessions 15:15 - 16:30	REPEAT SESSION: Radiation Oncology Contouring Workshop - Locally Advanced NSCLC (pre-signup and laptop required) 15:15 - 16:30			
16:00					
16:30					
17:00	Concurrent Abstract & Education Sessions 16:45 - 18:00	Crowd-Sourced Workshop* 16:45 - 18:00			
17:30					
18:00	The Backyard Steps Experience <i>A charitable initiative from The Ricky Rubio Foundation in collaboration with the WCLC Wellness Challenge.</i> 18:00 - 20:30		Industry Symposia 18:30 - 19:30		
18:30					
19:00					
19:30					
20:00					
20:30					
21:00					
21:30					
22:00					

*Please find crowd-sourced workshop titles below:

- 16:45 - 18:00:** Sybil: Using a Deep Learning Model to Predict Lung Cancer Risk in the Real World

PROGRAM AT A GLANCE

Monday, September 8, 2025



PROGRAM AT A GLANCE

Tuesday, September 9, 2025



PROGRAM AT A GLANCE

INDUSTRY SPONSORED SYMPOSIA

Saturday, September 6, 2025

09:00 - 10:00	IS01: Industry Sponsored Symposium by AstraZeneca: Preparing NSCLC for the Future of Diagnostic Biomarker Testing	IS02: Industry Sponsored Symposium by Eli Lilly and Company: Precision Starts Early: The Evolving Role of Biomarker Testing in Early-Stage NSCLC
10:30 - 11:30	IS04: Industry Sponsored Symposium by Daiichi Sankyo and MSD: Empowering Clinicians in SCLC Management: Key Insights on Diagnosis, Treatment, and Emerging Strategies	
12:00 - 13:00	IS05: Industry Sponsored Symposium by Abbvie: What SEZ6 Says About Small Cell Lung Cancer (SCLC) and Neuroendocrine Neoplasms (NENs)	IS06: Industry Sponsored Symposium by Pfizer: Sustained Clinical Benefit in 1L ALK+ aNSCLC: How to Optimise Outcomes for Our Patients
13:30 - 14:30	IS08: Industry Sponsored Symposium by Accord Healthcare: Recent Developments in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer	

Sunday, September 7, 2025

13:45 - 14:45	IS11: Industry Sponsored Symposium by AstraZeneca: Maximising a Multidisciplinary Approach: Shaping the Future of Lung Cancer Care with Immunotherapy	IS12: Industry Sponsored Symposium by Johnson & Johnson: Advancing EGFR-mutant NSCLC Care	IS13: Industry Sponsored Symposium by Nuvation Bio Inc.: Under the MicRO-Scope: Focusing on ROS1+ NSCLC	IS14: Industry Sponsored Symposium by Regeneron: NSCLC Reimagined: Novel Treatment Strategies in Advanced NSCLC
18:30 - 19:30	IS15: Industry Sponsored Symposium by Natera: Signatera Ultrasensitive MRD Testing for Lung Cancer			

Monday, September 8, 2025

13:45 - 14:45	IS16: Industry Sponsored Symposium by Daiichi Sankyo, Inc.: Multidisciplinary Care for Patients with Brain Metastases in EGFRm NSCLC or SCLC	IS17: Industry Sponsored Symposium by Boehringer Ingelheim International GmbH: Targeted Therapies, Personalized Care: Patient-Centered Advances for the Treatment of NSCLC and SCLC	IS18: Industry Sponsored Symposium by MSD: A Decade of Progress: Advances in Immunotherapy for NSCLC?	IS19: Industry Sponsored Symposium by AstraZeneca: Metastatic EGFRm NSCLC: Adapting to Patients, Grounded in Evidence
---------------	---	--	--	--

PROGRAM AT A GLANCE

SATELLITE CME SYMPOSIA

Saturday, September 6, 2025

10:30 - 11:30	IS03: Satellite EBAC/CME Symposium by Answers in CME on Behalf of Daiichi Sankyo, Inc.: Reshaping the Management of Metastatic NSCLC: Tackling HER2 Overexpression to Elevate Outcomes
13:30 - 14:30	IS07: Satellite EBAC/CME Symposium by PeerVoice on behalf of Bayer: Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC
15:00 - 16:00	IS09: Satellite CME Symposium by Physicians' Education Resource on Behalf of Summit Therapeutics, Inc.: A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sunday, September 7, 2025

18:30 - 19:30	IS10: Satellite CME Symposium by Physicians' Education Resource on Behalf of AstraZeneca: Tumor Board: Advances in Managing EGFR-Mutant NSCLC - Applying Evidence Across the Disease Continuum
---------------	---




Find WCLC News at **ILCN.org**

Stay informed on the latest from #WCLC25 at [ILCN.org](https://www.ilcn.org)
the official news source of the IASLC, the only global association
dedicated to the multidisciplinary study of lung cancer.



**IASLC 2025 World
Conference on Lung Cancer**

SEPTEMBER 6-9, 2025 | BARCELONA, SPAIN



02

PROGRAM: SATURDAY

IASLC 2025 WORLD CONFERENCE ON LUNG CANCER
CONQUERING LUNG AND OTHER THORACIC CANCERS WORLDWIDE IN THE 21ST CENTURY.

FRIDAY, SEPTEMBER 5, 2025

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

08:00 – 16:00 IASLC ACADEMY WORKSHOP
(BY INVITATION ONLY)

ROOM 12

08:00 – 16:00 IASLC STAGING COMMITTEE MEETING
(BY INVITATION ONLY)

ROOM 10

SATURDAY, SEPTEMBER 6, 2025

07:30 – 11:30 IASLC PARTNERS FOR THORACIC CANCER CARE MEETING
(BY INVITATION ONLY)

MEETING ROOM C

 NOT FOR CME CREDIT

**08:15 – 09:45 WS01 - HUMANS HELPING HUMANS: OVERCOMING
COMPASSION FATIGUE AND BUILDING RESILIENCE IN
ONCOLOGY CARE**

ROOM 10

 NOT FOR CME CREDIT

Chair: Shani Shilo, Israel

08:15 Welcome & Introduction
Shani Shilo, Israel

08:20 WS01.02 Impact of Compassion Fatigue and Resilience-Building Strategies
Jennifer Bickel, USA

08:40 WS01.03 Panel Discussion:
Clarissa Mathias, Brazil, Elaine Shum, USA, Fred Hirsch, USA, Maria Mathias, Brazil

09:40 Q&A

HOD Highlight of the Previous Day
HOW Hands-On Workshop
MA Mini Oral Abstract Session
OA Oral Abstract Session

P Poster
PT Poster Tour
PL Plenary
WS Workshop

08:15 - 09:45 WS02 - PERSONALIZING APPROACHES TO SCLC: TRANSLATING NEW UNDERSTANDINGS OF SCLC HETEROGENEITY INTO BIOMARKER-DRIVEN SMALL CELL LUNG CANCER THERAPIES

ROOM 09



Chair: Anne Chiang, USA

08:15 Welcome & Introduction
 Anne Chiang, USA

Part 1 - "Tissue is the Issue": Best Practices and New Technologies in SCLC

08:20 WS02.01 - Panel Discussion
 Moderator: SoYeon Kim, USA
 Panelists: Ignacio Wistuba, USA, Alberto Chiappori, USA, Kurt Schalper, USA, Alexander Bagaev, USA, Zsolt Megyesfalvi, Austria

Part 2: Translating New Understanding of SCLC Subtypes and Biology to the Clinic
 Moderator: Nan Sethakorn, USA

08:50 WS02.02 - New Insights into SCLC Biology and Subtypes
 Lauren Byers, USA

09:10 WS02.03 - Biomarker-driven Clinical Trials
 Anne Chiang, USA

09:25 WS02.04 - Translational Approaches to Studying SCLC
 Ana Ortega Franco, UK

09:40 Q&A

08:30 - 11:30 WS03.01 - EARLY CAREER INVESTIGATOR WORKSHOP - PART 1

ROOM 03



Chairs: Sabita Jiwnani, India and Jair Bar, Israel and Zhaohui Arter, USA and Ticiana Leal, USA
 Panelists: Keith Kerr, Canada, Carl Ferreira, Brazil

Part 1: Oncology Career Strategies: Navigate, Network, and Thrive

08:30 Welcome & Introduction
 Jair Bar, Israel

08:37 WS03.01.02 - Study Design 101: Key Study Types, Critical Components, and Pitfalls to Avoid
 Jair Bar, Israel

08:45 WS03.01.03 - Biostatistic Basics: Sample Size, Statistical Plan, and Key Concepts
 Matthew Smeltzer, USA

08:54 WS03.01.04 - From Bench to Bedside: A Translational Study
 Arianna Marinello, France

09:03 WS03.01.05 - Panel Discussion: Translational Study
 Matthew Smeltzer, USA, Patrick Forde, USA, Alessandra Curioni, Switzerland

09:12 WS03.01.06 - Learning from Practice: A Real-World Study
 Rafeh Naqash, USA

09:21 WS03.01.07 - Panel Discussion: Real-World Study
 Matthew Smeltzer, USA, Patrick Forde, USA, Alessandra Curioni, Switzerland

09:30 WS03.01.08 - Clinical Trials in Action: A Clinical Trial Study
 Chul Kim, USA

09:39 WS03.01.09 - Panel Discussion: Clinical Trial Study
 Matthew Smeltzer, USA, Patrick Forde, USA, Alessandra Curioni, Switzerland

09:48 WS03.01.10 - Summary
 Matthew Smeltzer, USA, Patrick Forde, USA, Alessandra Curioni, Switzerland

09:53 Break

Part 2: Oncology Career Strategies: Navigate, Network, and Thrive

09:58 WS03.01.11 - The Importance of Career Development in Thoracic Oncology
 Tindara Franchina, Italy

10:03 WS03.01.12 - Charting Your Course: Making the Most from Early to Mid-Career
 Narjust Florez, USA

10:13 WS03.01.13 - Bridging the Gap: Cultivating Your Role as a Clinician-Scientist in Oncology
 Jonathan David Spicer, Canada

10:23 Q&A

10:28 WS03.01.14 - Panel Discussion: Navigating Different Phases and Diverse Pathways in Lung Cancer

Moderator: Sabita Jiwnani, India
 Panelists: David Moore, UK, Fiona Hegi-Johnson, Australia, Clarissa Baldotto, Brazil, Linda Martin, USA, Mihaela Aldea, USA, Navneet Singh, India

11:03 Q&A

11:08 WS03.01.15 - Unlocking Career Growth: How IASLC Can Boost Your Professional Development
 Karen Kelly, USA

Early Career Investigator Workshop will continue at 13:00.

08:30 - 11:30 WS04 - JOINT IASLC-CSCO-CAALC SESSION: GLOBAL PERSPECTIVES IN LUNG CANCER TREATMENT: TACKLING REAL-WORLD CHALLENGES TOGETHER

ROOM 06



Chairs: Karen Kelly, USA, Yi Long Wu, China, Caicun Zhou, China, Chunxue Bai, China, Si-Yang Liu, China, Fei Zhou, China, Dawei Yang, China

08:30 Welcome & Introduction Including Statement of the Objectives of the Session
 Karen Kelly, USA, Yi Long Wu, China, Caicun Zhou, China, Chunxue Bai, China, Si-Yang Liu, China, Fei Zhou, China, Dawei Yang, China

08:40 WS04.02 - Case Scenario 1: Early-Stage Lung Cancer
 Dawei Yang, China

08:45 WS04.03 - Case Scenario 1: Panel Discussion
 Moderators: Chunxue Bai, China, Dawei Yang, China
 Panelists: Helmut Prosch, Austria, Mara Antonoff, USA, Feng-Ming Kong, China

09:05 WS04.04 - Case Scenario 2: Locally Advanced Lung Cancer
 Si-Yang Liu, China

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

- 09:10 WS04.05 - Case Scenario 2: Panel Discussion**
Moderators: Yi Long Wu, China, Si-Yang Liu, China
Panelists: Helmut Prosch, Austria, Mara Antonoff, USA, Feng-Ming Kong, China, Keith Kerr, Canada, Carl Ferreira, Brazil
- 09:30 WS04.06 - Case Scenario 3: Metastatic Lung Cancer**
Fei Zhou, China
- 09:35 WS04.7 - Case Scenario 3: Panel Discussion**
Moderators: Caicun Zhou, China, Fei Zhou, China
Panelists: Helmut Prosch, Austria, Mara Antonoff, USA, Feng-Ming Kong, China
- 09:55 Take Away Message from Each Panelist**
- 10:05 Interactive Audience Polling**
- 10:22 WS04.8 - A Phase II Trial of Induction Camrelizumab Plus Chemotherapy Followed by Chemoradiotherapy and Consolidation in Limited-Stage SCLC**
Di Liu, China
- 10:28 WS04.9 - Toripalimab Consolidation After Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase II, Randomized Controlled Study**
Pengxin Zhang, China
- 10:34 WS04.10 - Clinical Outcomes and Single-Cell Map of Neoadjuvant Immunochemotherapy for Stage II-IIIb LS-SCLC: A Real-World Study**
Chen Huang, China
- 10:40 WS04.11 - Discussant WS04.08 - WS04.10**
Qian Chu, China
- 10:49 Q&A**
- 10:54 WS04.12 - Efficacy and Safety of TQB2102, a Biparatopic HER2-Targeting ADC, in HER-2 Aberrant NSCLC: A Phase II Study**
Li Zhang, China
- 11:00 WS04.13 - Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study**
Jie Wang, China
- 11:06 WS04.14 - IFI6-High Cancer-Associated Fibroblasts Impede Immunotherapy Response in NSCLC**
Leyi Lin, China
- 11:12 WS04.15 Discussant WS04.12 - WS04.14**
Xiuning Le, USA
- 11:21 Q&A**
- 11:26 Closing Remarks**

08:30 - 11:30 WS05 - IASLC / IMIG WORKSHOP

ROOM 07

NOT FOR CME CREDIT

Chair: Aaron Mansfield, USA

- 08:30 Welcome & Introduction**
Aaron Mansfield, USA
- 08:35 WS05.02 - Update on ASCO Guidelines for Mesothelioma, Reconciling Controversies in Management**
Hedy Kindler, USA
- 08:50 WS05.03 - Novel Minimally Invasive Surgical Approaches**
Stefan Watzka, Austria
- 09:05 WS05.04 - Applications of Radiation in Mesothelioma**
Crispin Hiley, UK
- 09:20 WS05.05 - Young Investigator: Treatment of Mesothelioma After First Line Immunotherapy**
Cornedine de Gooijer, Netherlands
- 09:35 WS05.06 - Young Investigator: Impact of Soluble Mesothelin on Mesothelin-Targeting Therapies**
Katherine Smith, USA
- 09:50 Q&A**
- 09:55 WS05.07 - Clinical and Pathologic Phenotyping of Mesotheliomas Developing in Carriers of Germline BAP1 Mutations**
Michele Carbone, USA
- 10:10 WS05.08 - Young Investigator: Impact of Epigenetic Alterations in Mesothelioma: Methods of Analysis of DNA Methylation in Mesothelioma Diagnosis**
Janah Vandenhoeck, Belgium
- 10:25 WS05.09 - Young Investigator: AI/Deep Learning and Transcriptomic Profile to Improve Classification and Response to Treatment**
Nicolas Alcala, France
- 10:40 WS05.10 - Panel Discussion: Diagnostic Dilemmas in Mesothelioma: Diving into the Differential**
Francoise Galateau-Salle, France & Sonja Klebe, Australia
- 11:00 WS05.11 - Bench to Bedside: Impact of Genomics of Treatment of Mesothelioma**
Thomas John, Australia
- 11:20 Q&A**
- 11:25 Closing Remarks**
Arnaud Scherpereel, France

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

08:30 - 11:30 WS06.01 - 2025 IASLC CT SCREENING SYMPOSIUM (TICKETED SESSION)

ROOM 08

NOT FOR CME CREDIT

Chairs: Rudolf Huber, Germany, Catherine Jones, Australia, Antoni Rosell, Spain, Betty Tong, USA, Milena Cavic, Serbia

- 08:30 Welcome & Introduction**
Milena Cavic, Serbia
- 08:35 Group Work**
- 09:00 WS06.01.01 - Introduction to Session 1: Designing an Optimal Lung Cancer Screening Program**
Rudolf Huber, Germany
- 09:05 WS06.01.02 - Australia National Lung Cancer Screening Program**
Miranda Siemienowicz, Australia
- 09:15 WS06.01.03 - Inclusion of Smoking Cessation in a LCS Program**
Stephanie Land, USA
- 09:25 WS06.01.04 - SOLACE Project**
Anna Kerpel-Fronius, Hungary
- 09:35 WS06.01.05 - Reimbursement and Cost Effectiveness**
Nicole Rankin, Australia
- 09:45 Q&A**
- 10:10 Break**
- 10:20 WS06.01.06 - Introduction to Session 2: Examples of Running Lung Cancer Screening Programs**
Catherine Jones, Australia
- 10:25 WS06.01.07 - Bunando Medical Center Tanzania**
Nestory Masalu, Tanzania
- 10:35 WS06.01.08 - Republic of Korea**
Yeol Kim, Republic of Korea
- 10:45 WS06.01.09 - USA Program with Breast Cancer Screening Program**
Kim Sandler, USA
- 10:55 WS06.01.10 - Denmark Program**
Michael Stegner, Denmark
- 11:05 Q&A**

The 2025 IASLC CT Screening Symposium will continue at 13:00.

09:00 - 10:00 INDUSTRY SPONSORED SYMPOSIA

See page 228 for more information.

10:00 - 11:30 WS07 - IMPLICATION OF THE NEW TNM ON THE MANAGEMENT OF THYMIC MALIGNANCIES

ROOM 10

ACCME ACCREDITED BY IASLC

Chair: Marco Chiappetta, Italy

- 10:00 Welcome & Introduction**
Marco Chiappetta, Italy
- 10:05 WS07.01 - Unsolved Issues in Thymic Malignancies Staging Systems and What's New in the 9th TNM Edition**
Enrico Ruffini, Italy

Part 1: Guidelines and Research in Thymic Malignancies: Looking for a Common Language

- 10:15 Moderator Introduction**
Anja Roden, USA
- 10:20 WS07.02 - Limits of Current Guidelines on Thymic Malignancies Management**
Wentao Fang, China
- 10:30 WS07.03 - Future Research Topics Based on New**
Anja Roden, USA

Part 2: Future Guidelines: How the 9th TNM Should Change Clinical Practice

- 10:40 WS07.04 - Changes in Imaging Description**
Edith Marom, Israel
- 10:44 WS07.05 - What's New in Specimen Evaluation**
Malgorzata Szolkowska, Poland
- 10:48 WS07.06 - Surgical Approach and Indication: What Should Be Considered?**
Jeffrey Velotta, USA
- 10:52 WS07.07 - The Oncologist Point of View**
Fateme Ardeshir Larijani, USA
- 10:56 WS07.08 - Radiotherapy: When and How**
Annemarie Shepherd, USA
- 11:00 Q&A and Open Discussion**
Moderators: Marco Chiappetta, Italy, Andreas Rimner, Germany and Anja Roden, USA
Discussants: Enrico Ruffini, Italy, Wentao Fang, China, Annemarie Shepherd, USA, Edith Marom, Israel, Malgorzata Szolkowska, Poland, Jeffrey Velotta, USA, Fateme Ardeshir Larijani, USA

10:00 - 11:30 WS08 - PRACTICAL APPLICATION OF GENE-EDITING FOR THE VERIFICATION OF NOVEL LUNG CANCER BIOMARKERS: FROM GENE DISCOVERY TO PRE-CLINICAL AND BEYOND

ROOM 09

NOT FOR CME CREDIT

Chair: Paola A. Marignani, Canada

- 10:00 Welcome & Introduction**
Paola A. Marignani, Canada
- 10:05 WS08.02 - Biomarker Discovery and Optimization of New Therapeutic Tools**
Chiara Ambrogio, Italy
- 10:25 WS08.03 - scRNAseq Analysis of Primary Tumors and Machine Learning Integration**
Paola Marignani, Canada

HOD Highlight of the Previous Day
HOW Hands-On Workshop
MA Mini Oral Abstract Session
OA Oral Abstract Session

P Poster
PT Poster Tour
PL Plenary
WS Workshop

10:45 WS08.04 - Detection of Early-Stage Lung Cancer*Christian Rolfo, USA***10:55 WS08.05 - Therapeutic Lung Cancer Biomarkers***David P. Carbone, USA***11:05 Panel Discussion and Q&A****10:30 – 11:30 INDUSTRY SPONSORED SYMPOSIUM***See page 229 for more information.***10:30 – 11:30 SATELLITE CME SYMPOSIUM***See page 231 for more information.***11:30 – 13:00 AWARDS LUNCHEON
(LIMITED CAPACITY, FIRST COME FIRST SERVED)****ROOM 01 + 02****LIVESTREAMED***Host: Sandip Patel, USA*

Join us for a special luncheon honoring the rising stars of the lung cancer research community. During this luncheon, we will recognize outstanding participants from programs such as the International Mentorship Program, the IASLC Academy, Education Award winners, IASLC Foundation grant recipients, and many more.

This is a moment to applaud the dedication, innovation, and promise of early career researchers who are shaping the future of lung cancer science and care. Enjoy a meal, connect with peers, and be part of a celebration of excellence and emerging talent in the global fight against thoracic cancers.

12:00 – 13:00 INDUSTRY SPONSORED SYMPOSIUM*See page 229 for more information.***13:00 - 14:15 WS03.02 - EARLY CAREER INVESTIGATOR WORKSHOP - PART 2****ROOM 03****NOT FOR CME CREDIT***Chair: Zhaohui Arter, USA***13:00 Welcome & Introduction***Zhaohui Arter, USA***13:03 WS03.02.02 - Boosting My Career: How IASLC Grants Made a Difference***Biagio Ricciuti, USA***13:08 WS03.02.03 - IASLC Grant Workshop: Small Group Discussion**

Panelists: Jose Benítez, France, Roberto Ferrara, Italy, Alessio Cortellini, Italy, Tianhong Li, USA, Biagio Ricciuti, USA, Masaaki Ito, Japan, Luiz Araujo, Brazil, Celine Mascaux, France, Christina Baik, USA, Lyudmila Bazhenova, USA, Balazs Halmos, USA, Triparna Sen, USA

13:53 Group Learning and Q&A*Zhaohui Arter, USA**The Early Career Investigator Workshop will continue at 14:30.***13:00 - 16:00 WS06.02 - 2025 IASLC CT SCREENING SYMPOSIUM
(TICKETED SESSION) - CONTINUATION****ROOM 08****NOT FOR CME CREDIT**

Chairs: Rudolf Huber, Germany, Catherine Jones, Australia, Antoni Rosell, Spain, Betty Tong, USA, Milena Cavic, Serbia

13:00 Introduction to Session 3: Downstream Effects of Screening Implementation*Betty Tong, USA***13:05 WS06.02.02 - Medical Imaging (CT/PET)***Sally Ayesa, Australia***13:15 WS06.02.03 - Endoscopic Techniques***Antoni Rosell, Spain***13:25 WS06.02.04 - Radiotherapy (Non-Surgical Treatments)***Suresh Senan, Netherlands***13:35 WS06.02.05 - Surgical Treatments***Chi-Fu Jeffrey Yang, USA***13:45 Q&A****14:10 Break****14:20 Introduction to Session 4: Alternative Methods for Early Detection of Lung Cancer***Milena Cavic, Serbia***14:25 WS06.02.06 - Exhaled Air and Blood-Based Biomarkers***Stephen Lam, Canada***14:35 WS06.02.07 - Artificial intelligence and Radiomics for Chest X-Rays and CTs***Catherine Jones, Australia***14:45 WS06.02.08 - Incidental Pulmonary Nodules***Helmut Prosch, Austria***14:55 Q&A****15:10 Group Discussion****15:50 Conclusion****13:00 - 16:00 WS09 - IASLC & ITONF: NURSE & AHP WORKSHOP****ROOM 07****NOT FOR CME CREDIT**

Chairs: Michelle Turner, USA, Caitlin Broderick, Australia, Katherine Kuhns, USA, Nicole Kiss, Australia, Melanie Rabbets, Australia, Mary Duffy, Australia

13:00 Welcome & Introduction*Michelle Turner, USA and Caitlin Broderick, Australia***13:05 WS09.02 Welcome to: Pillar 1 Introduction, Advances in Treatment, Latest Updates & Innovations***Katherine Kuhns, USA***13:10 WS09.03 - Advances in Medical Markers: Latest Insights & Applications***Michelle Turner, USA***13:25 WS09.04 - From Trial to Treatment: Educational Support Across the Care Continuum, Bridging Knowledge Gaps for Nurses from Research to Standard of Care Application***Amanda Kluxen, USA*

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

- 13:40 WS09.05 - Radiation Toxicity: Advances in Management & Prevention**
Gerard Hanna, Ireland
- 14:05 Q&A**
Caitlin Broderick, Australia
- 14:05 WS09.06 - Welcome to: Pillar 2 Introduction, Living Well with Cancer: Managing Life Beyond Diagnosis**
Nicole Kiss, Australia
- 14:10 WS09.07 - Supporting & Educating Patients Following Curative Treatments: Understanding the Risk of Recurrence**
Charlotte Smith, UK
- 14:25 WS09.08 - Immunotherapy: The Silent Struggles, Coping with Long Term Toxicities**
Stephanie McDonald, USA
- 14:40 WS09.09 - Taking the Fear Out of Dying: Discussions with Your Patients**
Maria Ftanou, Australia
- 14:55 Networking Break**
- 15:15 WS09.10 - Introduction**
Melanie Rabbets, Australia
- 15:20 WS09.11 - International Comparison of Lung Cancer Screening**
Hannah Jongebloed, Australia
- 15:30 WS09.12 - The Interface Between the Nurse and the Pharmacist, Dentist, Nutritionist & Psychologist**
Gisele Farias, Brazil
- 15:40 WS09.13 - Microbiome Study: Key Findings & Next Steps**
Gisele Fraga, Brazil
- 15:50 WS09.14 - Nurse-Led Self-Management Education to Improve Cancer Patient Treatment Adherence in Ethiopia: Mixed Methods, Experience-Based Co-design PhD Research**
Dejen Alem, Ethiopia
- 16:00 WS09.15 - Summary & Close**
Mary Duffy, Australia

13:00 - 14:15 WS10 - DEBATES, DISCUSSIONS & DIDACTICS ON SCIENCE COMMUNICATIONS IN 2025

ROOM 09

NOT FOR CME CREDIT

Chairs: Jarushka Naidoo, Ireland and Matthew Smeltzer, USA

- 13:00 Welcome & Introduction**
Jarushka Naidoo, Ireland and Matthew Smeltzer, USA
- 13:02 WS10.02 - Combatting Misinformation in Science**
Solange Peters, Switzerland
- 13:12 WS10.03 - Debate: Is Social Media No Longer an Appropriate Platform for Scientific Discourse? YES**

- 13:17 WS10.04 - Debate: Is Social Media No Longer an Appropriate Platform for Scientific Discourse? NO**
Stephen Liu, USA
- 13:22 WS10.05 - Discussion: Picking a Platform: Twitter/X, LinkedIn, Bluesky, TikTok, Weibo, or the Good Old-Fashioned Podium?**
Panelists: Hidehito Hironouchi, Japan, Eric Singhi, USA, Stephen Liu, USA, Solange Peters, Switzerland
- 13:37 WS10.06 - Not-So-Lost in Translation: How To Break Down a Scientific Message**
Tony Mok, China
- 13:47 WS10.07 - Debate: Are Print Journals Prehistoric? YES**
Ana Velazquez Manana, USA
- 13:52 WS10.08 - Debate: Are Print Journals Prehistoric? NO**
Martin Edelman, USA
- 13:57 WS10.09 - Discussion: How Will AI Revolutionize Science Communications**
Panelists: Tony Mok, China, Martin Edelman, USA, Fiona Hegi-Johnson, Australia, Ana Velazquez Manana, USA, Annabelle Gurwitch, USA

13:00 - 15:00 WS11 - AI USAGE FOR RADIATION ONCOLOGY: WHERE ARE WE AND WHERE WILL WE GO?

ROOM 10

NOT FOR CME CREDIT

Chair: Daniel Przybysz, Brazil

Workshop Faculty: Daniel Przybysz, Brazil, Léo Franco, Spain, Eric Talbot, USA, William Kennedy, USA

13:00 - 15:00 WS12 - GGO MANAGEMENT AND TREATMENT - INTRAOPERATIVE ELECTROMAGNETIC NAVIGATION BRONCHOSCOPY (ENB) GUIDED MARKING AND MINIMALLY INVASIVE RESECTION

ROOM 12

NOT FOR CME CREDIT

Chairs: Stefan Watzka, Austria and Thomas Klikovits, Austria

- 13:00 Welcome & Introduction**
Stefan Watzka, Austria and Thomas Klikovits, Austria

Part 1: Lectures

- 13:05 WS12.02 - Diagnostic Work-up of GGOs (Pathological Correlation, Radiology, Diagnostic Principals)**
Stefan Watzka, Austria
- 13:25 WS12.03 - Importance of Minimally Invasive Surgery for Early-Stage Lung Cancer Including GGO**
Didier Schneider, Switzerland
- 13:45 WS12.04 - ENB Basics and Marking Techniques**
Thomas Klikovits, Austria

Part 2: Practical Aspects

- 14:05 WS12.05 - Group 1: ENB Planning According to 2 Real-Life Cases - How We Do It**
Thomas Klikovits, Austria
- 14:25 WS12.06 - Group 2: Demonstration of ENB Tools (Fiducial Marker, Injection)**
Lisa Schulte, Austria
- 14:45 Q&A**

HOD Highlight of the Previous Day
HOW Hands-On Workshop
MA Mini Oral Abstract Session
OA Oral Abstract Session

P Poster
PT Poster Tour
PL Plenary
WS Workshop

13:30 – 14:30 INDUSTRY SPONSORED SYMPOSIUM

See page 230 for more information.

13:30 – 14:30 SATELLITE CME SYMPOSIUM

See page 231 for more information.

14:30 – 16:00 WS03.03 - EARLY CAREER INVESTIGATOR WORKSHOP - PART 3

ROOM 03

NOT FOR CME CREDIT

Chair: Ticiana Leal, USA

- 14:30** **Welcome & Introduction**
Ticiana Leal, USA
- 14:33** **WS03.03.02 - How to Successfully Publish Your Manuscript: Winning Over Reviewer #2**
Jennifer Carlisle, USA
- 14:43** **WS03.03.03 - Tips & Pearls for Delivering an Oral Presentation**
Natasha Leighl, Canada
- 14:53** **WS03.03.04 - Using AI Tools to Streamline Presentation Creation**
Arsela Prelaj, Italy
- 15:03** **Q&A**
- 15:13** **WS03.03.05 - Panel Discussion: Expert Insights on Publishing and Presentations**
Moderator: Ticiana Leal, USA
Panelists: William William Jr., Brazil, Junko Tanizaki, Japan, Vanita Noronha, USA, Kenneth O'Byrne, Australia, Tannia Soria, Ecuador
- 15:48** **Q&A**

14:30 – 16:00 WS13 - LATAM WORKSHOP

ROOM 06

NOT FOR CME CREDIT

Chairs: Lucia Viola, Colombia and Luis Raez, USA

- 14:30** **Welcome & Introduction**
Lucia Viola, Colombia and Luis Raez, USA
- 14:32** **WS13.02 - Implementation of EBUS and Minimal Invasive Surgery in LATAM How Far We Have Gone?**
Stella Martínez, Colombia
- 14:42** **WS13.03 - How We Can Use Artificial Intelligence To Improve Lung Cancer Screening in LATAM**
Gilberto de Castro, Brazil
- 14:52** **WS13.04 - Progress in Molecular Testing in Latin America, Where We Are Now?**
Isabella Barcelos Favato, Brazil

- 15:02** **WS13.05 - Improving Clinical Research in Latin America**
Maria Clara Rodriguez, Uruguay
- 15:12** **WS13.06 - How We Can Increase Scientific Collaborations and Publications in LATAM**
Pedro Aguiar Jr., Brazil
- 15:22** **WS13.07 - Performance of Lung Nodule and Cancer Risk Calculators in Identifying Primary Lung Cancer Across Screening and Incidental Nodule Populations**
Francisco Sarmento Neto, Brazil
- 15:27** **WS13.08 - Drug Repurposing for Metastatic Lung Adenocarcinoma Therapy Using AI-Guided Single-Cell Gene Expression Profiles**
Maria Raquel Fernandes, Brazil
- 15:32** **WS13.09 - Lung Cancer's Price Tag: Escalating Hospitalization Costs in Brazil Over the Past Two Decades**
Jean Henri Maselli Schoueri, Brazil
- 15:37** **WS13.10 - Abstract Discussion**
Carlos Aliaga, Peru
- 15:47** **Q&A**

14:30 – 16:00 WS14 - FROM GUIDELINES TO IMPLEMENTATION IN NSCLC: PERTINENT CONSIDERATIONS OF ADHERENCE TO CONSENSUS STANDARDS OF CARE IN CLINICAL PRACTICE

ROOM 09

NOT FOR CME CREDIT

Chair: Daniel Gomez, USA

- 14:30** **Welcome & Introduction**
Daniel Gomez, USA
- Part 1: Pertinent Considerations in the Development of International Guidelines**
- 14:32** **WS14.02 - NCCN Guidelines**
Gregory Riely, USA
- 14:42** **WS14.03 - ESMO Guidelines**
Sanjay Popat, UK
- 14:52** **WS14.04 - CHEST Guidelines**
Douglas Arenberg, USA
- 15:02** **WS14.05 - Themes and Differences Between Methodologies and Approaches**
Daniel Gomez, USA
- Part 2: The IASLC Approach of "Common Sense Oncology" - Applying Guidelines in Low-Resourced Regions and Unique Clinical Contexts**
- 15:09** **WS14.06 - Definitive Management of Patients of Special Populations**
Jyoti Malhotra, USA
- 15:16** **WS14.07 - Brain Metastases**
Irina Veytsman, USA
- 15:23** **WS14.08 - Oligometastatic Lung Cancer**
Nagla Karim, USA
- 15:30** **Q&A**

Part 3: Patient and Guideline Panel Discussion and Perspective

15:35 **WS14.09 - Panel Discussion**
Moderator: Daniel Gomez, USA
Panelists: Gregory Riely, USA, Sanjay Popat, UK, Douglas Arenberg, USA, Nagla Karim, USA, Irina Veytsman, USA, Jyoti Malhotra, USA, Jim Pantelas, USA

15:00 – 16:00 **SATELLITE CME SYMPOSIUM**

See page 232 for more information.

16:15 - 17:45 **PL01 - OPENING PLENARY WITH DISTINGUISHED SERVICE AWARDS - TRANSFORMING LUNG CANCER THROUGH SOCIETAL PROGRESS**

PLENARY HALL

 **LIVESTREAMED**

 **NOT FOR CME CREDIT**

Chairs: Noemi Reguart, Spain and Umberto Malapelle, Italy

PL01.01 - Welcome Remarks

PL01.02 - IASLC Distinguished Service Award Presentations

PL01.03 - From Smoking to Solutions: Advancing Tobacco Control for Better Lung Health in Europe
Filippos Filippidis, UK

PL01.04 - The Bridge Between Art and Medicine
Giovanna Cassese, Italy

PL01.05 - Playing for a Cause: How Sport Can Inspire Progress in Lung Cancer
Ricky Rubio, Spain

17:45 – 18:45 **PRESS CONFERENCE**

ROOM CC7 AB

 **NOT FOR CME CREDIT**

17:45 – 19:15 **WELCOME RECEPTION**

EXHIBIT HALL

 **REFRESHMENTS PROVIDED**



SUNDAY, SEPTEMBER 7, 2025

HOD Highlight of the Previous Day
HOW Hands-On Workshop
MA Mini Oral Abstract Session
OA Oral Abstract Session

P Poster
PT Poster Tour
PL Plenary
WS Workshop

08:15 - 10:30 **PL02 - PRESIDENTIAL SYMPOSIUM 1 WITH LECTURESHIP AWARD PRESENTATIONS**

PLENARY HALL

 **LIVESTREAMED**

 **NOT FOR CME CREDIT**

Chairs: Paul Van Schil, Belgium and Heather Wakelee, USA

PL02.01 - Robert J. Ginsberg Lectureship Award for Surgery
Andrea Wolf, USA

PL02.02 - James D. Cox Lectureship Award for Radiation Oncology
Suresh Senan, Netherlands

PL02.03 - IASLC Lectureship Award for Tobacco Control and Smoking Cessation
Lawson Eng, Canada

PL02.04 - First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC: FLAURA2 Final Overall Survival
David Planchard, France

PL02.05 Discussant
Daniel Tan, Singapore

Q&A

PL02.06 - Aumolertinib plus Chemotherapy for NSCLC with EGFR and Concomitant Tumor Suppressor Genes (ACROSS 2): Phase III Study
Jie Wang, China

PL02.07 Discussant
Jordi Remon, Spain

Q&A

PL02.08 - Iponescimab vs Placebo Plus Chemo, Phase 3 in Patients with EGFR+ NSCLC Progressed with 3rd gen EGFR-TKI Treatment: HARMONI
Jonathan Goldman, USA

PL02.09 Discussant
Suresh Ramalingam, USA

Q&A

PL02.10 - Pivotal ARROS-1 Efficacy and Safety Data: Zidesantinib in TKI Pre-treated Patients with Advanced/Metastatic ROS1+ NSCLC
Alexander Drilon, USA

PL02.11 Discussant
Anne-Marie Dingemans, Netherlands

Q&A

HOD Highlight of the Previous Day
HOW Hands-On Workshop
MA Mini Oral Abstract Session
OA Oral Abstract Session

P Poster
PT Poster Tour
PL Plenary
WS Workshop

PL02.12 - Phase 3 Trial of Crizotinib vs Observation for Surgically Resected Early-Stage ALK+ NSCLC

David Gerber, USA

PL02.13 Discussant

Jessica Lin, USA

Q&A

10:30 - 12:00 POSTER VIEWING BREAK WITH P1 PRESENTERS IN ATTENDANCE

EXHIBIT HALL



REFRESHMENTS PROVIDED



NOT FOR CME CREDIT

Track 04: Screening and Early Detection

Rows: 01-06

Track 07: Early-Stage Non-small Cell Lung Cancer

Rows: 06-12

Track 11: Metastatic Non-small Cell Lung Cancer – Immunotherapy

Rows: 12-20

Track 17: Global Health, Health Services, and Health Economics

Rows: 20-28

10:45 - 11:30 NON-PROFIT PRESENTATION

See page 235 for more information.

10:45 - 11:45 ANNOUNCING THE IASLC-LANCET COMMISSION ON LUNG CANCER: A TRANSFORMATIVE GLOBAL APPROACH

ROOM 10



SPECIAL SESSION



NOT FOR CME CREDIT

Chairs: Karen Kelly, USA and Vania Wisdom, UK

10:45 Welcome & Introduction

Karen Kelly, USA and Vania Wisdom, UK

10:47 The Global Burden of Lung Cancer: An Urgent and Escalating Crisis

David J. Hunter, UK

10:57 The Power of Lancet Commissions in Shaping Global Health

Vania Wisdom, UK

11:02 Partnership for Impact – IASLC and The Lancet

Karen Kelly, USA

11:07 The Vision for the IASLC-Lancet Commission on Lung Cancer

C S Pramesh, India

11:17 Panel Discussion and Audience Questions

David J. Hunter, UK, Vania Wisdom, UK, Karen Kelly, USA, C S Pramesh, India, Mei Ling Yap, Australia, Caleb Ekwuenu, Nigeria, William William, Brazil

10:45 - 11:45 PRESS CONFERENCE

ROOM CC7 AB



NOT FOR CME CREDIT

12:00 - 13:15 ES01 - IMMUNOTHERAPY PARTNERS: EXCITING AND CHALLENGING RELATIONSHIPS

Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy



ACCME ACCREDITED BY IASLC

ROOM 08

Chairs: Edward Garon, USA and Anne-Marie Dingemans, Netherlands

12:00 Welcome & Introduction

Edward Garon, USA and Anne-Marie Dingemans, Netherlands

12:02 ES01.01 - Tobacco Awareness Moment: Lung Cancer Outcomes in the Setting of Smoking and Immunotherapy

Abhishek Shankar, India

12:05 ES01.02 - Dangerous Relationships: Immune Checkpoint Inhibitors and Steroids, Proton-Pump Inhibitors and Antibiotics/Probiotics

Naoki Furuya, Japan

12:17 ES01.03 - New Relationships: Bispecifics Combining (Dual) Immune Checkpoints and Other Targets

Giannis Mountzios, Greece

12:29 ES01.04 - A Unique Relationship: Microbiome and Immunotherapy

Misako Nagasaka, USA

12:41 ES01.05 - Considering Toxicity and Quality of Life Issues with Novel Immunotherapeutic Agents: The Patient's Perspective

Seamus Cotter, Ireland

12:53 Q&A

12:00 - 13:15 ES02 - USING PRECLINICAL MODELS TO TACKLE THE THERAPEUTIC CHALLENGES IN LUNG CANCER

Track: Tumor Biology – Preclinical Biology



ACCME ACCREDITED BY IASLC

ROOM 05

Chairs: Triparna Sen, USA and Montse Sanchez-Cespedes, Spain

12:00 Welcome & Introduction

Triparna Sen, USA and Montse Sanchez-Cespedes, Spain

12:02 ES02.01 - Rare Molecular Alterations in Lung Cancer

Guilherme Harada, Brazil

12:09 Discussion

12:19 ES02.02 - Leveraging Preclinical Models To Decipher Heterogeneity and Plasticity in SCLC

Esra Akbay, USA

12:26 Discussion

HOD Highlight of the Previous Day
HOW Hands-On Workshop
MA Mini Oral Abstract Session
OA Oral Abstract Session

P Poster
PT Poster Tour
PL Plenary
WS Workshop

12:36 ES02.03 - Identification of the HER2-ADC Sensitivity Determinant Using a 3D Co-Culture System

Ryohei Katayama, Japan

12:43 Discussion

12:53 ES02.04 - Mapping the Tumour Microenvironment in NSCLC Across Space and Time

Mihaela Angelova, UK

13:00 Discussion

13:10 Q&A

12:00 - 13:15 ES03 - SCLC: THE KNOWN AND UNKNOWN IN EVERYDAY PRACTICE WITH EXPERT INSIGHTS

Track: Small Cell Lung Cancer and Neuroendocrine Tumors



ROOM 07

Chairs: Luis Paz-Ares, Spain and Junko Tanizaki, Japan

12:00 Welcome & Introduction

Luis Paz-Ares, Spain and Junko Tanizaki, Japan

12:02 ES03.01 - Panel Discussion

Panelists: Afshin Dowlati, USA, Suresh Senan, Netherlands, Sabina Berezowska, Switzerland, Kate Sinclair, UK

12:50 Q&A

12:00 - 13:15 ES04 - JOINT IASLC - GLCC ADVOCACY SESSION: OVERCOMING CHALLENGES TO ENSURE BETTER OUTCOMES FOR PEOPLE LIVING WITH LUNG CANCER

ROOM 09

Chairs: Carolyn Aldige, USA and Kim Norris, USA

12:00 Welcome & Introduction

Jesme Fox, UK and Kim Norris, USA

12:02 ES04.01 - Reading a Clinical Trials Paper - Clinical Trial Stages and Assessing Response. What do Advocates Need to Know?

Emily Stone, Australia

12:12 ES04.02 - Success in the England Lung Cancer Screening Program. What Learnings for Advocates of Other Screening Programs in Development?

Richard Lee, UK

12:22 ES04.03 - Informing and Supporting Those on Long Term Systemic Therapies - Addressing Psychosocial Issues and Common Long Term Adverse Effects

Bernard Gaspar, Spain

12:32 ES04.04 - Stigma and Negativity in Lung Cancer. Is There Cause for Optimism?

Maureen Rigney, USA

12:42 ES04.05 - The IASLC STARS Program. Impacting a Generation of Lung Cancer Research Advocates
Andrew Ciupek, USA

12:52 Q&A

12:00 - 13:15 ES05 - HOW WE DO LUNG CANCER SCREENING

Track: Screening and Early Detection



ROOM 04

Chairs: David Baldwin, UK and Douglas Wood, USA

12:00 Welcome & Introduction

David Baldwin, UK and Douglas Wood, USA

12:02 ES05.01 - Tobacco Awareness Moment: Read Out on the Smoking Cessation at Lung Examination

Jamie Ostroff, USA

12:05 ES05.02 - Screening and Early Detection of Lung Cancer in High-Risk Populations: Insights from Regions with China's Highest Lung Cancer Morbidity and Mortality Rates

Long Jiang, China

12:17 ES05.03 - Lung Cancer Screening in Individuals with a Family History of Lung Cancer

Alison Chang, USA

12:29 ES05.04 - Maximizing Benefit from Incidental Findings

Rozemarijn Vliegthart, Netherlands

12:41 ES05.05 - The Use of Robotic Bronchoscopy: Screening and Therapy in One Procedure?

Pallav Shah, UK

12:53 Q&A

12:00 - 13:15 HOW01 - RADIATION ONCOLOGY CONTOURING WORKSHOP - LOCALLY ADVANCED NSCLC #1 (PRE-SIGN UP REQUIRED FOR CASE ASSIGNMENTS)

NOTE: DELEGATES ARE REQUIRED TO BRING THEIR LAPTOP



ROOM 11 *This session will be repeated today from 15:15 to 16:30.*

Chairs: Alexander Louie, Canada and Fiona Hegi-Johnson, Australia and Hongcheng Zhu, China

12:00 Welcome & Introduction

Alexander Louie, Canada and Fiona Hegi-Johnson, Australia and Hongcheng Zhu, China

HOW01.01 - Can EBUS Results in a Seismic Shift in Radiation Volumes

Melody Qu, Canada

HOW01.02 - Management Options for Neoadjuvant ChemoIO Patients Who Do Not Proceed to Surgery

Houda Bahig, Canada

HOW01.03 - Is There Still a Role for Post-Operative Radiotherapy?

Said Al Saifi, Oman

HOD Highlight of the Previous Day
HOW Hands-On Workshop
MA Mini Oral Abstract Session
OA Oral Abstract Session

P Poster
PT Poster Tour
PL Plenary
WS Workshop

12:00 - 13:15 MA01 - NEW DRUGS AND STRATEGIES IN LOCALLY ADVANCED NSCLC

Track: Local-Regional Non-small Cell Lung Cancer


ROOM 01

Chairs: Joe Chang, USA and Feng-Ming Kong, Hong Kong

- 12:00 Welcome & Introduction**
 Joe Chang, USA and Feng-Ming Kong, Hong Kong
- 12:02 MA01.01 - Surgical Outcomes and Oncological Quality of Surgery According to IASLC Criteria in NADIM II Trial**
 Jose Jarabo, Spain
- 12:07 MA01.03 - Metabolomic Analysis Identifies Histamine as a Key Predictive Factor for Perioperative Chemoimmunotherapy in NADIM II Trial**
 Pilar Mediavilla-Medel, Spain
- 12:12 Q&A**
- 12:17 MA01.04 - Neoadjuvant PD-(L)1 Blockade in Combination with Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer**
 Biagio Ricciuti, USA
- 12:25 MA01.05 - Tislelizumab Plus Chemotherapy Followed by Surgery or Radiotherapy and Adjuvant Tislelizumab in Unresectable Stage III NSCLC**
 Jiewei Liu, China
- 12:30 MA01.06 - Phase I/II Trial of Canakinumab with Chemoradiation and Durvalumab in Stage III Non-Small Cell Lung Cancer (ChHORUS)**
 Narek Shaverdian, USA
- 12:35 Q&A**
- 12:43 MA01.07 - Preliminary Results of the Phase I LuCa-MERIT-1 Trial: An Advanced NSCLC pt Cohort Treated with BNT116 + Cemiplimab Post CRT**
 Akin Atmaca, Germany
- 12:48 MA01.08 - Sequential Chemo-SaBr Following by Immunotherapy in Unresectable LA-NSCLC Unfit for Concurrent ChT-RT According to the START-NEW-ERA Trial**
 Paola Anselmo, Italy
- 12:53 Q&A**

12:00 - 13:15 MA02 - NEW TREATMENT STRATEGIES IN OTHER THAN EGFR-POSITIVE TUMORS

Track: Metastatic Non-small Cell Lung Cancer - Target Therapy


ROOM 02

Chairs: Xiuning Le, USA and Jon Zugazagoitia, Spain

- 12:00 Welcome & Introduction**
 Xiuning Le, USA and Jon Zugazagoitia, Spain

- 12:02 MA02.01 - Contemporary Landscape of Acquired Resistance to Next-Generation ALK Inhibitors: Paired Pre-/Post-Treatment Biopsy Analysis**
 Sarah Waliany, USA
- 12:07 MA02.02 - Updated Efficacy and Safety of Talrectinib in Patients with ROS1+ Non-small Cell Lung Cancer: The Global TRUST-II Study**
 Geoffrey Liu, Canada
- 12:12 MA02.03 - Repotrectinib in Patients with ROS1 Fusion-Positive (ROS1+) NSCLC: Long-Term Follow-Up from the Phase 1/2 TRIDENT-1 Trial**
 Byoung Chul Cho, Republic of Korea
- 12:35 Q&A**
- 12:43 MA02.04 - Updated Efficacy, Safety, and Genomic Data in Patients with Trk Fusion Lung Cancer Treated with Larotrectinib**
 Jessica Lin, USA
- 12:30 MA02.05 - Liquid Biopsy in BRAF V600E NSCLC Treated With Dabrafenib Plus Trametinib: Final Analysis of LIBRA Study (GOIRC-03-2020)**
 Alessandro Leonetti, Italy
- 12:40 Q&A**
- 12:48 MA02.06 - Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01**
 Melissa Johnson, USA
- 12:48 MA02.07 - Efficacy and Safety of GFH375 in Advanced Non-small Cell Lung Cancer Patients with KRAS G12D Mutation**
 Ziming Li, China
- 12:53 MA02.08 - Upfront Management of Brain Metastases (BM) in Oncogene-Addicted NSCLC Treated With Targeted Therapies: An EORTC Survey**
 Ana Ortega-Franco, UK
- 12:58 Q&A**

12:00 - 13:15 OA01 - SMOKING AND BEYOND: NAVIGATING RISK FACTORS IN LUNG CANCER

Track: Risk Factors, Risk Reduction & Tobacco Control


ROOM 03

Chairs: Angeline Low, Australia and Nir Peled, Israel

- 12:00 Welcome & Introduction**
 Angeline Low, Australia and Nir Peled, Israel
- 12:02 OA01.01 - Genetic and Air Pollution Scores Identify Individuals at Elevated Risk in a Lung Cancer Screening Cohort**
 Lianne Trap, Netherlands
- 12:12 OA01.02 - The Mirror Study: Tumor Microenvironment (TME) in Patients with Non-small Cell Lung Cancer Exposed to Indoor Radon +/- Tobacco Smoke**
 Marta Garcia de Herreros, Spain
- 12:22 OA01.03 - Lung Cancer Among People Who Never Smoked: Global Epidemiology and Initial Identification of Early Detection Biomarkers**
 Hilary Robbins, France

HOD Highlight of the Previous Day
HOW Hands-On Workshop
MA Mini Oral Abstract Session
OA Oral Abstract Session

P Poster
PT Poster Tour
PL Plenary
WS Workshop

12:32 OA01.04 - Investigating the Association Between Procedure Duration of Coronary Angiography and Intervention and Postoperative Cancer Risk
YiShen Chen, China

12:42 OA01.05 - Discussant
Mahdi Sheikh, France

12:52 Q&A

12:00 - 13:15 OA02 - LATEST DIAGNOSTIC AND MANAGEMENT OPTIONS TO IMPROVE SURVIVAL OUTCOMES IN EARLY-STAGE RESECTABLE NON-SMALL CELL LUNG CANCER

Track: Early-Stage Non-small Cell Lung Cancer

NOT FOR CME CREDIT

ROOM 06

Chairs: Heather Wakelee, USA and René Petersen, Denmark

12:00 Welcome & Introduction
Heather Wakelee, USA and René Petersen, Denmark

12:02 OA02.01 - SKYSCRAPER-05: Phase II Study of Perioperative Tiragolumab + Atezolizumab ± Chemotherapy in Locally Advanced Resectable NSCLC
Catherine Shu, USA

12:12 OA02.02 - Molecular Residual Disease (MRD) Analysis from NeoADAURA: Neoadjuvant Osimertinib ± Chemotherapy in Resectable EGFRm NSCLC
Collin Blakely, USA

12:22 OA02.03 - Overall Survival (OS) with Neoadjuvant Nivolumab Plus Chemotherapy by Surgical Outcomes in the Phase 3 CheckMate 816 Study
Tetsuya Mitsudomi, Japan

12:32 OA02.05 - Discussant
Joshua Reuss, USA

12:42 Q&A

13:15 - 15:15 Lunch Break

Exhibit Hall

LUNCH PROVIDED

13:45 - 14:45 HW01 - WORK-LIFE HARMONY: REDEFINING BALANCE IN THE DEMANDING FIELD OF ONCOLOGY

ROOM 12

Chair: Sandip Patel, USA

13:45 Welcome & Introduction
Sandip Patel, USA

13:50 HW01.01 - Leadership's Role in Building Work-Life Harmony: Departmental Strategies to Support Oncology Professionals
Maria Rosario Campelo, Spain

LUNCH PROVIDED

NOT FOR CME CREDIT

14:05 HW01.02 - Breaking the Myth of Perfect Balance: Navigating the Trade-offs in High-Stress Medical Careers
Mark Awad, USA

14:20 Q&A

13:45 - 14:45 INDUSTRY SPONSORED SYMPOSIA

See page 233 for more information.

14:15 - 15:00 POSTER TOURS

EXHIBIT HALL/EPOSTER LOUNGE

NOT FOR CME CREDIT

Note: Each Poster Tour will include 4 - 5 Posters (8min per Poster: 3min presentation by the Poster Presenter, followed by 2min Discussion by the Poster Lead and 3min Audience Q&A).

Poster Tour: PT1.01 - Risk Factors, Risk Reduction and Tobacco Control

ePOSTER LOUNGE STATION 1

Tour Lead: Ugo Pastorino, Italy

14:15 PT1.01.01 - Large Language Models to Extract Smoking History from Clinical Notes in EHR to Evaluate Lung Cancer Surveillance Strategies
TaeYoon Lee, USA

14:23 PT1.01.02 - Temporal Analysis of Smoking Profiles in Brazil Among Lung Cancer Patients and the Impact of 25 Years of Public Policies
Bruna Rezende, Brazil

14:31 PT1.01.03 - IMPRINT-Lung: Single-Arm, Multi-Center Phase II Trial of Immunotherapy With Pembrolizumab for Interception of High-Risk Lung Nodules
Jianjun Zhang, USA

Poster Tour: PT1.02 - Tumor Biology - Preclinical Biology

ePOSTER LOUNGE STATION 2

Tour Lead: David P. Carbone, USA

14:15 PT1.02.01 - Targeting NOX1/4-YAP/TEAD-CD47 Axis Promotes Macrophage Phagocytosis and Potentiates Radiotherapy Antitumor Efficacy in NSCLC
Xiaorong Dong, China

14:23 PT1.02.02 - Novel Organoid Models of Patient-Derived Lung Cancer in Decellularized Mouse Lung Tissue
Roya Navab, Canada

14:31 PT1.02.03 - GBC-11004: An AI-Driven Novel Kinase Target with Potential to Overcome Osimertinib Resistance in NSCLC
Jihye Ryu, Republic of Korea

14:39 PT1.02.04 - Mapping Gene-Environment Interactions Driving Small Cell Lung Cancer (SCLC) Initiation in Human Airway Organoids
Andrés Marco, Spain

Poster Tour: PT1.03 - Tumor Biology - Translational Biology

ePOSTER LOUNGE STATION 3

Tour Lead: Ucero Alvaro, Spain

14:15 PT1.03.01 - Precision Medicine Platform to Guide the Treatment of NSCLC
Sofia Merajver, USA

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

- 14:23** PT1.03.02 - Single-Cell Profiling of Tumor Lineage Plasticity and the Immune Microenvironment in Transformed Small Cell Lung Cancer
Jie Huang, China
- 14:31** PT1.03.03 - Drug Repurposing for Metastatic Lung Adenocarcinoma Therapy Using AI-Guided Single-Cell Gene Expression Profiles
Maria Raquel Fernandes, Brazil
- 14:39** PT1.03.04 - VIKTOR - the Virtual International Knowledgebase for Thoracic Oncology Research of the IASLC
Ferdinando Cerciello, Switzerland
- 14:47** PT1.03.05 - An AI-Based Predictive Tool for Druggable Mutations in Lung Cancer Using Nationwide Comprehensive Genomic Profiling Data
Hiroaki Ikushima, Japan
- Poster Tour: PT1.04 - Screening and Early Detection** ePOSTER LOUNGE STATION 4
Tour Lead: Chi-Fu Jeffrey Yang, USA
- 14:15** PT1.04.01 - Incidental Pulmonary Nodule Programs (IPN) Working Together with LDCT Scans and Artificial Intelligence (AI) Increase Lung Cancer Detection
Luis Raez, USA
- 14:23** PT1.04.02 - Performance of Lung Nodule and Cancer Risk Calculators in Identifying Primary Lung Cancer Across Screening and Incidental Nodule Populations
Francisco Sarmento Neto, Brazil
- 14:31** PT1.04.03 - The LEAP Study: A Biospecimen Bank for Validation of Liquid Biomarkers in a Lung Cancer Screening Cohort
Edwin Ostrin, USA
- 14:39** PT1.04.04 - Biomarker-Based Eligibility for Lung Cancer Screening - Validation of Protein-Based INTEGRAL-Risk Model in the LC3 Consortium
Mattias Johansson, France
- 14:47** PT1.04.05 - Subclassification of Abnormal Cells into Precancerous and Malignant Categories Based on 3D Cellular Imaging
Michael Meyer, USA
- Poster Tour: PT1.05 - Pulmonology and Staging** ePOSTER LOUNGE STATION 5
Tour Lead: Kwun Fong, Australia
- 14:15** PT1.05.01 - Impact of Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy on Next-Generation Sequencing
Kenya Sato, Japan
- 14:23** PT1.05.02 - Development of an AI Image Analysis System for Malignancy Classification in Rapid On-Site Cytologic Evaluation of Lung Cancer
Tetsuya Sakai, Japan
- 14:31** PT1.05.03 - Comparison Between Lymph Node Station- and Zone-Based Classification: Analysis With the 9th IASLC Node Descriptors in Surgically Resected NSCLC
Shia Kim, Republic of Korea

- 14:39** PT1.05.04 - Use of an Ultrathin Bronchoscope with a Larger Working Channel Enhances Diagnostic Yield in Cone-Beam CT-Guided Transbronchial Biopsy
Naoya Kawakita, Japan
- Poster Tour: PT1.06 - Pathology and Biomarkers** ePOSTER LOUNGE STATION 6
Tour Lead: Keith Kerr, UK
- 14:15** PT1.06.01 - ERBB2 (HER2) Fusions in Lung Cancer Are Targetable by Anti-HER2 Small Molecules and Antibody-Drug Conjugates
Marc Ladanyi, USA
- 14:23** PT1.06.02 - Distinct Bronchoalveolar Lavage Fluid Microbiome and Metabolome Profiles in EGFR-Mutated and Wild-Type Non-Small Cell Lung Cancer
Lv Wu, China
- 14:31** PT1.06.03 - Loss of MTAP Expression in Thymic Carcinomas: Insights From a Retrospective Multi-Institutional, Global Study
Anja Roden, USA
- 14:39** PT1.06.04 - Signatures of Functional CD8 T, Marginal Zone/Memory B and NK Cells in PBMC Predict Survival in NSCLC Patients Receiving Chemoimmunotherapy
Jialei Wang, China
- 14:47** PT1.06.05 - Enhancing Spread Through Air Spaces Diagnosis Using AI Diagnostician: A Multi-Center Study
Hongmei Wu, China
- Poster Tour: PT1.07 - Early-Stage Non-small Cell Lung Cancer** ePOSTER LOUNGE STATION 7
Tour Lead: Nasser Khaled Altorki, USA
- 14:15** PT1.07.01 - IASLC Multidisciplinary Recommendations for Pathological Response Evaluation of Resected Lymph Nodes After Neoadjuvant Therapy in NSCLC
Sabina Berezowska, Switzerland
- 14:23** PT1.07.02 - Neoadjuvant Ensartinib for ALK-Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC): A Multicenter, Real-World Study
Xi Zhang, China
- 14:31** PT1.07.03 - Adjuvant Osimertinib in IB-IIIB NSCLC with Uncommon EGFR Mutations (Admin): Mutation Profile and ctDNA Dynamics
Chengwu Liu, China
- 14:39** PT1.07.04 - Radiomics Model Based on Synthesized PET for Predicting Neoadjuvant Therapy Pathologic Response in NSCLC (CPT-LC-NEO Trial)
Maotao Weng, China
- Poster Tour: PT1.08 - Local-Regional Non-small Cell Lung Cancer** ePOSTER LOUNGE STATION 8
Tour Lead: Alona Zer, Israel
- 14:15** PT1.08.01 - Neoadjuvant Almonertinib Followed by Chemo-Immunotherapy in II-IIIB EGFR-TKI, Interim Analysis of a Single Arm, Phase II Study (NEOVADE)
Jun-tao Lin, China
- 14:23** PT1.08.02 - 5-Y Outcomes of Stereotactic Ablative Radiotherapy in 101 Unresectable LA-NSCLC Patients: The START-NEW-ERA Phase II Trial
Fabio Arcidiacono, Italy
- 14:31** PT1.08.03 - Chemoradiation/Immunotherapy (IO) for Stage III NSCLC: Timing of IO, and the Benefits/Selection in Elderly & Black Patients
John Varlotto, USA

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

- 14:39 PT1.08.04 - Cachexia in Patients with Unresectable Stage III NSCLC**
Cristina Muñoz-Pinedo, Spain
- 14:47 PT1.08.05 - Radioresistance of NSCLC Tumors Is Mediated by Immunosuppressive Cell Populations. Strategies to Sensitize Tumors by Targeting Innate Immunity**
Sergio León, Spain
- Poster Tour: PT1.09 - Metastatic Non-small Cell Lung Cancer - Local Therapies** **ePOSTER LOUNGE STATION 9**
Tour Lead: Hossein Borghaei, USA
- 14:15 PT1.09.01 - Chemoradiotherapy Plus Tislelizumab in Advanced or Metastatic NSCLC: A Prospective, Multicenter, Phase II Study**
Sheng Lin, China
- 14:23 PT1.09.02 - Double Lung Transplantation in Patients with Metastatic Lung-Limited Non-small Cell Lung Carcinoma (NSCLC): A Case Series**
Young Kwang Chae, USA
- 14:31 PT1.09.03 - Dormant Tumor Maintenance and Immune Evasion in Induced Oligometastatic Lung Cancer**
Rui Fu, China
- 14:39 PT1.09.04 - Incomplete Cryoablation Promotes Recurrence and Progression of KRAS-Driven Lung Adenocarcinoma via the NF κ B-CCL20-MAPK/MEK/ERK Axis**
Zeyi Liu, China
- 14:47 PT1.09.05 - Preclinical Safety Assessment of a Conformable Electrode for Bronchoscopy-Guided Radiofrequency Ablation**
Min Jee Kim, Republic of Korea

15:15 - 16:30 WHAT DO THIS YEAR'S POLICY DEVELOPMENTS IN LUNG CANCER MEAN FOR YOU?

ROOM 12



Chair: *Helena Wilcox, UK*

- 15:15 Welcome & Introduction**
Helena Wilcox, UK
- 15:20 IASLC Global Policy Report: A New Tool to Monitor and Inform Policy**
Andreas Charalambous, Cyprus
- 15:25 Global Commitment Begins with Consensus: Aligning Efforts and Strengthening National Implementation**
Mary Bussell, USA
- 15:30 The Asia Pacific Lung Cancer Consensus Statement and Priorities for the Region**
Herbert Loong, China
- 15:35 Integration of Smoking Cessation Support in the Setting of Lung Cancer Screening**
Mahdi Sheikh, France
- 15:40 IARC Handbooks Volume 21: Lung Cancer Screening**
Xiaoshuang Feng, France

- 15:45 The Lung Health Resolution: Taking an Integrated Approach to Lung Cancer**
Yannick Romero, Switzerland
- 15:50 Q&A**
- 16:25 Closing Remarks**
Helena Wilcox, UK

15:15 - 16:30 ES07 - ADVANCED EGFR MUTANT NSCLC TREATMENT OPPORTUNITIES AND LEPTOMENINGEAL DISEASE IN ONCOGENE DRIVEN NSCLC

Track: *Metastatic Non-small Cell Lung Cancer - Targeted Therapy*



ROOM 02

Chairs: *Sewanti Limaye, India and Laura Book, USA*

- 15:15 Welcome & Introduction**
Sewanti Limaye, India and Laura Book, USA
- 15:17 ES07.01 - Treatment Options for Common Sensitizing EGFR Mutant Advanced NSCLC?**
Jessica Menis, Italy
- 15:29 ES07.02 - Treatment Option for Uncommon EGFR and EGFR ex20ins Advanced NSCLC?**
Aaron Tan, Singapore
- 15:41 ES07.03 - Treatment Options for Sequencing EGFR/ALK Treatments? Mechanisms of Resistance**
Rossana Ruiz, Peru
- 15:53 ES07.04 - Leptomeningeal Disease in Oncogene Driven NSCLC: Diagnostic and Treatment Opportunities**
Helena Yu, USA
- 16:05 Q&A**

15:15 - 16:30 ES08 - NAVIGATING THE SPECTRUM OF OLIGOMETASTATIC DISEASE IN NSCLC

Track: *Metastatic Non-small Cell Lung Cancer - Local Therapies*



ROOM 01

Chairs: *Wen-Zhao Zhong, China and Pablo Munoz Schuffenegger, Chile*

- 15:15 Welcome & Introduction**
Wen-Zhao Zhong, China and Pablo Munoz Schuffenegger, Chile
- 15:17 ES08.01 - Decoding Oligometastatic NSCLC: Ready to Molecular Classification?**
Raphael S Werner, Germany
- 15:29 ES08.02 - Understanding Multiple Classifications: Definitions and Patient Selection in Focus**
Qing Zhou, China
- 15:41 ES08.03 - Tobacco Awareness Moment: Lung Cancer Outcomes in the Setting of Smoking and Radiotherapy**
Jacek Jassem, Poland
- 15:44 ES08.04 - Precision Radiotherapy & Strategic Approaches in OM disease**
Chiaojung Jillian Tsai, Canada

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

15:56 ES08.05 - Survivorship in the Oligometastatic State
Annabelle Gurwitsch, USA

16:08 Q&A

15:15 - 16:30 ES09 - WHAT ARE THE BEST PRACTICES FOR INVASIVE STAGING FOR NSCLC IN THE ERA OF CHEMO-IMMUNOTHERAPY?

Track: Pulmonology and Staging



ROOM 04

Chairs: Motoko Tachihara, Japan and Zeno Gouw, Netherlands

15:15 Welcome & Introduction
Motoko Tachihara, Japan and Zeno Gouw, Netherlands

15:17 ES09.01 - Challenges and Limitations of Nodal Staging in TNM
James Huang, USA

15:29 ES09.02 - EBUS and Optimal Staging for Clinical N0-N1 NSCLC
Tracey Leong, Australia

15:41 ES09.03 - Restaging After Neoadjuvant Therapy - PRO
Sergi Call, Spain

15:53 ES09.04 - Restaging After Neoadjuvant Therapy - CON
Sanjay Popat, UK

16:05 Q&A

15:15 - 16:30 ES10 - NAVIGATING MULTIDISCIPLINARY CARE: THE POWER OF COMMUNICATION IN A PATIENT'S JOURNEY

Track: Patient Advocacy



ROOM 03

Chairs: Caleb Egwuenu, Nigeria and Upal Basu Roy, USA

15:15 Welcome & Introduction
Caleb Egwuenu, Nigeria and Upal Basu Roy, USA

15:17 ES10.01 - Voices of Experience: A Young Patient's Key Communication Moments
Sydney BARNED, USA

15:27 ES10.02 - ERAS/ Pre-Operative Assessment. Is It Really Patient-Centered?
Aki Kobayashi, Japan

15:37 ES10.03 - Patient Preferences and Discussion in Lung Cancer Screening Participation
David Chi-Leung, China

15:47 ES10.04 - Handling Difficult Conversations in Lung Cancer Care: Case Scenarios
Ornagh Kestell, Ireland, Rasheda Persinger, USA

15:57 Q&A

15:15 - 16:30 ES11 - OPTIMAL MANAGEMENT OF EARLY STAGE PLEURAL MESOTHELIOMA - CASE SCENARIOS AND INNOVATIVE MANAGEMENT STRATEGIES

Track: Mesothelioma, Thymoma, and Other Thoracic Tumors



ROOM 05

Chairs: Ritu Gill, USA and Ivy Ng, Singapore

15:15 Welcome & Introduction
Ritu Gill, USA and Ivy Ng, Singapore

15:17 ES11.01 - Chemotherapy for PM-End of an Era?
Federica Grosso, Italy

15:29 ES11.02 - Innovating the Local Approach: SMART Radiotherapy
John Cho, Canada

15:41 ES11.03 - What Happens When the Diagnosis Defies the Golden Rules?
Malgorzata Szolkowska, Poland

15:53 ES11.04 - Surgery in MPM: Convincing or Conditional?
Marc de Perrot, Canada

16:05 ES11.05 - How to Navigate the Patient at the Heart of Care
Melissa Culligan, USA

16:17 Q&A

15:15 - 16:30 ES12 - VAPING TO STOP, VAPING TO START

Track: Risk Factors, Risk Reduction & Tobacco Control



ROOM 07

Chairs: Silvia Novello, Italy and Olalekan Ayo-Yusuf, South Africa

15:15 Welcome & Introduction
Silvia Novello, Italy and Olalekan Ayo-Yusuf, South Africa

15:17 ES12.01 - Other Than Cigarette: The Other Tools. Status of the Art
Enrica Capelletto, Italy

15:25 ES12.02 - eCig as Valid Aid to Stop
Rachael Murray, UK

15:33 ES12.03 - eCig and Health Outcomes: Epidemiological and Public Health Challenges
Pawan Kumar Singh, India

15:41 ES12.04 - eCig Versus Other Tools/Methods to Stop Smoking
Nicola Lindson, UK

15:49 Round Table

HOD Highlight of the Previous Day
HOW Hands-On Workshop
MA Mini Oral Abstract Session
OA Oral Abstract Session

P Poster
PT Poster Tour
PL Plenary
WS Workshop

15:15 - 16:30 HOW02 - *REPEAT SESSION* RADIATION ONCOLOGY CONTOURING WORKSHOP - LOCALLY ADVANCED NSCLC #2 (PRE-SIGN UP REQUIRED FOR CASE ASSIGNMENTS)

NOTE: **DELEGATES ARE REQUIRED TO BRING THEIR LAPTOP**

NOT FOR CME CREDIT

ROOM 11

Chairs: Alexander Louie, Canada and Fiona Hegi-Johnson, Australia and Hongcheng Zhu, China

- 12:00 Welcome & Introduction**
 Alexander Louie, Canada and Fiona Hegi-Johnson, Australia and Hongcheng Zhu, China
- HOW02.01 - Can EBUS Results in a Seismic Shift in Radiation Volumes**
 Melody Qu, Canada
- HOW02.02 - Management Options for Neoadjuvant ChemoIO Patients Who Do Not Proceed to Surgery**
 Houda Bahig, Canada
- HOW02.03 - Is There Still a Role for Post-Operative Radiotherapy?**
 Said Al Saifi, Oman

15:15 - 16:30 MA03 - NEW ADVANCES IN CIRCULATING BIOMARKERS

Track: Pathology and Biomarkers

NOT FOR CME CREDIT

ROOM 06

Chairs: Ross Juergens, Canada and Ming Tsao, Canada

- 15:15 Welcome & Introduction**
 Ross Juergens, Canada and Ming Tsao, Canada
- 15:17 MA03.01 - Ultrasensitive MRD Improves Detection in Resectable Stage I NSCLC**
 Zachary Coyne, Canada
- 15:22 MA03.02 - Clinical Performance of a Tumor Informed Whole Genome Based ctDNA Assay for Predicting Recurrence in Early-Stage Resectable NSCLC**
 Gaston Becharano, USA
- 15:27 MA03.03 - SAVANNAH: Biomarker Concordance and Acquired Resistance to Osi+Savo in Patients with EGFRm MET-OverExp and/or Amp NSCLC**
 Christina Baik, USA
- 15:32 Q&A**
- 15:40 MA03.04 - Comparative Analysis of Circulating Tumor DNA Monitoring Strategies in Advanced NSCLC With MET Exon 14 Skipping Treated with Ensartinib**
 Yang Xia, China
- 15:45 MA03.05 - Circulating Tumor DNA Tumor Fraction as a Precision Biomarker for Radiotherapy in Oligometastatic NSCLC**
 Kaushal Parikh, USA

- 15:50 MA03.06 - Intrathecal Pemetrexed for Lung Adenocarcinoma Leptomeningeal Metastasis: A Study on Efficacy and Liquid Proteomics**
 Xiaorong Dong, China
- 15:55 Q&A**
- 16:03 MA03.07 - Multi-Omic Analyses of CSF Reveal Genomic Instability and Suppressed Microenvironment After TKI Resistance in Patients with Brain Metastases**
 Meichen Li, China
- 16:08 MA03.08 - Identification of Circulating microRNA Signature for Diagnosis and Prognosis of Checkpoint Inhibitor-Related Pneumonitis**
 Haiyi Deng, China
- 16:13 MA03.09 - Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive-Stage Small Cell Lung Cancer**
 Yinghui Xu, China
- 16:18 Q&A**

15:15 - 16:30 OA03 - UNRAVELLING TUMOR EVOLUTION AND BOOSTING IMMUNOTHERAPY EFFICACY

Track: Tumor Biology - Translational Biology

NOT FOR CME CREDIT

ROOM 08

Chairs: Ignacio Wistuba, USA and John Le Quesne, UK

- 15:15 Welcome & Introduction**
 Ignacio Wistuba, USA and John Le Quesne, UK
- 15:17 OA03.01 - Multiomic Single Cell Profiling Reveals Novel Evolutionary Trajectories in Lung Carcinogenesis**
 Huizhao Hong, China
- 15:27 OA03.02 - Deciphering Genomic Evolution of Metastatic Organotropism with Large-Scale Paired Primary Lung Cancers and Metastases**
 Wen-Fang Tang, China
- 15:37 OA03.03 - Rilevegostomig Enhances Ex Vivo Immune Activation in Patient-Resected NSCLC Tumors Over PDX or PDX/aTIGIT Combination Therapy**
 Jeremy Ratiu, USA
- 15:47 OA03.04 - TNFSF8-Targeting CpG Peptide Vaccine Reduces ICB Pneumonitis While Boosting Cancer Immunotherapy Efficacy**
 Zi-Xuan Rong, China
- 15:57 OA03.05 - Discussant**
 Yi-Long Wu, China
- 16:07 Q&A**

HOD Highlight of the Previous Day
HOW Hands-On Workshop
MA Mini Oral Abstract Session
OA Oral Abstract Session

P Poster
PT Poster Tour
PL Plenary
WS Workshop

15:15 - 16:30 OA04 - FROM AI TO PSYCHOSOCIAL SUPPORT: NEW FRONTIERS IN LUNG CANCER MULTIDISCIPLINARY CARE

Track: Multidisciplinary care: Nursing, Allied Health and Palliative Care



ROOM 09

Chairs: Stephanie McDonald, USA and Juan Carlos Laguna, Spain

- 15:15 Welcome & Introduction**
Stephanie McDonald, USA and Juan Carlos Laguna, Spain
- 15:17 OA04.01 - Perceptions of Dyspnea and Quality of Life Before and After Lung-Sparing Surgery: A Pilot Mixed Methods Study**
Melissa Culligan, USA
- 15:27 OA04.02 - Implementation of Large Language Model and GraphRAG-Assisted Decision Support for Multidisciplinary Team Cancer Care**
Su Chen, China
- 15:37 OA04.03 - Association of Pre- and Postdiagnosis Physical Activity, Promotion, and Maintenance with Lung Cancer Survival: A Nationwide Cohort Study**
Yeon Wook Kim, Republic of Korea
- 15:47 OA04.04 - Resiliency Among Older Adults Receiving Lung Cancer Treatment (ROAR-LCT): A Phase II - RCT Supportive Care Intervention**
Carolyn Presley, USA
- 15:57 OA04.05 - Discussant**
Andreas Charalambous, Cyprus
- 16:07 Q&A**

16:45 - 18:00 ES06 - JOINT IASLC-ESTRO SESSION: SAFETY AND SYNERGY OF RADIOTHERAPY IN EGFR AND ALK NSCLC

ROOM 09



Chairs: Houda Bahig, Canada and Gerard Walls, UK

- 16:45 Welcome & Introduction**
Houda Bahig, Canada and Gerard Walls, UK
- 16:47 ES06.01 - Recent and Ongoing Clinical Trials**
Shankar Siva, Australia
- 16:59 ES06.02 - Best Practices with Brain Metastases**
Kevin Chua, Singapore
- 17:11 ES06.03 - Timing and Toxicity with Radiation and Targeted Therapies**
Florence Katie Keane, USA
- 17:23 ES06.04 - Case-based Considerations and Controversies**
Michael Tjong, Canada
- 17:35 Q&A**

16:45 - 18:00 ES13 - HOW WELL DO YOU KNOW YOUR ADCS?

Track: Metastatic Non-small Cell Lung Cancer - Cytotoxic Therapy



ROOM 01

Chairs: Alfredo Addeo, Switzerland and Francesco Cortiula, Netherlands

- 16:45 Welcome & Introduction**
Alfredo Addeo, Switzerland and Francesco Cortiula, Netherlands
- 16:47 Contestants**
Ross Jeurgens, Canada, Alessandra Curioni, Switzerland, Herbert Loong, China, Leonardo Rojas, Colombia
- 17:35 Q&A**

16:45 - 18:00 ES14 - MULTIOMIC SPATIAL BIOLOGY, LIQUID BIOPSY

Track: Tumor Biology - Translational Biology



ROOM 03

Chairs: Caroline Dive, UK and Milena Cavic, Serbia

- 16:45 Welcome & Introduction**
Caroline Dive, UK and Milena Cavic, Serbia
- 16:47 ES14.01 - Patient Derived Tumor Fragments**
Krijn Dijkstra, UK
- 16:59 ES14.02 - Multiomic Spatial Biology**
Kurt Schalper, USA
- 17:11 ES14.03 - Tobacco Awareness Moment: Nicotine and Tumor Growth and Metastasis of Lung Cancer**
Courtney Granville, USA
- 17:14 ES14.04 - Methylation Analysis as an Integrative Tool for Early Detection**
Chaimaa Mounjid, Morocco
- 17:26 ES14.05 - Next Generation Liquid Biopsies**
Atocha Romero, Spain
- 17:38 Q&A**

16:45 - 18:00 ES15 - LOCAL INTERVENTIONS FOR EARLY STAGE NON-SMALL CELL LUNG CANCER

Track: Early-Stage Non-small Cell Lung Cancer



ROOM 08

Chairs: Gavitt Woodard, USA and William William, Brazil

- 16:45 Welcome & Introduction**
Gavitt Woodard, USA and William William, Brazil
- 16:47 ES15.01 - Expanding the Role of Radiation Therapy**
Drew Moghanaki, USA
- 16:59 ES15.02 - Percutaneous Ablation**
Carole Ridge, UK
- 17:11 ES15.03 - Endobronchial Ablation**

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

Joyce Chan, China

17:23 ES15.04 - Novel Interventional Bronchoscopic Techniques
Thomas Gaisl, Switzerland

17:35 Q&A

16:45 - 18:00 ES16 - IMPROVING OUTCOMES FROM LUNG CANCER GLOBALLY: WHERE EVERYONE'S VOICE MATTERS

Track: Global Health, Health Services, and Health Economics



ROOM 05

Chairs: Valerie Rusch, USA and Raymond Osarogiagbon, USA

16:45 Welcome & Introduction
Valerie Rusch, USA and Raymond Osarogiagbon, USA

16:47 ES16.01 - Round Table Discussion 1: Overcoming Global Challenges to Diagnostics and Molecular Testing for Lung Cancer
Michael Boyer, Australia, Yishan Chuang, USA, Rodrigo Dientsmann, Spain, Matthew Evison, UK

17:12 ES16.02 - Key Takeaways (Panel 1)
Clarissa Mathias, Brazil

17:17 ES16.03 - Round Table Discussion 2: Improving Access to Novel Targeted and Immunotherapy Drugs for Lung Cancer in LMICs
Shankar Prinja, India, Annie Wong, New Zealand, Jill Feldman, USA

17:42 ES16.04 - Key Takeaways (Panel 2)
Navneet Singh, India

17:47 Q&A

16:45 - 18:00 ES17 - UPDATES ON LUNG CANCER PATHOLOGY

Track: Pathology and Biomarkers



ROOM 07

Chairs: Luisella Righi, Italy and Soo-Ryum Yang, Japan

16:45 Welcome & Introduction
Luisella Righi, Italy and Soo-Ryum Yang, Japan

16:47 ES17.01 - Pulmonary or Not Pulmonary? The Diagnosis of Cancer of Unknown Primary (CUP) on a Small Sample (Biopsy or Cytology)
Kenzo Hiroshima, Japan

16:59 ES17.02 - Advances in Grading of NSCLC
Andre Moreira, USA

17:11 ES17.03 - Tobacco Awareness Moment: Smoking Status and Biomarkers of Lung Cancer Prognosis
Mahdi Sheikh, France

17:14 ES17.04 - Pitfalls in the Diagnosis of Lung Cancer
Giuseppe Pelosi, Italy

17:26 ES17.05 - WHO Reporting System for Lung Cytopathology
Lukas Bubendorf, Switzerland

17:38 Q&A

16:45 - 18:00 ES18 - NAVIGATING THE CHALLENGES OF LOCALLY ADVANCED NSCLC

Track: Local-Regional Non-small Cell Lung Cancer



ROOM 04

Chairs: Juan Carlos Trujillo, Spain and Doloros Isla, Spain

16:45 Welcome & Introduction
Juan Carlos Trujillo, Spain and Doloros Isla, Spain

16:47 ES18.01 - Resectability: Defining the Indefinable in Lung Cancer Surgery
Jon Villena, USA

16:59 ES18.02 - Integrating Radiation Therapy in the Era of Neoadjuvant Immunotherapy: Strategies and Synergies
Alexander Louie, Canada

17:11 ES18.03 - Advancing Targeted Approaches in Stage III NSCLC: EGFR and Beyond
Ibiayi Dagogo-Jack, USA

17:23 ES18.04 - Raising the Bar: Optimizing Immunotherapy in Unresectable Stage III NSCLC
Francesco Passiglia, Italy

17:35 Q&A

16:45 - 18:00 OA05 - IMMUNOTHERAPY FOR SPECIAL POPULATIONS

Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy



ROOM 06

Chairs: Federico Cappuzzo, Italy and Jane Sui, Ireland

16:45 Welcome & Introduction
Federico Cappuzzo, Italy and Jane Sui, Ireland

16:47 OA05.01 - ASTRUM-002: First-Line Serplulimab Plus Chemotherapy With or Without HLX04 in Advanced Nonsquamous Non-small Cell Lung Cancer
Yuankai Shi, China

16:57 OA05.04 - A Randomized Phase 3 Study of Niraparib Plus Pembrolizumab as Maintenance Therapy for Advanced/Metastatic NSCLC: ZEAL-1L
Solange Peters, Switzerland

17:07 OA.05 - Discussant
Hossein Borghaei, USA

17:13 OA05.02 - First-Line Atezolizumab Plus Chemotherapy in Elderly Patients with Advanced NSCLC, IFCT-1805 Elderly: A Randomized, Multicenter, Phase 3 Trial
Céline Mascaux, France

17:23 OA05.03 - NIVIPI-Brain: Phase 2 Study of Nivolumab + Ipilimumab Combined with Chemotherapy in NSCLC With Synchronous Brain Metastases
Ernest Nadal, Spain

HOD Highlight of the Previous Day
HOW Hands-On Workshop
MA Mini Oral Abstract Session
OA Oral Abstract Session

P Poster
PT Poster Tour
PL Plenary
WS Workshop

17:33 OA05.05 - Discussant
Lizza Hendriks, Netherlands

17:39 Q&A

16:45 - 18:00 OA06 - NOVEL ADCs IN SCLC

Track: *Small Cell Lung Cancer and Neuroendocrine Tumors*

NOT FOR CME CREDIT

ROOM 02

Chairs: Jhanelle Gray, USA and Raffaele Califano, UK

16:45 Welcome & Introduction
Jhanelle Gray, USA and Raffaele Califano, UK

16:47 OA06.01 - A First-In-Human Phase 1 Study of SHR-4849 (IDE849), a DLL3-Directed Antibody-Drug Conjugate, in Relapsed SCLC
Linlin Wang, China

16:57 OA06.02 - Safety and Efficacy of QLC5508 in Previously Treated Patients with Small Cell Lung Cancer: Updated Data from a Phase 1 Study
Caicun Zhou, China

17:07 OA06.03 - Ifinatamab Deruxtecan (I-DXd) in Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase 2 IDEate-Lung01 Study
Myung-Ju Ahn, Republic of Korea

17:17 OA06.04 - Safety and Efficacy of ABBV-706, a Seizure-related Homolog Protein 6-targeting Antibody-drug Conjugate, in R/R SCLC
Lauren Byers, USA

17:27 OA06.05 - Discussant
Tatsuya Yoshida, Japan

17:37 Q&A

16:45 - 18:15 WS15 - SYBIL: USING A DEEP LEARNING MODEL TO PREDICT LUNG CANCER RISK IN THE REAL WORLD

ROOM 10

NOT FOR CME CREDIT

Chair: Lecia Sequist, USA

16:45 Welcome and Introduction
Lecia Sequist, USA

16:50 WS15.02 - Sybil Implementation Consortium
Raymond Osarogiagbon, USA

16:58 WS15.03 - Technical Aspects of Sybil Installation
Florian Fintelmann, USA

17:13 WS15.04 - Real World Experience
Mary Pasquinelli, USA

17:18 WS15.05 - Real World Experience
Pan Chyr Yang, Taiwan

17:23 WS15.06 - Real World Experience
William Mayfield, USA

17:28 WS15.07 - Real World Experience
Stephen Lam, Canada

17:33 WS15.08 - Panel Discussion
Chang Allison, USA, Peter Mikhael, USA, Jill Feldman, USA, Raymond Osarogiagbon, USA, Florian Fintelmann, USA, Mary Pasquinelli, USA, Pan Chyr Yang, Taiwan, William Mayfield, USA, Stephen Lam, Canada

18:00 - 20:30 THE BACKYARD STEPS EXPERIENCE

A charitable initiative from The Ricky Rubio Foundation during the IASLC World Conference on Lung Cancer as part of the IASLC Wellness Challenge. Let's climb the stairs to Montjuïc together! Bus transfers will be provided at 18:00 from the following pick up points:

18:00 FIRA Gran Via, North Entrance, Hall 8, Meeting Point: Wellness Challenge Counter, Registration Area, Ground Floor
18:00 Hotel Porta Fira
18:00 Hotel Melia Sarria
18:00 Hotel Nobu
18:00 INNSIDE Barcelona Apolo

Return transfers to above listed points will be provided (except FIRA Gran Via).

For more information, visit: <https://therickyrubiofoundation.org/reto-backyard/#K18>

18:30 - 19:30 INDUSTRY SPONSORED SYMPOSIUM

See page 234 for more information.

18:30 - 19:30 SATELLITE CME SYMPOSIUM

See page 235 for more information.

19:30 - 22:00 FACULTY DINNER (BY INVITATION ONLY)



IASLC |  | 2025 World Conference
on Lung Cancer
SEPTEMBER 6-9, 2025 | BARCELONA, SPAIN



CLOSING LUNCH

Not So Trivial: A WCLC Interdisciplinary Quiz Challenge

Don't miss it!

A dynamic and engaging session where some of the field's most renowned names go head-to-head in a spirited competition. It is the perfect way to close out the Conference with great food and high energy!



Hall 6 – Plenary Hall



Tuesday, September 9 14:15 – 15:45



04

PROGRAM:
MONDAY

IASLC 2025 WORLD CONFERENCE ON LUNG CANCER
CONQUERING LUNG AND OTHER THORACIC CANCERS WORLDWIDE IN THE 21ST CENTURY.

MONDAY, SEPTEMBER 8, 2025

HOD Highlight of the Previous Day
HOW Hands-On Workshop
MA Mini Oral Abstract Session
OA Oral Abstract Session

P Poster
PT Poster Tour
PL Plenary
WS Workshop

08:30 – 10:30 **PL03 - PRESIDENTIAL SYMPOSIUM 2 WITH LECTURESHIP AWARD PRESENTATIONS**

PLENARY HALL

LIVESTREAMED **NOT FOR CME CREDIT**

Chairs: Alex Adjei, USA and Caicun Zhou, China

PL03.01 - Tsuguo Naruke Lectureship Award for Surgery

Kazuhiro Yasufuku, Canada

PL03.02 - Heine H. Hansen Lectureship Award for Small Cell Lung Cancer

Ying Cheng, China **IN MEMORIAM**

PL03.03 - Incoming and Outgoing IASLC President's Address

Paul Van Schil, Belgium and Caicun Zhou, China

PL03.04 - EA5181: Phase 3 Trial of Concurrent and Consolidative Durvalumab vs Consolidation Durva Alone for Unresectable Stage 3 NSCLC

John Varlotta, USA

PL03.05 - Hypofractionated vs Conventional Fractionated Radiotherapy With Concurrent Chemotherapy for LS-SCLC: A Multi-Center Phase III Trial

Nan Bi, China

PL03.06 Discussant

Corinne Faivre-Finn, UK

Q&A

PL03.07 - Adjuvant Chemotherapy (CT) vs CT-immunotherapy for R0 Stage IB-IIIA NSCLC Patients (NADIM ADJUVANT): A Randomized, Phase 3 Trial

Mariano Provencio, Spain

PL02.08 Discussant

Tina Cascone, USA

Q&A

PL03.09 - Survival Outcome of VATS Compared to Open Lobectomy for Lung Cancer: An Individual Patient Data Meta-analysis of Randomised Trials

Jacie Law, UK

PL02.10 Discussant

Ayumi Suzuki, Japan

Q&A

PL03.11 - Spread Through Airspaces (STAS) and Prognosis in the Phase III JCOG0802/WJOG4607L Trial of Segmentectomy vs Lobectomy in NSCLC

Yasushi Yatabe, Japan

PL03.12 Discussant

Luisella Righi, Italy

Q&A

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

PL03.13 - Comparing 74 vs 80 as the Upper Age Limit for Lung Cancer Screening: A Multi-Centre Cohort Study
Patrick Goodley, UK

PL03.14 Discussant
Pan Chyr Yang, Taiwan

Q&A

10:30 – 12:00 POSTER VIEWING BREAK WITH P2 PRESENTERS IN ATTENDANCE

EXHIBIT HALL



Track 02: Tumor Biology – Preclinical Biology	Rows: 01-05
Track 05: Pulmonology and Staging	Rows: 05-07
Track 06: Pathology and Biomarkers	Rows: 07-17
Track 08: Local-Regional Non-small Cell Lung Cancer	Rows: 17-23
Track 10: Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy	Rows: 23-25
Track 15: Multidisciplinary Care: Nursing, Allied Health and Palliative Care	Rows: 25-28

10:45 – 11:45 HOD01 - HIGHLIGHTS OF THE DAY - SUNDAY ABSTRACTS

EXHIBIT HALL/EPOSTER LOUNGE



10:45	HOD01.01 - Lung Cancer Risk Factors and Tumor Biology <i>Christian Rolfo, USA</i>
10:55	HOD01.02 - Early-Stage Non-small Cell Lung Cancer <i>Pierre Emanuel Falcoz, France</i>
11:05	HOD01.03 - Metastatic Non-small Cell Lung Cancer - Immunotherapy <i>Federico Cappuzzo, Italy</i>
11:15	HOD01.04 - ADCs for SCLC <i>Lauren Byers, USA</i>
11:25	HOD01.05 - Presidential Symposium Abstract Highlights (Sunday) <i>Martin Reck, Germany</i>

10:45 – 11:45 PRESS CONFERENCE

ROOM CC7 AB



10:45 – 11:45 THE WHO INTEGRATED LUNG HEALTH RESOLUTION: WHAT IT IS AND WHY IT MATTERS TO THE LUNG CANCER COMMUNITY

ROOM 10



Chair: Karen Kelly, USA

10:45 Welcome & Objectives
Karen Kelly, USA

10:47 Supporting the WHO Lung Health Resolution and Next Steps for Impact
Yannick Romero, Switzerland

10:57 Multidisciplinary Panel Discussion: Translating Policy into Practice
Panelists: Jesme Fox, UK, David Baldwin, UK, Wen-Zhao Zhong, China, Samuel Kareff, USA, Andrea Bezjak, Canada, Claudia Henschke, USA, Yasushi Yatabe, Japan, Andreas Charalambous, Cyprus

11:32 Q&A

11:42 Closing Remarks & Call to Action
Karen Kelly, USA

12:00 – 13:15 HOW03 - ROBOTIC NAVIGATIONAL BRONCHOSCOPY WORKSHOP #1 (LIMITED CAPACITY - FIRST COME FIRST SERVED)

ROOM 11 *This workshop will be repeated today 15:30 - 16:45.*



Workshop Faculty: Thomas Gaisl, Switzerland and Gian-Marco Monsch, Switzerland

12:00 – 13:15 ES19 - HOW TO IMPROVE EFFICACY OF IMMUNOTHERAPY IN METASTATIC NSCLC?

Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy



ROOM 06

Chairs: Delvys Rodriguez-Abreu, Spain and Ola Khorsid, Egypt

12:00	Welcome & Introduction <i>Delvys Rodriguez-Abreu, Spain and Ola Khorsid, Egypt</i>
12:02	ES19.01 - Combining Novel Immune Checkpoint Inhibitors Is the Way to Go <i>Melissa Johnson, USA</i>
12:14	ES19.02 - Combining ICIs With ADCs Is the Way to Go <i>Sun-Min Lim, Republic of Korea</i>
12:26	ES19.03 - Combining ICIs with Molecular Targeted Agents Is the Way to Go <i>Rafael Rosell, Spain</i>
12:38	ES19.04 - Combining ICIs With Novel Immunotherapeutics (Vaccines, Cellular Immunotherapy) <i>Vamsidhar Velcheti, USA</i>
12:50	Q&A

HOD Highlight of the Previous Day
HOW Hands-On Workshop
MA Mini Oral Abstract Session
OA Oral Abstract Session

P Poster
PT Poster Tour
PL Plenary
WS Workshop

12:00 - 13:15 ES20 - LEVERAGING OMICS TO UNDERSTAND THE BIOLOGY OF LUNG CANCER

Track: Tumor Biology – Preclinical Biology



ROOM 05

Chairs: Guilherme Harada, Brazil and A El Halali, China

12:00 Welcome & Introduction

Guilherme Harada, Brazil and A El Halali, China

12:02 ES20.01 - Therapeutic Strategies to Tackle Specific Tumor Suppressor Gene Alteration Contexts

Montse Sanchez, Spain

12:14 ES20.02 - Revealing New Vulnerabilities in Lung Adenocarcinoma Using Proteomics

Antonio Maraver, France

12:26 ES20.03 - Liquid Biopsy Using ctDNA Methylation to Subtype Small Cell Lung Cancer

Caroline Dive, UK

12:38 ES20.04 - The Preclinical Genomics of Lung Cancer Plasticity and Metastasis

Triparna Sen, USA

12:50 Q&A

12:00 - 13:15 ES21 - WHAT WE NEED TO KNOW ABOUT LUNG NEUROENDOCRINE NEOPLASMS (NENS): INSIGHTS FROM A MULTIDISCIPLINARY PERSPECTIVE

Track: Small Cell Lung Cancer and Neuroendocrine Tumors



ROOM 04

Chairs: Claudio Martin, Argentina and José Trigo, Spain

12:00 Welcome & Introduction

Claudio Martin, Argentina and José Trigo, Spain

12:02 ES21.01 - NEN, NET, or NEC? Clarifying Classification Through the Pathologist's Lens

Marina Baine, USA

12:14 ES21.02 - What We Need to Know About the Molecular Spectrum of NENs

Jules Derks, Netherlands

12:26 ES21.03 - Defining the Role of Surgery in the Management of Thoracic NENs

Keiju Aokage, Japan

12:38 ES21.04 - Advances on Systemic Therapy for Lung NENs Beyond SCLC

Jaume Capdevila, Spain

12:50 Q&A

12:00 - 13:15 ES22 - ADDING VALUE TO LUNG CANCER CARE: MULTIDISCIPLINARY TOXICITY MANAGEMENT FOR NEW THERAPIES

Track: Multidisciplinary Care: Nursing, Allied Health & Palliative Care

ROOM 03

Chairs: Santiago Viteri, Spain and Caitlin Broderick, Australia

12:00 Welcome & Introduction

Santiago Viteri, Spain and Caitlin Broderick, Australia

12:02 ES22.01 - Antibody Drug Conjugates

Beth Sandy, USA

12:14 ES22.02 - Targeted Therapies

Gisele Fraga Moreira, Brazil

12:26 ES22.03 - Immunotherapy

Jorgina Serra López, Spain

12:38 ES22.04 - Innovating AI for Toxicity Monitoring

Loïc Verlingue, France

12:50 Q&A

12:00 - 13:15 ES23 - ENHANCING EFFICIENCY AND QUALITY IN SCREENING PROGRAMS

Track: Screening and Early Detection



ROOM 07

Chairs: Jeffrey Yang, USA and Hecheng Li, China

12:00 Welcome & Introduction

Jeffrey Yang, USA and Hecheng Li, China

12:02 ES23.01 - Exploring What Matters to Patients in Screening and Early Detection Programs

Satoko Yamaoka, Japan

12:19 ES23.02 - Radiology Standards in Nodule Management

Anand Devaraj, UK

12:36 ES23.03 - How to Reach the Target Population and Maximize Uptake

Renda Wiener, USA

12:53 ES23.04 - How to Run an Efficient Screening Review Meeting

Emma O'Dowd, UK

13:10 Q&A

HOD Highlight of the Previous Day
HOW Hands-On Workshop
MA Mini Oral Abstract Session
OA Oral Abstract Session

P Poster
PT Poster Tour
PL Plenary
WS Workshop

12:00 - 13:15 ES24 - JOINT IASLC - ASCO SESSION: TERMINATING LUNG CANCER: HARNESSING AI TO TRANSFORM THE BATTLE TO CONQUER LUNG CANCER

ROOM 09



Chairs: Courtney Coschi, Canada and Vincenzo L'Imperio, Italy

- 12:00 Welcome & Introduction**
 Courtney Coschi, Canada and Vincenzo L'Imperio, Italy
- 12:02 ES24.01 - Code Against Cancer: From Big Data to Big Impact in Lung Cancer Care**
 Sandip Patel, USA
- 12:17 ES24.02 - Reading Between the Slices: AI Revolution in Radiology**
 Yeon Wook Kim, Republic of Korea
- 12:27 ES24.03 - Smarter Than Your Average Slide: How AI Is Rewriting the Diagnostic Playbook**
 Vincenzo L'Imperio, Italy
- 12:37 ES24.04 - Smart Drugs, Smarter Science: The AI Revolution in Cancer Therapeutics**
 Maria Chiara Garassino, USA
- 12:47 ES24.05 - Panning for Gold: Mining the Electronic Health Record Using AI**
 Mihaela Aldea, France
- 12:57 Panel Discussion with all Speakers and Chairs**

12:00 - 13:15 MA04 - MULTI-MODAL TREATMENT OF RESECTABLE LUNG CANCER-OUTCOMES OF TARGETED TREATMENTS AND IMMUNOTHERAPIES IN EARLY-STAGE LUNG CANCER

Track: Early-Stage Non-small Cell Lung Cancer



ROOM 01

Chairs: Enriqueta Felip, Spain and Martin Reck, Germany

- 12:00 Welcome & Introduction**
 Enriqueta Felip, Spain and Martin Reck, Germany
- 12:02 MA04.01 - No Versus Systematic Mediastinal LN Dissection for GGO-Dominant Lung Adenocarcinoma: A Multicenter, Phase III, Non-Inferiority RCT**
 Yang Zhang, China
- 12:07 MA04.02 - Nautika1: Clinical Outcomes and Pathologic Regression with Neoadjuvant Alectinib in Resectable Stage IB-IIIB ALK + NSCLC**
 Jay Lee, USA
- 12:12 MA04.03 - Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I A EGFR Mutated NSCLC With High Risk (APPOINT)**
 Wei Zhang, China
- 12:17 Q&A**

- 12:25 MA04.04 - Perioperative Pembrolizumab in Non-Small Cell Cancer (NSCLC): 4-Year Outcomes by Nodal Status in the KEYNOTE-671 Study**
 Heather Wakelee, USA
- 12:30 MA04.05 - Patient-Reported Outcomes with Perioperative Nivolumab by Nodal Status in Patients with Resectable NSCLC From Checkmate 77T**
 Jonathan Spicer, Canada
- 12:35 MA04.06 - Neoadjuvant Pembrolizumab: Multi-Omics Characterization of the Tumoral Immune Response Reveals Distinct Mechanisms of Action**
 Benedikt Niedermaier, Germany
- 12:40 Q&A**
- 12:48 MA04.07 - A Phase 2 Multicenter Umbrella Trial Assessing Tislelizumab ± Anti-TIGIT or Anti-LAG-3 mAb ± Chemotherapy in Resectable NSCLC**
 Peng Zhang, China
- 12:53 MA04.08 - Perioperative Tislelizumab for Resectable Non-small Cell Lung Cancer: Final Analysis of RATIONALE-315**
 Dongsheng Yue, China
- 12:58 MA04.09 - Patterns of Progression and Recurrence with Perioperative Durvalumab in Patients with Resectable NSCLC from AEGEAN**
 Manuel Cobo Dols, Spain
- 13:03 Q&A**

12:00 - 13:15 OA07 - EXPANDING HORIZONS IN ADVANCED NSCLC INTEGRATING LOCAL THERAPY

Track: Metastatic Non-small Cell Lung Cancer - Local Therapies



ROOM 08

Chairs: Lilian Faroni, Brazil and Myung-Ju Ahn, Republic of Korea

- 12:00 Welcome & Introduction**
 Lilian Faroni, Brazil and Myung-Ju Ahn, Republic of Korea
- 12:02 OA07.01 - Final Analysis of Brighstar: LCT With Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC**
 Yasir Elamin, USA
- 12:12 OA07.02 - Tumor Burden Metrics at Oligoprogression and Survival After SBRT in NSCLC: An Analysis of the Randomized Phase II CURB Trial**
 Matthew McMillan, USA
- 12:22 OA07.03 - Stereotactic Ablative Radiotherapy in Oligo-Metastatic NSCLC Patients: START NEW ERA#OLIGO Non-Randomised Phase II Trial**
 Fabio Arcidiacono, Italy
- 12:32 OA07.04 - Molecular and Early Outcomes of a Randomized Phase II Trial of Primary Tumor Resection Following EGFR TKI in Metastatic NSCLC**
 Pei-Hsing Chen, Taiwan
- 12:42 OA07.05 - Discussant**
 Pablo Munoz Schuffenegger, Chile
- 12:52 Q&A**

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

12:00 - 13:15 OA08 - IMPROVING OUTCOMES IN EGFR AND KRAS MUTANT TUMORS, MORE IS BETTER?

Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy



ROOM 02

Chairs: Fabrice Barlesi, France and Stephanie Saw, Singapore

- 12:00 Welcome & Introduction**
Fabrice Barlesi, France and Stephanie Saw, Singapore
- 12:02 OA08.01 - BMS-986504 in Patients with Homozygous MTAP-Deletion (Del): Clinical Results in Patients with NSCLC Enrolled in CA240-0007**
Pasi A. Jänne, USA
- 12:12 OA08.02 - Efficacy and Safety of 1L Olomorasib + Chemoimmunotherapy in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01**
Marcelo Negrao, USA
- 12:22 OA08.03 - COMPEL: Osimertinib + Platinum-Based Chemotherapy in Patients with EGFRm Advanced NSCLC and Progression on 1L Osimertinib**
Giulia Pasello, Italy
- 12:32 OA03.04 - Primary Endpoint Results from SHERLOCK: a Phase 2 Trial of Sotorasib, Bevacizumab and Chemotherapy in Advanced KRAS G12C NSCLC**
Chee Lee, Australia
- 12:42 OA03.05 - Discussant**
Maurice Perol, France
- 12:52 Q&A**

13:00 - 14:00 LATAM STEERING COMMITTEE MEETING
(BY INVITATION ONLY)

MEETING ROOM A

13:15 - 15:15 Lunch Break



13:30 - 14:30 MEET THE EDITORS WITH ALEX A. ADJEI AND EMILY STONE

EXHIBIT HALL, IASLC JOURNAL LOUNGE



13:30 - 14:45 DEI02 - INCLUSION IN ACTION: ADDRESSING HIDDEN AND EMERGING INEQUITIES IN THORACIC ONCOLOGY

ROOM 10



Chairs: Denis Moro Sibilot, France and Oscar Arrieta, Mexico

- 13:30 Welcome & Introduction**
Denis Moro Sibilot, France and Oscar Arrieta, Mexico
- 13:32 DEI02.01 - Displaced but Not Forgotten: Addressing Refugee Challenges in Thoracic Oncology Care**
Amy Nolan, Ireland
- 13:42 DEI02.02 - Lost in Translation: Removing Language Barriers to Ensure Equitable Cancer Treatment**
Coral Olazagasti, USA
- 13:52 DEI02.03 - Healing Across Beliefs: Overcoming Culture and Religious Divides in Thoracic Oncology**
Om El Khair, Egypt
- 14:02 DEI02.04 - The Geography of Disparity: Bridging the Gaps of Rural vs. Urban Thoracic Cancer Care**
Jie Wang, China
- 14:12 Q&A**

13:45 - 14:45 DEI01 - NAVIGATING GENDER EQUITY IN THE DAILY LIFE OF A THORACIC ONCOLOGIST

ROOM 03



Chair: Julia Rotow, USA, Enric Carcereny, Spain

- 13:45 Welcome & Introduction**
Julia Rotow, USA
- 13:47 DEI01.01 - Is She the Right Fit for the Position? Navigating Gender Bias and Career Advancement**
Pilar Garrido, Spain
- 13:57 DEI01.02 - This is Called 'Local Politics': Navigating Gender Issues and Conflict at Work**
Helena Linardou, Greece
- 14:07 DEI01.03 - 'You Need to Be in the Operating Room. No, You Need to Be at Playground.' Navigating Gender Issues and Life Roles**
Maria Teresa Ruiz Tsukazan, Brazil
- 14:17 DEI01.04 - 'You Need to Find Your People.' Gender Factors on Mentorship, Sponsorship, and Positive Work Environment**
Gerard G. Hanna, Ireland
- 14:27 Panel Discussion**

13:45 - 14:45 INDUSTRY SPONSORED SYMPOSIA

See page 236 for more information.

HOD Highlight of the Previous Day
HOW Hands-On Workshop
MA Mini Oral Abstract Session
OA Oral Abstract Session

P Poster
PT Poster Tour
PL Plenary
WS Workshop

14:15 – 15:00 POSTER TOURS

EXHIBIT HALL/EPOSTER LOUNGE



Note: Each Poster Tour will include 4 – 5 Posters (8min per Poster: 3min presentation by the Poster Presenter, followed by 2min Discussion by the Poster Lead and 3min Audience Q&A).

Poster Tour: PT2.10 - Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy

ePOSTER LOUNGE STATION 1

Tour Lead: Rami Manochakian, USA

- 14:15** **PT2.10.01 - Incidence and Severity of Interstitial Lung Disease Associated with Antibody-Drug Conjugates in NSCLC and SCLC: A Meta-Analysis**
Roberto Borea, USA
- 14:23** **PT2.10.02 - Peripheral Neuropathy and Efficacy of Telisotuzumab Vedotin in c-Met Protein-Overexpressing NSCLC: LUMINOSITY Study**
Hidehito Horinouchi, Japan
- 14:31** **PT2.10.03 - Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study**
Jie Wang, China
- 14:39** **PT2.10.04 - Efficacy and Safety of TQB2102, a Biparatopic HER2-Targeting ADC, in HER-2 Aberrant NSCLC: A Phase II Study**
Li Zhang, China

Poster Tour: PT2.11 - Metastatic Non-small Cell Lung Cancer – Immunotherapy

ePOSTER LOUNGE STATION 2

Tour Lead: Jin Hyoung Kang, Republic of Korea

- 14:15** **PT2.11.01 - Predictors of Response to PD-(L)1 Blockade in Patients with Oncogene-Driver Negative NSCLC Without History of Tobacco Use**
Eleonora Gariazzo, USA
- 14:23** **PT2.11.02 - Rescue by Radiotherapy and Anti-CTLA4/PD-1 After Failure of Anti-PD-1 Therapy in Metastatic NSCLC Patients: the RECLAIM study**
Ezgi Ulas, Netherlands
- 14:31** **PT2.11.03 - Phase I Study of Trametinib, Anlotinib, and Tislelizumab in KRAS-Mutant NSCLC: Safety, RP2D, and Preliminary Efficacy**
Baohui Han, China
- 14:39** **PT2.11.04 - Divergent Mechanisms of Hyper-Progressive Disease in Non-small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors**
Seohee Shim, Republic of Korea
- 14:47** **PT2.11.05 - IFI6-High Cancer-Associated Fibroblasts Impede Immunotherapy Response in NSCLC**
Leyi Lin, China

Poster Tour: PT2.12 - Metastatic Non-small Cell Lung Cancer – Targeted Therapy

ePOSTER LOUNGE STATION 3

Tour Lead: Myung-Ju Ahn, Republic of Korea

- 14:15** **PT2.12.01 - Osimertinib Combined with Tegavivint Is Safe and Tolerable as First-Line Therapy in Patients with Metastatic EGFR-Mutated NSCLC**
Regan Memmott, USA
- 14:23** **PT2.12.02 - Effect of JIN-A02, a Novel 4Th-Generation EGFR-TKI, on Multiple EGFR Mutations in Comparison with 3Rd-Generation EGFR-TKIs**
Hee-Yeon Kim, Republic of Korea
- 14:31** **PT2.12.03 - Zongertinib in Patients with Previously Treated HER2-Mutant NSCLC and Brain Metastases at Baseline: Beamion LUNG-1**
Gerrina Ruiter, Netherlands
- 14:39** **PT2.12.04 - Osimertinib + Savolitinib in EGFRm Advanced NSCLC With MET Overexp and/or Amp Post-Progression on Osimertinib: SAVANNAH PROs**
Silvia Novello, Italy

Poster Tour: PT2.13 - Small Cell Lung Cancer and Neuroendocrine Tumors

ePOSTER LOUNGE STATION 4

Tour Lead: Katherine Scilla, USA

- 14:15** **PT2.13.01 - A Phase II Trial of Induction Camrelizumab Plus Chemotherapy Followed by Chemoradiotherapy and Consolidation in Limited-Stage SCLC**
Di Liu, China
- 14:23** **PT2.13.02 - Multi-Cycle Low-Dose Radiotherapy Reshapes Immunochemotherapy for ES-SCLC: The SPUR Phase II Trial**
Zhuoran Yao, China
- 14:31** **PT2.13.03 - Spatial Multiomics Profiling Reveals Distinct Tumor Microenvironment and Therapeutic Targets in EGFR-Mutant NSCLC Transformed to SCLC**
Bingnan Zhang, USA
- 14:39** **PT2.13.04 - Real-World Multi-Institution Analysis of Patients with Small Cell Lung Cancer Treated with Tarlatamab**
Alissa Cooper, USA

Poster Tour: PT2.14 - Mesothelioma, Thymoma, and Other Thoracic Tumors

ePOSTER LOUNGE STATION 5

Tour Lead: Sean Dooloo, UK

- 14:15** **PT2.14.01 - SYSTEMS-2: A Randomised Phase II Study of Radiotherapy Dose Escalation in Pleural Mesothelioma**
Iain Phillips, UK
- 14:23** **PT2.14.02 - Human- and AI- Whole Slide Image Assessment of Tumor Immune Microenvironment of Pleural Mesothelioma in Prediction of Patients Outcome**
Giuseppe Maggioni, Italy
- 14:31** **PT2.14.03 - Molecular Correlates of Response to Atezolizumab Plus Carboplatin and Paclitaxel in Patients with Thymic Carcinoma**
Yukina Shirai, Japan
- 14:39** **PT2.14.04 - Efficacy and Safety of Adebrelimab Plus Chemotherapy as Neoadjuvant Treatment for Unresectable Locally Advanced Thymic Carcinoma**
Ning Xu, China
- 14:47** **PT2.14.05 - Redefining Clinical Outcomes for Peritoneal Mesothelioma (PeM) in the Era of Immunotherapy**
Yamato Takabe, USA

HOD Highlight of the Previous Day
HOW Hands-On Workshop
MA Mini Oral Abstract Session
OA Oral Abstract Session

P Poster
PT Poster Tour
PL Plenary
WS Workshop

Poster Tour: PT2.15 - Multidisciplinary Care: Nursing, Allied Health and Palliative Care

ePOSTER LOUNGE STATION 6

Tour Lead: Lucia Viola, Colombia

- 14:15** **PT2.15.01 - A Randomized Controlled Trial on the Effect of Oncologist's Recommendations on Exercise, Sedentary, and Quality of Life in Patients with NSCLC**
Alice Avancini, Italy
- 14:23** **PT2.15.02 - Young Lung Cancer: The Psychosocial Needs Assessment**
Narjust Florez, USA
- 14:31** **PT2.15.03 - Examining the Role of Frailty Assessments in Older Adult with Lung Cancer to Identify Patient Vulnerabilities and Exploring Patient Outcomes**
Philip Papayanis, USA
- 14:39** **PT2.15.04 - Impact of Physical Exercise on Quality of Life in Patients with Advanced Lung Cancer**
Ana López Martín, Spain
- Poster Tour: PT2.16 - Patient Advocacy**
- Tour Lead: Antoinette Wozniak, USA*
- 14:15** **PT2.16.01 - Current Patient, Caregiver and Provider Attitudes Toward Use of AI in Lung Cancer Patient Navigation**
Courtney Granville, USA
- 14:23** **PT2.16.02 - Patients Who Reach Clinical Trials and Those Who Do Not, a Structural Analysis of Access Disparities in Japan**
Kazuo Hasegawa, Japan
- 14:31** **PT2.16.03 - Overcoming Lung Cancer Nihilism and Fatalism to Foster Compassion, Empathy, and Support**
Jamie Studts, USA
- 14:39** **PT2.16.04 - Advancing Lung Cancer Advocacy in Low- and Middle-Income Countries**
Caleb Egwuenu, Nigeria
- 14:47** **PT2.16.05 - Survivorship Needs for Patients with NSCLC Treated with Oral Targeted Therapies**
Caroline Burley, USA

Poster Tour: PT2.17 - Global Health, Health Services, and Health Economics

ePOSTER LOUNGE STATION 8

Tour Lead: Mauricio Cuello Toledo, Uruguay

- 14:15** **PT2.17.01 - Point-Of-Care Rapid Tissue Diagnosis at Primary Consultation: Optimizing TIME to Treatment in the Neoadjuvant Era**
Biniyam Kidane, Canada
- 14:23** **PT2.17.02 - Impact of Timely Treatment Initiation on Outcomes in Non-small Cell Lung Cancer. A Registry Based Observational Study**
Louis Irving, Australia
- 14:31** **PT2.17.03 - Accelerated Biological Aging Is Correlated with the Incidence and Poor Prognosis of Young Lung Cancer**
Yuxuan Liao, China

- 14:39** **PT2.17.04 - First Assessment of IASLC Inclusive Practices and Challenges: Results from the Diversity, Equity, and Inclusion Survey**
Narjust Florez, USA
- 14:47** **PT2.17.05 - Benefits of Adjuvant Alectinib in ALK+ Early-Stage Non-small Cell Lung Cancer, Recurrences Avoided and Savings for the Spanish Health System**
Javier de Castro, Spain

14:45 - 15:30 IASLC BUSINESS MEETING

ROOM 09

REFRESHMENTS PROVIDED

NOT FOR CME CREDIT

- Welcome from the IASLC President
- CEO Report
- CSO Report
- CFO Report
- JTO & JTO CRR Report
- Passing of the Gavel

15:30 - 16:45 ES25 - ONCOGENE ADDICTED NSCLC: WORLDWIDE CASE BASED DISCUSSIONS

Track: Metastatic Non-small Cell Lung Cancer - Targeted Therapy

ACCME ACCREDITED BY IASLC

ROOM 03

Chairs: Alessandra Curioni, Switzerland and Kaushal Parikh, USA

- 15:30** **Welcome & Introduction**
Alessandra Curioni, Switzerland and Kaushal Parikh, USA
- 15:32** **ES25.01 - For ROS1 Fusion NSCLC, Is There Still a Place for Sequential Treatment Starting with Crizotinib?**
Daniel Tan, Singapore
- 15:47** **ES25.02 - HER2 Mutant NSCLC: ADC vs TKI, Challenges**
Pilar Garrido, Spain
- 16:02** **ES25.03 - BRAF and MET Mutant Tumors, How to Treat?**
Shirish Gadgil, USA
- 16:17** **ES25.04 - NSCLC and KRAS G12C Mutation Second Line or in First Line?**
Helena Linardou, Greece
- 16:32** **Q&A**

15:30 - 16:45 ES26 - OLIGOMETASTATIC DILEMMAS: REAL-WORLD CASES, INSIGHTS, AND MULTIDISCIPLINARY SOLUTIONS

Track: Metastatic Non-small Cell Lung Cancer - Local Therapies

ACCME ACCREDITED BY IASLC

ROOM 01

Chairs: Matthias Guckenberger, Switzerland and Vanessa Costa Menezes, Brazil

- 15:30** **Welcome & Introduction**
Matthias Guckenberger, Switzerland and Vanessa Costa Menezes, Brazil
- 15:32** **Panel Discussion**
Gianluca Milanese, Italy, Hidehito Horinouchi, Japan, Mara Antonoff, USA, Gabriela Antelo, Spain, Tiffani Tyer, USA

HOD Highlight of the Previous Day
HOW Hands-On Workshop
MA Mini Oral Abstract Session
OA Oral Abstract Session

P Poster
PT Poster Tour
PL Plenary
WS Workshop

15:30 - 16:45 ES27 - IMAGING TOOLS FOR STAGING: NEW KIDS ON THE BLOCK

Track: Pulmonology and Staging



ROOM 08

Chairs: Mylene Truong, USA and Marisol Arroyo, Mexico

- 15:30 Welcome & Introduction**
Mylene Truong, USA and Marisol Arroyo, Mexico
- 15:32 ES27.01 - Tobacco Awareness Moment: Integrating Smoking Status as a Prognostic Factor in the TNM Lung Cancer Staging Criteria**
Lawson Eng, Canada
- 15:35 ES27.02 - What's New in CT as a Staging Tool**
Jonas Kroschke, Switzerland
- 15:47 ES27.03 - Imaging Controversies in Lung Cancer Staging**
Kyongmin Sarah Beck, Republic of Korea
- 15:59 ES27.04 - PET/CT in Lung Cancer Staging: Challenges in Interpretation**
Jeremy Erasmus, USA
- 16:11 ES27.05 - Systematic EBUS Staging to Guide Therapy**
Daniel Steinfort, Australia
- 16:23 Q&A**

15:30 - 16:45 ES28 - PERSONALIZED CANCER CARE: FROM DIAGNOSIS TO SURVIVORSHIP

Track: Patient Advocacy



ROOM 02

Chairs: Jill Feldman, USA and Hideo Ichimura, Japan

- 15:30 Welcome & Introduction**
Jill Feldman, USA and Hideo Ichimura, Japan
- 15:32 ES28.01 - Access to Early Detection Programs for People with an Increased Risk of Lung Cancer: Participant's Perspective**
Jurg Hurter, Switzerland
- 15:42 ES28.02 - Elevate Patient Outreach and Advocacy: Leveraging Social Media**
Eric Singhi, USA
- 15:52 ES28.03 - Caregiver and HCP Compassionate Fatigue Care**
Shani Shilo, Israel
- 16:02 ES28.04 - Policy and Survivorship: Enhancing Access and Opportunities**
Lauren Pretorius, South Africa
- 16:12 ES28.05 Patient-centred Perioperative Surveillance**
Brendon Stiles, USA
- 16:22 Q&A**

15:30 - 16:45 ES29 - THYMIC MALIGNANCIES - HOW TO MOVE THE FIELD FORWARD

Track: Mesothelioma, Thymoma, and Other Thoracic Tumors



ROOM 10

Chairs: Mariana Brandao, Belgium and Nicolas Girard, France

- 15:30 Welcome & Introduction**
Mariana Brandao, Belgium and Nicolas Girard, France
- 15:32 ES29.01 - What's New on the Medical Side for Thymus**
Ross Soo, Singapore
- 15:44 ES29.02 - Adjuvant Radiotherapy -When, Where and How?**
Cengel Keith, USA
- 15:56 ES29.03 - Which Classification Do We Use?**
Deepali Jain, India
- 16:08 ES29.04 - How Much Thymus and Lymph Nodes Do We Need to Get Out?**
Alessandro Mariani, Brazil
- 16:20 Q&A**

15:30 - 16:45 ES30 - LUNG CANCER AND RISK FACTORS: EXPLORING BEYOND CIGARETTE SMOKING

Track: Risk Factors, Risk Reduction & Tobacco Control



ROOM 04

Chairs: Abhishek Shankar, India and Randi Williams, USA

- 15:30 Welcome & Introduction**
Abhishek Shankar, India and Randi Williams, USA
- 15:32 ES30.01 - Environmental Risk for Lung Diseases**
Gianluigi De Gennaro, Italy
- 15:44 ES30.02 - Occupational Exposure and Risk of Airway Cancer**
Laura Mezquita, Spain
- 15:56 ES30.03 - Rural Areas and Professional or Accidental Exposure to Pesticides**
Monireh Seyyedsalehi, Italy
- 16:08 ES30.04 - Indoor Domestic and Professional Cooking and the Risk of Disease**
Stephen Lam, Canada
- 16:20 Q&A**

15:30 - 16:45 HOW04 - *REPEAT SESSION* ROBOTIC NAVIGATIONAL BRONCHOSCOPY WORKSHOP #2 (LIMITED CAPACITY - FIRST COME FIRST SERVED)

ROOM 11



Workshop Faculty: Thomas Gaisl, Switzerland and Gian-Marco Monsch, Switzerland

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

15:30 - 16:45 MA05 - PRECISION IN LUNG CANCER SCREENING

Track: Screening and Early Detection



ROOM 09

Chairs: Ricardo Sales Santos, Brazil and Hilary Robbins, France

- 15:30 Welcome & Introduction**
Ricardo Sales Santos, Brazil and Hilary Robbins, France
- 15:32 MA05.01 - A Systematic Approach to Appropriate Guideline-Based Management of Incidentally Detected Pulmonary Nodules the Mayo Clinic Experience**
Robert Anderson, USA
- 15:37 MA05.02 - The Preliminary Results of Taiwan National LDCT Lung Cancer Screening for Smokers and Nonsmokers with a Family History of Lung Cancer**
Pan Chyr Yang, Taiwan
- 15:42 Q&A**
- 15:50 MA05.03 - Validation of Sybil in a Minority Population: Results from the Sybil Implementation Consortium: UIC, MGH, Baptist, Wellstar**
Mary Pasquinelli, USA
- 15:55 MA05.04 - SENTINLO Systemwide Early Notification Tool for Imminent Nascent Lung Cancer**
Alexander Krule, USA
- 16:00 MA05.05 - Analysis of Longitudinal Low-Dose CT Sybil Scores in Two Canadian Cohorts**
Clinton Durney, Canada
- 16:05 Q&A**
- 16:13 MA05.06 - Integrating Circulating Protein Biomarkers in Nodule Malignancy Prediction Model Based on Five International Lung Cancer Screening Cohorts**
Elham Khodayari Moez, Canada
- 16:18 MA05.07 - Breathomics for Early Non-Invasive Detection of Lung Cancer: A Prospectively Multicenter Study Using TD-GC-MS and Portable Micro-GC**
Runchen Wang, China
- 16:23 MA05.08 - Cell-Free DNA Methylation Markers in Serum and Bronchial Washing for Lung Cancer Detection: A Prospective Observational Study**
Yechan Song, Republic of Korea
- 16:28 MA05.09 - Precise Diagnosis of Small Malignant Pulmonary Nodules Driven by Peripheral Single-Cell Immune Signatures: A Prospective Multi-Center Study**
Yang Xia, China
- 16:33 Q&A**

15:30 - 16:45 MA06 - IMPROVING CARE JUDICIOUSLY

Track: Global Health, Health Services, and Health Economics



ROOM 06

Chairs: Justin Gainor, USA and Mariano Provencio, Spain

- 15:30 Welcome & Introduction**
Lecia Sequist, USA and Mariano Provencio, Spain
- 15:32 MA06.01 - Real-World Outcomes of First-Line Immunotherapy Intensification of Patients with Advanced Non-small Cell Lung Cancer (aNSCLC)**
Xiao Wang, USA
- 15:37 MA06.02 - Paradigm Shift in Lung Cancer Mortality in the USA: A Multifaceted Success Story**
Muhammad Islam, USA
- 15:42 MA06.03 - Pharmacoeconomic Analysis of NADIM 2 Trial: Cost-Effectiveness of Perioperative Chemo-Immunotherapy in Resectable Stage III NSCLC**
Bartomeu Massuti, Spain
- 15:47 Q&A**
- 15:55 MA06.04 - Improving Preoperative ctDNA Detection in NSCLC Through Mechanistic Profiling and Multiregion-Informed Customization**
Yue He, China
- 16:00 MA06.05 - Impact of Bronchoalveolar Lavage Combined with mNGS in Patients with Checkpoint Inhibitor Pneumonia: A Prospective Cohort Study**
Zhenhua Zhou, China
- 16:05 MA06.06 - Overall Survival Among Patients with Oncogene Driven Lung Cancers Treated on Clinical Trials Compared to Standard Care**
Ashley Sestito, Australia
- 16:10 Q&A**
- 16:18 MA06.07 - Benchmarking CT Foundation Models for Survival Prediction in NSCLC Patients**
Beshoy Guirges, Italy
- 16:23 MA06.08 - Is Weight-Based Pembrolizumab Dosing as Effective as Standard Fixed Dose in Advanced NSCLC?**
Ari Raphael, Israel
- 16:28 MA06.09 - Assessing the Impact of Project ASCENT, a Multi-Level Lung Cancer Screening Intervention Targeting Hispanic/Latin Individuals**
Manmeet Ahluwalia, USA
- 16:33 Q&A**

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

15:30 - 16:45 OA09 - NEW ADVANCES IN PATHOLOGY

Track: Pathology and Biomarkers

NOT FOR CME CREDIT

ROOM 05

Chairs: Cristina Teixido, Spain and Ellen Nascimento, Brazil

- 15:30 Welcome & Introduction**
Cristina Teixido, Spain and Ellen Nascimento, Brazil
- 15:32 OA09.01 - Machine Learning Assessment of Pathologic Response in Lung Resections After Neoadjuvant Therapy - IASLC MPR Project**
Sanja Dacic, USA
- 15:42 OA09.02 - I3LUNG-PDSS: A Multimodal AI-Based Clinical Decision Support System for Predicting Immunotherapy Efficacy in Metastatic NSCLC**
Arsela Prelaj, Italy
- 15:52 OA09.03 - Real-World Assessment of TROP2-NMR by Quantitative Continuous Scoring (QCS) in Non-small Cell Lung Carcinoma (NSCLC)**
Fernando Lopez-Rios, Spain
- 16:02 OA09.04 - Discussant**
Vincezo L'imperio, Italy
- 16:12 Q&A**

15:30 - 16:45 OA10 - OPTIMIZING SYSTEMIC THERAPY: BRIDGING NEW & OLD

Track: Metastatic Non-small Cell Lung Cancer - Cytotoxic Therapy

NOT FOR CME CREDIT

ROOM 07

Chairs: Virginia Calvo, Spain, Pieter Postmus, Netherlands

- 15:30 Welcome & Introduction**
Virginia Calvo, Spain, Pieter Postmus, Netherlands
- 15:32 OA10.01 - Intracranial Efficacy of Datopotamab Deruxtecane (Dato-DXd) in Patients with Advanced/Metastatic NSCLC in TROPION-Lung01**
Elvire Pons-Tostivint, France
- 15:42 OA10.02 - Bevacizumab Plus Chemotherapy Versus Chemotherapy in Untreated Non-Squamous NSCLC With Brain Metastases: A Randomized, Phase 3 Study**
Meichen Li, China
- 15:52 OA10.03 - Phase I/II Study of Iza-Bren (BL-B01D1) as Monotherapy in Patients with Locally Advanced or Metastatic EGFR Mutated NSCLC**
Wenfeng Fang, China
- 16:02 OA10.04 - Phase II Study of Iza-Bren (BL-B01D1) Combo with Osimertinib in EGFR Mutated Locally Advanced or Metastatic NSCLC Patients**
Fei Zhou, China
- 16:12 OA10.05 - Discussant**
Antonio Passaro, Italy
- 16:22 Q&A**

16:00 - 17:00 EDITORIAL RECEPTION
(BY INVITATION ONLY)

FIRST FLOOR - WALKWAY TO PLENARY HALL

REFRESHMENTS PROVIDED

17:00 - 18:15 ES31 - ADCs: CURRENT CONTROVERSIES

Track: Metastatic Non-small Cell Lung Cancer - Cytotoxic Therapy

ACCME ACCREDITED BY IASLC

ROOM 02

Chairs: Riyaz Shah, UK and Fiona McDonald, UK

- 17:00 Welcome & Introduction**
Riyaz Shah, UK and Fiona McDonald, UK
- 17:02 ES31.01 - Leveraging ADCs for the HER Pathways. Where Do These Compounds Fit in HER2 and EGFR Space?**
Susan Scott, USA
- 17:14 ES31.02 - Trop2 ADCs: Is There Hope or Is All Is Lost?**
Stephanie Saw, Singapore
- 17:26 ES31.03 - Emerging ADCs: The Next Generation**
Giuseppe Banna, UK
- 17:38 ES31.04 - Biomarkers for ADCs: IHC and Beyond**
Sewanti Limaye, India
- 17:50 Q&A**

17:00 - 18:15 ES32 - EXPERIMENTAL DESIGN FOR DISSECTING IMMUNE EVASION, CELL PLASTICITY, AND DRUG RESISTANCE

Track: Tumor Biology - Translational Biology

ACCME ACCREDITED BY IASLC

ROOM 03

Chairs: Deepali Jain, India and Triparna Sen, USA

- 17:00 Welcome & Introduction**
Deepali Jain, India and Triparna Sen, USA
- 17:02 ES32.01 - Lung Cancer Plasticity**
Tuomas Tammela, USA
- 17:14 ES32.02 - Immune Evasion in Early Lung Cancer**
Celine Mascaux, France
- 17:26 ES32.03 - The Lung Cancer Microbiome**
Sara Pilotto, Italy
- 17:38 ES32.04 - Drug Persister Cells in NSCLC**
Hiromichi Ebi, Japan
- 17:50 Q&A**

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

17:00 - 18:15 ES33 - PRECISION FRONTIERS: TARGETED THERAPIES IN EARLY-STAGE LUNG CANCER

Track: Early-Stage Non-small Cell Lung Cancer



ROOM 08

Chairs: Jamie Chافت, USA and Antonio Calles, Spain

- 17:00 Welcome & Introduction**
Jamie Chافت, USA and Antonio Calles, Spain
- 17:02 ES33.01 - EGFR Mutant Non-small Cell Lung Cancer**
Peng Zhang, China
- 17:14 ES33.02 - ALK Rearranged Non-small Cell Lung Cancer**
Jay Lee, USA
- 17:26 ES33.03 - Other Actionable Oncogenic Alterations**
Erin Gillaspie, USA
- 17:38 ES33.04 - Managing Toxicities, Surgery and Quality of Life**
Margherita Majem, Spain
- 17:50 Q&A**

17:00 - 18:15 ES34 - NARROWING DISPARITIES FOR EFFECTIVE MANAGEMENT OF LUNG CANCER ON A GLOBAL SCALE

Track: Global Health, Health Services, and Health Economics



ROOM 05

Chairs: Helena Masua, Kenya and Samuel Kareff, USA

- 17:00 Welcome & Introduction**
Helena Masua, Kenya and Samuel Kareff, USA
- 17:02 ES34.01 - Bronchoscopy and Interventional Radiology in Resource Limited Settings (Challenges and Cost Related to Tissue Acquisition, Diagnosis and Staging)**
Emmet O'Brien, Ireland
- 17:13 ES34.02 - Cost-Effective Processing of Tissue Samples in Resource Limited Settings in the Era of Precision Oncology (Access to and Cost of Immunochemistry and Molecular Biomarker Testing)**
Amanjit Bal, India
- 17:24 ES34.03 - Improving Access to Surgery in Resource Limited Settings (Availability of Minimally Invasive Surgery, Wait Times, Cost)**
Tomohito Saito, Japan
- 17:35 ES34.04 - Advanced Radiation Therapy Technologies in Resource Limited Settings (SBRT for Early Stage, Concurrent Chemoradiation for Locally Advanced NSCLC & SCLC-LD, Palliative Thoracic/Brain/Bone Radiation for Metastatic Disease)**
May Abdel Wahab, Austria

- 17:46 ES34.05 - Targeted and Immunotherapy Drug Access in Resource Limited Settings (Availability/Approvals/Cost/Cost-Effectiveness)**
Sze-Wai Chan, South Africa

17:57 Q&A

17:00 - 18:15 ES35 - EGFR AS A BIOMARKER: PAST, PRESENT, FUTURE

Track: Pathology and Biomarkers



ROOM 07

Chairs: Beatriz Bellosillo, Spain and Christian Rolfo, USA

- 17:00 Welcome & Introduction**
Beatriz Bellosillo, Spain and Christian Rolfo, USA
- 17:02 ES35.01 - The Past: Discovery of EGFR and the Advances in Approach to Diagnosis**
Jaclyn LoPiccolo, USA
- 17:14 ES35.02 - The Present: Evolving Landscape of Treatment and Resistance to EGFR Inhibitors**
Clarissa Baldotto, Brazil
- 17:26 ES35.03 - The Present: How Do Different Parts of the World Approach EGFR Biomarkers (Due to Population Prevalence)**
Jinyong Kim, Republic of Korea
- 17:38 ES35.04 - The Future: The Landscape of EGFR Histology and Histological Transformation**
Fernando Lopez Rios, Spain

17:50 Q&A

17:00 - 18:15 ES36 - STAGE III NSCLC: HOW FAR CAN WE PUSH THE LIMITS? BATTLE OF PERSPECTIVES

Track: Local-Regional Non-small Cell Lung Cancer



ROOM 09

Chairs: Nasser Altorki, USA and Ernest Nadal, Spain

- 17:00 Welcome & Introduction**
Nasser Altorki, USA and Ernest Nadal, Spain
- 17:02 ES36.01 - Revision of Cases**
Marcelo Sánchez, Spain
- 17:12 ES36.02 - Panel Discussion**
Benjamin Solomon, Australia, Salma Jabbour, USA, Fabio Ynoe de Morales, Canada, Young Tae Kim, Republic of Korea, Paula Ugalde, USA, Esther Conde, Spain, Julien Mazieres, France, José Sanz-Santos, Spain

17:00 - 18:15 OA11 - BEYOND TNM - NEW HORIZONS IN PROGNOSTICATION

Track: Pulmonology and Staging

NOT FOR CME CREDIT

ROOM 04

Chairs: Anna Rita Larici, Italy and Fredrick Asirwa, Kenya

17:00 Welcome & Introduction

Anna Rita Larici, Italy and Fredrick Asirwa, Kenya

17:02 OA11.01 - Impact of Smoking Status on the Prognosis of Lung Cancer in the IASLC Ninth Edition TNM Classification Database

JTO Simultaneous Publication

Lawson Eng, Canada

17:12 OA11.02 - Molecular Alterations and Survival: Analyses from IASLC 9th Edition Staging Database

JTO Simultaneous Publication

Fred R. Hirsch, USA

17:22 OA11.03 - The Survival Impact of Subdividing Clinical and Pathologic N2 Descriptors in a Population-Based Surgical Cohort

Jessica Rice, USA

17:32 OA11.04 - Validation and Refinement Proposal of the Ninth Edition n Descriptor for Non-small Cell Lung Cancer Receiving Neoadjuvant Therapy

Haojie Si, China

17:42 OA11.05 - Discussant

Masahiro Tsuboi, Japan

17:52 Q&A

17:00 - 18:15 OA12 - NOVEL CLINICAL APPROACHES AND TRANSLATIONAL INVESTIGATION IN MESOTHELIOMA

Track: Mesothelioma, Thymoma, and Other Thoracic Tumors

NOT FOR CME CREDIT

ROOM 01

Chairs: Serap Akyurek, Turkey and Joachim Aerts, Netherlands

17:00 Welcome & Introduction

Serap Akyurek, Turkey and Joachim Aerts, Netherlands

17:02 OA12.01 - IASLC Mesothelioma Staging Project: Impact of Molecular Alterations on Survival in a Cohort From 9th Edition Database

Valerie Rusch, USA

17:12 OA12.02 - CCTG IND227, a Randomized Trial of Chemotherapy + Pembrolizumab in Advanced Pleural Mesothelioma: Updated Analyses

Scott Laurie, Canada

17:22 OA12.03 - Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Resectable Diffuse Pleural Mesothelioma

Joshua Reuss, USA

17:32 OA12.04 - Radiation Reprograms CDKN2A/p16 Wild Type Epithelioid Mesothelioma Towards an Immune Responsive Tumor Microenvironment

Marc De Perrot, Canada

17:42 OA12.05 - Discussant

Nicolas Girard, France

17:52 Q&A

17:00 - 18:15 OA13 - OPTIMIZING FRONT-LINE TREATMENT IN SCLC

Track: Small Cell Lung Cancer and Neuroendocrine Tumors

NOT FOR CME CREDIT

ROOM 06

Chairs: Gabriela Fernandez, Portugal and Samuel Rosner, USA

17:00 Welcome & Introduction

Gabriela Fernandez, Portugal and Samuel Rosner, USA

17:02 OA13.01 - Safety and Survival Update of Tarlatamab with Anti-PD-L1 as 1L Maintenance After Chemo-IO for ES-SCLC: DeLLphi-303 Ph1b Trial

Kelly Paulson, USA

17:12 OA13.02 - Global Phase 2 Randomized Trial of BNT327 (Pumitamid; PD-L1 x VEGF-A bsAb) + Chemotherapy for 1L ES-SCLC: Dose Optimization Analysis

John Heymach, USA

17:22 OA13.03 - RYZ101 (225Ac-DOTATATE) + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor-Expressing Extensive-Stage SCLC

Aaron Mansfield

17:32 OA13.04 - Highly Proliferative (G3) Lung Carcinoids: IASLC Pathology Committee Study With Proposal for Inclusion in WHO Classification

Natasha Rekhtman, USA

17:42 OA13.05 - Discussant

Charles Rudin, USA

17:52 Q&A

18:30 - 20:00 IASLC FOUNDATION APPRECIATION RECEPTION
(TICKETED EVENT)

OFFSITE: RESTAURANT MIRABÉ

19:30 - 23:00 IASLC CELEBRATION NIGHT
(TICKETED EVENT)

OFFSITE: TIBIDABO PARK

Arrive in style on the brand-new funicular, indulge in local cuisine and drinks, and enjoy live music and entertainment. Take in breathtaking panoramic views of the city while connecting with peers and sharing a night of celebration. Don't miss this special evening filled with great company and unforgettable moments!

Transportation from various Conference hotels provided. Check your ticket for details.



When it comes to unexplained muscle weakness and fatigue in SCLC patients

LEAVE NO STONE UNTURNUED

Your patients may also have Cancer-Associated LEMS,
which can make it difficult to get out of a chair or climb stairs

LEMS=Lambert-Eaton myasthenic syndrome; SCLC=small cell lung cancer; VGCC-Ab=voltage-gated calcium channel antibody.

Visit Booth 408 to learn how a VGCC-Ab test,
both P/Q and N types, can confirm a diagnosis.^{1,2}



References: 1. Gilhus NE. *Autoimmune Dis.* 2011;2011:973808. 2. Titulaer MJ, et al. *Lancet Neurol.* 2011;10(12):1098-1107.

© 2025 Catalyst Pharmaceuticals, Inc. All Rights Reserved. CAL-0015-1 May 2025

05
PROGRAM:
TUESDAY

IASLC 2025 WORLD CONFERENCE ON LUNG CANCER
CONQUERING LUNG AND OTHER THORACIC CANCERS WORLDWIDE IN THE 21ST CENTURY.

TUESDAY, SEPTEMBER 9, 2025

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

07:00 – 08:30 AFRICA STEERING COMMITTEE MEETING
(BY INVITATION ONLY)

MEETING ROOM A

08:30 – 10:00 PL04 - SCIENTIFIC PLENARY WITH LECTURESHIP AWARD PRESENTATIONS: FROM LEARNERS TO LEADERS: ADVANCING ONCOLOGY TRAINING FOR THE NEXT GENERATION OF THORACIC ONCOLOGISTS

PLENARY HALL

 LIVESTREAMED

 NOT FOR CME CREDIT

Chairs: Isabelle Opitz, Switzerland and Jarushka Naidoo, Ireland

Welcome & Introduction

Isabelle Opitz, Switzerland and Jarushka Naidoo, Ireland

PL04.01 Clifton F. Mountain Lectureship Award for Staging

Jin Mo Goo, Republic of Korea

PL04.02 Fred R. Hirsch Lectureship Award for Translational Research

Mary Beth Beasley, USA

PL04.03 Daniel C. Ihde Lectureship Award for Medical Oncology

Lizza Hendriks, Netherlands

PL04.04 Data-Driven Oncology: How Big Data and AI Can Transform Lung Cancer

Arsela Prelaj, Italy

PL04.05 Unlocking the Complete Molecular Code: The Future of Thoracic Oncology Diagnostics with Epigenetics, Fragmentomics, Proteomics, Spatial Technologies, and Bioinformatics

Victor Velculescu, USA

PL04.06 Empowering the Next Generation of Surgical Oncologists: Leveraging Technology for Oncologic Surgical Training

Lars Konge, Denmark

Q&A

09:00 – 16:00 IASLC REVIEWER WORKSHOP
(BY INVITATION ONLY)

Chair: Vun-Sin Lim, China

MEETING ROOM C

 NOT FOR CME CREDIT

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

10:00 – 11:30 POSTER VIEWING BREAK WITH P3 PRESENTERS IN ATTENDANCE

EXHIBIT HALL



Track 01: Risk Factors, Risk Reduction & Tobacco Control	Rows: 01-06
Track 03: Tumor Biology – Translational Biology	Rows: 06-11
Track 09: Metastatic Non-small Cell Lung Cancer – Local Therapies	Rows: 11-12
Track 12: Metastatic Non-small Cell Lung Cancer – Targeted Therapy	Rows: 12-19
Track 13: Small Cell Lung Cancer and Neuroendocrine Tumors	Rows: 20-23
Track 14: Mesothelioma, Thymoma, and Other Thoracic Tumors	Rows: 23-25
Track 16: Patient Advocacy	Rows: 25-27
Track 18: Clinical Trials in Progress	Rows: 28-36

10:15 – 11:15 HOD02 - HIGHLIGHTS OF THE DAY - MONDAY ABSTRACTS

EXHIBIT HALL/EPOSTER LOUNGE



10:15	HOD02.01 - Pathology <i>Fernando Lopez-Rios, Spain</i>
10:25	HOD02.02 - Local and Systemic Therapies <i>Enriqueta Felip, Spain</i>
10:35	HOD02.03 - Targeted Therapies <i>Charu Aggarwal, USA</i>
10:45	HOD02.04 - Advances in SCLC, Mesothelioma and Thymic Malignancies <i>Rafal Dziadziuszko, Poland</i>
10:55	HOD02.05 - Presidential Symposia Abstracts (from Monday) <i>Benjamin Besse, France</i>

10:15 – 11:15 PRESS CONFERENCE

ROOM CC7 AB



11:30 – 12:45 ES37 - CHALLENGING SCENARIOS FOR IMMUNOTHERAPY TREATMENT

Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy



ROOM 02

Chairs: Natasha Leighl, Canada and Thanyanan Baisamut, Thailand

11:30	Welcome & Introduction <i>Natasha Leighl, Canada and Thanyanan Baisamut, Thailand</i>
11:32	ES37.01 - Immunotherapy in Auto-Immune Diseases and Organ Transplant Recipients: Can They Go Together? <i>Naoka Murakami, USA</i>

11:44 ES37.02 - Patients Older Than 75 Years of Age or Frail (PS 2/3)

Roberto Ferrara, Italy

11:56 ES37.03 - Immunotherapy and Brain Metastases

Thomas John, Australia

12:08 ES37.04 - Is It Feasible to Restart Immunotherapy After Severe Immune-Related Toxicity?

Satoru Miura, Japan

12:20 Q&A

11:30 – 12:45 ES38 - WHAT PROVIDERS NEED TO KNOW TO PERSONALIZE CARE FOR RESECTABLE LUNG CANCER

Track: Early-Stage Non-small Cell Lung Cancer



ROOM 08

Chairs: Fabiana Cecere, Italy and Ricardo Terra, Brazil

11:30	Welcome & Introduction <i>Fabiana Cecere, Italy and Ricardo Terra, Brazil</i>
11:32	ES38.01 - EGFR, ALK, PD-L1 and Emerging Biomarkers <i>Sara Najmeh, USA</i>
11:44	ES38.02 - Extent of Lung Resection After Neo-Adjuvant Treatment <i>Shun-ichi Watanabe, Japan</i>
11:56	ES38.03 - Lymph Node Management After Induction: Challenges and Extent of Lymphadenectomy <i>Carlos Galvez, Spain</i>
12:08	ES38.04 - Circulating Tumor DNA to Guide Management of Patients With Resectable NSCLC <i>Sinchita Roy Chowdhuri, USA</i>
12:20	Q&A

11:30 – 12:45 ES39 - BREAKING NEW GROUND: CHALLENGING ADVANCES IN SCLC THERAPY

Track: Small Cell Lung Cancer and Neuroendocrine Tumors



ROOM 04

Chairs: Jacob Sands, USA and Susan Harden, Australia

11:30	Welcome & Introduction <i>Jacob Sands, USA and Susan Harden, Australia</i>
11:32	ES39.01 - Challenges and Perspectives in LS-SCLC <i>Kenneth O'Byrne, Australia</i>
11:44	ES39.02 - Challenges and Novel Strategies in Advanced SCLC <i>Noura Choudhury, USA</i>
11:56	ES39.03 - Rethinking Radiotherapy in the Era of New Standards for SCLC <i>Anthony Levy, France</i>
12:08	ES39.04 - Choosing Wisely: Strategies for Navigating Therapeutic Options in Special SCLC Populations <i>Motoko Tachihara, Japan</i>
12:20	Q&A

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

11:30 - 12:45 ES40 - UNITING FORCES: MULTIDISCIPLINARY APPROACHES TO HOLISTIC LUNG CANCER CARE

Track: Multidisciplinary Care: Nursing, Allied Health & Palliative Care



ROOM 03

Chairs: Lucia Viola, Colombia and Carlos Cabrera-Galvex, Spain

- 11:30 Welcome & Introduction**
Lucia Viola, Colombia and Carlos Cabrera-Galvex, Spain
- 11:32 ES40.01 - Finding Your Voice: Speech and Swallowing Strategies for Lung Cancer Patients**
Eduardo Rios, Spain
- 11:44 ES40.02 - Exercise and Optimization in Patients with Lung Cancer: The Role of Physiotherapy in Enhancing Lung Cancer Patients' Quality of Life**
Morten Quist, Denmark
- 11:56 ES40.03 - The Heart of Care: Empowering Lung Cancer Patients Through Oncology Nursing Support**
Mary Duffy, Australia
- 12:08 ES40.04 - Living with Dignity: Palliative Care Strategies to Enhance Quality of Life in Lung Cancer**
Guida Da Ponte, Portugal
- 12:20 Q&A**

11:30 - 12:45 HOW05 - NEXT GENERATION SEQUENCING CLINICAL REPORT DECODIFICATION IN NON-SMALL CELL LUNG CANCER #1
(LIMITED CAPACITY - FIRST COME FIRST SERVED)

ROOM 11 This session will be repeated today from 13:00 to 14:15.



- 11:30 HOW05.01 - Next Generation Diagnosis in Patients with Non-small Cell Lung Cancer**
Ola Khorshid, Egypt
- 11:50 HOW05.02- Report Next Generation Sequencing Data for Clinical Interpretation**
Christian Rolfo, USA
- 12:10 HOW05.03 - Hands-On Practical Training**
Gianluca Russo, Italy

11:30 - 12:45 MA07 - NEW PERSPECTIVES IN PATHOLOGY BIOMARKERS

Track: Pathology and Biomarkers



ROOM 09

Chairs: Fernando Lopez-Rios, Spain and Veronica Cheung, Australia

- 11:30 Welcome & Introduction**
Fernando Lopez-Rios, Spain and Veronica Cheung, Australia

- 11:31 MA07.01 - A Grading System for Invasive Squamous Cell Carcinoma of the Lung: A Multi-Institutional Study by the IASLC Pathology Committee**
Mari Mino-Kenudson, USA
- 11:36 MA07.02 - Development and Prospective Validation of a Chromatin-Based Classification for Small-Cell Lung Cancer**
Anish Thomas, USA
- 11:41 MA07.03 - Morphological Implication of Invasive Lung Adenocarcinoma -Analysis Employing AI Method Based on Noguchi's Classification**
Hitomi Kawaii, Japan
- 11:46 Q&A**
- 11:54 MA07.04 - Integration of a Molecular Prognostic Classifier Enhances Conventional Staging of Lung Adenocarcinoma**
Hanie Abolfathi, Canada
- 11:59 MA07.05 - Lung Cancer with Spread of Tumor Through Air Spaces: Transcriptomic Biosignature of Primary Tumors and Expression Analysis Airway Tumor Clusters**
Whitney Brandt, USA
- 12:04 Q&A**
- 12:12 MA07.06 - Characterization of Protein Arginine Methyltransferase 5 (PRMT5) Expression in Methylthioadenosine Phosphorylase (MTAP) Deleted NSCLC**
Robert Hsu, USA
- 12:17 MA07.07 - Validation Analysis of MET IHC as a Biomarker for Amivantamab-Lazertinib Response in Post-Osimertinib EGFR-Mutated NSCLC**
Benjamin Besse, France
- 12:22 MA07.08 - MFAP4+ Pericytes Promote Tc17-Mediated Pneumonitis Induced by the Combination of Radiotherapy & Immunotherapy**
Xue Bai, China
- 12:27 MA07.09 - Three-Year Survival Update and Biomarker Analysis of Neoadjuvant Chemoimmunotherapy in Potentially Resectable Stage IIIA/IIIB NSCLC**
Kewei Ma, China
- 12:32 Q&A**

11:30 - 12:45 MA08 - COMMON AND UNCOMMON EGFR MUTATIONS, NEW TREATMENTS IN THE HORIZON

Track: Metastatic Non-small Cell Lung Cancer - Targeted Therapy



ROOM 01

Chairs: Alessio Cortellini, Italy and Cheryl Ho, Canada

- 11:30 Welcome & Introduction**
Alessio Cortellini, Italy and Cheryl Ho, Canada
- 11:32 MA08.01 - A Multinational Phase 2 Randomized Pivotal Study of Sunvozertinib in Pretreated NSCLC with EGFR Exon 20 Insertion Mutations**
Mengzhao Wang, China
- 11:37 MA08.02 - Ziplertinib in NSCLC Patients (Pts) With EGFR Exon 20 Insertion (Ex20Ins) Mutations Who Received Prior Amivantamab**
Zofia Piotrowska, USA

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

11:42 **MA08.03 - First-Line Subcutaneous Amivantamab Plus Chemotherapy in EGFR Exon 20 Insertion-Mutated Advanced NSCLC: Results From PALOMA-2**
Sun-Min Lim, Republic of Korea

11:47 **Q&A**

11:55 **MA08.04 - Phase 2 Interim Results of Ziplertinib in Patients with NSCLC Harboring Uncommon Non-Exon 20 Insertion EGFR Mutations**
Hibiki Udagawa, Japan

12:00 **MA08.05 - PALOMA-2: Subcutaneous Amivantamab Administered Every 4 Weeks (Q4W) Plus Lazertinib in First-Line EGFR-Mutated Advanced NSCLC**
Susan Scott, USA

12:05 **Q&A**

12:13 **MA08.06 - Comparison of Asandeutertinib and Osimertinib in EGFR-Mutated NSCLC with Brain Metastases: Interim Analysis of the ESAONA Pivotal Study**
Yuankai Shi, China

12:18 **MA08.07 - OCELOT: A Pan-Canadian Study of Osimertinib for Patients with Treatment Naive Advanced NSCLC with Uncommon EGFR Mutations**
Daniel Breadner, Canada

12:23 **Q&A**

11:30 - 12:45 OA14 - CANCER EVOLUTION AND DRUG RESISTANCE

Track: Tumor Biology - Preclinical Biology



ROOM 05

Chairs: Yuchen Han, China and Diego de Miguel Perez, USA

11:30 **Welcome & Introduction**
Yuchen Han, China and Diego de Miguel Perez, USA

11:32 **OA14.01 - Glutamine Metabolic Reprogramming Drives Evolution of Lung Adenocarcinoma**
Yang Wang, China

11:42 **OA14.02 - DCBLD2high Tumor-Derived Retinoic Acid Orchestrates Macrophages to Drive Vascular Immunosuppression and Immunotherapy Resistance**
Shangbiao Li, China

11:52 **OA14.03 - Functional Characterization of Osimertinib-Induced Drug Tolerant Persists in Lung Adenocarcinoma**
Kristyna Gorospe, Canada

12:02 **OA14.04 - Genetic Inactivation of the Epigenetic Regulator ATF7IP: Functional Impact in Lung Adenocarcinomas**
Juan Morillas, Spain

12:12 **OA14.05 - Panorama of Chromosomal Instability in 1209 Lung Cancer Genomes**
Lixing Yang, USA

12:22 **OA14.06 - Discussant**
Roberto Bianco, Italy

12:32 **Q&A**

11:30 - 12:45 OA15 - GLOBAL LUNG CANCER SCREENING STRATEGIES

Track: Screening and Early Detection



ROOM 07

Chairs: Long Jiang, China and Giulia Pasello, Italy

11:30 **Welcome & Introduction**
Long Jiang, China and Giulia Pasello, Italy

11:32 **OA15.01 - Results of the Croatian National Lung Cancer Screening Program**
Miroslav Samaržija, Croatia

11:42 **OA15.02 - Preliminary Results of the Singapore Lung Cancer Screening Through Integrating CT With Other Biomarkers (SOLSTICE) Study**
Gillianne Lai, Singapore

11:52 **OA15.03 - Female Asian Nonsmoker Screening Study (FANSS): A U.S. Based Lung Cancer Screening Program in a Non-Smoking Population**
Elaine Shum, USA

12:02 **OA15.04 - Discussant**
David Baldwin, UK

12:12 **Q&A**

11:30 - 12:45 OA16 - BUILDING BRIDGES BETWEEN RESECTABLE AND UNRESECTABLE STAGE III NSCLC

Track: Local-Regional Non-small Cell Lung Cancer



ROOM 06

Chairs: Giulia Veronesi, Italy and Cecile Le Pechoux, France

11:30 **Welcome & Introduction**
Giulia Veronesi, Italy and Cecile Le Pechoux, France

11:32 **OA16.02 - RAPID-RT: Using Rapid-Learning to Assess the Survival Impact of Limiting Dose to a New Cardiac Avoidance Area During Lung Cancer Radiotherapy**
Corinne Faivre-Finn, UK

11:42 **OA16.03 - Sequencing of Radiotherapy and Immunotherapy Stratifies Pneumonitis Risk: A Propensity-Matched Multicenter Study**
Wei Wei, China

11:52 **OA16.04 - Prognostic Value of Residual Viable Tumor in Lymph Nodes of Non-small Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy**
Tianxiao Han, China

12:02 **OA16.05 - Discussant**
Matthew Hatton, UK

12:12 **Q&A**

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

13:00 - 14:15 ES41 - CHALLENGES IN ONCOGENE DRIVEN NSCLC: YOUNG PATIENTS, ECONOMIC TOXICITY, FEASIBILITY FOR DE-ESCALATING TKI

Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy



ROOM 08

Chairs: Jordi Remon, France and Vanita Noronha, India

- 13:00 Welcome & Introduction**
Jordi Remon, France and Vanita Noronha, India
- 13:02 ES41.01 - Oncogene Addicted NSCLC in Young Patients: Incidence and Outcome on Targeted Therapies**
Hossein Borghaei, USA
- 13:12 ES41.02 - Pregnancy in Oncogene Addicted NSCLC: Incidence, Feasibility and Risks**
Martina Imbimbo, Italy
- 13:22 ES41.03 - How to Reduce Inequalities into Access to Targeted Therapies Worldwide, Financial Burden**
Luis Corrales, Costa Rica
- 13:32 ES41.04 - Is It Feasible the De-Escalation Treatment with TKI in Oncogene Addicted NSCLC**
Halmos Balaz, USA
- 13:42 ES41.05 - How to Explain to Your Children You Are a Patient with Lung Cancer?**
Terri Conneran, USA
- 13:52 Q&A / Panel Discussion**

13:00 - 14:15 ES42 - PATIENT AND EXPERTS DIALOGS FOR NEOADJUVANT, ADJUVANT OR PERIOPERATIVE MODALITIES FOR RESECTABLE NSCLC

Track: Early-Stage Non-small Cell Lung Cancer



ROOM 02

Chairs: Kristen Marrone, USA and Yuko Oya, Japan

- 13:00 Welcome & Introduction**
Kristen Marrone, USA and Yuko Oya, Japan
- 13:02 ES42.01 - Patient Board**
Yvonne Diaz, UK, Debra Montague, UK, Merel Hennink, Netherlands
- 13:17 ES42.02 - Neoadjuvant**
Maria Rosario Campelo, Spain
- 13:29 ES42.03 - Adjuvant**
Mary O'Brien, UK
- 13:41 ES42.04 - Perioperative**
David Jones, USA
- 13:53 Discussion**

13:00 - 14:15 ES43 - CONFOUNDING CASES OF PULMONARY NODULES: ADVANCES IN THE DIAGNOSIS AND MANAGEMENT OF SUBSOLID AND GROUND GLASS OPACITIES

Track: Pathology and Biomarkers



ROOM 07

Chairs: Jia Luo, USA and Wei Gu, USA

- 13:00 Welcome & Introduction**
Jia Luo, USA and Wei Gu, USA
- 13:02 ES43.01 - The Radiologist: Neoplastic or Not Neoplastic?**
Mathias Prokop, Netherlands
- 13:12 ES43.02 - The Pathologist: The Diagnostic Workflow of Lung GG or SS Nodule**
Veronica Cheung, Australia
- 13:22 ES43.03 - The Oncologist: Multiple Primaries or Metastases?**
Edurne Arriola, Spain
- 13:32 ES43.04 - The Surgeon: To Resect or Not to Resect?**
Andrea Billè, UK
- 13:42 ES43.05 - The Patient Advocate/Nurse Practitioner: Patient and Clinician Perspective on Lung Nodules**
Stephanie Canty, USA
- 13:52 ES43.06 - The Radiation Oncologist View: How to Treat?**
Sara Ramella, Italy
- 14:02 Q&A**

13:00 - 14:15 ES44 - ADDRESSING SPECIAL CONDITIONS TO BRIDGE GAPS IN UNRESECTABLE NSCLC

Track: Local-Regional Non-small Cell Lung Cancer



ROOM 04

Chairs: Monica Castro, Argentina and Dusty Donaldson, USA

- 13:00 Welcome & Introduction**
Monica Castro, Argentina and Dusty Donaldson, USA
- 13:02 ES44.01 - Tackling Cancer Cachexia in Locally Advanced NSCLC**
Puneeth Iyengar, USA
- 13:14 ES44.02 - Optimizing the Management of Treatment-Related Pneumonitis**
Samantha Aso, Spain
- 13:26 ES44.03 - Caring for Long-Term Survivors After Curative Chemoradiation**
Nicole Rankin, Australia
- 13:38 ES44.04 - Novel Approaches for Patients Who Are Unfit for Concurrent Chemoradiotherapy**
Andrea Filippi, Italy
- 13:50 Q&A**

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

13:00 - 14:15 HOW06 - *REPEAT SESSION* NEXT GENERATION SEQUENCING CLINICAL REPORT DECODIFICATION IN NON-SMALL CELL LUNG CANCER #2

(LIMITED CAPACITY - FIRST COME FIRST SERVED)

ROOM 11

NOT FOR CME CREDIT

- 11:30 HOW06.01 - Next Generation Diagnosis in Patients with Non-small Cell Lung Cancer**
Ola Khorshid, Egypt
- 11:50 HOW06.02- Report Next Generation Sequencing Data for Clinical Interpretation**
Christian Rolfo, USA
- 12:10 HOW06.03 - Hands-On Practical Training**
Gianluca Russo, Italy

13:00 - 14:15 MA09 - DIVING DEEP INTO DIVERSITY: OLD AND NEW RISKS FOR LUNG CANCER

Track: Risk Factors, Risk Reduction & Tobacco Control

NOT FOR CME CREDIT

ROOM 05

Chairs: Rachael Murray, UK and Biagio Ricciuti, USA

- 13:00 Welcome & Introduction**
Rachael Murray, UK and Biagio Ricciuti, USA
- 13:02 MA09.01 - Association of Air Pollution Exposure with Lung Screening Outcomes and Lung Cancer Risk in the Taiwan TALENT Study**
Rafael Meza, Canada
- 13:07 MA09.02 - Impact of Air Pollution and EGFR Mutation on Epigenetic Age and Lung Cancer: A Pilot Study**
Anna McGuire, Canada
- 13:12 MA09.03 - Determining the Role of Fine Particulate Matter (PM2.5) in Lung Cancer Initiation**
Peiyao Wang, Canada
- 13:17 Q&A**
- 13:25 MA09.04 - Maternal Preconception Vaping of Nicotine Induces Severe Airway Remodeling in Offspring and Reduces Airway Progenitor Cells in D. Melanogaster**
Leizhi Shi, Germany
- 13:30 MA09.05 - The Effect of Lung Cancer Screening on Smoking Behaviors - No Evidence of a 'License to Smoke' Effect**
Matthew Callister, UK
- 13:35 MA09.06 - Impact of Smoking Cessation at Diagnosis on Overall Survival in Lung Cancer Patients: A Comprehensive Meta-Analysis**
Dong Won Park, Republic of Korea

13:40 Q&A

13:48 MA09.07 - Body Roundness Index and Polygenic Risk Score Improve Lung Cancer Risk Prediction Over BMI: Prospective Analyses in the UK Biobank
Wenxuan Li, China

13:53 MA09.08 - Germline Variants in Indian NSCLC Patients with Familial Aggregation: A Prospective Cohort Study
Prabhat Malik, India

13:58 MA09.09 - Unraveling Ancestry Disparities and Intratumoral Heterogeneity in Non-small Cell Lung Cancer
Wenxiang Wang, China

14:03 Q&A

13:00 - 14:15 MA10 - LONGER FOLLOW UP AND NEW IO COMBINATIONS

Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy

NOT FOR CME CREDIT

ROOM 06

Chairs: Sara Goldberg, USA

- 13:00 Welcome & Introduction**
Sara Goldberg, USA
- 13:02 MA10.01 - Phase II Trial of Serplulimab Plus Bevacizumab and Chemotherapy for Treatment-Naïve Non-Squamous NSCLC With Brain Metastases (SUPER BRAIN)**
Hui Yu, China
- 13:07 MA10.02 - CAN-2409 With Continued Immune Checkpoint Inhibitor (ICI) in Patients with Stage III/IV NSCLC With Inadequate Response to ICI**
Charu Aggarwal, USA
- 13:12 MA10.03 - Efficacy and Safety of Cadonilimab Plus Pulocimab in NSCLC Patients Who Progressed Following Prior Immunotherapy: A Phase 1b/2 Study**
Yulong Zheng, China
- 13:17 Q&A**
- 13:25 MA10.04 - Low-Pass Wgs Reveals Clonal Evolution of CNAs Associated with Response to the First-Line Immunotherapy or Chemoimmunotherapy in NSCLC Patients**
Marcin Nicoś, Poland
- 13:30 MA10.05 - Phase I/II Study of Nivolumab and Ipilimumab with Concurrent Stereotactic Radiosurgery for Intracranial Metastases From NSCLC**
Mehmet Altan, USA
- 13:35 MA10.06 - IMscin002 Final Analysis: Patient Preference and Safety of Atezolizumab by Subcutaneous and Intravenous Administration**
Federico Cappuzzo, Italy
- 13:40 Q&A**
- 13:48 MA10.07 - Impact of Myeloid Growth Factor Support on Outcomes in RELATIVITY-104: Insights from Clinical and Preclinical Data in NSCLC**
Vamsidhar Velcheti, USA
- 13:53 MA10.08 - Anti-PD-1 Re-Challenge After Immune Priming by CTLA-4 Inhibition and Immune Boosting Through Radiotherapy in Advanced NSCLC: The RAD-IO Trial**
Daphne van der Geest, Netherlands

HOD Highlight of the Previous Day
HOW Hands-On Workshop
MA Mini Oral Abstract Session
OA Oral Abstract Session

P Poster
PT Poster Tour
PL Plenary
WS Workshop

13:58 MA10.09 - Cemiplimab Plus Chemotherapy vs Chemotherapy in Advanced NSCLC: 5-Year Results from Phase3 EMPOWER-Lung 3 Part 2 Trial

Ana Baramidze, Georgia

14:03 Q&A

13:00 - 14:15 MA11 - INNOVATIVE THERAPEUTIC STRATEGIES AND MOLECULAR INSIGHTS IN SCLC AND NEUROENDOCRINE TUMORS

Track: Small Cell Lung Cancer and Neuroendocrine Tumors



ROOM 01

Chairs: Tatiane Montella, Brazil and Julio Oliveira, Portugal

13:00 Welcome & Introduction

Tatiane Montella, Brazil and Julio Oliveira, Portugal

13:02 MA11.01 - Phase 1 Study of DLL3-Targeted CAR-T Cells Armored with dnTGFB2 in Small-Cell Lung and Large-Cell Neuroendocrine Cancers

Adam Schoenfeld, USA

13:07 MA11.03 - Tifcemalimab Plus Toripalimab and Chemotherapy as a First-Line Therapy in ES-SCLC: A Phase Ib/II Study

Ziming Li, China

13:12 Q&A

13:20 MA11.04 - Safety of Lurbinectedin + Atezolizumab as 1L Maintenance Treatment in ES-SCLC: Results from the Phase 3 IMforte Study

Martin Reck, Germany

13:25 MA11.05 - Comparative Outcomes of Lobectomy and Sub-Lobar Resections in Pulmonary Carcinoids: A Multicentre Retrospective Cohort Study

Michal Dziedzic, Poland

13:30 MA11.06 - Multiomic Profiling of Inter-Lesion Heterogeneity in Small Cell Lung Cancer: A Multicenter Rapid Research Autopsy Program

Zsolt Megyesfalvi, Austria

13:35 Q&A

13:43 MA11.08 - Longitudinal Circulating Tumor DNA Dynamics Predict Therapeutic Efficacy in ES-SCLC Treated with Immunotherapy

Chunxia Su, China

13:48 MA11.09 - Circulating Tumor DNA Refines Consolidation Immunotherapy for Limited-Stage SCLC

Nan Bi, China

13:53 MA11.10 - IFITM3 Enhances Immunotherapy Sensitivity Through MHC-I Regulation in Small Cell Lung Cancer

Xinyu Liu, China

13:58 Q&A

13:00 - 14:15 OA17 - BALANCING COST, CARE AND PATIENT CHOICE IN REAL WORLD JOURNEY AND RESEARCH

Track: Patient Advocacy



ROOM 09

Chairs: Barbara Melosky, Canada and Thomas Stinchcombe, USA

13:00 Welcome & Introduction

Barbara Melosky, Canada and Thomas Stinchcombe, USA

13:02 OA17.01 - Stigma and Psychological Distress in Patients with Lung Cancer: A Possible Role of EMDR (Eye Movement Desensitization and Reprocessing) Therapy

Annamaria Catino, Italy

13:12 OA17.02 - Knowledge and Shared Decision Making - a European Experience

Debra Montague, Switzerland

13:22 OA17.03 - The Patient Voice on Required Research Biopsies: Results of a Survey Study Exploring the Perspective of Patients with Lung Cancer

Faith Abodunrin, USA

13:32 OA17.04 - Financial Toxicity in Patients Who Received Targeted Therapy for Lung Cancer

Caroline Burley, USA

13:42 OA17.05 - Discussant

William William Jr, Brazil

13:52 Q&A

13:00 - 14:15 OA18 - THE BEST ROAD: REDUCING DISPARITIES AND IMPROVING EARLY DETECTION RATES

Track: Global Health, Health Services, and Health Economics



ROOM 03

Chairs: Verna Vanderpuye, Ghana and George Oblitas, Peru

13:00 Welcome & Introduction

Verna Vanderpuye, Ghana and George Oblitas, Peru

13:02 OA18.01 - Improving Lung Cancer Outcomes Through Policy a Global Perspective on Risk Reduction, Early Detection, Care and Survivorship

Andreas Charalambous, Cyprus

13:12 OA18.02 - Emerging Disparities in Lung Cancer Burden in the Americas: A GLOBOCAN-Based Projection to 2050

Gabriela Carmona De Souza, Brazil

13:22 OA18.03 - Cost Effectiveness of Australian Lung Cancer Screening Eligibility Criteria: A Comparison Study

Chellan Kumarasamy, Australia

13:32 OA18.04 - Sociodemographic and Healthcare Factors Associated with Enrollment in a Clinical Trial Integrating Tobacco Cessation and Lung Cancer Screening

Efrén Flores, USA

13:42 OA18.05 - Discussant

Cecilia Pompili, UK

13:52 Q&A

14:15 – 15:45 **CLOSING LUNCH - NOT SO TRIVIAL: A WCLC INTERDISCIPLINARY QUIZ CHALLENGE**

PLENARY HALL



Quizmaster: Stephen Liu, USA

Don't miss it! A dynamic and engaging session where some of the field's most renowned names go head-to-head in a spirited competition. It is the perfect way to close out the Conference with great food and high energy!

ON-DEMAND

HOD03 - HIGHLIGHTS OF THE DAY - TUESDAY ABSTRACTS


- | | |
|-----------------|--|
| HOD03.01 | Tumor Biology
<i>Cristina Teixido, Spain</i> |
| HOD03.02 | Screening
<i>Pan Chyr Yang, Taiwan</i> |
| HOD03.03 | Local-Regional NSCLC
<i>Lilian Faroni, Brazil</i> |
| HOD03.04 | Patient Advocacy and Global Health
<i>Jia Luo, USA</i> |

IASLC CELEBRATION NIGHT

Tibidabo, Barcelona



Purchase Your
Tickets at the
Registration
Desk by
September 7.



SEPT 08

TIBIDABO BARCELONA

19:30 – 23:00

IMPORTANT: Please ensure you have a copy of your e-ticket to gain access. Your e-ticket has been emailed to you from: wclc2025-registration@icsevents.com.

INCLUDED WITH YOUR TICKET:

- Bus Transfers from Key Locations
- Round-trip Funicular Rides
- Spanish Cuisine and Beverages
- Exclusive Access to Select Park Rides
- Live Entertainment
- Panoramic Views of Barcelona



2025 World Conference
on Lung Cancer

SEPTEMBER 6-9, 2025 | BARCELONA, SPAIN

WCLC 2025'S GOT TALENT

THANK YOU TO OUR AMAZING PERFORMERS!

PERFORMING AT THE
OPENING PLENARY:

ANDREAS RIMNER, GERMANY
HENRY PARK, USA
SANTIAGO VITERI, SPAIN
TOM JOHN, AUSTRALIA
SANJAY POPAT, UK

PERFORMING AT THE
CLOSING LUNCH:

DAVID LEE, USA



2026 World Conference
on Lung Cancer

SEPTEMBER 12 - 15, 2026 | SEOUL, REPUBLIC OF KOREA

WANT TO BE ON STAGE IN SEOUL?

Watch out for the WCLC 2026 Call for Talent on wclc.iaslc.org




06

POSTERS & EPOSTERS

IASLC 2025 WORLD CONFERENCE ON LUNG CANCER
CONQUERING LUNG AND OTHER THORACIC CANCERS WORLDWIDE IN THE 21ST CENTURY.

Each poster has a unique number that provides important information when and where it will be presented. Poster Number Format: **P1.04.11**

Example: **P1.04.11**



Sunday, September 7, 2025 – P1 Posters

Presenters in Attendance: **10:30 – 12:00**

Track 04: Screening and Early Detection

Track 07: Early-Stage Non-Small Cell Lung Cancer

Track 11: Metastatic Non-small Cell Lung Cancer – Immunotherapy

Track 17: Global Health, Health Services, and Health Economics

Rows: 01 – 06

Rows: 06 – 12

Rows: 12 – 20

Rows: 20 – 28

Monday, September 8, 2025 – P2 Posters

Presenters in Attendance: **10:30 – 12:00**

Track 02: Tumor Biology – Preclinical Biology

Track 05: Pulmonology and Staging

Track 06: Pathology and Biomarkers

Track 08: Local-Regional Non-small Cell Lung Cancer

Track 10: Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy

Track 15: Multidisciplinary Care: Nursing, Allied Health and Palliative Care

Rows: 01 – 05

Rows: 05 – 07

Rows: 07 – 17

Rows: 17 – 23

Rows: 23 – 25

Rows: 25 – 28

Tuesday, September 9, 2025 – P3 Posters

Presenters in Attendance: **10:00 – 11:30**

Track 01: Risk Factors, Risk Reduction & Tobacco Control

Track 03: Tumor Biology – Translational Biology

Track 09: Metastatic Non-small Cell Lung Cancer – Local Therapies

Track 12: Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Track 13: Small Cell Lung Cancer and Neuroendocrine Tumors

Track 14: Mesothelioma, Thymoma, and Other Thoracic Tumors

Track 16: Patient Advocacy

Track 18: Clinical Trials in Progress

Rows: 01 – 06

Rows: 06 – 11

Rows: 11 – 12

Rows: 12 – 19

Rows: 19 – 23

Rows: 23 – 25

Rows: 25 – 27

Rows: 27 – 36

POSTERS (P1):

SUNDAY, SEPTEMBER 7, 2025

i 10:30 – 12:00 Presenters in Attendance

TRACK 04: SCREENING AND EARLY DETECTION

- P1.04.01** Stage Shift and Then Some - St. Elizabeth Healthcare's Notable Journey, 50,000 Screens Later
Michael Gieske, USA
- P1.04.02** Performance of AI Vs. Radiologists in the 4-IN-THE-LUNG-RUN Lung Cancer Screening Trial: Annual Follow-Up Results
Marjolein Heuvelmans, Netherlands
- P1.04.03** Comorbidities and Social Factors in Lung Cancer Screening Eligibility: Insights from the ColaUS and Lc65 Cohorts in Switzerland
Louis Gros, Switzerland
- P1.04.04** Effect of Social Determinants of Health on Lung Cancer Screening Uptake in the U.S
Elizabeth Seitz, USA
- P1.04.05** Diminishing Eligibility for Lung Cancer Screening According to Standardized Screening Guidelines
Janet Song, USA
- P1.04.06** AI Performance for Lung Nodule Growth in UK Lung Cancer Screening: Expert Consensus and Histological Validation
Michael Davies, UK
- P1.04.07** Projection of the Lung Cancer Screening Eligible Population in Argentina from 2000 to 2050
M. Victoria Salgado, Argentina
- P1.04.08** Program Guidelines for Australia's National Lung Cancer Screening Program: A Robust and Consultative Development Approach
Nicole Rankin, Australia
- P1.04.09** Size Distribution and Short-Term Progression of New Nodules From the 4ITLR Lung Cancer Screening Trial
Marjolein Heuvelmans, Netherlands
- P1.04.10** Lung Cancer Screening Completion Rates as Predicted by Social Deprivation
Randi Williams, USA
- P1.04.11** New Nodule Lung Cancer in the UK Lung Cancer Screening Trial: Characteristics and Comparison with NELSON
Michael Davies, UK
- P1.04.12** Smoking Duration Lung Screening Criteria (Potter Criteria) Captures More Underrepresented Individuals at Risk for Lung Cancer
Teri Hill, USA
- P1.04.13** The Impact of Reconstruction Kernel and Hounsfield Unit Threshold on Emphysema Quantification from Lung Cancer Screening Data
Hailan Liu, Netherlands
- P1.04.14** Age, Risk Thresholds and Cost-Effectiveness: Evaluating Lung Cancer Screening Using the PLCom2012 Model
Megha Sikarwar, Germany
- P1.04.15** Lung Cancer Screening in Switzerland: Baseline Results from the Vaud Pilot Project
Cédric Bongard, Switzerland
- P1.04.16** Real-World Outcomes of Lung Cancer Screening and High-Risk Lung-RADS 4 Nodules at VA Northern California Health Care System
Cristhian Ochoa, USA

- P1.04.17** Poor Utilization of Lung Cancer Screening Among Cancer Survivors in the USA
Alexis Chidi, USA
- P1.04.18** Diagnosis of Sub-Cm Lung Nodules with Deep Learning Segmentation and Radiomics-Based Machine Learning Classifiers
Ian Janzen, Canada
- P1.04.19** Evaluating the Impact of Electronic Reminders on Lung Cancer Screening
Carolyn Chang, USA
- P1.04.20** Barriers to Lung Cancer Screening Among Overdue Patients; a Quality Improvement Initiative
Sania Choudhary, USA
- P1.04.21** Molecular Profiles of Clinical and Radiological Features in Pre-Invasive Lung Adenocarcinoma
Yi-Duo Lin, China
- P1.04.22** The Relationship Between Nodular Pleural Tail Sign and Metastasis or Recurrence of Peripheral Lung Cancer
Anle Yu, China
- P1.04.23** Real-World Predictive Performance of Lung-RADS in the Evaluation of Part-Solid Nodules
Seulgi You, Republic of Korea
- P1.04.24** TabPFN Empowered the Ternary Classification of Histological Subtypes in Stage IA LUADs Based on AI Analyzed Histogram Features
Guotian Pei, China
- P1.04.25** Incidental Findings from the Annual Follow-Up in the 4-In-The-Lung-Run Lung Cancer Screening Trial
Carlijn van der Aalst, Netherlands
- P1.04.26** The Impact of Brain MRI Surveillance on Survival Outcomes in Initially CNS Metastasis-Free Non-small Cell Lung Cancer
Seong-Eun Kim, Republic of Korea
- P1.04.27** Radiologic Features Identification of Pathologic Tumor Invasion in Pure Ground-Glass Nodules
Yeqing Zhu, China
- P1.04.28** Correlation Between Dosimetric Parameters and Radiation-Induced Pulmonary Toxicity in Lung Cancer Radiotherapy
Luísa Assunção, Brazil
- P1.04.29** Female Asians Who Never Smoked with Lung Adenocarcinomas (FANSA) Have Unique Survival Outcomes: An ILCCO Analysis
Zachary Coyne, Canada
- P1.04.30** Screening of Paraptosis-Related Prognostic Genes in Lung Adenocarcinoma by Bioinformatics Analysis and Experimental Validation
Tao Zhang, China
- P1.04.31** Implementation of a Lung Cancer Risk Prediction Algorithm: Early Findings from the Lungflag™ Pilot at Geisinger Health System
Matthew Facktor, USA
- P1.04.32** Moving Forward in Early Detection: The ACS/NLCRT Best Practice Guide for Building Lung Cancer Early Detection Programs
Carey Thomson, USA
- P1.04.33** Sybil Pilot for Incidental Pulmonary Nodules
Renelle Myers, Canada
- P1.04.34** AI Powered Incidental Pulmonary Nodule Program Demonstrates High Lung Cancer Detection Rate: Canadian IDEAL Study
Renelle Myers, Canada
- P1.04.35** Impact of Lung Cancer Screening Eligibility Criteria on Participants' Characteristics and Healthcare Resources
Maria Cabrera, Spain

- P1.04.36** LungFlagTM Risk Prediction Validation on Canadian Ever Smokers Pre-Classified as High Risk for Lung Cancer
Sukhinder Atkar-Khattra, Canada
- P1.04.37** Systematic Enrolment for Lung Cancer Screening Ensures Rapid Stage Shift of Diagnosed Lung Cancers at a Population Level
Tanel Laisaar, Estonia
- P1.04.38** The Coincidental Findings of Lung Nodules With AI-Assisted Chest X-Rays in the Tuberculosis Screening Project
Prakaitip Susilparat, Thailand
- P1.04.39** Markov Model Approach to Optimize Lung Cancer Screening and Early Detection in Patients with Smoking Associated Diseases
Clarisse Buton, France
- P1.04.40** Improving Lung Cancer Risk Prediction in Asbestos Exposed Individuals: The AQC Ensemble Model
Chellan Kumarasamy, Australia
- P1.04.41** Survival Differences Following Surveillance Detected Vs. Symptom Detected Recurrence in Patients with Lung Cancer
Nadia Moss, Netherlands
- P1.04.42** Circulating Tumor Cells Combined with Solid Nodular Ratio to Predict High-Risk Pathological Subtypes of Stage IA Lung Adenocarcinoma
Bingyu Rao, China
- P1.04.43** Evaluating the Role of Digital Tomosynthesis in Lung Cancer Screening: A Cost-Effective Alternative to Annual LDCT in Resource-Limited Settings
Natthaya Triphuridet, Thailand
- P1.04.44** Clinical Efficiency of Repeat CT-Guided Transthoracic Needle Biopsy of Peripheral Lung Lesions
Sofya Samsonik, Russian Federation
- P1.04.45** Multi-Center Validation of a Circulating 9-microRNA Signature for Lung Cancer Early Detection
Fabrizio Bianchi, Italy
- P1.04.46** Predicting Malignancy in Ground-Glass Opacity Using Multivariate Regression and Deep Learning Models: A Proof-Of-Concept
Abed Agbarya, Israel
- P1.04.47** Breathomics Meets Deep Learning: A Novel Approach for Early Detection of Lung Cancer
Annamaria Catino, Italy
- P1.04.48** Rapid Intra-Operative Detection of Visceral Pleural Invasion in Non-small Cell Lung Cancer Using Label-Free Multiphoton Microscopy
Suyi Chen, China
- P1.04.49** Targeting VEGFR3 Nir Fluorescent Probe for Identification of NSCLC Metastatic Lymph Nodes an Exploratory Study on Surgical Navigation
Lintong Yao, China
- P1.04.50** Fluorescein-Free Confocal Laser Endomicroscopy for Intraoperative Diagnosis of Pulmonary Nodules: A Comparative Study with Frozen Section
Jiawei Xie, China
- P1.04.51** Exploring the Potential of Multimodal Cough Analysis as a Pre-Screening Tool for Non-small Cell Lung Cancer Detection
Arsela Prelaj, Italy
- P1.04.52** A Clinically Applicable and Generalizable Deep Learning Model for Segmenting Anterior Mediastinal Tumors Across Multiple Institutions
Hirokazu Watanabe, Japan
- P1.04.53** Potential for AI as First Reader in Lung Cancer Screening
Giovanni Leuzzi, Spain

TRACK 07: EARLY-STAGE NON-SMALL CELL LUNG CANCER

- P1.07.01** Wearable-Based Evaluation of Tubeless Thoracic Surgery for Early-Stage Lung Cancer
Runchen Wang, China
- P1.07.02** Septum-Guided Segmentectomy vs Lobectomy for Deeply Located cT1abN0M0 Non-small Cell Lung Cancer
Qing Wang, China
- P1.07.03** Effectiveness of a Generalizable AI Based Automated Workflow Recognition Model in Multiple Approaches to Lung Resection
Seiyu Ohtani, Japan
- P1.07.04** MRD Combined with Radiological Tumor Volume as Tool to Identify Resected NSCLC Patients at High Risk of Recurrence
Roberta Minari, Italy
- P1.07.05** Real-World Biomarker Testing and Treatment Initiation in Patients with Resected Early-Stage NSCLC (eNSCLC) in the US and UK
Samantha Reiss, USA
- P1.07.06** Impact of Mediastinal Lymph Node Dissection/Sampling on Survival in Frozen Section-Upgraded Invasive Lung Adenocarcinoma
Yu Xing Huang, China
- P1.07.07** The Presence of STAS Leads to Poor Prognosis After Sublobar Resection in Stage I NSCLC: Results from an Individual Patient Data Metanalysis
Filippo Tommaso Gallina, Italy
- P1.07.08** Comparing Outcomes of Different Surgical Methods for Small-Sized NSCLC With VPI- A Population-Based Study
Xu-Heng Chiang, Taiwan
- P1.07.09** Real-World Efficacy of an AI-Driven 3D Reconstruction System on Pulmonary Surgery
Jiayi Geng, China
- P1.07.10** Prognostic Impact of Resection Margin Distance in Patients with Completely Resected Stage INSCLC After Lobectomy
Shia Kim, Republic of Korea
- P1.07.11** AI-Based 3D Reconstruction in Lung Surgery
Sayzana Kassahun, Germany
- P1.07.12** Independent Risk Factors for Occult Lymph Node Metastasis in cIA Left Upper Lobe Lung Adenocarcinoma: A Nomogram-Based Prediction Model
Weijie Zhu, China
- P1.07.13** Impact of TP53 Co-Mutation in Resected Early-Stage EGFR-Mutated Lung Adenocarcinoma
Tatsuya Masuda, Japan
- P1.07.14** Exploring the Effect of Surgical Resection on Quality of Life in Older Adults for Stage IA Non-small Cell Lung Cancer
Jiafang Zhang, USA
- P1.07.15** Oncologic Outcomes of Sublobar Versus Lobar Resection for Clinical Stage IA Pure Solid Non-small Cell Lung Cancer
Sumin Shin, Republic of Korea
- P1.07.16** The Association Between Sarcopenia and Postoperative Outcomes and Survival in Lung Cancer Patients Who Underwent Curative Resections
Isabel Emmerick, USA
- P1.07.17** A Neglected Dimension in Lung Cancer Surgery: Sleep Disorders Before and After Anatomical Resection
Riccardo Orlandi, Italy
- P1.07.18** Peri-Operative Immune Cell Profiling in Lung Cancer Resection: A Longitudinal Study
Laura Staunton, Ireland
- P1.07.19** Prospective Cohort Study on Stage IA Non-small Cell Lung Cancer in Older Adults (>80 Years): Prevalence, Surgical Treatment, and Complications
Louis Gros, Switzerland

- P1.07.20** Feasibility of Limited Resection in Invasive Mucinous Adenocarcinoma of the Lung
Haeun Kim, Republic of Korea
- P1.07.21** Lobectomy Versus Multi-Segmentectomy for Left Upper Lobe Lung Cancer: A Propensity Score-Matched Analysis
Naoki Takeno, Japan
- P1.07.22** LANTERN: AI Model for Postoperative Complications Prediction for NSCLC Lung Resection: Prospective Multicentric Study and Extern Validation
Filippo Lococo, Italy
- P1.07.23** Impact of Pulmonary Resection on Early Postoperative Cardiac Function
Toshimasa Okazaki, Japan
- P1.07.24** Radicality of Lymphadenectomy in NSCLC Resection: Impact on Survival. Results from the Spanish Video-Assisted Thoracic Surgery Group (GEVATS)
Carme Obiols, Spain
- P1.07.25** Trajectories of Synchronous Subsolid Nodules in Patients with Resected Subsolid Lung Adenocarcinoma: A Multicenter Cohort Study
Seyoung Jung, Republic of Korea
- P1.07.26** Applicability of Artificial Intelligence Based Tumor Segmentation in Planning for Sublobar Resection in Lung Cancer: A Meta-Analysis
Prosenjit Das, India
- P1.07.27** A Newly Developed 3D Simulation System for the Preoperative Planning for Central-Located Lung Cancer
Fengwei Li, China
- P1.07.28** Segmentectomy vs Lobectomy for Clinical Stage IA1-2 NSCLC and Upstaging Due to Pathologic Visceral Pleura Infiltration
Hafsa Kaman, Germany
- P1.07.29** Prediction of Postoperative Pulmonary Function and Blood Flow Redistribution Using SPECT/CT in Patients Undergoing Lobectomy
Deog Gon Cho, Republic of Korea
- P1.07.30** Beyond the Lung: Distinct Recurrence Patterns of Mucinous and Non-Mucinous Lung Adenocarcinoma After Surgery
Hyo Kyen Park, Republic of Korea
- P1.07.31** Adjuvant Immunotherapy for Clinically Node-Negative Non-small Cell Lung Cancer
Giorgio Caturegli, USA
- P1.07.32** Prognostic Value of Consolidation-To-Tumor Ratio in Stage IA Solid Predominant Non-Mucinous Adenocarcinoma
Yura Ahn, Republic of Korea
- P1.07.33** Sublobar Resection Versus Lobectomy in Peripheral NSCLC After Neoadjuvant Chemoimmunotherapy: A Retrospective Study
Qing Liang, China
- P1.07.34** Toxicity Profile for Connective Tissue Disease Patients Treated with Lung Stereotactic Body Radiation Therapy
Gregory Videtic, USA
- P1.07.35** Stereotactic Body Radiation Therapy for Medically Inoperable Stage I/II EGFRm NSCLC: Global, Multicenter, Retrospective Study
Steven Lin, USA
- P1.07.36** A Three-Gene Signature Predicting Local Recurrence in Stage I-III NSCLC Patients Treated with Radiation Therapy
Victor Lee, USA
- P1.07.37** Using Tissue and Blood to Find Oncogenic Drivers Upfront in Patients with Lung Cancer Evaluated for Neoadjuvant Therapy-LEADER
Jules Lin, USA
- P1.07.38** Neoadjuvant Irupinalkib in Resectable ALK/ROS1 Fusion-Positive NSCLC: Updated Results of the Exploratory Neo-INFINITY Study
Guodong Zhang, China

- P1.07.39** Pooled Efficacy and Safety Profile of Neoadjuvant Therapies in Operable EGFR-Mutant Non-small Cell Lung Cancer: A Meta-Analysis
YunChu Wei, China
- P1.07.40** Detection of ctDNA Prior to Neoadjuvant Osimertinib Treatment Correlates with Decreased EFS in EGFR-Mutated NSCLC
Tyiesha Brown, USA
- P1.07.41** Exhaled Breath Analysis in Patients with Resectable NSCLC Treated with Neoadjuvant Immune Checkpoint Inhibitors
Kristof Cuppens, Belgium
- P1.07.42** Multi-Temporal Imaging and CT-To PET Translation Based Predictive Model on Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer Patients
Minjian Li, China
- P1.07.43** Clinico-Genomic Correlates of Pathologic Response to Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage NSCLC
Edoardo Garbo, USA
- P1.07.44** Multicenter Assessment of Clinical-Radiomic Predictors for Pathologic Response in NSCLC Patients Receiving Neoadjuvant Chemoimmunotherapy
Mengzhe Zhang, China
- P1.07.45** Transforming Outcomes with Neoadjuvant Chemo-Immunotherapy in Operable Non-small Cell Lung Cancer (NSCLC): A Propensity-Matched Analysis
Nehemias Guevara Rodriguez, USA
- P1.07.46** Adjuvant Systemic Therapy for Resected Stage IB-IIA NSCLC (AJCC 8th Edition): A Real-World Cohort Study from SEER Database
Changtai Zhao, China
- P1.07.47** Early Treatment Discontinuation of Osimertinib in the Adjuvant Setting: Insights from the ADAURA Study
Christian Grohé, Germany
- P1.07.48** Furmonertinib as Adjuvant Therapy in Postoperative EGFR-Mutated Stage IB-IIA NSCLC with High-Risk Pathological Factors
Xiao-Long Li, China
- P1.07.49** Limited Impact of Adjuvant Chemotherapy in ALK-Positive Stage II-III Adenocarcinoma: A Multicenter CReGYT-03 ALK Study
Akira Hamada, Japan
- P1.07.50** Aumolertinib as Adjuvant Therapy in EGFRm Stage I-III NSCLC with High-Grade Histological Patterns: 3-Year Dfs Rate Updated
L. Wang, China
- P1.07.51** Safety and Tolerability of Adjuvant Atezolizumab in Pd-L1>50% NSCLC Patients: Real-World Data from the Italian ATLAS Registry
Maria Lucia Reale, Italy
- P1.07.52** Clinicopathologic Risk Score to Guide Adjuvant Chemotherapy in Stage IB NSCLC: Toward Integration of AI-Assessed Tumor Immune Signatures
Jeongmin Seo, Republic of Korea
- P1.07.53** Aumolertinib as Adjuvant Therapy in I-III EGFRm NSCLC: Also Effective in Patients with Multiple Prognostic Risk Factors
Qian Xue, China
- P1.07.54** The Effect of Adjuvant EGFR-TKI Therapy on the Prognosis of Pathological Stage I Invasive Lung Adenocarcinoma with Sensitive EGFR Mutation
Zetao Liu, China
- P1.07.55** Molecular Profiling of Neo-Adjuvant IO Disclosures Residual Cancer Cells in pCR NSCLC: A Single Cell Analysis of CTONG 1804
Si-Yang Liu, China

- P1.07.56** Combining Lymph Nodes and Tumor Radiomics Enhances Immunotherapy Efficacy Prediction in Non-small Cell Lung Cancer
Weijie Zhan, China
- P1.07.57** Alterations in the Gut Microbiota and Metabolites in Patients with Liver Injury Induced by Third-Generation EGFR-Targeted Drugs
Jia-Xuan Li, China

TRACK 11: METASTATIC NON-SMALL CELL LUNG CANCER – IMMUNOTHERAPY

- P1.11.01** First-Line Nivolumab Plus Ipilimumab in Combination with Chemotherapy for Metastatic NSCLC: Real World Data in Italy
Francesco Agustoni, Italy
- P1.11.02** Impact of Prophylactic Use of Cardioprotective L-Carnitine on First-Line Chemoimmunotherapy in Advanced NSCLC: A Cohort Study
Cheng Han, China
- P1.11.03** Long-Term Efficacy of Immune Checkpoint Inhibitors in Pulmonary Cancer with Rhabdoid Features: A Single-Center Retrospective Analysis
May-Lucie Meyer, Switzerland
- P1.11.04** Prediction of Overall Survival in Lung Cancer Patients with Different Organ Metastases: A SEER Population-Based Cohort Study
Kang Qin, USA
- P1.11.05** Efficacy and Multi-Omics Insights of Immune Checkpoint Inhibitors in NSCLC With Leptomeningeal Metastasis
Li-Bo Tang, China
- P1.11.06** Risk Factors and Prognosis of Immune Checkpoint Inhibitor-Induced Pneumonia in Lung Cancer with Interstitial Lung Disease
Tsukasa Ueda, Japan
- P1.11.07** Impact of Radiotherapy and Immune Checkpoint Inhibitor Combination in Advanced NSCLC: Real-World Data (RWD) Analysis
Joaquim Bosch-Barrera, Spain
- P1.11.08** Peripheral Inflammatory Biomarkers Predict Immunotherapy Retreatment Outcomes in Advanced NSCLC
Jiaxin Zhong, China
- P1.11.09** SBRT Combined with Tislelizumab and Granulocyte-Macrophage Colony-Stimulating Factor in Advanced NSCLC Progressing on Immunotherapy
Guangxian You, China
- P1.11.10** Serum Neopterin and Mortality in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
Martina Spisarova, Czech Republic
- P1.11.11** Survival Impact of Pneumonitis in Older Patients with Non-Squamous NSCLC Treated with Pembrolizumab and Pemetrexed: Insights from CJLSG1901
Yoshihito Kogure, Japan
- P1.11.12** Impact of Body Composition on Immunotherapy Response in Non-small Cell Lung Cancer
Xin Zheng, China
- P1.11.13** A Phase II Study of Camrelizumab Plus Docetaxol in Advanced NSCLC Pre-Treated with Immune Checkpoint Inhibitors and Chemotherapy
Jin Zhou, China
- P1.11.14** Depth of Response to Immunotherapy Is Associated with Survival Outcomes in Oligoprogressive NSCLC: A Real-World Data Analysis
Daniel Gomez, USA
- P1.11.15** PD-(L)1 Inhibitors for Treatment of Locally Advanced or Metastatic NSCLC in Asian and Non-Asian Patients: A Meta-Analysis
Nicolas Girard, France

- P1.11.16** Gut Microbiota: Associations Between Composition and Response to Immunotherapy in Non-small Cell Lung Cancer
Gisele Moreira, Brazil
- P1.11.17** PD-(L)1 Inhibitors Rechallenge in Patients with Advanced NSCLC Previously Treated with Immunotherapy: A Systematic Review and Meta-Analysis
Daniele Marinelli, Italy
- P1.11.18** Real-World Characterization of Response Kinetics in Patients with Metastatic NSCLC Receiving First-Line Immunotherapy
Melina Marmarelis, USA
- P1.11.19** Real-World Outcomes of Nivolumab Plus Ipilimumab in Elderly NSCLC Patients (≥75): A Retrospective Analysis
Soichiro Minami, Japan
- P1.11.20** Camrelizumab-Based Therapy-Induced RCCEP in Advanced NSCLC Patients: A Pooled Analysis of Two Phase III Registration Trials
Caicun Zhou, China
- P1.11.21** Target Lesion Necrosis Percentage as a Predictor for Response to Immune Checkpoint Inhibitors in NSCLC: A Retrospective Analysis
Arjun Narula, India
- P1.11.22** Extracellular Vesicle-Derived LncRNA Signatures in Serum for Diagnosis and Prognosis of Checkpoint Inhibitor-Related Pneumonitis
Yilin Yang, China
- P1.11.23** Co-Culturing LCOs and Lymphocytes Derived from Pleural Effusion Potentially Implement Personalized Immunotherapy
Xu-Hui Guan, China
- P1.11.24** Real-World Evidence of Primary Resistance to First-Line Chemo-Immunotherapy in Advanced Lung Adenocarcinoma
Marianna Peroni, Italy
- P1.11.25** Genomic Characterizers, Survival and Prognostic Analysis of Advanced NSCLC With Kirsten Rat Sarcoma Mutations With Brain Metastases
Yi Chen, China
- P1.11.26** Temporal Optimization of Radiotherapy-Immunotherapy Synergy for NSCLC Brain Oligo-Metastases: Prospective Assessment of Prognosis Outcomes
Xiaomei Gong, China
- P1.11.27** Optimal Immunotherapy Regimen for STK11 or KEAP1 Mutant Metastatic Non-small Cell Lung Cancer
Natalie Shammas, USA
- P1.11.28** Nomogram and Effectiveness of Bone-Modifying Agents in Advanced Driver-Negative NSCLC: A Retrospective Real-World Study
Lingyun Zhang, China
- P1.11.29** ICIs Plus Paclitaxel-Based Chemotherapy Is an Optional Treatment for Transformed SCLC After EGFR-TKI
Yuyan Wang, China
- P1.11.30** The Efficacy of Immunotherapy for Patients with Advanced Lung Cancer and Oncogenic Driver Alterations
Jiaxin Zhong, China
- P1.11.31** Dynamic Monitoring of Circulating Tumor Cells and Single-Cell Sequencing Predict Therapeutic Efficacy in Advanced Lung Cancer
Chao Zhao, China
- P1.11.32** Quality of Life Outcomes from the Phase 3 Study of Atezolizumab + Bevacizumab and Chemotherapy (ATLAS, KCSG-LU19-04) in EGFR/ALK- Mutated NSCLC
Eun Joo Kang, Republic of Korea
- P1.11.33** The Role of Rhamnose Derived from Gut Microbiome in Modulating the Efficacy of Non-small Cell Lung Cancer Immunotherapy
Xu Han, China

- P1.11.34** First-Line Camrelizumab Plus Chemotherapy in 3004 Patients with Advanced Non-Squamous NSCLC: A Nationwide Retrospective Study
Zhonghui Wei, China
- P1.11.35** RATIONALE-303: Long-Term Outcomes with Tislelizumab in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
Kirsha Naicker, UK
- P1.11.36** Strengthening Real World Evidence Generation Through an Expanding Multicenter Canadian Lung Cancer Registry
Paul Wheatley-Price, Canada
- P1.11.37** Impact of Immunotherapy on Overall Survival in Advanced Non-small Cell Lung Cancer: A Real-World Evidence Analysis
Enric Carcereny, Spain
- P1.11.38** Measuring the Effect of Age and Ethnicity on Outcomes in Patients with Advanced Lung Cancer Treated with Immunotherapy: A New Zealand Analysis
Annie Wong, New Zealand
- P1.11.39** The BLIP Score: A Tool for Non-small Cell Lung Cancer Patients with Brain Metastases
Marcus Skribek, Sweden
- P1.11.40** The Hidden Impact of Creatinine Clearance Estimation Method on Pemetrexed-Based Chemoimmunotherapy in NSCLC With Low PD-L1 Expression
Naoya Nishioka, Japan
- P1.11.41** Intrapleural Dual Blockade of IL-6 and PD-L1 Reprograms CAF Dynamics and the Tumor Microenvironment in Malignant Pleural Effusion
Ping Zhan, China
- P1.11.42** Dual Immune Checkpoint Blockade With CTLA-4 and PD-(L)1 Inhibitors in NSCLC: A Reconstructed Patient Data Meta-Analysis
Alessandro Di Federico, Italy
- P1.11.43** Analysis of Characteristics and Predictive Factors for Long-Term Benefit of Immunotherapy in Advanced NSCLC
Wei Song, China
- P1.11.44** Efficacy and Safety of Immunotherapy as First-Line Treatment in Metastatic Pulmonary Large-Cell Neuroendocrine Carcinoma
Huiwen Yang, China
- P1.11.45** Real-World Prognosis of Non-Squamous NSCLC Patients with Liver, Bone, or Brain Metastases Treated with Frontline Therapies
Mona Cai, USA
- P1.11.46** RATIONALE-303: Post-Hoc Analysis of Tislelizumab Monotherapy in Previously Treated Non-small Cell Lung Cancer with Metastases
Kirsha Naicker, UK
- P1.11.47** Clinical Outcomes of Immune Checkpoint Inhibitors Treatment for Postoperative Recurrence in Non-small Cell Lung Cancer
Yoshito Imamura, Japan
- P1.11.48** Scoreit - Is IC3 Similarly Predictive as TC3 for Single Agent PD-1/PD-L1 Immune Checkpoint Inhibition in Metastatic NSCLC (mNSCLC)
Nadine Olejnik, Germany
- P1.11.49** The Impact of the Lung Microbiome on Checkpoint Inhibitor Pneumonitis: Early Findings from the Australian TRACKER Lung Cancer Biobank
Senthuran Shivakumar, Australia
- P1.11.50** Survival Outcomes in Advanced Pulmonary Sarcomatoid Carcinoma Treated with Immunotherapy: An NCDB Analysis
Muskan Agarwal, USA
- P1.11.51** Effects of Immune Checkpoint Inhibitors on the Pulmonary Circulation in Lung Cancer Patients
Xia Yang, China

- P1.11.52** Impact of Disease Progression on Pros in Patients Receiving Cemiplimab/Chemotherapy Versus Chemotherapy for aNSCLC: EMPOWER-Lung 3 Part 2
Konstantin Penkov, Russian Federation
- P1.11.53** Organ-Specific Survival in Metastatic NSCLC Patients Treated with Chemo-Immunotherapy: A Machine Learning-Based Retrospective Analysis
Kang Qin, USA
- P1.11.54** Lack of Durable Response to ICI Therapy in Advanced NSCLC: The Role of Circulating Lazy T Cells
Arianna Palladini, Italy
- P1.11.55** Identifying Patients Cured from Metastatic Non-small Cell Lung Cancer (mNSCLC) With Anti-PD-(L)1 Therapy
Natalie Vokes, USA
- P1.11.56** Distinct Predictive Effects of PD-L1 Tps on Immunotherapy Outcomes and Immunophenotype in Squamous Versus Non-Squamous NSCLC
Valentina Santo, USA
- P1.11.57** Association Between CD274 (PD-L1) Gene Expression and PD-L1 Immunohistochemistry in Non-small Cell Lung Cancer Specimens
Richard Huang, USA
- P1.11.58** Efficacy of First-Line Treatment in Driver-Negative Non-small Cell Lung Cancer with Liver Metastases: A Bayesian Network Meta-Analysis
Lingyun Zhang, China
- P1.11.59** Effect of IFNG Expression Levels on Real-World Survival Outcomes in Patients with Metastatic Non-small Cell Lung Cancer Receiving Immunotherapy
Michael Rossi, USA
- P1.11.60** Interstitial Lung Abnormalities and MUC5B Polymorphism in Immune Checkpoint Inhibitor Pneumonitis
Mehmet Altan, USA
- P1.11.61** Effects of Probiotic Duration and Type on Immunotherapy Efficacy in Non-small Cell Lung Cancer with or Without Antibiotics
Weichi Luo, China
- P1.11.62** Deep Learning Histopathology Model for PD-L1 (TPS) and Immunotherapy Outcome Prediction in Non-small Cell Lung Cancer
Masoud Tafavvoghi, Norway
- P1.11.63** Shifts of Mutational Signatures Reveal Response Variability to Pembrolizumab-Based Immunotherapy in NSCLC Patients
Natalia Galant, Poland
- P1.11.64** Vision Foundation Model to Predict Immunotherapy Treatment Response in Lung Cancer Patients
Daniel Gomez, USA
- P1.11.65** Ivonescimab Versus Pembrolizumab for PD-L1-Positive NSCLC: A Subgroup Analysis of HARMONI-2 by Tumor PD-L1 Expression Level
Lei Wang, China
- P1.11.66** Cost-Effective Machine Learning for Predicting Survival in NSCLC Patients on Immunotherapy: Insights from the APOLLO11 Study
Vanja Miskovic, Italy
- P1.11.67** VEGFR1/PD-L1 CAR-T Cell Treatment of Solid Tumor-Derived Malignant Pleural Effusion/Ascites
Dan Li, China
- P1.11.68** Multi-Omic Profiling Identifies Key Factors Associated with Response to Ivonescimab (AK112) in Non-small Cell Cancer
Haowei Wang, China
- P1.11.69** Efficacy of Immunotherapy ± Chemotherapy in Metastatic NSCLC with KRAS, STK11, or KEAP1 Mutations: A Network Meta-Analysis
Skyler Taylor, USA

- P1.11.70** Immune Cell Infiltration and Spatial Associations in the Tumor Microenvironment Following Dual ICI or ICI-Chemotherapy
Natalie Vokes, USA
- P1.11.71** RMT in Non Small Cell Lung Cancer
Amit Kulkarni, USA
- P1.11.72** Phase II Study of Combination Azacitidine and Entinostat and Nivolumab in Patients with Metastatic Non-small Cell Lung Cancer
Kristen Marrone, USA
- P1.11.73** Tiragolumab Plus Atezolizumab and Bevacizumab in Immunotherapy-Refractory, Pd-L1+, Advanced Non-Squamous Non-small Cell Lung Cancer
Joshua Reuss, USA
- P1.11.74** Phase Ib Study of Golidocitinib Plus Anti-PD-1 in Anti-PD-1 Treated Advanced NSCLC: Dose-Escalation Safety Using BOIN Design
Hua Zhong, China
- P1.11.75** A Phase 2 Study of PCSK9 Inhibitor, Alirocumab, and PD1 Inhibitor, Cemiplimab, in Advanced Immunorefractory Metastatic NSCLC
Eziafa Oduah, USA
- P1.11.76** Bevacizumab Plus Serplulimab and Chemotherapy for EGFR-TKI-Resistant Non-Squamous Non-small Cell Cancer: A Phase2Study
Qiming Wang, China
- P1.11.77** A Comprehensive Analysis of Front-Line Regimens for Stage IV Non-Squamous Non-small Cell Lung Cancer: A 13-Year Experience
Naveen Rehman, USA
- P1.11.78** NAI, An IL-15 Superagonist, A New Class Of Lymphocyte Stimulating Agent (LSA) Prolongs OS In NSCLC By Reversing Lymphopenia
Sandeep Reddy, USA
- P1.11.79** A Meta-Analysis on Anti-PD-1/L1 With or Without Anti-VEGF Plus Chemotherapy in EGFR-Mutant or ALK-Rearranged NSCLC Progressing on TKIs
Rogelio Jr. Velasco, Philippines
- P1.11.80** Tumor-Derived Complement Factor B Drives Tumor Growth and Anti-PD-1 Resistance in STK11-Mutant Lung Adenocarcinoma
Edwin Yau, USA
- P1.11.81** Low-Dose Nivolumab With Platinum Doublet Chemotherapy in Patients with Advanced Central Squamous Cell Lung Cancer (SCAR)
Pawan Singh, India
- P1.11.82** Study of THIO Sequenced with Cemiplimab in 3rd Line Immune Checkpoint Inhibitor-Resistant aNSCLC: Improvement in PFS
Victor Zaporozhan, USA
- P1.11.83** Ivonescimab Versus Pembrolizumab for PD-L1-Positive NSCLC: A Subgroup Analysis of HARMONI-2 by Tumor Histology
Anwen Xiong, China
- P1.11.84** Phase II Trial of Tislelizumab Combined With Anlotinib and 2-Cycle Chemotherapy as First-Line Treatment for Advanced NSCLC
Wen Jun Tang, China

TRACK 17: GLOBAL HEALTH, HEALTH SERVICES, AND HEALTH ECONOMICS

- P1.17.01** Sociodemographic Factors in Access to Robotic-Assisted Oncologic Lung Resection, a USA (US) National Cancer Database Analysis
Isabel Emmerick, USA
- P1.17.02** Socioecological Factors Associated with Lung Cancer Clinical Trial Enrollment: Real-World California Cancer Registry Data
Angel Arizpe, USA

- P1.17.03** Stage Iv Nonsquamous Non-small Cell Lung Cancer (NSCLC) Biomarker Testing Disparities and Outcomes: A Population-Based Study
Surbhi Singhal, USA
- P1.17.04** Prioritizing Lung Cancer Screening in Middle-Income Countries: A Feasibility-Need Framework to Guide Implementation
Hamida Petrovic, France
- P1.17.05** Evolution of Neoadjuvant Treatment for Non Small Cell Lung Cancer (NSCLC) in Brazil: An Analysis from the Brazilian Lung Cancer Registry
Ricardo Terra, Brazil
- P1.17.06** Who Gets a Biopsy? Disparities in Histological Confirmation and Survival Among Lung Cancer Patients
Damien Urban, Israel
- P1.17.07** Comparing Baseline Characteristics of NSCLC Patients Receiving Radiotherapy in Real-World Practice and Clinical Trials
Gerard Walls, UK
- P1.17.08** Routine Self-Administration of a Nursing Demographic Survey to Patients Starting TKIs Identifies At-Risk Individuals
Hailey Vlahos, Canada
- P1.17.09** The Impact of Out-Of-Pocket Costs, Travel Distances and Clinic Visits on Quality of Life for Patients on TKIs
Kezia Rafique, Canada
- P1.17.10** Treating Without Guidelines: Management and Outcomes of Lung Cancer During Pregnancy
Nehemias Guevara Rodriguez, USA
- P1.17.11** Clinical and Molecular Characterization of Lung Cancer in Never-Smokers Identified Through an Incidental Nodule Program
José Fernando Moura, Brazil
- P1.17.12** Unwarranted Variation in Lung Cancer Care in Perth, Western Australia: A Lung Cancer Clinical Quality Data Platform Report
Jessica Nash, Australia
- P1.17.13** Biomarker Testing Timeliness for Patients with Lung Cancer
Bingtao Xiang, USA
- P1.17.14** Regional Disparities in Late-Stage Lung Cancer Outcomes in Sweden - Insights from Population-Based Data
Anders Berglund, Sweden
- P1.17.15** Social Vulnerability and Survival Outcomes in Stages I-II Lung Cancer: A Predictive Nomogram-Based Analysis
Priscila Berenice Costa, Brazil
- P1.17.16** Racial and Ethnic Disparities in Receipt of Guideline Concordant Treatment for Early-Stage NSCLC in Los Angeles County
Albert Farias, USA
- P1.17.17** Financial Distress and Concerns Prior to Cancer-Directed Treatment Among Patients With NSCLC
Ana Velazquez Manana, USA
- P1.17.18** Victorian Lung Cancer Registry Impacts on Multi-Disciplinary Lung Cancer Meeting Presentation
Tom John, Australia
- P1.17.19** Impact of Race and Ethnicity on the ENGAGE-Derived Lung Cancer Screening Recommendations: Implications for Risk Assessment
Iakovos Toumazis, USA
- P1.17.20** Optimal Lung Cancer Outcomes for People from Rural and Remote Areas: An Overview of the Problem and a Research Program to Reduce Disparities
Anna Ugalde, Australia

- P1.17.21** Gender Disparities in Remote Patient Monitoring: Analysis From 973 Lung Cancer Patients Treated Across 42 Sites in France and Belgium
Claudia Parisi, France
- P1.17.22** Concordance of HER2 Protein Overexpression by IHC and ERBB2 Gene Amplification by NGS in Lung Cancer
Samrat Yeramaneni, USA
- P1.17.23** Role of Lung Microbiome on Precise Diagnosis of Patients with Checkpoint Inhibitor Pneumonia: Result from a Prospective Cohort Study
Zhenhua Zhou, China
- P1.17.24** Mixed Methods IASLC Global Survey and Provider Interview Study of Us NSCLC Biomarker Testing Practices and Clinical Processes
Joyce Chen, USA
- P1.17.25** Cost-Effectiveness of Initial Pan-TRK IHC Followed by RNA-NGS for NTRK Fusion Detection in Patients with NSCLC in China
Yuchen Han, China
- P1.17.26** Evaluation of Large Language Models for Clinical Decision Support in Lung Cancer Treatment: ChatGPT-4.5 Vs. Deepresearch Vs. AvoMD
Jiyon Lyu, Republic of Korea
- P1.17.27** Assessing Sarcopenia in Lung Cancer: Feasibility and Training Considerations of Using Quantitative Imaging Metrics from CT Scans
Chandana Adhikarla, USA
- P1.17.28** Developing a Multifaceted Implementation Strategy to Increase Clinical Trial Accruals in Thoracic Oncology
Kadi Dick, USA
- P1.17.29** Access to Novel Therapies for the Treatment of NSCLC in 18 EU Member States
Urska Jancic, Slovenia
- P1.17.30** Deep Learning-Based Lung Tumor Segmentation for Survival Prediction in NSCLC Patients
Beshoy Guirges, Italy
- P1.17.31** Feasibility of Integrating Ai-Assisted Lung Cancer Screening in High Tuberculosis Burden Settings
Vincent Balanag, Philippines
- P1.17.32** Comparing ChatGPT's and Google Gemini'S Responses to Lung Cancer Questions
Chanwoo Kim, Republic of Korea
- P1.17.33** Addressing Educational Gaps in Lung Cancer Care: Insights Based on Global Practice Setting and Experience
Michelle Worst, USA
- P1.17.34** Assessing the Outcome of 10-Year Lung Cancer Survivors and the Necessity of Long-Term Postoperative Surveillance
Satoshi Shiono, Japan
- P1.17.35** Patient Navigation and the Opportunity to Improve Experiences and Outcomes of Lung Cancer Care
Jessica Hooper, UK
- P1.17.36** Perspectives on Health-Related Quality of Life Among Physicians and Patients with ALK-Positive NSCLC in China
Yan Huang, China
- P1.17.37** Providing Equal Access to Lung Cancer MDT Consultation Through Digital Innovation
Xinghua Cheng, China
- P1.17.38** A Two-Layer MDT Model as the Standard of Care for Lung Cancer - a Good MDT Example with High-Volume Patients in Central Western China
Zhen He, China
- P1.17.39** Clinical Predictive for Early Mortality in Stage IV Lung Cancer Without Targetable Mutations from Country with High Smoking Prevalence
Anas Zayed, Jordan

- P1.17.40** Impact of Remote MDT Through a Digital Platform: Insights From 70 Patient Follow-Ups
Xiaojuan Zhang, China
- P1.17.41** Bridging Gaps in Lung Cancer Care: The Quantitative Impact of Inter-Hospital Remote MDT Consultations in China
Wen Gao, China
- P1.17.42** Canadian Consensus Recommendations for Multi-Disciplinary Team Meetings in Lung Cancer Care
Marcos Gallego-Llorente, Spain
- P1.17.43** Association Between Pretreatment Emotional Distress and EGFR-TKI Therapeutic Response in EGFR-Mutant Non-small Cell Cancer
Zhang Yang, China
- P1.17.44** Multiomic Interaction Among Host and Tumor Immunity for Chemo De-Escalation. People Phase II Trial, First Line Pembrolizumab in Low PD-L1 NSCLC
Cecilia Silvestri, Italy
- P1.17.45** Multidisciplinary Digital Platform for Independent Adjudication of ILD/Pneumonitis Related to T-DXd Treatment
William Nassib William Jr, Brazil
- P1.17.46** The Best Care One-Lung Program; a Pathway for Lung Cancer Screening in Primary Care
Christian Finley, Canada
- P1.17.47** Safety and Efficiencies of Specialist Lung Cancer Nurse-Enabled Pulmonary Nodule Management: An Australian Demonstration
Vanessa Brunelli, Australia
- P1.17.48** Characteristics and Associated Survival of Patients Diagnosed with Non-small Cell Lung Cancer in Western Kenya
Atundo Murunga, Kenya
- P1.17.49** Real-World Outcomes with IO and Chemo-IO Demonstrate Unmet Need for 1L KRAS G12C-Mutant Advanced NSCLC in the US
Kristin Sheffield, USA
- P1.17.50** Correlation Between Clinical and Pathological Stage in Resected NSCLC
Giordano Cittolin Santos, USA
- P1.17.51** Real World Outcomes of Metastatic Mucinous Adenocarcinoma of Lung
Dhauna Karam Prasad, USA
- P1.17.52** Real-World Treatment and Survival in KRASG12C-Mutated Locally Advanced/Metastatic Non-small Cell Lung Cancer in England
Alastair Greystoke, UK
- P1.17.53** Real-World Experience With EGFR-Positive NSCLC in Resource-Limited Settings: A Decade-Long Single Center Study from Jordan
Kamal Al-rabi, Jordan
- P1.17.54** Long-Term Outcomes from Pembrolizumab in Patients with Advanced PD-L1 =50% NSCLC and Poor PS: A Transformer-Based AI Approach
Alessio Cortellini, Italy
- P1.17.55** Transforming Prognostication: A 5-Year Follow-Up Study to Unravel Prognostic Predictors Across Age Groups in NSCLC Using Transformer-Based AI
Leonardo Brunetti, Italy
- P1.17.56** Clinical Features and Outcomes of Lung Cancer in Young Patients
Bingfei Xu, China
- P1.17.57** Estimates of Clinical Endpoints in Matched Patients Between the French Cancer Cohort (FCC) and Durvalumab Stage III NSCLC Eap
Icherak Charkaoui, France
- P1.17.58** Real-World (RW) Study of Biomarker Testing Patterns Among Patients with Early-Stage Resected NSCLC in the USA
Sandip Patel, USA

- P1.17.59** Real-World Uptake of Immunotherapy for Stage III-IV Non-small Cell Lung Cancer: Insights from the National Cancer Database (2016-2021)
Brittany Morguelan, USA
- P1.17.60** Characterizing Multi-Timepoint Lung Cancer Progression with Dynamic Bayesian Network, Structural Equation Modeling and Random Forest Model
Wei Liu, China
- P1.17.61** Rebiopsy in Oncogene-Driven Lung Cancer: Real-World Practices in ALK, EGFR, and ROS1 Cohorts in the Australian AURORA Longitudinal Cohort Study
Susan Harden, Australia
- P1.17.62** Real-World Insights on Treatment Patterns and Outcomes in ROS1 NSCLC: An Australian Multicenter Study (AURORA)
Malinda Itchins, Australia
- P1.17.63** Docetaxel and Docetaxel Plus Ramucirumab Demonstrate Similar Real-World Overall Survival: A Contemporary Analysis
Ling-I Hsu, USA
- P1.17.64** Acinar Cell Lung Carcinoma: A Unique Subtype of NSCLC Adenocarcinoma, Insights from the AACR Project Genie Database
Anas Zayed, Jordan
- P1.17.65** Age-Associated Incidence of Somatic Mutations and Survival Outcomes in Non-small Cell Lung Cancer
Sarah Sertich, USA
- P1.17.66** Impact of Concurrent Tissue and Liquid Comprehensive Genomic Profiling (CGP) on Receipt of First-Line (1L) Therapy in a NSCLC
Jonathan Riess, USA
- P1.17.67** A Large-Scale Network Study on Impact of Immune Checkpoint Therapy in Metastatic Non-small Cell Lung Cancer: The iCan mNSCLC Study-A-Thon
Ilkka Ilonen, Finland
- P1.17.68** Real-World Validation of Other Disease Morbidity After Lung Cancer Surgery Using a Japanese Database in Reference to JCOG0802/WJOG4607L
Takeuchi Taihei, Japan
- P1.17.69** A Real-World Study of Advanced ALK-Fusion NSCLC Patients Receiving First-Line ALK-TKI Therapy with Telehealth Care
Di Zheng, China
- P1.17.70** Clinicomolecular Characteristics and Treatment Patterns in Stage IV NSCLC: A Retrospective Study from Southwestern Ontario
M. Sara Kuruvilla, Canada
- P1.17.71** Treatment Changes Over 12 Months of Observation for ALK and EGFR-Positive NSCLC - Results From a Real-World Study
Upal Basu Roy, USA
- P1.17.72** Clinical and Dosimetric Predictors for Post-Radiotherapy Lung Cancer Recurrence: A Model for Resource-Limited Settings
Renne Aguiar, Brazil
- P1.17.73** Misperception of Unintentional Weight Loss and Anorexia More Prevalent in Lung Cancer Among Other Solid Tumors in a Mexican Cohort
Saul Campos-Gomez, Mexico
- P1.17.74** Bridging Data Gaps in Brazilian Lung Cancer Surgery Care: The Evolution of the Brazilian Lung Cancer Registry (RBCP)
Maria Tzukazan, Brazil
- P1.17.75** Realizing Digital Transformation in Health: Findings from the TRANSITION Project
Andreas Charalambous, Cyprus
- P1.17.76** Facilities and Workforce Available for Thoracic Oncologic Care and Research in Nigeria, a Low-Middle Income Country (LMIC)
Kelechi Okonta, Nigeria

- P1.17.77** Lung Cancer Consensus: Uniting for a Healthier World
Mary Bussell, USA
- P1.17.78** Living Systematic Review Linked to Guidelines and Regulatory Approvals as a Treatment Decision Support Tool in NSCLC
Anna Forsythe, USA
- P1.17.79** Assessing Radiotherapy Access and Patient Experience in Lung Cancer Treatment: A Survey on Financial and Logistical Challenges
Divya Khosla, India
- P1.17.80** Economic Burden of Disease Management and Recurrences After Complete Resection of Early-Stage ALK+ Non-small Cell Lung Cancer (NSCLC) in Spain
Rocio Gordo, Spain
- P1.17.81** Unveiling the Natural History of Lung Cancer by Sex, Histology, and Nodule Type Using Mathematical Modeling
Iakovos Toumazis, USA
- P1.17.82** Lung Cancer's Price Tag: Escalating Hospitalization Costs in Brazil Over the Past Two Decades
Jean Henri Maselli Schoueri, Brazil
- P1.17.83** Implementation of Lung Cancer Screening by Family Physicians in the U.S.: Results of a National Survey
Ella Kazerooni, USA

POSTERS (P2): MONDAY, SEPTEMBER 8, 2025

i Presenters in Attendance: 10:30 – 12:00

TRACK 02: TUMOR BIOLOGY – PRECLINICAL BIOLOGY

- P2.02.01** Characterizing UPP1 Expression in Non-Tumor Cells of Lung Cancer and its Clinical Implications
Yin Li, China
- P2.02.02** R-Loop-Associated DNA Damage Facilitates Chemosensitivity of NSCLC
Hongchengcheng Chen, China
- P2.02.03** Ferroptosis-Induced SUMO2 Lactylation Counteracts Ferroptosis by Enhancing ACSL4 Degradation in Lung Adenocarcinoma
Guangyao Shan, China
- P2.02.05** CXCL12/CXCR4 Axis Mediates M2 Monocyte Polarization-Induced Immune Resistance in NSCLC Liver Metastasis
Qi Wang, China
- P2.02.06** Functional Impact of Missense Mutations Affecting Immune Response Genes in Human Cancer
Cristina Diaz, Spain
- P2.02.07** Targeting SLC4A7 Reprograms the Acidic Tumor Microenvironment to Overcome Immunotherapy Resistance in NSCLC
Hao Qin, China
- P2.02.08** A Unique VEGFA-Expressing CAF Subpopulation Emerges in TKI-Resistant Lung Cancer to Mediate Immunotherapy Sensitization and Adverse Outcomes
Jingze Wang, China
- P2.02.09** Early-Stage Lung Adenocarcinoma: PLVAP-Driven Regulation of the Tumor Microenvironment
Dawei Yang, China
- P2.02.10** Emotional Distress Following Lung Cancer Surgery and Tandospirone Dual Benefits for Chemotherapy
Xichun Qin, China
- P2.02.11** SRC Activation Drives Acquired Pemetrexed Resistance in Non-small Cell Lung Cancer and Is Targetable by Dasatinib
Jeongmin Seo, Republic of Korea
- P2.02.12** hUC-MSC-Derived Exosomes Mitigates Immune Checkpoint Inhibitor-Associated Lung Injury by Suppressing GSDME-Mediated Pyroptosis
Zekun Chenli, China
- P2.02.13** Macrophages Exhibit Enhanced Cholesterol Efflux in Early-Stage Lung Adenocarcinoma
Dawei Yang, China
- P2.02.14** Urolithin A Alleviates Radiation Pneumonitis by Activating PINK1-PRKN-Mediated Mitophagy
Xiaomei Gong, China
- P2.02.15** Drug Tolerance and Persistence to EGFR Inhibitor Treatment Are Mediated by an ILK-SFK-YAP Signaling Axis in Lung Adenocarcinoma
Rocky Shi, Canada
- P2.02.16** Identification of Deruxtecán-Induced Methylome Signature in NSCLC Cell Lines
Arjan Gower, USA
- P2.02.17** GNAZ as a Tumor Suppressor Marker Inhibits Tumor Development Through Interaction with the KIF11 Protein
Shuning Kong, China

- P2.02.18** Crosstalk Between Oncogenic Signaling Pathways and Immune Checkpoint Proteins in Pleural Mesothelioma
Muhammad Hashim, Austria
- P2.02.19** SIN3A/MIR22HG/Beclin1 Axis Regulates Both Autophagy and Ferroptosis in Lung Adenocarcinoma
Xiaobi Huang, China
- P2.02.20** Targeting BTN1A1 in Pd=D-L1-Negative NSCLC: A Clinically Actionable Immune Checkpoint for Docetaxel-Based Combination Therapy
Stephen Yoo, USA
- P2.02.21** CTNBN1 Activates LINC01426 to Promote Metabolic Reprogramming in Lung Adenocarcinoma Cells by Regulating NFAT5 Nuclear Translocation
Qiyu Fang, China
- P2.02.22** Analysis of FGF19 in Lung Squamous Cell Cancer Tissue and Cell Models
Lukas Koszik, Austria
- P2.02.23** Screening of Autophagy Related Genes in Lung Squamous Cell Carcinoma and Study of Their Mechanisms of Action
Simiao Lu, China
- P2.02.24** Zongertinib Has Activity Against NRG1 Fusion Positive Tumor Cells
Yuji Shibata, USA
- P2.02.25** Elevated SGO2 Expression in Lung Adenocarcinoma Promotes Migration and Invasion by Regulating MAD2, Correlating with Poor Prognosis
ChuanDong Zhu, China
- P2.02.26** Establishment of a HER2 Overexpressing Lung Squamous Cell Carcinoma Cell Line Sensitive to Targeted and Cytotoxic Therapies
Satoshi Suzuki, Japan
- P2.02.27** Osimertinib Increases Expression of HER2 and Combination With T-DXd, a HER2-Directed ADC, Enhances Its Efficacy in PDX Models of EGFR Mutant NSCLC
Nicolas Floch, UK
- P2.02.28** Proteasome Inhibitor Causes Proteotoxic Death and Reshapes TME in LKB1-Deficient NSCLC by Blocking Er-Stress Repair Addiction
Zhong-Yi Dong, China
- P2.02.29** CXCR2 Inhibitor Plus KRAS G12C Inhibitor Remodels Immunosuppressive Tumor Microenvironment in KRAS G12C-Mutant NSCLC?
Jiuwei Cui, China
- P2.02.30** Targeting MTA2 Lactylation as a Therapeutic Strategy to Overcome Chemoresistance in Lung Adenocarcinoma
Ren Shencheng, China
- P2.02.31** The Changes of Macrophage in EGFR Mutant TKI-Resistant Patients with Lung Cancer
Shuxin Zhu, China
- P2.02.32** Homeostatic Dysregulation of Systemic CD8+ T Cell Compartment in Lung Cancer Patients
Ju Sik Yun, Republic of Korea
- P2.02.33** Radiotherapy Induces Ferroptosis and Activates STING Pathway to Reverse Immunotherapy Resistance in LKB1-Mutant Lung Cancer
Yan-Pei Zhang, China
- P2.02.34** Synergistic Antitumor Effect of an XPO1 Inhibitor and/or Sotorasib With V-ATPase Inhibitors Pretreatment in KRAS G12C NSCLC
Jessica González, Spain
- P2.02.35** Association of Intratumoral Microbiota Composition with Tertiary Lymphatic Structure of Lung Adenocarcinoma
WeiJie Zhan, China
- P2.02.36** Canakinumab Interception Trial and Preclinical Studies Reveal Stage-Dependent Biology in Lung Cancer and Precancers
Jianjun Zhang, USA

- P2.02.37** ERBB3-BCAR4 Is a Recurrent and Oncogenic Fusion in Lung Adenocarcinoma Cases That Lack Other Driver Alterations
Kevin Levine, USA
- P2.02.38** Single-Cell RNA-Sq Reveals Potential Mechanism of RUNX3 Reshaping TME in NSCLC
Xiaohui Chen, China
- P2.02.39** Fulzerasib, a KRAS-G12C Inhibitor, Has Synergistic Antitumor Effect with Omeprazole Pretreatment in KRAS G12C NSCLC
Mengxin Zhou, Spain
- P2.02.40** Multiomics Assessment of Lung Adenocarcinoma Subtypes Defined Through Tumor Purity-Adjusted DNA Methylation
Deborah F. Nacer de Oliveira, Sweden
- P2.02.41** Feasibility of Flow Super RCA for KRAS Mutation Detection in Liquid Biopsies of Advanced Lung Adenocarcinoma: Pilot Study
Luis Posado-Domínguez, Spain
- P2.02.42** Effect of MTHFR Gene Mutation on the Efficacy of Tyrosine Kinase Inhibitor Treatment in Lung Cancer Patients
Wenmei Su, China
- P2.02.43** Multi-Omic Approach Elucidates the Underlying Mechanism of HA-Coated Neohesperidin Nanoparticles Against Lung Cancer
Ruchi Pandey, India
- P2.02.44** Research on the Mechanism of Gut Microbiota Promoting NSCLC Distant Metastasis Through Its Metabolite Testosterone
Chen-Guang Liu, China
- P2.02.45** Modulated Electro-Hyperthermia Enhances Tumor Cell Susceptibility to Gamma Delta T Cell-Mediated Cytotoxicity and Tumor Infiltration
Chi Chiu, Taiwan
- P2.02.46** V-Atpase Inhibitors Enhance the Effect of Tepotinib (c-Met Inhibitor) or RMC-6236 (Pan-Ras(ON) Inhibitor) in KRAS-Mutant NSCLC
Kevin València-Clua, Spain
- P2.02.47** Hypoxia-Driven SERBP1-SLC25A5-ND6 Axis Regulates Mitochondrial Metabolic Reprogramming to Promote Metastasis in Non-Small Cell Lung Cancer
Chuanyong Mu, China

TRACK 05: PULMONOLOGY AND STAGING

- P2.05.01** The Role of Robotic-Assisted Bronchoscopy and Endobronchial Ultrasound in Diagnosing and Staging Pulmonary Carcinoid
Shreya Podder, USA
- P2.05.02** Evolution and Survival Impact of Endobronchial Ultrasound (EBUS) Adequacy in Two Population-Based Lung Cancer Cohorts
Matthew Smeltzer, USA
- P2.05.03** Minimizing Atelectasis in ENB: A Propensity-Matched Study of Laryngeal Mask Ventilation Strategy
Yuan Xu, China
- P2.05.04** Electromagnetic Navigation-Guided 3D Conformal Microwave Ablation for High-Risk Peripheral Pulmonary Nodules
Yawei Liu Yawei Liu, China
- P2.05.05** Prediction of Distant Metastasis Using CT/PET-Based Radiomics in Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Ayah Al-Bzour, Jordan
- P2.05.06** Mature Results of a High-Precision Clinical Protocol for Staging Non-small Cell Lung Cancer (NSCLC) of the Left Lung
Lucia Cabanillas-Paredes, Spain

- P2.05.07** The Effect of Adrenal Gland Metastasis on the Course of Lung Cancer
Guntulu Ak, Turkey
- P2.05.08** Discordance Between Clinical and Pathological Invasive Size in Early Stage Non-small Cell Lung Cancer
Taeyoung Yun, Republic of Korea
- P2.05.09** Proposed Modification of Clinical T Categorization for Early-Stage Lung Adenocarcinoma: A Data-Driven Multicenter Quantitative Analysis
Bing-yu Rao, China
- P2.05.10** Prognostic Factors in IIB-IIIB Patients with Nodal Involvement Underwent Surgery for NSCLC
Marco Chiappetta, Italy
- P2.05.11** Prognostic Impact of Organ-Specific Metastasis in Non-small Cell Lung Cancer
Woo Kyung Ryu, Republic of Korea
- P2.05.12** Lymph Node Pathologic Grading Strategy: Under the Backdrop of the IASLC Grading System for Invasive Lung Adenocarcinoma
Chaoqiang Deng, China
- P2.05.13** M1a With Pleural or Pericardial Effusion Have Worse Survival Than Those with Pleural or Contralateral Lung Metastasis When Receiving EGFR-TKIs
Xiang Chen, China
- P2.05.14** Clinical Versus Pathological T Staging in Lung Adenocarcinoma: Discrepancies and Prognostic Implications
Libing Yang, China
- P2.05.15** Management-Oriented Classification of Lung Neuroendocrine Tumors Based on a French Surgical Cohort of 1,915 Patients from the EPITHOR Database
Romain Vergé, France
- P2.05.16** Comparative Discriminative Performance of Number-Based and 9th Edition N Classifications in NSCLC: Exploring Statistically Valid Cut-offs
Donghee Kim, Republic of Korea
- P2.05.17** European Single-Center Validation of the 9Th TNM Staging System in Over 3,300 Surgically Treated NSCLC Patients
Inna Schott, Germany

TRACK 06: PATHOLOGY AND BIOMARKERS

- P2.06.01** Prognostic Value of a Combined Model Using CT and PET/CT Parameters for Predicting STAS in Stage I Lung Adenocarcinoma
Kyongmin Beck, Republic of Korea
- P2.06.02** Invading Through External Elastic Lamina Is Predictive of Poorer Outcomes in Pulmonary Non-Mucinous Invasive Adenocarcinoma
ChiHung Chiang, Taiwan
- P2.06.03** Diagnostic Performance of Frozen Section in Determining Histological Patterns and Spread Through Air Spaces in Lung Adenocarcinoma
Haojie Si, China
- P2.06.04** Artificial Intelligence-Led Characterisation of Lethal Morphologies in Lung Adenocarcinoma
Kai Rakovic, UK
- P2.06.05** Diagnosis of the Novel IASLC Grading System Using Intraoperative Frozen Section: A Prospective Multi-Center Trial
Fangqiu Fu, China
- P2.06.06** Bronchiolar Adenoma with Malignant Transformation? New Insights Based on Morphologic, Immunophenotypic, and Genomic Analysis of 13 Cases
Yan Huang, China
- P2.06.08** ERBB2 Mutations in Non-small Cell Lung Cancer - Findings from a Large UK Cohort
David Moore, UK
- P2.06.09** Clinical, Racial, and Genetic Differences in Non-small Cell Lung Cancer Between Young a

- Older Patients in the AACR Project Genie Database
Kamal Al-rabi, Jordan
- P2.06.10** Prognostic Impact of TP53 Co-Mutations with EGFR vs KRAS in Advanced Non-small Cell Lung Cancer: A cBioPortal Analysis
Divya Chukkalore, USA
- P2.06.11** Factors Impacting Receiving EGFR Test Results Before Initial Treatment Among Stage IV Non-small Cell Lung Cancer Patients
Jeffery Scott, MD, USA
- P2.06.12** TP53/RB1-Mutant Squamous Cell Lung Cancers: Clinicopathologic Features and Outcomes
Mark Kris, USA
- P2.06.13** Actionable Mutation Profiles and Survival Outcomes in Invasive Mucinous Adenocarcinoma of the Lung
Jongwoo Kim, USA
- P2.06.14** Adoption of a 50-Gene Targeted Next Generation Sequencing Hotspot Panel in Non-small Cell Lung Cancer in a Tertiary Institution in Singapore
Kenneth Sooi, Singapore
- P2.06.15** Genomic Alterations in Lung Cancers Associated with Fibrosing Interstitial Lung Diseases in a French Multicentric Cohort
Edouard GUENZL, France
- P2.06.16** Identification of Molecular Signatures Linked to Early-Stage Lung Adenocarcinoma with STAS Using Spatial Transcriptomics
Kazuya Hisamatsu, Japan
- P2.06.17** Cellular Heterogeneity and Tertiary Lymphoid Structure Dynamics Predict Overall Survival in Immune Checkpoint Therapy-Treated NSCLC Patients
James Wingrove, USA
- P2.06.18** Computational Modeling of Comprehensive Genomic Profiling to Predict Chemotherapy Benefit in Advanced NSCLC
Charu Aggarwal, USA
- P2.06.19** A Multi-Source Pathology-Based Model for Gene Mutation and Recurrence Risk Prediction in Lung Cancer
Huan Li, China
- P2.06.20** Assessment of Molecular Testing in Stage IV Non-small Cell Lung Cancer Patients Across American Oncology Network
Jeffery Scott, MD, USA
- P2.06.21** Differential Gene Expression and Pathway Analysis of Invasive Mucinous Adenocarcinoma
Jongwoo Kim, USA
- P2.06.22** Pathological Characterization of Molecularly Screened Diffuse Pleural Mesothelioma
Giorgia Impalà, Italy
- P2.06.23** CDKN2A Deletion Is an Independent Predictive Biomarker for Immunotherapy Response in Patients with Advanced NSCLC
Hyo Sup Shim, Republic of Korea
- P2.06.24** Primary Pulmonary Neuroendocrine Immunophenotype Carcinoma Harboring Driver Gene Mutation/Fusions: Neuroendocrine Neoplasm?
Bingxia Zhang, China
- P2.06.25** Clinical Implications of TROP2 Expression in Lung Adenocarcinomas
Kazuya Takamochi, Japan
- P2.06.26** The Clinicopathological Characteristics and Prognostic Analysis of SMARCA4-Deficient Non-small Cell Lung Cancer
Jing Zhang, China
- P2.06.27** Unlocking the Genetic Link: Exploring Germline EGFR T790M Mutations in NSCLC and Implications for Targeted Treatment and Familial Screening
Sahana Shiggaon, USA

- P2.06.28** GPC3 Upregulation After Neoadjuvant Chemoimmunotherapy Associates with Adverse Outcomes and Tumor Heterogeneity in Squamous NSCLC
Linqiang Jiang, China
- P2.06.29** Bridging Histopathology and Molecular Profiling: AI-Powered Virtual Multiplex Immunofluorescence Staining for LUAD Prognosis
Yu Lei, China
- P2.06.30** ITGBL1: A Predictive Biomarker for IPF-LUSC Comorbidity Risk in Lung Transplant Candidates
Zhanglin Yang, China
- P2.06.31** Translational Analysis of NSD3 Gene Amplification in Lung Squamous Cell Carcinoma: Clinical Impact and Prognostic Insights from Histopathology
Shugo Takahashi, Japan
- P2.06.32** Impact of piR_004530 Reactivation in Lung Cancer: Implications for Recurrence and Survival of Lung Squamous Cell Carcinoma Patients
Yangyi He, Spain
- P2.06.33** Prognostic Significance and Therapeutic Potential of LILRB4 in MDSC-Mediated Immunosuppression in NSCLC
Sakiko Kumata, Japan
- P2.06.34** Tumor Heterogeneity Based Prognostic Score: What the Specimen Tells Us in the Intelligent Era?
Ziling Huang, China
- P2.06.35** Extracellular Vesicle RNA Diversity in Lung Adenocarcinoma: Driving Immunosuppression and Metastasis
Shen Lao, China
- P2.06.36** Proteomic Atlas Reveals Organ-Specific Metabolic and Functional Shifts in Preclinical ICB-Related Pneumonitis and Colitis
Zi-Xuan Rong, China
- P2.06.37** NGS Testing in Lung Cancer Within the Catalan Precision Oncology Program: The ICO-HUB Comprehensive Cancer Center Experience
Miguel Mosteiro Lamas, Spain
- P2.06.38** BTN1A1 and Nuclear YAP1 Co-Expression as Predictive Biomarkers for Nelmastobart Efficacy in Lung Cancer: Findings from a Phase 1 Trial
Stephen Yoo, USA
- P2.06.39** Predicting Relapse and TKI Response Using DNA and RNA EGFR VAF in EGFR-Mutant Lung Adenocarcinoma
Hsuan-Yu Chen, Taiwan
- P2.06.40** Integrated Molecular Analysis of Advanced NSCLC Depicts Molecular Signatures Associated with Tyrosine Kinase Inhibitors Efficacy
Paolo Bironzo, Italy
- P2.06.41** Real-World Data and Utility of Newly Proposed Grading System from IASLC for Invasive Lung Adenocarcinoma in Japan
Kyoshiro Takegahara, Japan
- P2.06.42** NSD3 Overexpression Predicts Prognosis and Immune Cell Infiltration Patterns in Lung Squamous Cell Carcinoma: A Bioinformatics Analysis
Wei Wang, China
- P2.06.43** Estimating Tumour Microenvironment Cellular States from Bulk RNAseq Produces Biomarkers of Clinical Outcome Across Stages
Marcelo Hurtado, France
- P2.06.44** More Than a Mutation: Prevalence of HER2 Overexpression, Amplification, and Mutations by Histology in NSCLC
Jennifer Marks, USA
- P2.06.45** A Novel Predictive Gene Signature for Liver Metastasis (LM) in NSCLC Using a Comprehensive Linked Clinical-Molecular Database
Simon Papillon-Cavanagh, USA

- P2.06.46** Multi-Omics Analysis Reveals Genomic Features Associated with Combination Immunotherapy Benefit in Advanced NSCLC
Lailing Li, China
- P2.06.47** Axl Receptor Shedding and EMT in Lung Adenocarcinoma: Prognostic Implications Based on STAS
Shuji Mishima, Japan
- P2.06.48** Histology-Specific Genomic and Immune Predictors of Resistance to Neoadjuvant Chemoimmunotherapy in Early-Stage Non-small Cell Lung Cancer
Tae Hee Hong, Republic of Korea
- P2.06.49** Spatial Metabolomic Profiling Reveals Dynamic Metabolic Reprogramming During Lung Squamous Cell Carcinoma Evolution
Hao Qin, China
- P2.06.50** Transcriptomic Profiling Identifies a Prognostic and Predictive Immune Signature in Patients (Pts) With Lung Squamous Cell Carcinoma (LUSC)
Ayah Al-Bzour, Jordan
- P2.06.51** Tumour Tissue Extracellular Vesicle (EV) Biomarkers of Lung Cancer in Patients With or Without Heavy Smoking Histories
Kwun Fong, Australia
- P2.06.52** Survival and Mutational Differences of GPER and Estrogen Receptor (ER) in NSCLC
Robert Hsu, USA
- P2.06.53** TP53 Mutations Drive Therapeutic Resistance in ALK-Rearranged Lung Adenocarcinoma
Meng-Min Wang, China
- P2.06.54** miR-Roring IFN-Gamma Pathway Activity as a Predictive Tool for Immunotherapy Response in Non-small Cell Lung Cancer
Roberto Cuttano, Italy
- P2.06.55** Association Between Pathologic Necrosis and Postoperative Recurrence in Stage IA Non-small Cell Lung Cancer
Yongfei Fan, China
- P2.06.56** Enhancing Lung Cancer Diagnosis and Early Recurrence Risk Detection via Bedside Atomic Force Microscopy
Jordi Alcaraz, Spain
- P2.06.57** TIM-1+ B Cells Promote Immune Suppression and Predict Poor Prognosis in Lung Adenocarcinoma
Junxu Wen, China
- P2.06.58** Predictive Value of Tumor Microenvironment Biomarkers in Neoadjuvant Immunotherapy Combined with Chemotherapy for Locally Advanced NSCLC
Xu Wang, China
- P2.06.59** Multi-Level Screening of MET Aberrations in Treatment-Resistant Non-small Cell Lung Cancer: A Report From LC-SCRUM-TRY
Tetsuro Taki, Japan
- P2.06.60** Multimodal Diagnostic Model for Intraoperative Diagnosis and Surgery Strategy in Stage IA LUAD (SuRIImage V2): A Prospective, Multicentric Study
Lintong Yao, China
- P2.06.61** ASPIRATION. Australian Nationwide Cohort Study to Assess Impact of Comprehensive Genomic Profiling in Metastatic Lung Cancer
Nick Pavlakis, Australia
- P2.06.62** Integrin-86 Modulates the Tumor Microenvironment and Serves as a Prognostic Marker in Lung Squamous Cell Carcinoma
Fawzi Abu Rous, USA
- P2.06.63** The Role of the Lower Airway Microbiome in Predicting Treatment Response to Immunotherapy in Patients With Non-small Cell Lung Cancer
Anna McLean, Australia

- P2.06.64** Fusion Transcript Burden Is Associated with Clinical Outcomes in Patients with Resected NSCLC
Jeffrey Borgia, USA
- P2.06.65** An Ensemble Approach to Predict Three-Class PD-L1 Expression From H&E Whole-Slide Images
Vanja Mišković, Italy
- P2.06.66** Novel Predictive Spatial Biomarker in NSCLC: Discriminant of Niches Unlocking Treatment Sensitivity (DONUTS)
Michael Fotheringham, Canada
- P2.06.67** Retrospective Analysis of 124 LCNEC Tumors with Targeted Expression Profiling of 111 Samples Identifies Candidate Chemo-Sensitivity Biomarker
David Severson, USA
- P2.06.68** Enhancing Precision Medicine in NSCLC - The Importance of Tumor Metabolic Spatial Profiling in Immunotherapy Biomarker Discovery
Ken Bloom, Israel
- P2.06.69** Metabolite Enrichment Patterns Correlate with Race, Gender and BMI in Lung Cancer Patients
Joshua Pothan, USA
- P2.06.70** Concurrent Tissue and ctDNA-Based Genomic Profiling in Advanced Lung Cancer: A Prospective, Single-Institution Study
Saurav Verma, Canada
- P2.06.71** Clonal Hematopoiesis and Its Association with Lung Cancer Incidence and Immunotherapy Response: A Meta-Analysis
Dhruv Bansal, USA
- P2.06.72** Impact of Peripheral Electrolyte on Equilibrium Between Immunotherapy Toxicity and Survival in Advanced NSCLC Treated With PD-L1 Blockade
Ning Gao, China
- P2.06.73** Cerebrospinal Fluid Biomarkers in Patients with Leptomeningeal Metastasis of Lung Cancer
Xiaoxing Gao, China
- P2.06.74** Detection of Actionable Biomarkers in Liquid Biopsy from Non-small Cell Lung Cancer Patients Using NGS-Based Assays
Sergi Clavé, Spain
- P2.06.75** Liquid Biopsy NGS Accelerating Treatment Decision-Making in Non-small Cell Lung Cancer
Suset Almuinas de Armas, USA
- P2.06.76** Molecular Profiling of Lung Cancer Brain Metastases: Analysis Between Liquid Biopsy and Brain Metastasis Tissue Results
Rupesh Kotecha, USA
- P2.06.77** A Perioperative Circulating Tumor DNA Model for Landmark Detection in Non-small Cell Lung Cancer
Jia-Tao Zhang, China
- P2.06.78** Using a Personalized, Tumor-Informed Circulating DNA (ctDNA) to Monitor Treatment Outcomes in Lung Cancer Patients
Daniel Rosas, USA
- P2.06.79** Deciphering Genomic and Transcriptomic Heterogeneity in Circulating Tumor Cells at Diagnosis in Small Cell Lung Cancer: CTC-CPC Study
Charles Ricordel, France
- P2.06.80** Development of a Proteomics-Based Machine Learning Model for Diagnosing and Predicting Lung Cancer: Insights From the UK Biobank
Xiao Chen, China
- P2.06.81** Circulating Tumour Cells, Spread Through Air Space and Lymph-Nodal Micrometastasis in Surgically Resected Early-Stage NSCLC
Pietro Bertoglio, Italy

- P2.06.82** Cell Free DNA Dynamics in Exhaled Breath Condensate to Predict Outcomes to Immune Checkpoint Inhibition in Advanced NSCLC
David O'Reilly, Ireland
- P2.06.83** Multimethod Circulating Tumor DNA Profiling for Minimal Residual Disease Monitoring in Early-Stage Non-small Cell Lung Cancer
Qian Cui, China
- P2.06.84** Tracking CTC Phenotypes in SCLC Liquid Biopsies as a Diagnostic and Therapy Response Assessment Tool
Loukia Karacosta, USA
- P2.06.85** Clinical Utility of a "Plasma 1st Approach" for Molecular Diagnosis Using ctDNA in Advanced Lung Cancer, NHS England Pilot
Oliver Kennedy, UK
- P2.06.86** Development and Validation of Peripheral Blood 5-Protein Signature Predicting the Efficacy of Immunotherapy in Advanced NSCLC
Lei Cheng, China
- P2.06.87** Reversible Smoking-Dependent Hpg80 Increase, a Path to Identifying NSCLC-Negative Individuals: An Incentive to Quit Smoking?
Alexandre Prieur, France
- P2.06.88** CfDNA and WBC DNA Sequencing Through MSK-ACCESS Powered with SOPHiA DDM to Delineate Tumor and Clonal Hematopoiesis TP53 Variants in Lung Cancer
Florian Klemm, Switzerland
- P2.06.89** DYNAMALK: DYNAMIC ct-DNA in ALK+ NSCLC Under the Australasian Thoracic Cancers Longitudinal Cohort Biobank Study (AURORA)
Malinda Itchins, Australia
- P2.06.90** The Role of ctDNA Tumor Fraction in Advanced NSCLC and Its Impact on Patient Treatment Outcomes: A Prospective Real-World Study
Aya El Helali, China
- P2.06.91** Plasma Proteomic Profiling Identifies DHX9 as a Predictive Biomarker for Chemoimmunotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer
Lina Chen, China
- P2.06.92** Host-Derived Biomarkers of Inflammation and Body Composition Predict Immunotherapy Outcomes in Advanced NSCLC
Andrea De Giglio, Italy
- P2.06.93** Distinct Clinical and Biological Features of Five SCLC Subtypes Identified by Plasma Proteomic Analysis
David Gandara, USA
- P2.06.94** Integrating AI-Based Risk Stratification, LDCT, and Liquid Biopsy for Early Detection of Lung Cancer in High-Risk Individuals
Sewanti Limaye, India
- P2.06.95** Deep Learning-Based Prediction of Immunotherapy Efficacy in Non-small Cell Lung Cancer: Automated Tumor and Muscle Evaluation
Taichi Miyawaki, Japan
- P2.06.96** Exploration of the Heterogeneity of HER2 Expression in Potential Candidates for Antibody-Drug Conjugate in Non-small Cell Lung Cancer
Dongmei Lin, China
- P2.06.97** Monitoring the Risk of Second Primaries Through Blood miRNA Testing: Follow-Up of the BioMILD Lung Cancer Screening Trial
Gabriella Sozzi, Italy
- P2.06.98** Deep Learning-Based 18F-FDG PET/CT Radiomics Model for Predicting Pathological Response to Chemoimmunotherapy in NSCLC
Ao Li, China

- P2.06.99** Tumor-Associated Neutrophil Infiltration Predicts Benefit From Combination Chemoimmunotherapy in Non-small Cell Lung Cancer
Claire Norman, Canada
- P2.06.100** Initial Biomarker Results from the Phase 2A Study of AFM24 With Atezolizumab in Patients with Advanced/Metastatic NSCLC
Hye Ryun Kim, Republic of Korea
- P2.06.101** Neuroendocrine-Like Subtype or TMB-High Predicts Long-Term Survival Benefit from Sequential Thoracic Radiotherapy and ICI in ES-SCLC
Linlin Wang, China
- P2.06.102** Prevalence and Concordance Analysis of MET Amplification/Overexpression in a Phase 1 Study of Davutamis (REGN5093) in a NSCLC
Dimple Modi, USA

TRACK 08: LOCAL-REGIONAL NON-SMALL CELL LUNG CANCER

- P2.08.01** Double Lung Transplantation in Patients with Recent History of Malignancy
Young Kwang Chae, USA
- P2.08.02** Long Term Prognosis Following Wedge Resection in Peripheral = cT1b Non-small Cell Lung Cancer Patients Without Pulmonary Dysfunction
Taeyoung Yun, Republic of Korea
- P2.08.03** Different grades of Visceral Pleura Invasion in Lung Adenocarcinomas Correlate with Aggressiveness and Poor Prognosis
Stylianos Korasidis, Italy
- P2.08.04** Open Versus Thoracoscopic Versus Robotic Sleeve Lobectomy for Central Non-small Cell Lung Cancer: A Network Meta-Analysis
Haifeng Shen, China
- P2.08.05** Robotic-Assisted Versus Video-Assisted Sleeve Lobectomy for Central Non-small Cell Lung Cancer: A Multicenter Cohort Study
Haifeng Shen, China
- P2.08.06** Clinical Significance of Tertiary Lymphoid Structures in Surgically Resected Stage II-III Lung Adenocarcinoma
Taiyo Nakamura, Japan
- P2.08.07** Lymph Node Yield and Survival Among Lung Cancer Patients Treated with Neoadjuvant Systemic Therapy
Giorgio Caturegli, USA
- P2.08.08** Treatment Options and Prognosis for Lung Cancer in Elderly Patients (80 Years Old)
Mari Shinoda, Japan
- P2.08.09** Surgical Resection After Induction Therapy in Initially Unresectable Driver Mutation-Negative Stage III Non-small Cell Lung Cancer (NSCLC)
Hao Guo, China
- P2.08.10** Perioperative Outcomes of Extended Sleeve Resection at Our Institution
Chiaki Kanno, Japan
- P2.08.11** Management of High-Grade Endobronchial Pre-Invasive Lesion: To Treat or Not to Treat?
Illaa Shmesseim, Netherlands
- P2.08.12** Salvage Stereotactic Ablative Radiotherapy for Loco-Regional Recurrence After Initial Surgery According to the START NEW ERA Phase II Trial
Paola Anselmo, Italy
- P2.08.13** Radiation Dose to the Heart and Cardiac Substructures Associated with Adverse Cardiac Events in Locally-Advanced Non-small Cell Lung Cancer
Christopher Kelsey, USA
- P2.08.14** Tumor Volume Changes During Stereotactic Body Radiotherapy for Lung Tumors Under MRI Guidance
Chukwuka Eze, Germany

- P2.08.15** Cardiac Prioritized Planning in Locally Advanced Non-small Cell Lung Cancer: Comparison of Modern RT Techniques
Serap Akyurek, Turkey
- P2.08.16** National Real-World Data on the Treatment of Locally Advanced NSCLC With Chemoradiotherapy and Adjuvant Durvalumab
Martina Vrankar, Slovenia
- P2.08.17** Differential Cardiac Dose Evaluation and the Need of Planning Risk Volume (PRV) Margin for the Heart
Karthick Raja M, India
- P2.08.18** Evaluation of Target Volume Delineation Variability in NSCLC Radiotherapy
Lilian Faroni, Brazil
- P2.08.19** Proton Beam Therapy for Lung Cancer in Patients with Interstitial Lung Disease: Initial Experience From the UK
Caroline Maguire, UK
- P2.08.20** VMAT vs IMRT Technique in Locally Advanced Lung Cancer Radiotherapy Treatment Pulmonary Toxicity and Dosimetric Evaluation
Slavica Maric, Bosnia and Herzegovina
- P2.08.21** Mapping Early Failure After CRT and Durvalumab in NSCLC: Insights from a Real-World Cohort
Maja Lisik-Habib, Poland
- P2.08.22** In Field Progression Rates Following Concurrent Chemoradiotherapy for Stage III Non-small Cell Lung Cancer
Drew Moghanaki, USA
- P2.08.23** Safety and Biomarker Analysis of Nrg-Lu004: Phase I Trial of Radiotherapy with Durvalumab in PD-L1 High LA-NSCLC
Steven Lin, USA
- P2.08.24** Radiation Dose to the Circulating Blood Is Associated with Poor Overall Survival in Patients with Locally Advanced Non-small Cell Lung Cancer
Narek Shaverdian, USA
- P2.08.26** Randomized Phase II Trial of Adjuvant Radiochemotherapy, Concurrent Versus Sequential, in Resected pN2 NSCLC. ARCCS Trial
Paolo Borghetti, Italy
- P2.08.27** Impact of CD73 on Immune Evasive Contexture and Clinical Outcomes in Lung Adenocarcinoma in Neoadjuvant Immunotherapy
Minxing Chen, China
- P2.08.28** Impact of Neoadjuvant Chemoimmunotherapy vs Chemotherapy in Stage III NSCLC: Real-World Analysis from Spanish ReSECT Database
Xavier Vaillo, Spain
- P2.08.29** Phase 2 Trial of Neoadjuvant Tislelizumab Combined with Chemotherapy for Newly Diagnosed Stage III Unresectable NSCLC
Zhe Wu, China
- P2.08.30** IA-Based Prediction in NSCLC Patients Undergoing Neoadjuvant Radiochemotherapy
Claudia Tacconi, Italy
- P2.08.31** Clinical and Imaging Characteristics Associated With Pathologic Response After Neoadjuvant Chemoimmunotherapy in Stage II-III NSCLC
Dong Young Jeong, Republic of Korea
- P2.08.32** Single Cell Transcriptomic Analysis Reveals Tumor Immune Remodeling and Epithelial Cells Gene Signature After Neoadjuvant Immunotherapy
Yutao Liu, China
- P2.08.33** Quantitative Pathological Analysis of the Surgical Specimens of NSCLC After Neoadjuvant Immunochemotherapy
Yui Kaburkai, Japan

- P2.08.34** Serplulimab in Neoadjuvant Therapy for Locally Advanced Non-small Cell Lung Cancer: A Prospective Single-Arm Study
Jian Zeng, China
- P2.08.35** PD-L1 as a Predictive Biomarker in EGFR-Mutated Non-small Cell Lung Cancer with Neoadjuvant Immunochemotherapy
Yi-Fan Qi, China
- P2.08.36** Survival Outcomes in Locally Advanced NSCLC Patients Converted to Resectable Disease by Neoadjuvant Therapy
Ozden Altundag, Turkey
- P2.08.37** Neoadjuvant Chemoimmunotherapy in Resectable NSCLC. Real-World Evidence From a Spanish Multicenter Cohort
Karla Medina Sanchez, Spain
- P2.08.38** Identifying Risk Factors for Recurrence in Non-small Cell Lung Cancer Patients with PCR After Neoadjuvant Immunochemotherapy
Dongmei Lin, China
- P2.08.39** Targeting CHCHD3-cGAS to Remodel Immunosuppressive Microenvironment in Lung Adenocarcinoma: Mechanism and Clinical Translation
Mengzhe Zhang, China
- P2.08.41** The Influence of Perioperative Chemoimmunotherapy on Surgery for Resectable Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Shaoyi Chen, China
- P2.08.42** Impact of Delayed Initiation of Adjuvant Chemotherapy on Overall Survival Among Patients with Non-small Cell Lung Cancer
Esin Namoglu, USA
- P2.08.43** Perioperative Adebrelimab Plus Chemotherapy in Patients with Resectable Stage II-III NSCLC: 4-Year Update From a Phase 1b/3 Trial
Yi-Long Wu, China
- P2.08.44** Adverse Cardiovascular Events Related to Immune Checkpoint Inhibitors in Staging IB-IIIb Non-small Cell Lung Cancer: A Real-World Study
Jin Kang, China
- P2.08.45** Immune Gene Guided Multi-Scale Pathomic Signature in H&E-WSI Predict Neoadjuvant Immunotherapy Response in NSCLC
Shaowei Wu, China
- P2.08.46** COPD Reshape the Tumor Microenvironments of NSCLC and Potentiate Antitumor Efficacy of Anti-PD-1 Therapy
Xiaoke Chen, China
- P2.08.47** Lymphocyte Recovery and Risk for Immune Pneumonitis After Chemoradiation in Locally Advanced NSCLC
Monika Satoskar, USA
- P2.08.48** Pacific Real-World Experience at Hospital Doce De Octubre
Mariana Temes, Spain
- P2.08.49** Effect of the Immunological Circadian Rhythm on Treatment of Locally Advanced Non-small Cell Cancer with Immunotherapy
Ester Oliva-Poch, Spain
- P2.08.50** Tislelizumab with Chemotherapy as Neoadjuvant Therapy for Unresectable Stage III Lung Cancer: A Single-Arm, Phase II Trial
Xianming Hou, China
- P2.08.51** Outcomes from a Phase II Study of Hypofractionated Chemoradiation and Consolidation Immunotherapy in Locally-Advanced NSCLC
Gregory Vlacich, USA
- P2.08.52** Optimizing Lung Cancer Radiation Therapy: Integrating Immunotherapy and Targeted Therapy for Enhanced Clinical Outcomes
Thais Dias, Brazil

- P2.08.53** Safety Results of DEDALUS Trial: Sequential CT-IO, Hypofractionated RT and Consolidation IO in Unresectable Stage III NSCLC
Francesco Agostoni, Italy
- P2.08.54** Contemporary Treatment Patterns and Outcomes in Stage III NSCLC in the Immunotherapy Era
Houda Bahig, Canada
- P2.08.55** Comprehensive Analysis of Baseline Genomic Features and Plasma ctDNA Dynamics in Unresectable Locally Advanced NSCLC
Xiaoxing Gao, China
- P2.08.56** Sequencing of Chemoimmunotherapy in Resectable Locally Advanced NSCLC: Single Center Experience
Pranay Adavelly, USA
- P2.08.57** Small Volume Segmental Lung Autotransplantation for Treatment of Central Lung Cancer: One Case Report
Jinbao Xie, China
- P2.08.58** Advancing Care in NSCLC: Evaluating the Impact of New Treatment Modalities on Patient Outcome at the LTZ of the Comprehensive Cancer Center Zurich
Jorune Pikelis, Switzerland
- P2.08.59** SCGB1A1 Enhances Radioimmunotherapy Efficacy and Mitigates Pulmonary Toxicity via Dendritic Cell Functional Reprogramming
Yan-Pei Zhang, China
- P2.08.60** Telomere Length and Survival in Patients with Locally Advanced Unresectable Lung Cancer: Is There a Relationship?
Alfredo Marín-Muñiz, Spain

TRACK 10: METASTATIC NON-SMALL CELL LUNG CANCER – CYTOTOXIC THERAPY

- P2.10.01** Maintenance Pemetrexed/Pembrolizumab vs Maintenance Pembrolizumab Alone in Advanced Non-Squamous Non-small Cell Lung Cancer
Garth Stroehbehn, USA
- P2.10.02** Developments in Treatment of Non-small Cell Lung Cancer and Their Implications for National Practice.Registurk-Lung National Registry Study
Mahmut Gümüş, Turkey
- P2.10.03** Long-Term Pemetrexed Administration Poses Risk of Renal Function Decline
Tomoki Tamura, Japan
- P2.10.04** Real-World Evidence on the Efficacy of TS1 in Patients with Advanced Non-small Cell Lung Cancer
Chih-Yu Yeh, Taiwan
- P2.10.05** Real-World Efficacy of Second-Line Carboplatin Plus Pemetrexed in EGFR-Mutant NSCLC: an International, Multicentre Analysis
Martin Igor Gómez-Randulfe Rodríguez, UK
- P2.10.06** Docetaxel in NSCLC: A Multi-Centre Real World Evidence Analysis in the Immunotherapy Era
Christopher Theriau, Canada
- P2.10.07** Combined Immunoscore for Predictive Stratification of Unresectable Non-small Cell Lung Cancer
Oussama Aazzane, Morocco
- P2.10.08** Antibody-Drug Conjugates Versus Docetaxel for Previously Treated Advanced NSCLC: Systematic Review and Meta-Analysis of RCTs
Saqib Khan, Canada
- P2.10.09** Single-Cell RNA Sequencing Reveals Subtype-Specific Resistance Mechanisms to TROP2-Targeted ADCs in Non-small Cell Lung Cancer
Osama Younis, Jordan

- P2.10.10** Soluble Ceacam5 Resistant ADC for Effective Tumor Targeted Delivery with Clinically Validated Tumor Selective Linker Payload
Hwanhee Oh, Republic of Korea
- P2.10.11** Single-Cell RNA Sequencing Identifies ALCAM and GPNMB as Therapeutic Targets for ADC Development in Squamous Cell Carcinoma of the Lung
Osama Younis, Jordan
- P2.10.12** Trastuzumab Deruxtecan in Patients from China with Pretreated HER2-Mutant NSCLC: Final Results from the DESTINY-Lung05 Study
Buhai Wang, China
- P2.10.13** Sunvozertinib Combined with Bevacizumab in Previously Treated Advanced NSCLC With EGFR Exon 20 Insertion Mutations
Yongfeng Yu, China
- P2.10.14** Individualized Neoantigen Therapy With Unusual Radiotherapy Enhancement (iNATURE) a Phase II Randomized Study
Feng-Ming (Spring) Kong, China
- P2.10.15** Mechanistic Study of Osimertinib Combined with Sitravatinib to Overcome Acquired Osimertinib Resistance in Non-small Cell Lung Cancer
Xiang Wang, China
- P2.10.16** Paclitaxel Liposome Combined with Immunotherapy in the First-Line Treatment of Advanced NSCLC: Updated Results of a Real-World Study
Liyan Jiang, China
- P2.10.17** Dual PARG-TOP1 Inhibition Exacerbates DNA-Protein Crosslinks and Replication Stress: A Promising Strategy for Enhancing Top1i-ADC Efficacy
Reeja Maskey, USA

TRACK 15: MULTIDISCIPLINARY CARE: NURSING, ALLIED HEALTH AND PALLIATIVE CARE

- P2.15.01** Expedited Diagnostics Coordination Leads to Expedited Care in Advanced Stage Lung Cancer
Robert Anderson, USA
- P2.15.02** Communication Needs of Patients with Advanced Lung Cancer Receiving Immunotherapy: Results of a Qualitative Study
Matthias Villalobos, Germany
- P2.15.03** Predictive Value of LIPI Score in the Response to Immunotherapy in Very Elderly Patients with Advanced Non-small Cell Cancer
Alejandro Olivares Hernández, Spain
- P2.15.04** End-Of-Life Systemic Therapy and Survival in Metastatic Lung Cancer: A Territory-Wide Real-World Study of 24,608 Patients
Feng-Ming Kong, China
- P2.15.05** A Shared Decision Aid for First-Line Treatments of ALK+ Advanced Non-small Cell Lung Cancer: A Patient-Centered Approach
Thomas Stinchcombe, USA
- P2.15.06** Best Practices and Process Variations of Lung Cancer Multi-Disciplinary Teams: Insights from Europe and Israel
Helena Linardou, Greece
- P2.15.07** Effect of Message Framing in a Digital Lung Cancer Screening Decision Navigation Intervention: A Three-Arm Randomized Controlled Trial
Feifei Huang, China
- P2.15.08** Effects of a Decision Support Intervention for Patients with Advanced Lung Cancer: RCT-Results and Document Analysis
Matthias Villalobos, Germany
- P2.15.09** Long-Term Survival in Malignant Pleural Effusion: Validation of the LENT and PROMISE Scores
So Yeon Kim, Republic of Korea

- P2.15.10** Improving Patient-Reported Outcome Symptom Monitoring Using Bayesian Networks
Cindy Verberkt, Netherlands
- P2.15.11** Non-Cancer-Related Mortality in Lung Cancer Patients: The Role of Comorbidities in a 7-Year Retrospective Case-Control Study
Zamira Fernanda Gomez Giraldo, Colombia
- P2.15.12** Non-Pharmacological Dermatologic Care for the Prevention and Management of Immune-Related Skin Toxicities in Patients with Lung Cancer
Jorgina Serra López, Spain
- P2.15.13** Patient Self Management Education and Cancer Treatment Adherence in Low Middle Income Africa a Systematic Scoping Review
Dejen Tsegaye, Australia
- P2.15.14** Improving Access and Recruitment to Clinical Trials for Lung Cancer Using the Lung I-Act Tool: A Mixed Methods UK Wide Pilot Study
Christopher Dodd, UK
- P2.15.15** Impact of Palliative Care in Patients with Non-small Cell Lung Cancer and Brain Metastases: A Retrospective Quality Analysis
Rohit Singh, USA
- P2.15.16** ECMO as a Procedural Bridge for Malignant Airway Obstruction in Lung Cancer
Hyeong Jun Cho, Republic of Korea
- P2.15.17** Preliminary Results on Feasibility of Virtual Delivery of Exercise Therapy for Mitigation of Lung Cancer Decline
Lauren Curry, Canada
- P2.15.18** Quality of Life for Lung Cancer Survivors
Asha Kodan, USA
- P2.15.19** Assessment of NSCLC Treatments and Correlation with Hypogonadism in Male Patients with NSCLC
Richard Chahine, USA
- P2.15.20** Influence of Preoperative Mental Health on the Postoperative Outcome and Quality of Life After Anatomic Lung Resection
Uyen-Thao Le, Germany
- P2.15.21** Feasibility and Preliminary Efficacy of Multimodal Prehabilitation in Patients with NSCLC Receiving Neoadjuvant Therapy
Raquel Sebio-Garcia, Spain
- P2.15.22** A Nutritional Strategy to Mitigate Toxicities and Optimize Dose Intensity in Patients with Lung Cancer: The Nutricare Study
Carolyn Presley, USA
- P2.15.23** Uncertainty in Illness, Symptom Severity and Hope in Advanced Lung Cancer Patients Undergoing Immunotherapy
Yeur-Hur Lai, Taiwan
- P2.15.24** A National Survey of Lung Cancer Survivorship Care at USA Cancer Centers from the American Cancer Society
Matthew Schabath, USA
- P2.15.25** Trilaciclib's Myeloprotection in 1L Advanced Solid Tumors: Lung Cancer Data Analysis
Huijing Feng, China
- P2.15.26** Frequency of Adverse Events Reported Digitally by Patients with Advanced NSCLC: Analysis From CLIMEDIN, a HeCOG Study
Paris Kosmidis, Greece
- P2.15.27** Symptom Screening Using the Patient-Generated Subjective Global Assessment Adds Value to Routine Clinical Review
Chris Smith, UK
- P2.15.28** Lorlatinib-Associated Dyslipidemia: A Multicenter, Retrospective Analysis and Implications for Future Cardiovascular Disease
Fei Xu, China

- P2.15.29** Understanding the Psychosociological Burden of ALK+ NSCLC: Findings from the French Study «Living With ALK+ Cancer»
Jacques Cadranet, France
- P2.15.30** Impact of an Incidental Pulmonary Nodule Course Series on the Professional Development of Under-Resourced Multidisciplinary Teams
Holly Sanders, USA
- P2.15.31** Integrating Biomarker Testing in Early-Stage Lung Cancer with a Nurse-Led Multidisciplinary Approach Using the 4R Oncology Model
Raymond Liu, USA
- P2.15.32** Early Lung Cancer Detection and Multidisciplinary Care
Raymond Osarogiagbon, USA
- P2.15.33** A Comparative Study of the Significance of GPT-Enabled Counseling and Management of Pulmonary Nodules
Dawei Yang, China
- P2.15.34** Prompting and Medical Expertise Influence Large Language Model in Clinical Data Extraction: Findings from the APOLLO 11 Trial
Laura Mazzeo, Italy

TRACK 01: RISK FACTORS, RISK REDUCTION & TOBACCO CONTROL

- P3.01.01** Asian-Americans with Tobacco Use History Are Less Often Eligible for Screening Than White Individuals with Lung Cancer
Julie Barta, USA
- P3.01.02** Association Between Age and Lung Cancer Risk: Evidence from Lung Lobar Radiomics
Yuwei Li, China
- P3.01.03** Night Shift Work and Lung Cancer Risk: A Prospective Cohort Study with Mediator Analysis from the UK Biobank
Yi Feng, China
- P3.01.04** Bootstrap-Based Mediation Mendelian Randomization Unveils Gut Microbiota-Driven Metabolic-Immune Networks in Lung Cancer
Ying-Long Peng, China
- P3.01.05** Decoding the Sleep Enigma: A Proteomic Mediation Analysis Linking Healthy Sleep Patterns to Lung Cancer Risk
Yi Feng, China
- P3.01.06** Lung Cancer in Incidentally Detected Pulmonary Nodules: Stratified Analysis by Smoking History and Nodule Morphology
Filippe Moura de Gouvêa, Brazil
- P3.01.07** Socioeconomic Inequalities and Lung Cancer Outcomes: Evidence from an Integrated EHR Database and State Cancer Registry Data
Tae Yoon Lee, USA
- P3.01.08** Impact of Reproductive Factors on Lung Cancer Risk in Women: A Prospective Analyses in the UK Biobank
Ximin Gao, China
- P3.01.09** Survival Determinants and Socio-Demographic Disparities in Early Onset Lung Cancer in Young Adults: Insights from AI Modeling
Maroun Bou Zerdan, USA
- P3.01.10** Income, Tumour Stage, and Treatment in Patients with Non-small Cell Lung Cancer: A Population-Based Study in the Netherlands
Anouk Eijkelboom, Netherlands
- P3.01.11** Lung Cancer in Young Patients Under 45 Years: Clinical Characteristics, Histology and Molecular Profile
Parvin Akhmedov, Russian Federation

POSTERS (P3):

TUESDAY, SEPTEMBER 9, 2025

i Presenters in Attendance: 10:00 - 11:30

- P3.01.12** Associations Between Respiratory Diseases and Lung Cancer Risk, With New Insights into Acute Infections
Qiu Zhong, China
- P3.01.13** Lung Cancer Characteristics and Survival Among Smokers, Former Smokers, and Never Smokers Within an Australian Lung Cancer Registry
Susan Harden, Australia
- P3.01.14** The Rising Toll: Global Burden and Future Projections of Tracheal, Bronchus, and Lung Cancer in Women, 1990-2050
Jaimini Patoliya (Desai), India
- P3.01.15** Quantifying the Burden of Lung Cancer Attributable to Behavioral Risk Factors in OECD Countries Over Three Decades
Vatsalkumar Jetani, UK
- P3.01.16** Global Burden of Lung Cancer Attributed to High Fasting Plasma Glucose: A Benchmarking Analysis of G20 Countries (1990-2021)
Vatsalkumar Jetani, UK
- P3.01.17** Age-Sex Disparities in Global Burden and Trend of Lung Cancer and Its Attributable Risk Factors in the UK From 1990-2021
Prashant Gupta, India
- P3.01.18** The Journey to a Lung Cancer Diagnosis: Reports from the LEAD Study
Lauren Kiel, USA
- P3.01.19** Gender Differences in Lung Cancer Diagnosis, Treatment Patterns and Outcomes: A Systematic Literature Review
Nagla Fawzy Abdel Karim, USA
- P3.01.20** Lung Cancer Risk Factors in 35,530 People from the UKLS Trial Who Have Never Smoked
Lucy Shire, UK
- P3.01.21** Lifting the Smoke Screen: A Real-World Comparative Study of Lung Cancer in Never-Smokers Versus Ever-Smokers
Pragadeesh Thamarai Selvan, India
- P3.01.22** Deep Learning-Based CT Analysis Enhances Lung Cancer Risk Prediction in Never Smoking Women
Alexis Chidi, USA
- P3.01.23** The Impact of PM2.5 Exposure on the Genome of Patients with Lung Adenocarcinoma Who Have Never Smoked
Peiyao Wang, Canada
- P3.01.24** Economic Burden of Radon Attributable Non-small Cell Lung Cancer: A Cost Analysis
David Griffin, Canada
- P3.01.25** Residential Radon and Molecular Alterations in Non-small Cell Lung Cancer
Virginia Calvo, Spain
- P3.01.26** Respiratory Hazard Index Is Associated with Lung Cancer Development in Underrepresented Lung Cancer Screening Individuals
Frank Weinberg, USA
- P3.01.27** Environmental Carcinogenesis in Lung Cancer: Sodium Arsenite-Induced PML Dysregulation and LINE-1 Activation
Kennedy Whelan, Canada

- P3.01.28** Household Air Pollution and Mitochondrial DNA Fragmentation
Elizabeth Francis, USA
- P3.01.29** Identifying Long Term Air Pollution Exposure for Lung Cancer Risk in Canada
Renelle Myers, Canada
- P3.01.30** The Relationship of Particular Matter 2.5 and Mortality Rate of Patients with Lung Cancer and Lag Time Effect in Northern Thailand
Busyamas Chewaskulyong, Thailand
- P3.01.31** Physical Characterization of PM2.5 - Effects on Cellular Uptake, Dispersion, and Lung Cell Interactions
Isabella Mendoza Montealegre, Canada
- P3.01.32** Association of Long-Term Exposure to Fine Particulate Matter, Ozone, and Greenness with Lung Cancer Risk
Jin Hwa Lee, Republic of Korea
- P3.01.33** Global Trends in Tracheal, Bronchus, Lung Cancer Burden from Household Air Pollution
Shen Lao, China
- P3.01.34** Associating Pollution-Related Anthracotic Pigments Within Normal Lung Tissue with Lung Cancer Characteristics
Lucas Fung, Canada
- P3.01.35** Air Pollution and Lung Cancer Risk by Smoking Status: Findings from the UK Biobank
Alpamys Issanov, Canada
- P3.01.36** Feasibility of Implementing a Virtual Nursing-Led Smoking Cessation Clinic for Patients with Cancer
Sun Choi, Canada
- P3.01.37** Time-Dependent Analysis Reveals the Dual Role of Smoking in Non-small Cell Lung Cancer Immunotherapy
Ying-Long Peng, China
- P3.01.38** Effect of Smoking Cessation Duration on Lung Cancer Incidence: A Nationwide Retrospective Cohort Study in Korea
Myeong Geun Choi, Republic of Korea
- P3.01.39** From Nodule-Free to Nodule-Positive: Blood Biomarkers Bridge Smoking and Lung Cancer Risk
Wenjun Ye, China
- P3.01.40** 10 Years Post Implementation of a Smoking Cessation (SC) Program in Regional Cancer Centres in Ontario, Canada: Successes and Ongoing Challenges
William Evans, Canada
- P3.01.41** Impact of Smoking Status on Survival and Radiation Toxicity in Lung Cancer Patients Receiving RT
Gustavo Cunha, Brazil
- P3.01.42** Transitions in Cigarette and E-Cigarette Use in the PATH Study: A Multistate Transition Model Analysis of US Adults by Race and Ethnicity
Rossana Torres Alvarez, Canada
- P3.01.44** Comparison of Age-Adjusted Charlson Comorbidity Index and Modified Frailty Index as a Postoperative Prognostic Indicator for Lung Cancer
Masaya Yotsukura, Japan
- P3.01.45** Restrictive Lung Function and Smoking Increase Lung Cancer Risk in Tuberculosis Survivors: A Cohort Study
Yun-Gyoo Lee, Republic of Korea
- P3.01.46** Characterization of Patients with Lung Cancer Not Meeting Lung Cancer Screening Criteria: Identifying a High-Risk Group Beyond Tobacco Smoking
Juan Carlos Laguna, Spain
- P3.01.47** Presentation and Validation of Three Engage Variants of the PLCom2012 Lung Cancer Risk Prediction Model
Rafael Meza, Canada

- P3.01.48** Familial Lung Cancer and Hereditary Patterns in NSCLC - Implications for Risk Redefinition
Sulin Wu, USA
- P3.01.49** A Pro-Mitotic Gene Expression Module in Small Airways Links COPD Severity to Non-small Cell Lung Cancer
Vanessa das Gracias Pereira de Souza, Canada
- P3.01.50** Association Between Chronic Lung Diseases and Lung Cancer: A Bidirectional Two-Sample Mendelian Randomization Study
Weijie Zhu, China
- P3.01.51** Evidence Synthesis of Non-Screen-Eligible Cohorts and Implications for Lung Cancer Advocacy
Leah Fine, USA
- P3.01.52** Unseen Risks: Rethinking Lung Cancer Screening for Hispanic Communities
Coral Olazagasti, USA
- P3.01.53** Germline EGFR Mutations Are Enriched in the Southeast USA and Associated with High Penetrance of Non-small Cell Lung Cancer
Jenny O'Brien, USA

TRACK 03: TUMOR BIOLOGY - TRANSLATIONAL BIOLOGY

- P3.03.01** Rb Inactivation as a Hallmark of Squamous Transformation in EGFR-Mutant Lung Cancers
Mark Jeng, USA
- P3.03.02** WEE1 as the Target for Circumvention of ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutated Lung Cancer
Seiji Yano, Japan
- P3.03.03** Mechanisms of Osimertinib Tolerance in Mutant EGFR Lung Cancer PDX Models
Nhu-An Pham, Canada
- P3.03.04** Aggressive Lymph Node Dissection Is Linked to Poor Survival and Impaired Anti-Tumor Immunity in Non-small Cell Lung Cancer
Melek Agkoç, Turkey
- P3.03.05** Proteomic Analysis of Pleural Mesothelioma
Tetsuzo Tagawa, Japan
- P3.03.06** Integrated Bulk and Single-Cell Transcriptomics Reveals Immune Ecotype Heterogeneity in EGFR-Mutated Lung Adenocarcinoma
Shu Xian Zhang, China
- P3.03.07** Characterization of Live Cell Repository for Tumor Derived Pleural Mesothelioma Cells and Cancer Associated Fibroblasts
Mayura Meerang, Switzerland
- P3.03.08** Patient-Derived Tumour Organoids Recapitulate Keratinizing Lung Squamous Cell Carcinomas
Christina Cahill, Ireland
- P3.03.09** Synonymous Mutations in PDGFRA Exons 12 and 18 Correlate with Reduced Survival and Serum Iron Levels in Non-small Cell Lung Cancer
Xiaowei He, China
- P3.03.10** Establishment of Patient-Derived Organoids From EBUS-TBNA Cytological Samples in Lung Cancer Patients
Melissa Acosta-Plasencia, Spain
- P3.03.11** Anlotinib Exerts a Protective Effect on Radiation Lung Injury Through the Regulation of the Immune Microenvironment Mediated by M2c Macrophages
Huaiyu Wang, China
- P3.03.12** YAP-Driven Modulation of HER3-Mediated Adaptive Resistance to RET Inhibitors in RET-Altered Cancer
TADAAKI YAMADA, Japan

- P3.03.13** HLA II Genetics Shapes Lung Cancer Immunosurveillance
Ezekiel Olumuyide, USA
- P3.03.14** PCSK9-Mediated Immune Escape as a Mechanism of Acquired Resistance to PD-1/PD-L1 Blockade
Guang-Ling Jie, China
- P3.03.15** Investigating Mechanisms of Resistance in EGFR-Mutated Non-small Cell Lung Cancer Through High Resolution Transcriptomics
Eva Cabrera San Millan, Italy
- P3.03.16** CXCR2+ Neutrophils Influence Immunotherapy Efficacy in NSCLC Patients with KL Subtype
Xuefei Li, China
- P3.03.17** Intermittent Caloric Restriction Synergies With KRAS(OFF) Inhibitors in Preclinical Models of KRASG12C Lung Adenocarcinoma
Edoardo Garbo, Italy
- P3.03.18** Single-Cell Transcriptomic Analyses of Lung Immune Cells Reveal That MITF-Driven Plcb1HighMacrophages Induce Radiation-Induced Lung Injury
Huan Zhang, China
- P3.03.19** SFRP2highCAFs Trigger CD8+T Cell Apoptosis to Sustain Abscopal Resistance to Radioimmunotherapy in Lkb1-Mutant Lung Tumors
Yujie Zeng, China
- P3.03.20** Citrullinated Vimentin Is an Effective Target for CAR T Cells in Non-small Cell Lung Cancer
Jenny O'Brien, USA
- P3.03.21** Aptamer-Drug Conjugates for Leptomeningeal Carcinomatosis and Cancer-Associated Cachexia in Lung Cancer
Emily Lin, Taiwan
- P3.03.22** Tumor Treating Fields (TTFields) Downregulate DNA Repair and Show Efficacy in Small Cell Lung Carcinoma Preclinical Models
Tisdrey Torres, USA
- P3.03.23** Circular RNA Vaccine Synergizes with Anti-PD-1 to Augment Therapeutic Efficacy in Lung Cancer
Shaoyi Chen, China
- P3.03.24** Oxydock: Optimizing Lung Cancer-Targeted Therapy Through Oxygen-Responsive Molecular Docking
Arnav Pemmaraju, USA
- P3.03.25** A Combination Therapy Strategy That Targets Both KRAS-G12C and GSK3 for Non-small Cell Lung Cancer
Xian Gong, China
- P3.03.26** Ir-Metal Framework Loaded with Radiation-Responsive Anti-Angiogenic Prodrugs for Enhanced Radiotherapy Efficacy
Qin Zhang, China
- P3.03.27** The TXNRD1-IGF2BP3 Axis Promotes EGFR-TKI Resistance and Identifies a Therapeutic Vulnerability in NSCLC
Mengwei Yang, China
- P3.03.28** Tumor Treating Fields (TTFields) Concomitantly with Anti-PD-1 and Cisplatin in a Mouse Model of Non-small Cell Lung Cancer
Anat Klein-Goldberg, Israel
- P3.03.29** IAM1363 Is a Potent, Selective, and Irreversible HER2 and Pan-HER2 Mutant Small Molecule Inhibitor for the Treatment of HER2-Driven NSCLC
Zhongdong Huang, USA
- P3.03.30** Activation of EGFR Signaling Mediated by PTPRR Methylation Causes Resistance to KRAS Inhibitor Sotorasib
Hiroaki Kanemura, Japan

- P3.03.31** Transcriptomic Profiling Identifies a Prognostic and Predictive Inflammatory Signature in Patients with Lung Adenocarcinoma
Ayah Al-Bzour, Jordan
- P3.03.32** Multi-Omic Characterization of ALK Fusion LUADs Reveals Overactivation of DNA Replication as a Contributor to ALK TKI Resistance
Esther Redin, USA
- P3.03.33** Clinical and Genomic Landscape of BRAF-Mutant NSCLC Patients from the AACR GENIE BPC Cohort
Sandra Ortiz-Cuaran, France
- P3.03.34** Assessment of Minimal Residual Disease Using Liquid Biopsy in Patients with EGFR-Mutated Lung Cancer Treated with Osimertinib
Celia Delahaye, France
- P3.03.35** Association of Intestinal Flora and Metabolites with Bone Metastasis in Patients with Non-small Cell Lung Cancer
Jia-Xuan Li, China
- P3.03.36** Whole Genome Doubling Drives Genomic Instability and Poor Postoperative Outcomes in Stage I Driver-Negative Lung Adenocarcinoma
Masahiro Torasawa, Japan
- P3.03.37** Target Lipid Metabolism in Immune Microenvironment: Immunotherapy Sensitization and Combinatorial Strategies for NSCLC With Liver Metastases
Yujia Fang, China
- P3.03.38** Oncolytic Virus Effectively Delivers CD47 Blockade to Suppress Tumour Growth in Preclinical NSCLC Models
Kelsie Thu, Canada
- P3.03.39** Deep Learning Based Multiplex Imaging Platform for High Throughput ADC Targets Expression Quantification and Biomarker Discovery in NSCLC
Kenneth Bloom, Israel
- P3.03.40** PRMT9 mRNA Stabilized by IGF2BP1 in an m6A-Dependent Manner Promotes Proliferation and Metastasis of Lung Adenocarcinoma Cells
Jing-Hua Chen, China
- P3.03.41** FOXO3A Regulates NSCLC Radiotherapy Resistance Through PINK1/Parkin Pathway of Protective Mitophagy
Shilan Luo, China
- P3.03.42** Immune-Related Gene Expression Profiling and ALK-TKI Efficacy for Patients With ALK-Rearranged Non-small Cell Cancer
Takashi Kurosaki, Japan
- P3.03.43** Gut Klebsiella Pneumoniae Drives Lung Cancer Progression by Modulating Macrophage HPGDS and Suppressing the PGJ2-PPAR γ Signaling Pathway
Zixuan Hu, China
- P3.03.44** High Frequency of SMARCA4 Inactivating Mutations in Advanced NSCLC and Their Association with Low PD-L1 Expression
Maria Saigi Morgui, Spain
- P3.03.45** KRAS Mutations Shape an Oxidative, Immune-Cold Tumor Microenvironment Driving Chemo-Immunotherapy Resistance in Advanced NSCLC
Victor Seguí, Spain
- P3.03.46** Phenotyping Double Negative B Cells in Non-small Cell Lung Cancer
Liam Neilson, UK
- P3.03.47** Study of Genomic Intra-Tumor Heterogeneity and Acquired Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Pablo Navajas-Chocarro, Spain
- P3.03.48** Fluorescence Lifetime Imaging in Fixed NSCLC Samples Demonstrate Differences Between Tissue Compartments
Alexander Hunt, UK

- P3.03.49** Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer Cells Harboring RET Fusions
Eva Pros, Spain
- P3.03.50** cIRCCAMSAPI Induce Osimertinib Resistance in Lung Adenocarcinoma by Downregulating the Degradation Level of HSPA1A
Wenmei Su, China
- P3.03.51** FLT3LG Improve Therapeutic Sensitivity to Anti-PD-1 Therapy by Modulating Immune Cell Infiltration in NSCLC
Sida Qin, China
- P3.03.52** XPO1 Inhibition Reduces Tumor Growth Potential by Inhibiting WNT Signaling Pathway in Lung Squamous Cell Carcinoma
Vidushi Durani, USA
- P3.03.53** WISP3 Drives NSCLC Progression by Upregulating SDCBP via the TGF- β Signaling Pathway
Guanghui Gao, China
- P3.03.54** Influenza's Silent Warriors: Unveiling Lung Tumor Cell Assassination Through Macrophage Reprogramming via SAA4-MLKL Axis
Öznur Cetin, Germany

TRACK 09: METASTATIC NON-SMALL CELL LUNG CANCER – LOCAL THERAPIES

- P3.09.01** Validation of Lung Specific-Graded Prognostic Assessment Score in NSCLC with Brain Metastases from India
Sarath S, India
- P3.09.02** Stereotactic MR-Guided Adaptive Radiotherapy (SMART) for Ultracentral Non-small Cell Lung Cancer (NSCLC)
Crispin Hiley, UK
- P3.09.03** Efficacy of Radiotherapy in Patients with Oligo-Progressive Non-small Cell Cancer - A Retrospective Analysis
Tamar Barkan, Israel
- P3.09.04** Macrophage CD38 Expression as a Predictive Biomarker for the Abscopal Effect in Lung Cancer Undergoing Radiotherapy-Immune Therapy
Yuanjun Wu, China
- P3.09.05** Prognostic Value of TNM 9th Lymph Node Classification and Pathological Node Count in NSCLC Patients
Yoriko Sakata, Japan
- P3.09.06** Primary Tumor Resection Confers Survival Benefit in cM0sM1a Lung Adenocarcinoma
JiaYuan Tian, China
- P3.09.07** Local MDT Improve the Survival of Leptomeningeal Metastasis in NSCLC With EGFR Mutation From the CLM-Tree Registry
Weiping Hong, China
- P3.09.08** Tumor Treating Fields for Patients with Metastatic Non-small Cell Lung Cancer: Real World First Experience
Rupesh Kotecha, USA
- P3.09.09** Frequency and Prognostic Impact of Local Ablation Therapy for Oligoprogression in Non-small Cell Lung Cancer
Daisuke Morinaga, Japan
- P3.09.10** Safety and Efficacy of Co-Ablation System Therapy in Patients with Lung Cancer: A Single Arm Cohort Study
Shengxiang Ren, China

TRACK 12: METASTATIC NON-SMALL CELL LUNG CANCER – TARGETED THERAPY

- P3.12.01** Phase II Trial of First-Line Double-Dose Firmonertinib in Locally Advanced or Metastatic NSCLC With EGFR L858R (FIRM Study)
Meiqi Shi, China

- P3.12.02** Real-World Outcomes in Patients with NSCLC and Leptomeningeal Disease
Muskan Agarwal, USA
- P3.12.03** Retrospective Analysis of Age, EGFR Mutation Type, and TP53 Co-Mutation on Survival Outcomes in EGFR-Mutant Non-small Cell Lung Cancer
Eric Singhi, USA
- P3.12.04** Taltrectinib, a Next Generation Selective ROS1 Inhibitor, Exhibits a Differentiated Profile in ROS1 Fusion Models
Hitisha Patel, USA
- P3.12.05** Patterns of EGFR Mutations and Real-World Experience of Therapeutic Interventions - a Community Oncology Study
Kunal Jobanputra, India
- P3.12.06** Pralsetinib (Phase 1/2 ARROW Trial) Compared With Best Available Therapy (External Control) in Pretreated RET Fusion+ NSCLC
Domenico Galetta, Italy
- P3.12.07** Rezipertinib in EGFR-Mutated NSCLC Patients with CNS Metastases: CNS Efficacy from Phase 3 RAZOR Study
Jirong Peng, USA
- P3.12.08** Weight Gain Induced by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non-small Cell Lung Cancer: A Meta-Analysis and a Meta-Regression Study
Lorenzo Belluomini, Italy
- P3.12.09** Efficacy of Tepotinib Against Non-Adenocarcinoma MET Exon 14 Skipping NSCLC: A Subanalysis of the REAL-MET Study
Ryota Saito, Japan
- P3.12.10** Adapting RECIST for Real-World Data: Independent Imaging Read Methodology Over Successive Treatments in a NSCLC Data Registry
S. Peter Eggleton, Germany
- P3.12.11** Aumolertinib Plus Chemotherapy as First - Line for Ps 2 - 3 Advanced NSCLC with EGFR Mutations: A Phase 2 Subgroup Analysis
Yan Wei Li, China
- P3.12.12** Clinical Pharmacologic Characteristics of Taltrectinib
Lyudmila Bazhenova, USA
- P3.12.13** Long-Term Real-World Outcomes of Sotorasib in Second-Line and Beyond Treatment of KRAS G12C-Mutated Advanced NSCLC
Enriqueta Felip, Spain
- P3.12.14** Clinical Effectiveness and Safety of Tepotinib in Patients from Germany with MET Exon14 Skipping NSCLC: A Case Series
Frank Griesinger, Germany
- P3.12.15** Activity and Tolerability of MET TKIs in METex14 NSCLC: Updated Real-World Data From the Italian Biomarker Atlas Database
Maria Lucia Reale, Italy
- P3.12.16** Reduced Survival in Black Patients With EGFR-Mutant NSCLC
Karen Reckamp, USA
- P3.12.17** A Phase II Study of Firmonertinib Combined with Apatinib as First-Line Therapy in NSCLC Patients with EGFR Uncommon Mutations
Hai-Yan Xu, China
- P3.12.18** Vebreltinib Plus EGFR-TKI in EGFR-Mutated NSCLC With MET Amplification and/or Overexpression After Failure on EGFR-TKI: A Retrospective Study
HaiBo Wang, China
- P3.12.19** Optimizing Treatment Sequencing to Maximize Survival in ALK+ Advanced Non-small Cell Lung Cancer: A Modeling Study
Hannah Le, USA
- P3.12.20** VAF of EGFR Mutations in Relation to Early Tumor Shrinkage or Deepness of Response During Osimertinib in NSCLC Patients

- Giuseppe Bronte, Italy*
- P3.12.21** Biomarker Analysis and Final Efficacy of Lorlatinib in Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
Benjamin Solomon, Australia
- P3.12.22** A Phase II Study of Sunvozertinib Combined with Anlotinib in Treatment-Naïve NSCLC with EGFR Sensitive Mutations and Co-Mutations (WU-KONG32)
Yongchang Zhang, China
- P3.12.23** Tepotinib Efficacy in Poor Performance Status and Elderly Patients with MET Exon 14 Skipping NSCLC: A RELA-MET Subanalysis
Kazuhiro Nishiyama, Japan
- P3.12.24** Real-World Treatment of Osimertinib Monotherapy Versus Combination Therapy in Stage IV Non-small Cell Lung Cancer Patients
Edgardo Santos, MD, USA
- P3.12.25** First-Line HLX07 Plus Serplulimab with or Without Chemotherapy in Squamous Non-small Cell Lung Cancer: A Phase 2 Study
Yilong Wu, China
- P3.12.26** Adding Gefitinib to Target Acquired C797S Mutation After Progression on First-Line Osimertinib in EGFR-Mutant Advanced NSCLC
Zi-Ji Mao, China
- P3.12.27** Resistance Mechanisms of Novel Targeted Therapies to EGFR Exon 20 Insertion Mutation-Positive Non-small Cell Lung Cancer
Bin-Chi Liao, Taiwan
- P3.12.28** Association of PD-L1 Expression with Clinical Outcome in Advanced NSCLC With ALK Rearrangement
Nattanit Suriyaphan, Thailand
- P3.12.29** Effectiveness and Treatment Patterns in Patients with First-Line 2G ALK TKI Across the Esme French Real-World Cohort
Girard Nicolas, France
- P3.12.30** Histological Transformation as Resistance Mechanism in NSCLC: A Multicenter Study Exploring Clinico-Pathological and Molecular Features
Laura Masfarré, Spain
- P3.12.31** Rezipertinib in Advanced NSCLC Patients With EGFR T790M Mutation via Tissue/Plasma Samples: Pooled Analysis of 2 Clinical Studies
Yanqiu Zhao, China
- P3.12.32** Long-Term Survival Outcome After First-Line Osimertinib Monotherapy in Advanced/ Metastatic NSCLC: Results From LC-SCRUM-Asia
Hiroki Izumi, Japan
- P3.12.33** The Primary Endpoint Analysis of RELAY-Effusion; a Phase II Study of Ramucirumab Plus Erlotinib in EGFR-Mutated NSCLC With Pleural Effusion
Naoko Katsurada, Japan
- P3.12.34** Real-World Study in Patients With ALK+ Metastatic Non-small Cell Lung Cancer (mNSCLC) Treated with First-Line (1L) Lorlatinib
Shirish Gadgil, USA
- P3.12.35** Real-World Clinical Outcomes of Osimertinib in Patients with Recurrent EGFR Mutated Lung Adenocarcinoma: A Multicenter Study
Ichidai Tanaka, Japan
- P3.12.36** Multicenter Retrospective Study of Selpercatinib Treatment for Advanced or Recurrent RET Fusion-Positive NSCLC in Japan
Yasuhiro Mihashi, Japan
- P3.12.37** First-Line Lazertinib with or Without Local Ablative Radiotherapy in Oligo-Metastatic EGFR-Mutant NSCLC
Jii Bum Lee, Republic of Korea
- P3.12.38** Updated Clinical Results From FURTHER: A Study of Firmonertinib in TKI-Naïve, Advanced NSCLC With EGFR PACC Mutations

Xiuning Le, USA

- P3.12.39** Long-Term Overall Survival in Advanced EGFRm NSCLC Treated With 1L Osimertinib: Results From the US, Japan, Germany and China
Jorge Nieva, USA
- P3.12.40** Safety and Patient-Reported Outcomes with Tepotinib in Patients with METex14 Skipping NSCLC: =3-Years Follow-Up of VISION
Enriqueta Felip, Spain
- P3.12.41** Factors Associated with Clinical Outcomes in Patients with HER2-Mutant NSCLC Treated with Sevabertinib (BAY 2927088)
Xiuning Le, USA
- P3.12.42** Concurrent KRAS Mutations Render Single-Agent EGFR Inhibitors Futile in Advanced NSCLC
Misako Nagasaka, USA
- P3.12.43** A Phase II Study of Sunvozertinib Combined with Anlotinib in NSCLC Patients Harboring EGFR Ex20Ins and Uncommon EGFR Mutations
Hai-Yan Xu, China
- P3.12.44** A Retrospective Study of the Effect of Cumulative Smoking Dose on Clinical Course in People with EGFR-Mutated NSCLC Treated with Osimertinib
Takanori Ito, Japan
- P3.12.45** Aumolertinib for Treatment-Naïve EGFR-Mutant NSCLC Patients With Brain Metastases: Updated Efficacy Data From the ARTISTRY
Xiaojuan Zhang, China
- P3.12.46** Enhanced vs Standard Dermatologic Management with Amivantamab-Lazertinib in EGFRm Advanced NSCLC: The COCOON Global RCT (*JTO SIMULTANEOUS PUBLICATION*)
Byoung Chul Cho, Republic of Korea
- P3.12.47** A Phase II Study of Sunvozertinib Combined with Chemotherapy in EGFR-TKIs Resistant EGFRm Advanced NSCLC Patients (WU-KONG36)
Feifei Na, China
- P3.12.48** Efficacy and Safety of Savolitinib in Advanced or Metastatic METex14 NSCLC Patients with or Without Prior Immunotherapy
Yongfeng Yu, China
- P3.12.49** Clinical Significance of a Genomic Screening Platform of Non-small Cell Lung Cancer in Asia-Pacific: LC-SCRUM-AP
Muthukumar Thiagarajan, Malaysia
- P3.12.50** A Prognostic Model Based on a Concurrent Gene Mutational Signature for EGFR Mutant NSCLC with TKI Treatments
Qi Wang, China
- P3.12.51** Patient-Derived Organoids as Preclinical Models for Drug Resistance in NSCLC
Nikolina Radulovich, Canada
- P3.12.52** Aumolertinib Plus Anlotinib in Advanced EGFR-Mutant NSCLC With TP53 Co-Mutation: A Single-Arm, Phase II Study
Zhansheng Jiang, China
- P3.12.53** High-Dose Furmonertinib Plus Bevacizumab in EGFR-Mutant NSCLC With CNS Metastases After Resistance to Third-Generation EGFR-TKIs
Li Kun Chen, China
- P3.12.54** Predicting Osimertinib-Induced Pneumonitis in EGFR-Mutated NSCLC Using Multi-Modal Machine Learning Model
Kyujiro Nibuya, Japan
- P3.12.55** Efficacy of Vebreltinib in Advanced NSCLC Patients with MET Exon 14-Skipping: Post-Hoc Analysis of KUNPENG Study
Jin-Ji Yang, China
- P3.12.56** Medication Adherence to Osimertinib in Patients Diagnosed with Metastatic Non-small Cell Lung Cancer

Daniel Rosas, USA

- P3.12.57** Phase I/II Study of FHND9041 in T790M-Positive Advanced NSCLC Patients Progressed After Prior EGFR-TKI Therapy
Dechuang Yuan, China
- P3.12.58** Initial Results from Phase 1/2 Study of the RET-Selective Inhibitor Vepafestininib in Patients with RET-A aberrant Solid Tumors
Kiyotaka Yoh, Japan
- P3.12.59** A Phase Ib/II Study of Vebreltinib Plus Tislelizumab in Patients With MET-Amplified and PD-L1-Positive Locally Advanced or Metastatic NSCLC
Zhijie Wang, China
- P3.12.60** The Combination of USP24-i-101-Astemizole Sensitizes the Cytotoxicity of Taxol and Gefitinib in Drug-Resistant Lung Cancer
Jan-Jong Hung, Taiwan
- P3.12.61** Retrospective Multicenter Study Within the German Network Genomic Medicine Lung Cancer on RET Fusions as Resistance in EGFR-Mutant Lung Cancer
Cornelia Kropf-Sanchen, Germany
- P3.12.62** First-Line Osimertinib ± Platinum-Pemetrexed Chemotherapy for EGFR-Mutated Advanced NSCLC: FLAURA2 Non-Asian Country Cohort
Pasi A. Jänne USA
- P3.12.63** MTAPloss Is Frequent and Potentially Targetable with PRMT5 Inhibitors in Oncogene-Driven NSCLC
Mihaela Aldea, USA
- P3.12.64** Frontline Treatment Duration in MET-Amplified NSCLC After Third-Generation EGFR-TKI Failure: SACHI Study Insights
Lijuan Chen, China
- P3.12.65** First-Line Osimertinib ± Platinum-Pemetrexed in EGFR-Mutated Advanced NSCLC: FLAURA2 Clinical Outcomes by EGFRm Subtype
Samreen Ahmed, UK
- P3.12.66** Overcoming Osimertinib Resistance in EGFR<+ NSCLC: PI3K Inhibitor Combined with Osimertinib Restores Drug Sensitivity
Lin Jiang, China
- P3.12.67** Redefining Tolerability: A Head-To-Head IPD Toxicity Comparison of Amivantamab+Lazertinib vs Osimertinib+Chemotherapy in EGFR-Mutant NSCLC
Blerina Resuli, Germany
- P3.12.68** Regulating Autophagy Will Be a Potential Key Point in Overcoming EGFR TKI Resistance in Non-small Cell Lung Cancer
Seoree Kim, Republic of Korea
- P3.12.69** Updated Efficacy and Safety of Taletrectinib in Chinese Patients with ROS1+ Non-small Cell Lung Cancer: Phase 2 TRUST-I Study
Wei Li, China
- P3.12.70** Development of a Bispecific Antibody That Safely and Effectively Targets EGFR and B7H3 in NSCLC
Xinxin Zhi, China
- P3.12.71** Efficacy and Safety of Pralsetinib in Patients with Advanced Ret Fusion-Positive NSCLC: Phase 1/2 ARROW Study Final Data
Aaron Mansfield, USA
- P3.12.72** FIN-EGFR/CNS: Real World Survival and Patient Characteristics of EGFR Mutated NSCLC Patients With Cns Metastases in Finland
Maria Silvonien, Finland

TRACK 13: SMALL CELL LUNG CANCER AND NEUROENDOCRINE TUMORS

- P3.13.01** Effect of Patient Management System and Medical Resources on Outcomes of SCLC Treated with Chemo-ICI

Yuta Yamanaka, Japan

P3.13.02 The Effectiveness of Anatomical Versus Non-Anatomical Resection for Treatment of Small Cell Lung Carcinoma

Michal Dziedzic, Poland

P3.13.03 Proteomic Profiling of Small Cell Lung Cancer Patients Reveals Blood-Based Prognostic Proteins

Kristiina Boettiger, Austria

P3.13.04 Consolidation Thoracic Radiotherapy After Chemoimmunotherapy in ES-SCLC: A Multicentric Retrospective Analysis

Federico Monaca, Italy

P3.13.05 First-In-Human Study of 225Ac-ABD147 for SCLC and LCNEC Post-Chemotherapy: Pharmacokinetics, Biodistribution and Safety Insights

Sean Carlin, USA

P3.13.06 Comprehensive Assessment of the Tumor Microenvironment of Resected Small Cell Lung Cancer

Andréanne Gagné, Canada

P3.13.07 Real-World Implementation of Immunotherapy for Stage III-IV Small Cell Lung Cancer: Insights from the National Cancer Database (2016-2021)

Brittany Morguelan, USA

P3.13.08 Autologous Vax-NK/HCC Consolidation Therapy in ES-SCLC

In-Jae Oh, Republic of Korea

P3.13.09 Surface Targeting Strategies to Overcome Heterogeneity Associated with Treatment Resistance in Small Cell Lung Cancer (SCLC)

Allison Stewart, USA

P3.13.10 Real-World Outcomes of Prophylactic Cranial Irradiation (PCI) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in the US

Samantha Reiss, USA

P3.13.11 HER2- and TROP2-Directed Antibody Drug Conjugates Show Potent Antitumor Activities in Small Cell Lung Cancer

Bingnan Zhang, USA

P3.13.12 Multi-Institution Analysis Evaluating Safety, Efficacy and ctDNA Dynamics Following Tarlatamab in ES-SCLC and LCNEC Patients

Graeme Fenton, USA

P3.13.13 A Phase II Study of Vobramitamab Duocarmazine in Patients with Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer

Tina Roy, USA

P3.13.14 Lab Data-Based Prediction for Clinical Efficacy of Immunochemotherapy in ES-SCLC Using Statistical and Machine Learning Models

Shuichiro Hara, Japan

P3.13.15 First-Line Immunochemotherapy in ES-SCLC Patients with ECOG PS =2: Real-World Evidence From the ASTRUM-005R Trial

Lin Wu, China

P3.13.16 Survival Outcomes with Carboplatin Versus Cisplatin and the Impact of COVID-19 on Platinum Choice in SCLC in the Netherlands

Ilias Houda, Netherlands

P3.13.17 A Comparative Analysis of TNM 8 and TNM 9 Classification Systems in Small Cell Lung Cancer

Asaf Dan, Sweden

P3.13.18 Immunotherapy Pooled Analysis in 1L Extensive-Stage Small Cell Lung Cancer

Judith Pérez-Granado, USA

P3.13.19 High Throughput Drug Screening for Small Cell Lung Cancer Based on Machine Learning and Organoid Platforms

Xiaoyi Feng, China

P3.13.20 Integrative Spatial Analysis Reveals Ferroptosis Heterogeneity and Novel Therapeutic Vulnerabilities in Small Cell Lung Cancer

Chaoqiang Deng, China

P3.13.21 Refining Patient Selection for Prophylactic Cranial Irradiation in Limited-Stage Small Cell Lung Cancer: A Multicenter Cohort Study

Hye In Lee, Republic of Korea

P3.13.22 Efficacy and Safety of Surufatinib, Durvalumab in Combined with Chemotherapy as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer

Ying Hu, China

P3.13.23 Copy Number Gain of MYC-Paralogs Represents Proliferative Phenotype and Poor Prognosis in Resected Small Cell Lung Cancer

Yan Ju, China

P3.13.24 Longitudinal Plasma Proteomics Identifies Predictive Biomarkers for Anti-PD-L1 Therapy in SCLC

Guang-Ling Jie, China

P3.13.25 Comprehensive Immune Microenvironment Profile of EGFR-Mutant Non-small Cell Lung Cancer Transformation Towards Small Cell Lung Cancer

Yu Hui, China

P3.13.26 Sequencing of Stereotactic Body Radiation Therapy and Chemotherapy in Stage I Small Cell Lung Cancer: Practice Patterns and Outcomes

Henry Park, USA

P3.13.27 Toripalimab Consolidation After Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase II, Randomized Controlled Study

Pengxin Zhang, China

P3.13.28 Survival Outcomes in Advanced Large Cell Neuroendocrine Carcinoma of the Lung in Immunotherapy Era: An NCDB Analysis

Kim Chul, USA

P3.13.29 Somatostatin Receptor Expression and First-Line Somatostatin Analog Therapy: A Comparative Analysis in Thoracic Neuroendocrine Neoplasms

Mariia Vorobeve, Russian Federation

P3.13.30 Whole Exome Sequencing Analysis of Somatic Mutations in Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia

Hui Yu, USA

P3.13.31 Real-World Effectiveness and Safety of Lurbinectedin for Small Cell Lung Cancer (SCLC): Updates from Jazz EMERGE 402

Balazs Halmos, USA

P3.13.32 Real-World Outcomes of Patients with Bronchopulmonary Neuroendocrine Tumors Treated with Lutetium Lu 177 DOTATATE (Lutathera)

Giuseppe Maiocco, USA

P3.13.33 Clinical Outcomes and Single-Cell Map of Neoadjuvant Immunochemotherapy for Stage II-IIIb LS-SCLC : A Real-World Study

Chen Huang, China

TRACK 14: MESOTHELIOMA, THYMOMA, AND OTHER THORACIC TUMORS

P3.14.01 Global Trends in Asbestos Related Mesothelioma Mortality From 1990 to 2021

Kyle Edwards, USA

P3.14.02 Clinical Implications of BAP1 Status in Pleural Mesothelioma (PM)

Susana Cedres, Spain

P3.14.03 Loss of MHC Class I and II Defines an Immune Excluded Subtype in Pleural Mesothelioma

Jasper van Genugten, Netherlands

P3.14.04 High-Volume Surgical Centers for Pleural Mesothelioma Are Associated with Lower Perioperative Mortality

Darren Bryan, USA

P3.14.05 Survival Outcomes of Sequential Therapies in Malignant Pleural Mesothelioma: A Real-World Analysis of Second-Line Treatments

Michele Maffezzoli, UK

P3.14.06 Attitude of Italian Physicians Towards Germline and Somatic Genetic Testing in Pleural Mesothelioma: Preliminary Results of a Nationwide Survey

Giulia Pasello, Italy

P3.14.07 Recent Studies on Mesothelioma as a Model to Understand the Interaction of Gene and Environment (G X E)

Haining Yang, USA

P3.14.08 Genetically Defined Mouse Models of Malignant Pleural Mesothelioma Recapitulate Human MPM Phenotypes and Response to Therapy

Pooyeh Farahmand, UK

P3.14.09 Sex-Based Differences in Mesothelioma: Insights from the ICO Cancer Registry

Jesús Brenes, Spain

P3.14.10 Ultrasound Detection of Effusion and Neoplasia in Genetically Defined Mouse Models of Mesothelioma

Xinya Hong, UK

P3.14.11 Real-World Outcomes and Toxicity of First-Line Dual Immunotherapy in Unresectable Pleural Mesothelioma

Beatriz Jimenez Munarriz, Canada

P3.14.12 Pseudo-Senescence Induced by Palbociclib Does Not Sensitize Pleural Mesothelioma Cells to Combinations with Classical Senolytics

Iswarya Sreeram, Spain

P3.14.13 Sex and Histology Related Profile of Gut Microbiota (GM) in Pleural Mesothelioma (PM): Preliminary Results of a Prospective Observational Study

Federica Grosso, Italy

P3.14.14 Ten-Year Longitudinal Analysis of Mesothelioma Incidence: A Nationwide Cohort Study Based on the 2012 Korean Health Screening Registry

Kwanyong Hyun, Republic of Korea

P3.14.15 Thymic Cancer in France: A Comprehensive Analysis of Incidence Based on French National Healthcare Data

Álvaro López Gutiérrez, France

P3.14.16 Prospects of Applying convolutional Neural Network Models for Surgical Videos in Clinical Practice

Shuning Kong, China

P3.14.17 Oncological Outcomes of Complete Versus Limited Thymectomy in Stage I Thymic Epithelial Tumours

Riccardo Taje, Italy

P3.14.18 The Role of Induction Therapy Followed by Surgery in Advanced Thymic Epithelial Tumors: A Systematic Review and Meta-Analysis

Giovanni Leuzzi, Italy

P3.14.19 The Role of Tumors Size in Different Thymic Tumors Histology: Results Form the ESTS Thymic Database

Marco Chiappetta, Italy

P3.14.20 MTAP Deficiency in Thymic Epithelial Tumors

Jennifer Marks, USA

P3.14.21 Single-Nucleus RNA Sequencing Reveals Key Pathways and Prognostic Markers in Thymic Carcinoma

Xuehan Gao, China

P3.14.22 Outcomes to Systemic Standard-Of-Care Therapies in Patients With MTAP-Deleted Advanced Non-small Cell Lung Cancer

Julian Huang, USA

P3.14.23 The Mechanism of Immunotherapeutic Resistance in Pulmonary Sarcomatoid Carcinoma

Haoyue Guo, China

P3.14.24 Tracheal Resection Surgery: Comparison of Continuous Vs. Interrupted Suture of the Membranous Wall in a Series of 162 Cases

Pablo Pagliarlunga, Argentina

TRACK 16: PATIENT ADVOCACY

P3.16.01 Lung Cancer Patients' Understanding of and Involvement in Their Treatment and Care: Insights from a Global Patient Experience Survey

Jesme Fox, UK

P3.16.02 Cancer Patients' Advocacy and Policy Impact in Japan, How 3,623 Voices Halted a National Cost-Sharing Reform

Kazuo Hasegawa, Japan

P3.16.04 Lung Cancer Treatment in Brazil: The Gap Between Incorporation and Real-World Access

Luciana Holtz de Camargo Barros, Brazil

P3.16.05 Exploring Quality of Life in Oncogene Addicted NSCLC Patients and Their Caregivers

Massimiliano Cani, Italy

P3.16.06 The Saving Lungs Behind the Chair Model Is Increasing Lung Cancer Awareness in US Black Communities

Sydney Barned, USA

P3.16.07 Canadian Action Plan for Lung Cancer - Patient Perspective

Angus Pratt, Canada

P3.16.08 Feasibility of Engaging Latino Individuals in a Lung Cancer Screening Study Through Mychart

Arlette Chavez Iniguez, USA

P3.16.09 A Study of Testing Knowledge Regarding Lung Cancer Screening Among General Population and Caregivers

Nabanita Mandal, India

P3.16.10 Co-Designing a Resource to Reduce Stigma in Lung Cancer Screening

Kathleen McFadden, Australia

P3.16.11 A Pulmón - Lunging It: Climbing Mountains and Breaking Barriers in Lung Cancer Advocacy

Santiago Viteri, Spain

P3.16.12 Analysis of the Nationwide Database on the Penetration Rate of Lung Cancer Biomarker Tests in Japan

Takayuki Takahama, Japan

P3.16.13 Using Group Concept Mapping to Identify Research Priorities by Patient and Caregiver Stakeholders Affected by Lung Cancer

Jamie Ostroff, USA

P3.16.14 The Influence of Deprivation on Lung Cancer Care Experiences in Urban, Rural, and Coastal Areas: A Qualitative IPA Study

Samuel Cooke, UK

P3.16.15 Giving Back - Co-Creation of Data Dashboard to Share Survey Results with Patients and Caregivers

Bellinda King-Kallimanis, USA

P3.16.16 The Development of a Patient Education Lung Cancer Nodal Staging Video Toolkit: American Cancer Society National Lung Cancer Roundtable

Jeffrey Velotta, USA

- P3.16.17** Understanding the Awareness of Treatment, Clinical Trials, Biomarkers and Unmet Needs of Chinese NSCLC Patients: A Mixed-Methods Study in China
Xiuyu Cai, China
- P3.16.18** Beyond Clinical Outcomes: A Qualitative Exploration of Wellbeing Among People Living with Onco-Driven Lung Cancer
Virginia Harrison, UK
- P3.16.19** Multilevel Assessment of ChatGPT-4O in Radiation Oncology for Lung Cancer Patient Education
Chukwuka Eze, Germany
- P3.16.20** Improving Lung Cancer Screening Uptake in 20 Disadvantaged New York Counties: Early Findings from a Demonstration Project
Angela Gonnella, USA
- P3.16.21** The Role of Neighborhood Deprivation in Lung Cancer Diagnosis and Treatment
Brittney Nichols, USA
- P3.16.22** Frontline Insights in US Payer Barriers Impacting Patient Access and Participation in Comprehensive Lung Cancer Screening Programs
Angela Barry, USA
- P3.16.23** Facilitators to Patient Advocacy Group-Led Engagement of Diverse, Community, Clinical Sites in Multiple Research Types
Andrew Ciupek, USA

TRACK 18: CLINICAL TRIALS IN PROGRESS

- P3.18.01** Sex-Based Differences in STAS Positivity and Survival in Stage I Lung Adenocarcinoma: Is Female Prognosis Still Better Despite STAS?
Süleyman Güneş, Turkey
- P3.18.02** Sex-Based Differences in Immunotherapy Response via Blood Biomarkers in NSCLC: Interim Results from the ALICE Study
Melis Aykac-Bicer, Germany
- P3.18.03** Implementation Study of Lung Cancer Screening Combined with a Smoking Cessation RCT in the Flemish Region: The ZORALCS- and TAMIRO-Stop-Study
Charlotte Theuns, Belgium
- P3.18.04** MRDSEEKER (JCOG2111A): A Prospective Study to Evaluate MRD and Its Association with Prognosis in Curative-Intent NSCLC
Ken Masuda, Japan
- P3.18.05** Enrollment Update for the CSP #2005 Phase III Veterans Affairs Lung Cancer Surgery or Stereotactic Radiotherapy Study [VALOR]
David Harpole, USA
- P3.18.06** Phase 1b Study of a Novel Fluorescent Imaging Agent, LS301, for Lung Cancer Surgery to Localize Tumors and Assess Margins
Nick Staten, USA
- P3.18.07** Immunotherapy Combined with Radiotherapy as Neoadjuvant Therapy in Resectable NSCLC: A Single Arm, Phase II Clinical Study
Buhai Wang, China
- P3.18.08** Alectinib as Adjuvant Therapy in Resected ALK-Positive NSCLC: A Prospective Multicenter Cohort Study in China
Chang Chen, China
- P3.18.09** SUNRAY-02: A Phase 3 Study of Olomotasib and Immunotherapy in Stage II-III KRAS G12C-Mutant NSCLC After Definitive Therapy
Ernest Nadal, Spain
- P3.18.10** Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage IA3 EGFRm NSCLC With High Risk Factors
Baiqin Zhao, China


- P3.18.11** Adding Certolizumab to Neoadjuvant Chemoimmunotherapy - Control of Immune-Related Adverse Events and Prevention of Surgical Delays
Paul Paik, USA
- P3.18.12** ARIAN, Adjuvant Treatment With Sacituzumab and ZimberelimAb in Resected Patients: A Phase III Study - Trial in Progress
Mariano Provencio, Spain
- P3.18.13** Atezolizumab +/- Tiragolumab Before and After Chemoradiation for Unresectable Stage III Non-small Cell Lung Cancer (AFT-57)
Helen Ross, USA
- P3.18.14** Quick Start Durvalumab: A Phase II Pilot Study of Early Durvalumab Initiation Following Chemoradiation in Unresectable Stage II-III NSCLC
Stephanie Brinton, USA
- P3.18.15** Neoadjuvant and Adjuvant Chemoimmunotherapy in Resectable Stage II-III NSCLC: Interim Results of a Prospective Cohort Study
Yuan Xu, China
- P3.18.16** CROWD: Chemoradiotherapy with Surgery Followed by Consolidation Durvalumab for Initially Unresectable Stage III NSCLC
Ilias Houda, Netherlands
- P3.18.17** Neoadjuvant Chemoimmunotherapy with Immunosensitizing Radiation for Borderline Resectable Non-small Cell Lung Cancer (NeoRADjuvant)
Samuel Rosner, USA
- P3.18.18** Predictive Role of Respiratory Function Tests on Lung Toxicity in Stage III NSCLC Under Chemo-Radiotherapy and Durvalumab: Preludio Trial
Giuseppe Viscardi, Italy
- P3.18.19** The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial 2 (SPRINT2)
Nitin Ohri, USA
- P3.18.20** PELAGOS: Integrating Surgery and Radiotherapy in EGFR-Mutant N3-Stage III NSCLC After Conversion Therapy
Ailin Li, China
- P3.18.21** Durvalumab (D) and Chemotherapy Followed by Either Surgery + D or Chemoradiotherapy + D in Borderline Resectable Stage III NSCLC
Yu Wang, China
- P3.18.22** TRIPL: Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-small Cell Lung Cancer
Angelica D'Aiello, USA
- P3.18.23** Management of Synchronous Oligometastatic NSCLC with Surgical Resection of the Primary Tumor: Preliminary Results from the Prospective Trial
Pavel Karatkevich, Belarus
- P3.18.24** A Multicenter, Open Label, Dual Cohort Study: The Efficacy and Safety of Vinorelbine Combined with a First-Line Treatment for Metastatic NSCLC
Xiao Fu, China
- P3.18.25** Phase 2 Study of Carboplatin Plus Nab-Paclitaxel Rechallenge for NSCLC With Interstitial Lung Disease: TORG2442/CASTLE Study
Taku Itoh, Japan
- P3.18.27** An Exploratory Clinical Study of TROP2 ADC SHR-A1921 Combined with Adebrelimab for Advanced NSCLC After Failure of First-line Standard Therapy
Chunxia Su, China
- P3.18.28** KEYMAKER-U01 Substudy 01G: Pembrolizumab+Patritumab Deruxtecane±Chemotherapy in Previously Untreated Stage IV NSCLC
Melissa Johnson, USA
- P3.18.29** NAPISTAR 1-01: An International Phase I/II Trial of the Novel ADC TUB-040 in Advanced/Metastatic NSCLC Adenocarcinoma
Alexander Starodub, USA

- P3.18.30** A Phase II Clinical Study of Tafocicimab Combined with Sintilimab in the Treatment of Advanced NSCLC Who Failed the Previous Immunotherapy
Mengqing Xie, China
- P3.18.31** Phase II Study of CBDCA + Nab-PTX + Tremelimumab+Durvalumab for TTF-1 Negative Advanced non-sq NSCLC (WJOG17223L, TURNING)
Motoko Tachihara, Japan
- P3.18.32** Tislelizumab Combined with Bevacizumab and Nab-Paclitaxel as Second-Line Therapy for PD-1/L1 Inhibitor-Resistant Advanced NSCLC
Liping Lin, China
- P3.18.33** Intraleural Anti-PD-1 Antibody for the Treatment of Advanced Non-small Cell Lung Cancer with Malignant Pleural Effusion
Ping Zhan, China
- P3.18.34** TACTI-004, a Phase 3 Trial of Eftilagimod Alfa Plus Pembrolizumab (P) + Chemotherapy (C) vs Placebo + P + C in 1st Line NSCLC
Martin Sebastian, Germany
- P3.18.35** ARTEMIDE-Lung02: A Phase 3 Global Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for 1L Metastatic Squamous NSCLC
T. Hiltermann, Netherlands
- P3.18.36** Peripheral Immune and Hormonal Signatures Associated with Sex Differences in NSCLC Response to Checkpoint Inhibition
Susanne Hermann, Germany
- P3.18.37** A Phase 3 Trial of First-Line MK-3475A (Subcutaneous Pembrolizumab) for Stage IV NSCLC with PD-L1 TPS ≥50%
Balazs Halmos, USA
- P3.18.38** Phase 3 eOLVE-Lung02 Trial of Volrustomig + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic NSCLC with PD-L1 TC <50%
Melissa Johnson, USA
- P3.18.39** PRESERVE-003: A Phase 3 Study of Gotistobart Versus Docetaxel in Metastatic NSCLC After Progression on PD-(L)1 Inhibitors
Tianhong Li, USA
- P3.18.40** KRAS Peptide Vaccine Combined with Chemotherapy, Nivolumab and Ipilimumab in Advanced KRAS Mutated Non-small Cell Lung Cancer
Kristen Marrone, USA
- P3.18.41** A Phase II Study of Second-Line Cadonilimab, Bevacizumab and Docetaxel in Patients with Advanced NSCLC
Jian Chun Duan, China
- P3.18.42** Camrelizumab Combined with Chemotherapy and Local Consolidative Therapy for Untreated Oligometastatic NSCLC With PD-L1 Expression <50%
Li Ping Lin, China
- P3.18.43** A Phase II Study of IDH1 Inhibitor Combined with Serplulimab and Docetaxel in Previously Treated Advanced NSCLC (ChiCTR2400086196)
Shiji Zhang, China
- P3.18.44** Oral Metronomic Vinorelbine and PD-1 Inhibitors in Elderly Patients with Non-small Cell Cancer
Maojing Guan, China
- P3.18.45** A Multi-Cohort, Phase II Study of SHR0302 Combined With PD-1/PD-L1 Inhibitor for Treatment Naïve or Acquired Resistant to Immunology NSCLC
Xinyu Zhang, China
- P3.18.46** Ivonescimab Plus Platinum-Doublet Chemotherapy as First-Line Therapy for Locally Advanced/Metastatic SMARCA4-Deficient NSCLC
Yuan Liang, China
- P3.18.47** ATTEND: Randomized Phase III Trial of Tislelizumab and Chemotherapy with or Without Diphenhydramine in Advanced Non-small Cell Lung Cancer
Liang Liu, China

- P3.18.48** Phase II Clinical Trial of Trilaciclib in Combination With PD-1 Inhibitor and Chemotherapy as First-Line Treatment for (NSCLC)
Fei Li, China
- P3.18.49** Efficacy and Safety of Tislelizumab Combined with Tofacitinib and Docetaxel for NSCLC After Failure of First-Line Immunotherapy
Wang Xie, China
- P3.18.50** Induction Tislelizumab with Chemotherapy Followed by Surgery and Radiotherapy in Stage III-N3 Unresectable NSCLC (HURRICANE)
Ailin Li, China
- P3.18.51** Anlotinib Combined With PD-1 Blockade and Platinum Doublet Chemotherapy for PSC as First Line Treatment
Yongsheng Wang, China
- P3.18.52** Phase 3 Trial ResQ201A of NAI Plus Tislelizumab and Docetaxel Vs. Docetaxel Monotherapy for Advanced or Metastatic NSCLC Resistant to ICI Therapy
Leylah Drusbosky, USA
- P3.18.53** Phase 3 Clinical Trial ResQ201A of N-803 (NAI), Tislelizumab and Docetaxel Vs. Docetaxel Monotherapy for Advanced NSCLC Resistant to ICI Therapy
Sandeep Reddy, USA
- P3.18.54** Increasing the Dosing Interval of Osimertinib in Patients With EGFR-Mutated Advanced NSCLC (OSI-SAVE Study Design)
Maaïke van den Bos, Netherlands
- P3.18.55** A Phase II Study of Repotrectinib in ROS1-Positive Non-small Cell Lung Cancer Patients with Active Brain Metastasis - REPOSE
Thorsten Füreder, Austria
- P3.18.56** EGFR-Mutated Lung Cancer in Randomized Investigator-Initiated Study (ERIS): A National Phase III Trial from the Swedish Lung Cancer Study Group
Maria Planck, Sweden
- P3.18.57** Phase 1/2 Clinical Trial of JIN-A02, a 4th Generation EGFR-TKI in EGFR Mutant Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC)
Sun-Min Lim, Republic of Korea
- P3.18.58** Trastuzumab Deruxtecan + Pembrolizumab as First-Line Treatment in HER2-Overexpressing, PD-L1 TPS <50% NSCLC (DESTINY-Lung06)
William William Jr., Brazil
- P3.18.59** Resistance Mechanisms and Sequential Therapies Following 1st Line Lorlatinib in ALK+ NSCLC: A Real-World Study (LORES CTONG2501)
Ziming Li, China
- P3.18.60** The COALA (Cure Oncogene-Addicted Lung Adenocarcinoma) Network: A Nationwide Consortium to Improve Lung Cancer Outcome
Julien Mazieres, France
- P3.18.61** KRYSTAL-4: Phase 3 Study of Adagrasib Plus Pembrolizumab and Chemotherapy Intreatment-Naïve, Advanced KRAS G12C-Mutated NSCLC
Jarushka Naidoo, Ireland
- P3.18.62** TRUST-III: Phase 3 Head-To-Head Study of Taletrectinib vs Crizotinib in Patients with ROS1+ Non-small Cell Lung Cancer
Caicun Zhou, China
- P3.18.63** Phase 1 Study of FHND5071, a Novel Selective RET Inhibitor, in RET Fusion-Positive Advanced NSCLC
Dechuang Yuan, China
- P3.18.64** Phase 1 Study to Evaluate the Safety and Tolerability of CVHNLG Plus Pembrolizumab in Patients with Squamous NSCLC
Benjamin Besse, France
- P3.18.65** Trial in Progress - RASolve 301: A Phase 3 Study of Daraxonrasib (RMC-6236) Vs. Docetaxel in Patients with Previously Treated RAS Mutant NSCLC
Ferdinand Skoulidis, USA

- P3.18.66** Preliminary Safety and PK of the MET-TKI Do-2 in Advanced Solid Tumors with MET Aberrations: Phase I Study
Timothy Perera, Belgium
- P3.18.67** First-In-Human Phase I/II Trial of PFL-002/VERT-002 in Locally Advanced or Metastatic Solid Tumors Including NSCLC With MET Alterations
Julien Mazieres, France
- P3.18.68** First-In-Human Trial of PFL-241/STX-241 in Patients with Locally Advanced or Metastatic NSCLC Resistant to EGFR Tyrosine Kinase Inhibitors
Gerrina Ruiter, Netherlands
- P3.18.69** Efficacy and Safety of Befotertinib Plus Icotinib in Advanced NSCLC With Uncommon EGFR Mutations: A Phase II Study (Icombine)
Xue Hou, China
- P3.18.70** Combination of Osimertinib and Carotuximab for Advanced, EGFR-Mutated Non-small Cell Lung Cancer Patients
Karen Reckamp, USA
- P3.18.71** CA240-0007: BMS-986504 With Anti-PD-1 or Chemotherapy as Treatment for Advanced Solid Tumors with Homozygous MTAP Deletion
Konstantinos Leventakos, USA
- P3.18.72** Liquid Biopsy Guided Addition of Chemotherapy with TKI in Advanced EGFR Mutated NSCLC (LiquiACT)
Prabhat Malik, India
- P3.18.73** A Phase 1b/2 Study of Gocatamig and Ifinatamab Deruxtecan for Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer
Pedro Rocha, Spain
- P3.18.74** BNT324-01: A Phase 1b/2 Trial of BNT324/DB-1311 (B7H3 ADC) With BNT327 (PD-L1 x VEGF-A bsAb) in Lung Cancer (SCLC or NSCLC)
Adam Schoenfeld, USA
- P3.18.75** Tislelizumab in Combination With EP/EC Chemotherapy and Sequent Anlotinib Followed by Radiotherapy as First-Line Treatment for ES-SCLC
ZhenTian Liu, China
- P3.18.76** Efficacy and Safety of Cross-Line Adebreliamab Combined with Apatinib and Nab-Paclitaxel in Recurrent Small Cell Lung Cancer
Hongbo Wu, China
- P3.18.77** Efficacy and Safety of Adebreliamab Plus Irinotecan Liposome in ES-SCLC After First-Line Therapy: A Phase II Study (AIPATH)
Yudong Wang, China
- P3.18.78** A Prospective Study of Lurbinectedin Plusivonescimab Assecond-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Fei Zhou, China
- P3.18.79** Contralateral Esophageal-Sparing Technique Reduces High-Grade Esophagitis in Locally Advanced Small Cell Lung Cancer
Min Hu, China
- P3.18.80** A Phase 3 Study of Sacituzumab Govitecan in Patients with Previously Treated Extensive Stage Small Cell Lung Cancer
Afshin Dowlati, USA
- P3.18.81** A Phase II Study of First-Line Sintilimab Combined with Anlotinib and Platinum-Based Chemotherapy in Unresectable MPM
Xinyu Wu, China
- P3.18.82** Towards Harmonization of Clinical Care and Promoting Research for Thymic Epithelial Tumors: THETIS (Thymic Cancers Network in Switzerland)
Ambrogio Gagliano, Switzerland
- P3.18.83** Efficacy and Safety of Ivonescimab Plus Chemotherapy for Recurrent/Metastatic Thymic Carcinoma: A Phase II Study (iThyme)
Xue Hou, China

- P3.18.84** A Randomized Comparative Effectiveness Trial of Perioperative Physical Activity in Older Adults with Lung Cancer and Their Family Caregivers
Dan Raz, USA
- P3.18.85** A Personalized Nutrition and Physical Exercise Intervention to Enhance Early-Stage NSCLC Outcomes: The STARLight Study
Alice Avancini, Italy
- P3.18.86** Efbemalenograstim Alpha Prophylaxis for Intermediate-Risk FN Chemotherapy in NSCLC: A Multicenter Exploratory Study
Mengjie Li, China
- P3.18.87** EVEREST-2: Phase 1/2 Study of Logic-Gated Tmod CAR T A2B694 in Lung Cancer and Other Tumors Expressing MSLN With HLA-A*02 LOH
Salman Puneekar, USA



EPOSTER LISTINGS

ePosters will be available for viewing at the **ePoster stations** in the **Exhibit Hall** during **Exhibit Hall Opening Hours** and on the **Mobile App**.

Download the official **WCLC 2025 Mobile App** to view all ePosters.



Supported by: Nuvalent

TRACK 01: RISK FACTORS, RISK REDUCTION & TOBACCO CONTROL

- EP.01.01** Exercise Training Modalities in Patients with Lung Cancer: A Protocol for Systematic Review and Network Meta-Analysis
Yu Zhang, China
- EP.01.02** Long-Term Survival After Curative Surgery for Stage I-III NSCLC Patients in British Columbia, 2005-2021: A Population-Based Study
Yixian Chen, Canada
- EP.01.03** Young Patients with Non-small Cell Lung Cancer in Poland - a Comprehensive Epidemiological, Molecular and Prognostic Analysis
Magdalena Knetki-Wróblewska, Poland
- EP.01.04** Features, Demographics and Treatment Profiles of Primary Lung Cancer Cases in Nigeria: The Largest Single Centre Report in West Africa
Maruf Adewole, Nigeria
- EP.01.05** Mapping the Clinical Pathways in Lung Cancer: Evaluating the Inspire Program in the Brazilian Public Healthcare System
Robson Prudente, Brazil
- EP.01.06** Clinical Characteristics, Molecular Profile and Survival Outcomes in Young Lung Cancer Patients from Western India
Udip Maheshwari, India
- EP.01.07** Lung Cancer in Young: A Descriptive Study from Thoracic Oncology Clinic in Northern India
Samruddhi Chougale, India
- EP.01.08** Lung Cancer in Elderly Patients: Insights from a Community Oncology Setting in Western India
Pradip Kendre, India
- EP.01.09** NSCLC Epidemiology and Survival in Denmark, Finland, and Norway: A Decade of Real-World Insights from the LANDSCAPE Study
Åslaug Helland, Norway
- EP.01.10** Young Onset Lung Cancer: Clinical, Pathologic and Molecular Profile from a Tertiary Care Centre in India
Kenil Borda, India
- EP.01.11** Impact of Demographics and Smoking on Driver Gene Mutations Development in Non-small Cell Lung Cancer (NSCLC)
Tasneem Khallad, Jordan
- EP.01.12** A Causal Machine Learning Approach for the Prediction of Immune-Related Adverse Events in Lung Cancer Patients Receiving Immunotherapy
Fergus Reid, UK
- EP.01.13** Lung Cancer Burden in Latin America and the Caribbean, 1990-2021: A Comprehensive Analysis
Prashant Gupta, India

- EP.01.14** Pulmonary Pure Ground-Glass Nodule Follow-Up During Pregnancy and Lactation: A Case Report
Baolei Liang, China
- EP.01.15** Gender Disparities in Survival Outcomes of "Minimally Invasive Lung Squamous Cell Carcinoma"
Yucheng Ma, China
- EP.01.16** Differential Effect of Neoadjuvant Therapy in Locally Advanced Non-small Cell Lung Cancer Based on Sex
Henry Park, USA
- EP.01.17** Association Between Cigarette Smoking History and Germline Rare Variant Burden in a Cohort of Lung Cancer Patients
Stella Aslibekyan, USA
- EP.01.18** Family History of Lung Cancer in Lung Cancer in Never-Smokers, a Matched Case-Control Study
Hyun Seok Kwak, Republic of Korea
- EP.01.19** Characteristics of Lung Cancer in Never- and Light-Smokers: A Retrospective Study from Greece
Georgia Gomatou, Greece
- EP.01.20** Non-Smoking Lung Adenocarcinoma: Implications for Predominant Growth Patterns, Tumor Heterogeneity and Prognosis
Erik Rolf, Germany
- EP.01.21** Mapping Persistent and Irreversible Arsenic Effects on Lung Epithelium Using Integrated Transcriptome and Methylome Analysis
Melis Erkan, Canada
- EP.01.22** The Effectiveness of Offering Repeated Co-Located, Opt-Out Smoking Cessation Support Within Lung Cancer Screening
Rachael Murray, UK
- EP.01.23** Tobacco Smoking, Quit Attempts and Vaping Among an Online Sample of South African Cancer Survivors
Lekan Ayo-Yusuf, South Africa
- EP.01.24** Determinants Influencing Smoking Cessation Implementation in an Oncology Setting: Canadian Healthcare Provider Perspectives
William Evans, Canada
- EP.01.25** Identifying Effective Strategies to Support Smoking Cessation in Ontario Cancer Care Settings: A Consensus-Building Approach
Lawson Eng, Canada
- EP.01.26** Achievements and Future Directions of Tobacco Control in Lung Cancer Prevention in China
Xiuyi Zhi, China
- EP.01.27** Gender and Tobacco Use Status Shape Support for Endgame Strategies in India
Durre Aden, India
- EP.01.28** Changes in Respiratory Function in a Patient Undergoing Two Lung Resections
Nanami Hiraiwa, Japan
- EP.01.29** Association of the Cholesterol-Modified Prognostic Nutritional Index with the Survival After Lung Resection for Elderly Patients With NSCLC
Yuuki Matsui, Japan
- EP.01.30** Beyond Smoking: Exploring Risk Factors for Lung Cancer in Women
Muhammad Islam, USA
- EP.01.31** Vaping, Smoking and Lung Cancer in Adults Under Age 50: A Case-Control Study
Marisa Bittoni, USA

TRACK 02: TUMOR BIOLOGY – PRECLINICAL BIOLOGY

- EP.02.01** Investigating the MET Exon 14 Interactome in Lung Adenocarcinoma
Sarah Anna Okun, Canada
- EP.02.02** YB-1 Is a Survival Factor for Mesothelioma-Associated Fibroblasts
Marc Pinós, Austria
- EP.02.03** Investigating the Therapeutic Potential of DUSP4/6 Inhibition in Lung Adenocarcinoma
William Lockwood, Canada
- EP.02.04** Identification of a Novel Immunotherapy Target in EGFR-Mutant Lung Cancer Resistant to Immune Checkpoint Inhibitors
Kiichi Nitani, Japan
- EP.02.05** Three-Dimensional Visualization of Spreading Tumor Cell Through Air Spaces (STAS) Using High Resolution Phase-Contrast Imaging Method
Eunjue Yi, Republic of Korea
- EP.02.06** Natural Multiple Serine Synthase Inhibitors Modulate Tumor Microenvironment Polarization and Inhibit the Growth of Lung Cancer
Menghan Liu, China
- EP.02.07** Enhancing Alectinib Efficacy in ALKPositive Non-small Cell Lung Cancer by Targeting Mtor
Sofia D Merajver, USA
- EP.02.08** Exploratory Effect of Cisplatin on Autophagic Pathway in Human Lung Adenocarcinoma Cell Line
Diksha Diksha, India
- EP.02.09** Deciphering CD47-Mediated Platelet-Tumor Crosstalk and Its Role in NSCLC Metastasis
Asa Lau, Canada
- EP.02.10** Fumarate and Ass1 in KRAS-Mutant NSCLC: The Influence of Cetuximab in Combination with KRAS G12C Inhibitors (Sotorasib and Fulzerasib)
Daniel Olmo González, Spain
- EP.02.11** Clinical and Biological Significance of Cystathionine Gamma-Lyase in Pulmonary Adenocarcinoma
Yoko Kataoka, Japan
- EP.02.12** Identifying Acquired Resistance Mechanisms to Sotorasib in G12C Lung Adenocarcinoma (LuAD) Cell Lines (CL)
Marc Cucurtull Salamero, Spain

TRACK 03: TUMOR BIOLOGY – TRANSLATIONAL BIOLOGY

- EP.03.01** Identification and Validation of Recurrence-Associated Proteins in Stage I Lung Adenocarcinoma
Kei Suzuki, USA
- EP.03.02** An Integrating Multiomic Approach to Chart the Tumor Immune Microenvironment Associated to Immunotherapy Response in Non-small Cell Lung Cancer
Riccardo Taje, Italy
- EP.03.03** Tumor Heterogeneity Consisting of SCLC With RB1 Exon 19 Deletion and L718V Mutation-Positive Adenocarcinoma in EGFR-TKI Resistant Lung Cancer
Sho Kakuto, Japan
- EP.03.04** PD-L1-Regulated c-Met Phosphorylation Contributes to MET Amplification in EGFR Mutation NSCLC
Derek De-Rui Huang, Taiwan
- EP.03.05** The Study on the Mechanism of OM-85 in Regulating the Immune Microenvironment in Early-Stage Lung Adenocarcinoma
Dawei Yang, China
- EP.03.06** Blocking JNK Signaling as a Strategy to Fight EGFR-Driven Lung Cancer
Leizhi Shi, Germany

- EP.03.07** The Role of Tumour Intrinsic Inflammasome Mutations in Lung Adenocarcinoma
Daniel Gough, Australia
- EP.03.08** Tumor Treating Fields (TTFields) Concomitant with Antiangiogenic Therapy in Non-small Cell Lung Cancer in Vivo Model
Anat Klein-Goldberg, Israel
- EP.03.09** A New Treatment Approach for Non-small Cell Lung Cancer
Amila Suraweera, Australia
- EP.03.10** Evaluating the Role of the Blood-Brain Barrier in Intracranial Response Rates for Metastatic Lung Cancer
Tsu-Yu Unice Chang, Canada
- EP.03.11** Peritumoral B Lymphocyte Mediated Immune Response Is Associated with Survival in Patients with Non-small Cell Lung Cancer
Akif Turna, Turkey
- EP.03.12** Sex-Specific Blood-Based Immune Signatures Predict Response to First-Line Immunotherapy in Advanced NSCLC: A Prospective Translational Study
Amanda Tufman, Germany
- EP.03.13** LIF Is Associated with Poor Prognosis and Participates in Lung Cancer Growth and Implantation in Preclinical Models of NSCLC
Cristina Muñoz-Pinedo, Spain
- EP.03.14** Single-Cell Transcriptome Analysis Revealed an Activated Tumor Immune Microenvironment in KRAS Mutant NSCLC
Hao Wang, China
- EP.03.15** Chemotherapy Upregulates PD-L1 Expression via cGAS-STING Pathway in Non-small Cell Lung Cancer
Maryam Khalil, Canada
- EP.03.16** Cell-Specific Fluorescence Lifetime Values in Live Non-small Cell Lung Cancer Cells
Ava Russell, UK
- EP.03.17** Altered Immune Profile in Lung Cancer Patients with Pneumonitis
Po Hao Feng, Taiwan

TRACK 04: SCREENING AND EARLY DETECTION

- EP.04.01** Current Status of Lung Cancer Screening in Latin America
Lucia Viola, Colombia
- EP.04.02** Fully-Automated Classification of Parenchymal Low Attenuation-Clusters as Indicators of Pulmonary Emphysema in Lung Cancer Screening
Hailan Liu, Netherlands
- EP.04.03** Uptake and Impact of a Framework to Support Implementation of Low-Dose Computed Tomography (LDCT) Screening for Lung Cancer
Helena Wilcox, UK
- EP.04.04** A Relative Perspective on Whether Risk-Based Lung Screening Eligibility Prioritize People with Higher Competing Mortality
Xiaoshuang Feng, France
- EP.04.05** Lung Cancer Diagnosis Among Screening Participants in the Multi-Health-System Philadelphia Lung Cancer Learning Community
Julie Barta, USA
- EP.04.06** Health Beliefs and Adherence to Lung Cancer Screening in a Diverse, Real-World Population
Sheena Bhalla, USA
- EP.04.07** Participant and Provider Experiences in an Indigenous Focused Trial of Lung Cancer Screening in Aotearoa New Zealand
Kate Parker, New Zealand
- EP.04.08** Building Policy Recommendations Using an Implementation Framework for Low-Dose Computed Tomography Screening
Helena Wilcox, UK

- EP.04.10** Evaluating Primary Care Practice's LCS Smoking History Accuracy for Maori Patients - Implications for a Future Lung Cancer Screening Programme
Sue Crengle, New Zealand
- EP.04.11** Feasibility of AI-Assisted Mobile Low-Dose CT Screening in Underserved Communities in China
Weisheng Chen, China
- EP.04.12** Outcome of Lung RADS Category 4 in Lung Cancer Screening Population at Tertiary Hospital, Single Center Study
Soo-Youn Ham, Republic of Korea
- EP.04.13** Emphysema on Baseline CT Predicts COPD and Cardiovascular Death After 25 Years in Lung Cancer Screening
Jessica González, Spain
- EP.04.14** Pilot Lung Cancer Screening Program and "Lung Health Check" in Lleida: Preliminary Results
Anna Sánchez Cucó, Spain
- EP.04.15** Determinants of Lung Cancer Screening Intention Among Adults Eligible for Lung Cancer Screening
Hermine Poghosyan, USA
- EP.04.16** Piloting Lung Cancer Screening: Tumor Detection Rate, Psychological Distress and Incidental Findings
Kathrin Chiffi, Switzerland
- EP.04.17** Radiomics Predicts IASLC Grades of Invasive Pulmonary Adenocarcinoma by Distinguishing High-Grade Patterns and Predominant Subtypes
Sunyi Zheng, China
- EP.04.18** Preoperative Prediction of Grade 3 Invasive Non-Mucinous Adenocarcinoma Using Semiconductor 18F-FDG-PET/CT: A Diagnostic Accuracy Study
Hirotsugu Notsuda, Japan
- EP.04.19** Radiologic Characteristics of Solitary Pulmonary Capillary Hemangioma
Yeqing Zhu, China
- EP.04.20** Exploring Diffusion-Weighted Magnetic Resonance Imaging in Lung Cancer Screening
Krista Dollar, USA
- EP.04.21** Imaging Manifestations in 4 Cases of Invasive Pulmonary Adenocarcinoma with Indolent Growth
Anle Yu, China
- EP.04.22** Internal Validation of the IASTO-PDPI Lung Cancer Risk Level at Indonesia's National Respiratory Center, Persahabatan Hospital
Rachel Aritonang, Indonesia
- EP.04.23** Prediction of STAS Positivity in Non-small Cell Lung Cancer
Burcu Kilic, Turkey
- EP.04.24** Initial Experience with Cancer Screening Center: Model to Improve Lung Cancer Screening Uptake
Kei Suzuki, USA
- EP.04.25** Integrated Biological and Imaging Assessment for Pulmonary Nodule Malignancy: A Real-World Study with Large Cohort Modeling and Validation
Zihao Li, China
- EP.04.26** A Case Series on Video Fiber Optic Bronchoscopy in the Diagnosis of Non-small Cell Lung Cancer (NSCLC) Subtype: Squamous Cell
Setu Saxena, India
- EP.04.27** Enhancing Lung Cancer Screening: A Comparative Evaluation of Predictive Models for Malignancy in Pulmonary Nodules
Fabian Doerr, Germany
- EP.04.28** TD-GC-MS-Based Breath Analysis for Early Diagnosis of Lung Cancer
Kahraman Emri, Turkey

- EP.04.29** Tobacco-Related Atheromatous Disease as Eligibility Criteria for Lung Cancer Screening: A Prospective Evaluation
Elsa Armand, France
- EP.04.30** Second Primary Lung Cancer in Surgically Treated Breast Cancer Patients: Association or Incidental Finding?
Sara Ricciardi, Italy
- EP.04.31** Nomogram for Predicting Lung Cancer-Free Survival in Patients with Persistent Pulmonary Nodules
Jianjun Zhang, USA
- EP.04.32** The Impact of Symptom Monitoring on Survival Among Patients with Lung Cancer. a 4-Year Follow-Up of the SYMPRO-Lung Study
Marloes Hassing, Netherlands
- EP.04.33** Exhaled Breath Analysis Using Infrared Spectroscopy Combined with Machine Learning Algorithms for Lung Cancer Diagnosis
Kahraman Emri, Turkey
- EP.04.34** Preliminary Results of Added Benefit of Blood-Based Biomarkers in a Lung Cancer Screening Program
Kathrin Chiffi, Switzerland
- EP.04.35** Innovative Intraoperative Technique for Rapid Tumor Identification in Lung Cancer Through Spectral Characterization: A Promising Exploration
Ming Li, China
- EP.04.36** Evaluation of the Utility of msignal® for Lung Cancer Screening in a Rural Region of Northern Japan (Hokkaido Region)
Masato Aragaki, Japan
- EP.04.37** An Observational Study Evaluating the Benefits of AI-Assisted Lung Cancer Screening Using Chest X-Rays in Bangkok, Thailand
Chuleekorn Soudorn, Thailand
- EP.04.38** A Computational Framework for Estimating Transportability in Cancer Screening Trials
Aviona Conti, USA
- EP.04.39** Lung Cancer Early Screening via cfDNA Fragmentome Profiling
Yongsheng Wang, China
- EP.04.40** Preoperative Prediction of Occult Lymph Node Metastasis in Clinical Stage I NSCLC Using CT Radiomics, PET, and ctDNA
You Jin Oh, Republic of Korea
- EP.04.41** Detecting Minimal Residual Disease (MRD) in Lung Cancer Using an Epigenetic-Based Liquid Biopsy Approach
Ari Raphael, Israel
- EP.04.42** Alunghive: Autonomous Registry and Analytics System to Transform Clinical Workflow and Enable Multicenter Lung Cancer Screening Research
Michael Kammer, France
- EP.04.43** Chest X-Ray Analysis with Artificial Intelligence Software Aids in the Early Diagnosis of Lung Cancer- a Case Series
Deniz Koksai, Turkey

TRACK 05: PULMONOLOGY AND STAGING

- EP.05.01** Use of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Molecular Characterization of Non-small Cell Lung Cancer
Estrella Caballeria Lamelas, Spain
- EP.05.02** Evaluation of ROSE Utility in Multiplex Gene-Panel Testing Using Samples From EBUS-GS for Lung Cancer
Yukihiro Nakamura, Japan
- EP.05.03** Analysis of Left Upper Pulmonary Arterial Bronchial Concomitant Consistency Based on Three-Dimensional Reconstruction
Youjun Deng, China

- EP.05.04** SUVmax Predicts Pathologic Complete Response and Survival in Lung Cancer Patients Undergoing Neoadjuvant Treatment
Akif Turna, Turkey
- EP.05.05** Invasive Mediastinal Staging of NSCLC Using Vamla: Results and Perspectives
Yury Esakov, Russian Federation
- EP.05.06** Should We Screen Patients with Stage IV Non-small Cell Lung Cancer for Brain Metastases at Diagnosis?
Anouk Goudsmit, Belgium
- EP.05.07** Prognostic Impact of Double Positive in EGFR Mutation and PD-L1 Expression in Resected pNOMO G2-3 Adenocarcinoma
Masaaki Ito, Japan
- EP.05.08** Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) for Staging cNO-N1 Non-small Cell Lung Cancer
L. Cabanillas-Paredes, Mexico

TRACK 06: PATHOLOGY AND BIOMARKERS

- EP.06.01** Tumor-Infiltrating Lymphocytes as Predictors of Chemotherapy Response in Non-small Cell Lung Cancer: A Retrospective Cross-Sectional Study
Aline Caldart Tregnago, Brazil
- EP.06.02** Clinical Significance and Preoperative Prediction of High-Grade Subtypes in Early-Stage Lung Adenocarcinoma
Masashi Mikubo, Japan
- EP.06.03** Mucoepidermoid Carcinoma of the Lower Respiratory Tract with Few to None Intermediate/Squamous Cells: A Challenging Tumor Series
Giuseppe Pelosi, Italy
- EP.06.04** Extranodal Extension in Lung Adenocarcinoma: Pathological Insights and its Role as an Independent Prognostic Factor
Shunta Tsuchida, Japan
- EP.06.05** Extensive-Stage Small Cell Lung Cancer Compared with Metastatic Extrapulmonary Small Cell Cancers- a Retrospective Study
Parikshit Padhi, USA
- EP.06.06** Characterization of SMARCA4 and SMARCA2 Alterations in Early-Stage Pulmonary Adenocarcinomas
Andréanne Gagné, Canada
- EP.06.07** Clinicopathologic and Genomic Landscape of Lung Cancer Arising in Interstitial Lung Disease: An Expanded Cohort Analysis
Sehui Kim, Republic of Korea
- EP.06.08** Mutation Spectrum of EGFR Mutations in South Indian Population Identified by Next Generation Sequencing and Real TIME PCR
Vijayalakshmi Ramshankar, India
- EP.06.09** Integrated Clinical, Radiological and Molecular Profile of Lung Cancer Patients from an Incidental Nodule Detection Program
Francisco Sarmento Neto, Brazil
- EP.06.10** Hypoxia-Induced Cancer Stemness, Metastasis, Angiogenesis and Immune Modulation in Lung Adenocarcinoma
Qian Wang, USA
- EP.06.11** Comprehensive Genomic Profiling in Lung Cancer Management: Insights from North Sweden
Mikael Johansson, Sweden
- EP.06.12** Kita-Kyusu Lung Cancer Antigen-1 Positive Is Associated with Pathological High-Grade in Lung Adenocarcinoma
Yasuto Kondo, Japan

- EP.06.13** Molecular Alterations in Octogenarians with Early-Stage Lung Cancer: A Real-World Study
Jeffrey Zhu, USA
- EP.06.14** Decreased Expression of DAAM2 Is Correlated with Poor Prognosis and Tumor Immune Microenvironment in Lung Adenocarcinoma
Weibin Liu, China
- EP.06.15** Reflex Next Generation Sequencing Testing in NSCLC: Overcoming Barriers to Equitable Molecular Profiling in an Urban Healthcare Network?
Brianna Graham, USA
- EP.06.16** Immunophenotyping of the Molecular Subtypes of Small Cell Lung Cancer and Its Correlation with Prognostic and Therapeutic Implications
Sunil Pasricha, India
- EP.06.17** Immunological and Genetic Profile and Efficacy of Immunotherapy in NSCLC Patients with Mutations in KRAS and STK11 Genes
Michal Gil, Poland
- EP.06.18** Is There Any Association Between EGFR Alterations and PD-L1 Expression in NSCLC a Single Center Experience
Sevinç Ballı, Turkey
- EP.06.19** The Relationship Between PD-L1 Expression and Tumor Microenvironment in Lung Squamous Cell Carcinoma
Naoki Yanagawa, Japan
- EP.06.20** Stage-Dependent Increase in EGFR Mutation Rates in Early-Stage Lung Cancer at National Taiwan University Cancer Center
Tzu-Ning Kao, Taiwan
- EP.06.21** Genomic and Demographic Predictors of Survival in Patients with ALK Fusion NSCLC: Insights from a Single-Center Cohort
Karen Reckamp, USA
- EP.06.22** Genomic Insights Into ALK-Rearranged NSCLC: A Comprehensive Study
Warisa Khatoon, India
- EP.06.23** Comprehensive Genomic Profiling as a Key Determinator in Clinical Staging and Treatment Planning
Robert Auber, USA
- EP.06.24** Update of Mutation Status and PD-L1 Expression in Lung Cancer
Norma Pilnik, Argentina
- EP.06.25** Analysis of LAT1 Protein Expression and Clinical Characteristics of Patients with Primary Lung Cancer
Hayato Koba, Japan
- EP.06.26** Resectable Lung Cancer with KRAS Mutation May Have Less Lymphatic Metastasis
Chikara Nakagami, Japan
- EP.06.27** Challenges in Implementing Targeted Panel NGS for Biomarker Testing in Non-small Cell Lung Carcinoma in Resource-Constrained Settings
Aruna Nambirajan, India
- EP.06.28** Circadian CLOCK Expression in Non-small Cell Lung Cancer
Masaaki Inoue, Japan
- EP.06.29** Prognostic Impact of Lepidic Growth in Intermediate and High-Grade Lung Adenocarcinoma
Benedikt Niedermaier, Germany
- EP.06.30** Single-Cell RNA Sequencing Reveals a Subset of FSIPI Cancer Cells and Verified Its Value of Prognosis in Lung Adenocarcinoma
Shirong Zhang, China
- EP.06.31** Prognostic Impact of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 Expression in Non-small Cell Lung Cancer
Amna Almutrafi, Saudi Arabia

- EP.06.32** Elevated SERPINA3 Expression in Bronchoalveolar Lavage Fluid Predicts Poor Prognosis in Non-small Cell Lung Cancer
Joon Kim, Republic of Korea
- EP.06.33** Unique Features of the Tumor-Microenvironment in PL3 Non-small Cell Lung Cancer and Their Association with Post-Operative Outcomes
Ei Miyamoto, Japan
- EP.06.34** Retrospective Analysis of Genomic Testing and Survival Outcomes in Lung Cancer Patients from Western India
Udip Maheshwari, India
- EP.06.35** Role of PD-L1 Expression and TP53 Mutation as a Prognostic Factor in Early Stage NSCLC
Jana Pankovics, Switzerland
- EP.06.36** Non-small Cell Lung Cancer with Diffuse Coexpression of TTF-1 and P40: A Clinicopathologic and Molecular Study of 19 Cases
Jielu Lin, China
- EP.06.37** Clinical and Pathological Features of a High Altitude-Peruvian Population with Metastatic EGFR Mutated Lung Cancer
Jorge Zegarra Cárdenas, Peru
- EP.06.38** HLA-DQB1 Predicts Immunotherapy Response in NSCLC Through Augmented TCR Signaling
Yaxian Yang, China
- EP.06.39** Better Prediction of Resistance to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: Immunoresist Project
Basil Bertrand, France
- EP.06.40** The Role of Histology and Metabolic Parameters in Predicting Spread Through Air Spaces
Filippo Lococo, Italy
- EP.06.41** CD200 as a Novel Prognostic Biomarker in Early-Stage Lung Adenocarcinoma Immune Microenvironment
Luning Mao, China
- EP.06.42** Clinical Characteristics and Treatments of Patients with Advanced Non-Squamous NSCLC KRAS-Mutated with or Without STK11
Edyta Urbanska, Denmark
- EP.06.43** Using Artificial Intelligence to Leverage Phenotypic, Genomic and Proteomic Correlations in Lung Carcinoma Patients with MET Alterations
Susana Hernandez, Spain
- EP.06.44** Tertiary Lymphoid Structures in the Tumor Micro Immune Environment of EGFR Positive Lung Cancer Are Associated Prognosis
Hikaru Yamaguchi, Japan
- EP.06.45** Heterogeneity of Tumor Microenvironment and PD-L1 Expression in NSCLC and Tumor Draining Lymph Nodes After Solid Organ Transplantation
Zhaoqing Yu, Germany
- EP.06.46** Frequent Co-Existence of RBM10 Mutation in Patients with Non-Squamous NSCLCs Harboring EGFR Point Mutations
Kenichi Suda, Japan
- EP.06.47** A Ten-Gene DNA Damage Repair-Related Signature for Predicting Prognosis and Treatment Response in Non-small Cell Lung Cancer
Huixia Li, Hong Kong
- EP.06.48** Complementary Role of IHC in ALK Fusion Detection: A Validation Study of NSCLC NGS-Based Screening in Seven Laboratories
Sergi Clavé, Spain
- EP.06.49** Analysis of EGFR Mutations Using Highly Sensitive Digital Droplet PCR for EGFR Mutation-Positive NSCLC
Shinnosuke Takemoto, Japan
- EP.06.50** Development of a Novel AI-Augmented Small Cell Lung Cancer (SCLC) Algorithm for Accurately Classifying Cell Types From H&E
Kenneth Bloom, USA

- EP.06.51** Development of Novel IHC Assay for PD-L1 Detection in Non-small Cell Lung Cancer
Fangru Lian, USA
- EP.06.52** TTF-1 Negativity Predicts Poor Outcomes in Advanced Non-Squamous NSCLC Also in the Immunotherapy Era: A Multicenter Cohort and Meta-Analysis
Leonardo Brunetti, Italy
- EP.06.53** c-MET Expression in Non-Squamous NSCLC: Molecular Correlation and Interobserver and Intersample Concordance on Scoring
Mariko Muto-Ishizuka, USA
- EP.06.54** The Landscape of Actionable Genomic Alterations in Non-small Cell Lung Cancer. A Single Institution Quality Improvement Initiative
Ahmed AL Lawati, Canada
- EP.06.55** Racial Differences in ERBB2 Mutations in Lung Adenocarcinoma: Insights From a Multi-Cohort Study
Ya-Hsuan Chang, Taiwan
- EP.06.56** Genomic and Immune Characteristics Linked to Second-Line Combination Immunotherapy Outcome in EGFR-Mutated Advanced NSCLC
Lailing Li, China
- EP.06.57** Molecular Analysis of Driver Negative Lung Cancer for Rearrangements and Fusions Using a New HiC Sequencing Assay
Alex Hastie, USA
- EP.06.58** CEACAM5 as a Biomarker for Differentiating Ground-Glass Opacities from Other Lung Cancers
Gavitt Woodard, USA
- EP.06.59** DNA+RNA-NGS Testing in NSCLC Patients with Primary Resistance to First-Line Non-Targeted Therapy and Negative Driver Genes (Dream Study)
Baohui Han, China
- EP.06.60** Exploring the Role of the Oral Microbiome in Saliva Sputum Bronchoalveolar Fluid and Tissue Tumor in Lung Cancer a Systematic Review
Jairo Zuluaga León, Colombia
- EP.06.61** FGFR-2: A Prognostic Biomarker and Potential Therapeutic Target in NSCLC
Martin Barr, Ireland
- EP.06.62** Based on Labyrinth Microfluidic Chip in Evaluating Therapeutic Efficacy for Leptomeningeal Metastasis of Lung Cancer
Liang Xue, China
- EP.06.63** New Approaches for Enhancing the Efficacy of "Liquid Biopsy" in Non-small Cell Lung Cancer
Pavel Karatkevich, Belarus
- EP.06.64** ISET CTC-DNA Shows Higher Sensitivity than ctDNA in Early Stage Lung Cancer Patients
Patrizia Paterlini, France
- EP.06.65** Mosaic Chromosomal Alterations and the Risk of Incident Lung Cancer: A Systematic Review and Meta-Analysis
Dhruv Bansal, USA
- EP.06.66** Prediction of Immune-Related Adverse Events by Human Leukocyte Antigen (HLA) and Other Biomarkers in Patients with Non-small Cell Lung Cancer
Pablo Flores-Paco, Spain
- EP.06.67** Longitudinal ctDNA Profiling in HER2-Altered NSCLC Treated with HER2 ADC: Preliminary Results from the RESOLUTION Trial
Chunxia Su, China
- EP.06.68** Clonal Hematopoiesis (CH)-Derived Mutations Detected in Non-small Cell Lung Cancer (NSCLC) Liquid Biopsies (LBx)
David Kozono, USA
- EP.06.69** Real-World Utilization of Tissue-Free ctDNA Monitoring in Patients with Lung Cancer on Targeted Therapies +/- Chemotherapy
Amaya Gasco, USA

- EP.06.70** Development and Clinical Application of Ultra-Sensitive Digital EV Assay Targeting GLUT1 for Early Diagnosis of Non-small Cell Lung Cancer
Taketo Kato, Japan
- EP.06.71** Clinical Application of Expert Software Based on Tumor Biomarkers to Stratify Lc-Risk in a Hospital Thoracic Tumor Committee
Antonio Barco Sánchez, Spain
- EP.06.72** Lung Cancer EGFR Mutation Prediction via cfDNA Fragmentome Profiling
Yongsheng Wang, China
- EP.06.73** Co-Driver Mutations in Fusion-Positive NSCLC: Liquid Biopsy Insights From 2,369 Patients
Laila Roisman, Israel
- EP.06.74** Clinical Validity of Repeated CTCs and CAM-L Enumeration in Treatment Monitoring of Metastatic Non-small Cell Lung Cancer
Marco Siringo, Italy
- EP.06.75** Identifying Emergent Resistance Alterations in Patients with Advanced NSCLC Using Plasma Genotyping (DISCOVER)
Scarlet Berenice Urtecho Suarez, Canada
- EP.06.76** Real-World Use of Tissue-Free ctDNA Monitoring in Patients with Lung Cancer Receiving Immunotherapy and/or Chemotherapy
Amaya Gasco, USA
- EP.06.77** Exploring the Impact of Peripheral Immune Landscape on Immunotherapy Outcomes in Non-small Cell Lung Cancer
Ester Munera, Spain
- EP.06.78** T Lymphocyte Subpopulations as Predictive Biomarkers in Non-small Cell Lung Cancer Patients Treated with Anti-Pd(L)1 Inhibitors
Teresa Moran-Bueno, Spain
- EP.06.79** Liquid Biopsy Shortens Time to Diagnosis and Treatment Selection: Primary Results from the International L1St Study
Fabrice Barlesi, France
- EP.06.80** Immunological Markers of Prognosis in Lung Cancer: T-Cell Subpopulations and Their Correlation with Clinical Outcomes
Federica Biello, Italy
- EP.06.81** Observational Study of Concordance Between Tissue-Based ODxTT CDx and In-House Plasma OPA Gene Analysis in NSCLC Patients
Kentaro Nakanishi, Japan
- EP.06.83** Prognostic Impact of PD-L1 Expression in a Swiss Cohort of EGFR-Mutant Non-small Cell Lung Cancer Patients Treated with First-Line Osimertinib
Alexandra Schuler, Switzerland
- EP.06.84** Impact of Preoperative Brain Natriuretic Peptide Levels on Postoperative Outcomes in Lung Cancer Patients
Shinya Otsuka, Japan
- EP.06.85** Real-World Performance of NGS Panels in Detecting Actionable Genomic Alterations in NSCLC
Marina Querol Vilà, Spain
- EP.06.86** Evaluating Sustainment of Results in Quality Improvement Focused on Molecular Testing in Non-small Cell Lung Cancer Patients
Mike Gart, USA

TRACK 07: EARLY-STAGE NON-SMALL CELL LUNG CANCER

- EP.07.01** Prediction of Pathologic Low-Grade Malignant Adenocarcinoma in Radiologically Invasive C-Stage IA Non-small Cell Lung Cancer Measuring >2-3 Cm
Makoto Endo, Japan
- EP.07.02** Development and Validation of a High-Speed and High-Throughput 3D Reconstruction Algorithm in Pulmonary Vasculature and Nodules Localization
Zihao Chen, China
- EP.07.03** Lung Cancer: Artificial Intelligence, Biometrics and Modeling of Alive Supersystems for Best Management
Oleg Kshivets, Russian Federation
- EP.07.04** Pathological Investigation of Bronchial Stump and Bronchopleural Fistula After Anatomical Pulmonary Resection for Lung Cancer
Hiromasa Arai, Japan
- EP.07.05** Oncologic Outcomes of Segmentectomy Versus Lobectomy in Early-Stage Lung Adenocarcinoma with High-Risk Pathologic Features
Zhifei Li, China
- EP.07.06** Preserved Ratio Impaired Spirometry Are Associated with Poor Postoperative Outcomes in Clinical Stage I Non-Small Lung Cancer
Toshio Shiotani, Japan
- EP.07.07** Prognostic Analysis and Molecular Characteristics of Bubble-Like Appearance-Type Lung Adenocarcinoma
Kotaro Murakami, Japan
- EP.07.08** Quantifying Resection Margins in Lung Cancer Patients Undergoing Sublobar Resection Using CT-Based 3D Reconstruction
Mong-Wei Lin, Taiwan
- EP.07.09** Preliminary Results of One-Stop Shop: Results From the First Twenty-One Tumor Resections Compared to a Stage-Matched Control Group
Gian-Marco Monsch, Switzerland
- EP.07.10** Analysis of Residual Lung Volume After Segmentectomy Using 3DCT and Risk Factors for Decline in Postoperative Pulmonary Function
Seiyu Ohtani, Japan
- EP.07.11** Comparison of Robotic Assisted Thoracoscopic Lobectomy and Video-Assisted Thoracoscopic Lobectomy for Early Stage Non-small Cell Lung Cancer
Tomoyoshi Takenaka, Japan
- EP.07.12** The Impact of Quantification Parameters and Clinicopathologic Characteristics on the Prognosis of Stage Ia Invasive Lung Adenocarcinoma
Zetao Liu, China
- EP.07.13** Thoracoscopic Combined Anatomical Sublobar Resection for Deep Intersegmental Small-Sized Non-small Cell Lung Cancer
Yungang Sun, China
- EP.07.14** Contemporary Stereotactic Body Radiation Therapy Utilization Trends for Stage I Non-small Cell Lung Cancer
Drew Moghanaki, USA
- EP.07.15** Model Navigated Anchor Based Responsive CT Hybrid Surgery for Intraoperative Localization and Resection for Small Pulmonary Nodules
Xining Zhang, China
- EP.07.16** Minor Ground-Glass Opacity Differences Were Associated with Prognostic Variation in Solid-Predominant Clinical Stage IA Lung Adenocarcinoma
Pei-Hsing Chen, Taiwan
- EP.07.17** Patient Characteristics, Surgical Outcomes, and Treatment Decisions in Early-Stage Resected NSCLC in Canada
Anna McGuire, Canada

- EP.07.18** Optimizing Intraoperative Lymph Node Dissection in Stage I NSCLC: A Risk-Stratified Approach Based on CNN Model Predictions
Yuanyuan Fu, China
- EP.07.19** Temporal Advances of Surgical Outcomes in Posterior Segment Ectomy for Primary Lung Cancer
Ryota Kiriya, Japan
- EP.07.20** Evolution of Overall Survival (OS) After Good Quality Curative-Intent Lung Cancer Surgery in a Population-Based Cohort
Meredith Ray, USA
- EP.07.21** The Efficacy of the 'Lung Partial Resection Prior to Lobectomy Method' as a No-Touch Isolation Technique in Lung Cancer Surgery
Hiroyuki Adachi, Japan
- EP.07.22** Major Lung Resections for Non-small Cell Lung Cancer: Does Postoperative Pneumonia Remain a Life-Threatening Complication?
Konstantinos Grapatsas, Germany
- EP.07.23** Single Port Robot and Navigational Bronchoscopy During Single Episode of Anesthesia: Less Is More
Patrick Ross, USA
- EP.07.24** Study on Complex Segmentectomy Cases at Our Institution
Takuya Nagashima, Japan
- EP.07.25** Real-World Treatment Patterns and Outcomes of Stage I-III Resectable Non-small Cell Lung Cancer (NSCLC) in Portugal
Marta Soares, Portugal
- EP.07.26** A Novel Thoracic Localization Technique: Combining Intracorporeal Radiopaque Marker Suturing and Intraoperative Cone-Beam CT
Tzu-Ning Kao, Taiwan
- EP.07.27** Unravelling Sublobar Resections: Real-World Outcomes after Wedge vs Segmentectomy and Recurrence Risk Factors
Sara Fra, Spain
- EP.07.28** Real-Time Image-Guided Indocyanine Green Fluorescencedual-Visualization Technique for Thoracoscopic Segmentectomy
Feng Shao, China
- EP.07.29** Single-Port Robotic Anatomical Lung Resection Using the Novel Chinese SP1000 Robotic System: Initial Experience
Shengcheng Lin, China
- EP.07.30** Preop-Intraop Consistency in Thoracic Surgery: MRMC Reanalysis of Surgical Planning Accuracy
Heng Zhao, China
- EP.07.31** A Comparative Analysis of Sublobar Versus Lobar Resection for Early-Stage Non-small Cell Lung Cancer in Octogenarian Patients
Sangil Yun, Republic of Korea
- EP.07.32** Initial Experience with Robot-Assisted Thoracic Surgery for Anatomical Lung Resection: A Case Series of 40 Patients from a Japanese Regional Hospital
Toshiyuki Shima, Japan
- EP.07.33** The Pictorial Fit Frail Scale as a Preoperative Risk Stratification Tool in Lung Resection Patients
Desiree Steimer, USA
- EP.07.34** A Study of Lung Cancer Patients Who Survived for More Than 5 Years After Incomplete Resection
Fumihiko Hoshi, Japan
- EP.07.35** Comparative Analysis of Anterior and Posterior Approaches in Robotic Pulmonary Resection
Atsushi Osoegawa, Japan

- EP.07.36** Introduction of Dural-Port Robot Assisted Thoracoscopic Lung Dissection - Aiming for Reduce-Port RATS That Anyone Can Do
Hiroki Numanami, Japan
- EP.07.37** An Initial Experience of Resectable Non Small Cell Lung Cancer from a Tertiary Care Center
Sonal Raikwar, India
- EP.07.38** Immune Checkpoint Inhibitors May Not Fully Mitigate the Adverse Prognostic Impact of PD-L1 Expression in Early Lung Cancer
Ken Onodera, Japan
- EP.07.39** Simply the Best: Analysis Of 1000+ Patients Comparing Single-Fraction to Three-Fraction Lung SBRT for Early-Stage Inoperable Lung Cancer
Gregory Videtic, USA
- EP.07.40** Efficacy of Re-Irradiation with SABR of Lung Cancer After Primary SABR: A Single Centre Experience
Nagendran Balaramal, UK
- EP.07.41** Individualized SBRT for Ultra-Central NSCLC Achieves Optimal Tumor Control with Minimal Toxicity
Di Liu, China
- EP.07.42** Stereotactic Body Radiation Therapy Versus Surgery in Early-Stage Non-small Cell Lung Cancer. How Does Comorbidity Impact?
Arturo Navarro-Martin, Spain
- EP.07.43** The Role of FDG-PET/CT SUVmax in Predicting Treatment Outcomes and Progression Risk in SBRT for ES-NSCLC
Gloria Guardia, Spain
- EP.07.44** Perioperative Treatment Patterns and Clinical Outcomes in Early-Stage NSCLC: A Real-World Study (Peri-R-02)
Hua Zhong, China
- EP.07.45** Single-Cell Analysis Revealed the Characteristics of Tumors with Different Responses to Neoadjuvant Chemo Immunotherapy in Stage II-III NSCLC
Minglei Zhuo, China
- EP.07.46** Clinical and Radiologic Factors Associated with Surgical Eligibility After Neoadjuvant Chemoimmunotherapy in Stage II-III NSCLC
Junghee Lee, Republic of Korea
- EP.07.47** Real-World Implementation of Neoadjuvant Chemo-Immunotherapy in Resectable Non-small Cell Lung Cancer
Michael Shackcloth, UK
- EP.07.48** The Impact of Sarcopenia on Neoadjuvant Chemoimmunotherapy in Earlier Stage Resectable NSCLC
Daniele Marinelli, Italy
- EP.07.49** Neoadjuvant Sunvozertinib for Early-Stage NSCLC Patients with EGFR Exon 20 Insertion Mutation: A Case Series
Jinfeng Chen, China
- EP.07.50** Real-World Treatment Strategy and Postoperative Prognosis for Clinical Stage II/III NSCLC: A Multicenter Study
Taichi Matsubara, Japan
- EP.07.51** Long-Term EGFR-TKI as Neoadjuvant Therapy Effectively Achieved Depth of Pathological Response
Yuan Da Cheng, China
- EP.07.52** PD-L1 Tumor Expression Changes in Non-small Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy and the Relation with Pathologic Response
Mateusz Polaczek, Poland
- EP.07.53** Impact of Subcutaneous Fat on the Relative Dose Intensity of Adjuvant Chemotherapy in Patients with Non-small Cell Lung Cancer
Ikki Takada, Japan

- EP.07.54** Lymphatic Permeation as a Key Risk Factor for Recurrence in Pathological Stage IIA NSCLC Under the 9th TNM Classification
Yujin Kudo, Japan
- EP.07.55** Adjuvant Sunvozertinib for Early-Stage NSCLC Patients with EGFR Exon 20 Insertion Mutation: A Case Series
Xiaohan Chen, China
- EP.07.56** Efficacy and Safety of Postoperative Adjuvant Chemotherapy and Atezolizumab and Osimertinib Maintenance Therapy for NSCLC at Our Hospital
Masahide Ota, Japan

TRACK 08: LOCAL-REGIONAL NON-SMALL CELL LUNG CANCER

- EP.08.01** Surgery for Resectable Lung Cancer with Radiographic Disease Control After Chemoimmunotherapy: A Retrospective Cohort Study
Bingbing Lu, China
- EP.08.02** A Study of Patients with Lung Cancer Complicated with IPF Who Underwent Partial Pulmonary Resection
Madoka Toyoda, Japan
- EP.08.03** Surgical Outcomes in Induction and Perioperative Chemoimmunotherapy Trials: A Meta Analysis
Pietro Bertoglio, Italy
- EP.08.04** Reducing Medication Burden and Accelerating Recovery Through Tubeless Thoracic Surgery: A Large-Scale Real-World Study
Zihao Liu, China
- EP.08.05** Minimally Invasive Approaches for Pancoast Tumor Resection: A Comparative Analysis of Surgical Techniques and Outcomes
Fumiaki Watanabe, Japan
- EP.08.06** Survival Analysis and Nomogram for Postoperative Pulmonary Sarcomatoid Carcinoma Patients: SEER Database Analysis and External Validation
Zixuan Hu, China
- EP.08.07** The Role of Surgery After Neoadjuvant Immunotherapy in NSCLC: Refining the Multimodal Paradigm
Alejandra Libreros Niño, Spain
- EP.08.08** Complex Tracheobronchial Reconstruction for Locally Advanced T4N2M0 Non-small Cell Lung Cancer Using Three-Dimensional Models
Sergew Yeskov, Belarus
- EP.08.09** Aggravation of Tumor Necrosis After Transbronchial Biopsy in Lung Cancer: A Fatal Complication Despite Rescue Surgery
Shiho Hattori, Japan
- EP.08.10** N3 Stage May no Longer Be Considered Unresectable in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer: A Case Series
Hao Guo, China
- EP.08.11** Multimodality Approach for Locally Advanced Lung Cancer, When Is Surgery Most Beneficial in a Resource-Constrained Environments
Riad Abdel Jalil, Jordan
- EP.08.12** Occult Lymph Nodal Metastasis in Sub-Centimeter Lung Cancer: A Report of Seven Cases and Review of Literature
Xiao Wang, China
- EP.08.13** Machine Learning Prediction of Overall Survival in Stage III Unresectable NSCLC: Data Analysis from a Single Center Prospective Cohort
Sara Ramella, Italy
- EP.08.14** Adaptive Radiotherapy in Locally Advanced Lung Cancer - a Single-Centre Retrospective Study
Anil Tibdewal, India

- EP.08.15** Predicting Locations of In-Field Failure Leading to Proton Re-Irradiation for NSCLC
Nitin Ohri, USA
- EP.08.16** Impact of Pathological Subtypes and Radiation Dose on Survival in Lung Cancer: A Retrospective Analysis from a Single Institution
Thais Dias, Brazil
- EP.08.17** Patterns of Recurrence and Eligibility for Salvage Therapy After Curative Intent Treatment for Unresectable Stage III NSCLC
Eric Bhang, Canada
- EP.08.18** Concurrent Chemoradiotherapy (ConCRT) in Locally Advanced (LA) Non-small Cell Lung Cancer (NSCLC) In the Durvalumab Era
Haris Charalambous, Cyprus
- EP.08.19** Timing and Predictors of Lymphopenia in Lung Cancer Patients Undergoing Proton and Photon Chemoradiotherapy
Robert Press, USA
- EP.08.20** Comparative Survival Post-Radiotherapy in Small Vs. Non-small Cell Lung Cancer: Revisiting Prognostic and Dosimetric Factors
Renne Aguiar, Brazil
- EP.08.21** Sequential Radiotherapy Following Induction Immunochemotherapy/Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer
Yanhua Yang, China
- EP.08.22** Treatment Patterns and Clinical Outcomes in South Korean Patients with Unresectable Stage III EGFRm NSCLC Undergoing CRT
Jii Bum Lee, Republic of Korea
- EP.08.23** EMS to Lung Cancer Patients Receiving Platinum Doublet Concomitant Chemoradiotherapy
Anneyuko Saito, Japan
- EP.08.24** Pattern of Care in Locally Advanced NSCLC in India
Aswin Ravi, India
- EP.08.25** CRT Patterns and Short-Term Outcomes on Unresectable NSCLC in Routine Practices in Russia (PASSAT)
Marina Chernykh, Russian Federation
- EP.08.26** Blood Inflammatory Biomarkers Dynamics in Neoadjuvant Chemoimmunotherapy vs Chemotherapy Alone in Non-small Cell Lung Cancer
Marc Boada, Spain
- EP.08.27** Exploration of Targeted Sequential Surgery Combined Therapy for ROS1-Rearranged Non-small Cell Lung Cancer
Linqiang Jiang, China
- EP.08.28** Referral Rates to Medical Oncology Before Lung Cancer Surgery: A Quality Improvement Study in the Era of Perioperative Chemoimmunotherapy
Juliet Meir, USA
- EP.08.29** Pathologic Response After Neoadjuvant Chemoradiotherapy Versus Chemoimmunotherapy in Resected Stage III-N2 Non-small Cell Lung Cancer
Junghee Lee, Republic of Korea
- EP.08.30** The Outcome of Preoperative Therapy for Resectable NSCLC Patients with EGFR PACC Mutations
Wanpu Yan, China
- EP.08.31** Phase II Trial and Correlative Genomic Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in EGFR-Mutant Non-small Cell Cancer
Chao Zhang, China
- EP.08.32** Real-World Outcome of Neoadjuvant-Intent Therapy vs Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer
Yasmin Fakhari Tehrani, USA
- EP.08.33** A Real-World Study of Resectable NSCLC Following Neoadjuvant Immunotherapy: Should Postoperative Adjuvant Immunotherapy Be Recommended?
Ming Li, China

- EP.08.34** To Resect or Not to Resect: The Evolving Landscape of Definitive Therapy for Stage III NSCLC: Implications for Service Demand in Ireland
Conor Moloney, Ireland
- EP.08.35** Accurate Pathologic Response Assessment of Lung Squamous Cell Carcinoma Treated with Neoadjuvant Immunochemotherapy
Shaoling Li, China
- EP.08.36** Vebreltinib as Neoadjuvant Therapy in Three Cases of MET Exon 14 Skipping Mutation-Positive NSCLC: A Case Series
Yifei Zhou, China
- EP.08.37** Treatment Strategies for Unresectable Stage IIIA Lung Cancer After Neoadjuvant Therapy
Paula Rodríguez Hernaez, Spain
- EP.08.38** Real-World Data of Adjuvant Therapy with Aumolertinib for EGFR-Mutated NSCLC Patients
Honggang Liu, China
- EP.08.39** Adjuvant Therapy with Furmonertinib Significantly Reduces the Recurrence Rate in Lung Cancer Patients with Exon 20 Insertion Mutations
Jialu Chen, China
- EP.08.40** Immunotherapy Extended Survival in Patients with Recurrent Pulmonary Pleomorphic Carcinoma Following Surgery
Wakako Nagase, Japan
- EP.08.41** Tislelizumab Combined with Chemotherapy for Conversion Therapy in Stage III-N3 Non-small Cell Lung Cancer: A Phase 2, Single-Arm Trial
Kai MA, China
- EP.08.42** A Prognostic Marker for Consolidation Therapy with Durvalumab After Concurrent Chemoradiotherapy in NSCLC: The Utility of Serum CYFRA 21-1
Masahiro Ito, Japan
- EP.08.43** Surgical Stress After Lung Cancer Surgery Triggers the Outgrowth of Distant Metastases
Yo Kawaguchi, Japan
- EP.08.44** The Prognosis of NSCLC Patients Who Received Neoadjuvant Immunotherapy
Bolun Zhou, China
- EP.08.45** Real-World Long-Term Outcomes of First-Line Pembrolizumab in Advanced NSCLC and PD-L1 =50%: A Systematic Review and Meta-Analysis
Guilherme Franceschini Machado, Brazil
- EP.08.46** Neoadjuvant Immunotherapy Improves Recurrence-Free Survival in Resectable Non-small Cell Lung Cancer - a 10-Year Institutional Experience
Gavitt Woodard, USA
- EP.08.47** Consolidation Immunotherapy Impact in Non-small Cell Lung Cancer: A Descriptive Analysis
Manuel Quintana Déniz, Spain
- EP.08.48** PD-L1 Expression and Efficacy of Durvalumab Consolidation in Stage III EGFR-Mutant Non-small Cell Lung Cancer: A Multicenter Real-World Study
Insu Kim, Republic of Korea
- EP.08.49** Accurate Pathologic Response Assessment of Lung Adenocarcinoma Treated with Neoadjuvant Targeted Therapy
Shaoling Li, China
- EP.08.50** Excellent Response to Osimertinib-Based Regimens in Choroidal Metastasis in Patients with EGFR Exon 19 Deleted Non-small Cell Lung Cancer a Case Series
Natalie Shammass, USA
- EP.08.51** Impact of KRAS Mutations on Outcomes in Stage III Non-small Cell Lung Cancer Treated with Chemoradiation and Durvalumab
Nikhil Mankuzhy, USA
- EP.08.52** Is Attrition to Surgery Even Less in a Real-World Setting After Neoadjuvant Chemo-Immunotherapy for Non-small Cell Lung Cancer?
Raphael Werner, Switzerland

TRACK 09: METASTATIC NON-SMALL CELL LUNG CANCER – LOCAL THERAPIES

- EP.09.01** Feasibility of High Pressure Continuous Positive Airway Pressure to Reduce Respiratory Motion in Thoracic Irradiation
Sarit Appel, Israel
- EP.09.02** Consolidative Hypofractionated RT for Oligometastatic NSCLC
Bong Kyung Bae, Republic of Korea
- EP.09.03** Survival and Neurotoxicity of WBRT Vs. SRS in Individuals with Brain Metastases from Lung Cancer: Retrospective Study
Gustavo Cunha, Brazil
- EP.09.04** Duration of Systemic Therapy in Patients with Metastatic EGFR-Mutated NSCLC and Brain Metastases: First Vs. Third Generation TKIs
Alex Louie, Canada
- EP.09.05** Efficacy and Prognostic Factors of Radiotherapy in Brain Metastases From Non-small Cell Lung Cancer Patients: A Retrospective Study
Haiyu Zhou, China
- EP.09.06** Consolidative High-Dose Thoracic Radiotherapy in NSCLC Without Progression After First-Line Systemic Therapy with ICIs
Marco Galaverni, Italy
- EP.09.07** Cardiac Dosimetry and Clinical Outcomes in Individuals with Lung Cancer Undergoing Thoracic Radiotherapy: Retrospective Study
Gustavo Cunha, Brazil
- EP.09.08** Outcomes of SBRT in the Management of Adrenal Metastases from Lung Cancer - Retrospective Data from Tertiary Cancer Centre of India
Memtombi Ngasepam, India
- EP.09.09** Evaluation of Radiotherapy Use in Patients with Metastatic Solid Tumors: An Analysis of Real-World Data
Sofia Mendes, Brazil
- EP.09.10** Salvage Surgery After Nonoperative Treatment of Initially Unresectable Stage IIIB-IV Non-small Cell Lung Cancer
Raphael Werner, Switzerland
- EP.09.11** Prognostic Impact of Nodal Downstaging After Neoadjuvant Therapy on Survival in Oligometastatic Non-small Cell Lung Cancer
Nina Steinmann, Switzerland
- EP.09.12** Pleurodesis in cM0sM1a Lung Adenocarcinoma with Pleural Metastasis: Impact on Pleural Effusion Control and Survival Outcomes
JiaYuan Tian, China
- EP.09.13** Prognostic Analysis of Patients with Incidentally Diagnosed Pathological Stage IVA Non-small Cell Lung Cancer After Anatomical Resection
Ryotaro Matsuyama, Japan
- EP.09.14** Efficacy and Safety of Intrathecal Pemetrexed in NSCLC Patients with Leptomeningeal Metastases: A Retrospective Study
Tianli Zhang, China
- EP.09.15** CT-Guided Microwave Ablation as an Alternative Treatment for Non-Surgical Lung Cancer Patients: A Clinical Evaluation of Benefits and Risks
Chung-Yu Chen, Taiwan
- EP.09.16** Airway Stenting for the Treatment of Airway Stenosis in Advanced Lung Cancer; a Study of 20 Patients with Advanced Lung Cancer
Akaya Tsuji, Japan
- EP.09.17** Permanent Local Control After Orbital Cryoablation for Ocular Metastasis from Lung Cancer
Nuria Mederos Alfonso, Switzerland

TRACK 10: METASTATIC NON-SMALL CELL LUNG CANCER – CYTOTOXIC THERAPY

- EP.10.01** Retrospective Study of Pemetrexed Monotherapy for Non-small Cell Lung Cancer Patients by Renal Function
Taisaku Koyanagi, Japan

TRACK 11: METASTATIC NON-SMALL CELL LUNG CANCER – IMMUNOTHERAPY

- EP.11.01** The Challenge of Immunotherapy in Advanced Lung Cancer Patients With HIV: A Systematic Review of Case Reports
Tindara Franchina, Italy
- EP.11.02** Four Year-Experience with Immunotherapy in First Line Treatment of Advanced Lung Cancer in Patients with High and Very High Expression of PD-L1
Silvia Sequero, Spain
- EP.11.03** First Line Chemo-Immunotherapy Prognostic Factors Predicting Non-small Cell Lung Cancer Overall Survival
Riccardo Ronga, Italy
- EP.11.04** Camrelizumab-Induced Immune-Related Toxic Epidermal Necrolysis in Lung Adenocarcinoma: A Case Report and Literature Review
Man Sun, China
- EP.11.05** Prognostic Value of Hb/RDW and Its Correlation with Immune-Inflammatory Profile in NSCLC Receiving First-Line Immunotherapy
Federica Pecci, Italy
- EP.11.06** First-Line Immunotherapy for PD-L1 =50% Advanced NSCLC vs EGFR-TKIs in EGFR-Mutant NSCLC: A Retrospective Single-Center Study
Shun Futamura, Japan
- EP.11.07** Type2 Diabetes Mellitus Affect Prognosis and Immune Checkpoint Inhibitor Treatment Efficacy for Advanced Non Small Cell Lung Cancer
Yasuhiro Kato, Japan
- EP.11.08** Comparison of Efficacy and Safety of Combination Therapy with Atezolizumab and Chemotherapy in Non-small Cell Lung Cancer
Taichi Isobe, Japan
- EP.11.09** Predictive Value of Markers of Systemic Inflammation in Patients with Advanced NSCLC Treated With First-Line Immune Checkpoint Inhibitors
Katarina Lujic, Serbia
- EP.11.10** Clinicopathologic Features, Genetic Characteristics and Prognostic Analysis of Advanced Non-small Cell Lung Cancer, Not Otherwise Specified
Xiheng Yu, China
- EP.11.11** Real World Outcomes of First-Line Pembrolizumab with or Without Chemotherapy in Patients with Non-small Cell Lung Cancer
Surein Arulananda, Australia
- EP.11.12** Real-World Impact of Immune Checkpoint Inhibitors in Elderly Patients with Advanced NSCLC: A Retrospective Cohort Study from South Korea
Eun Young Heo, Republic of Korea
- EP.11.13** ICI Rechallenge in Non Small Cell Lung Cancer: A Retrospective Analysis of Efficacy and Prognostic Factors
Soichiro Minami, Japan
- EP.11.14** Impact of Bone Metastases on the Efficacy of First-Line Immunotherapy in Advanced NSCLC: An Analysis from a Prospective Real-World Study
Jing Zheng, China
- EP.11.15** Bimodal Onset and Pan-Cancer Uniformity of Immune-Mediated Liver Injury: A Retrospective Cohort Study
Xiaoke Chen, China

- EP.11.16** Immunotherapy Rechallenge of Advanced NSCLC Patients Who Progressed on 3rd-Generation of EGFR-TKI and Immunotherapy Sequentially
Shuyi Hu, China
- EP.11.17** Promising Effect of Nivolumab with Carboplatin, Paclitaxel, and Bevacizumab in EGFR-Mutant NSCLC Following EGFR-TKI Therapy
Akane Narumi, Japan
- EP.11.18** Non-small Cell Lung Cancer Metastases to Adrenal Glands Are Not Differentially Sensitive to Immune Checkpoint Inhibitors
Charles Soutif, Belgium
- EP.11.19** Efficacy and Safety of Continuing Tislelizumab After Progression of First-Line Tislelizumab in Patients with Advanced NSCLC
Boyu Qin, China
- EP.11.20** Real World-Outcomes of Advanced Non-Squamous NSCLC Patients Treated with First-Line Chemo-Immunotherapy According to KRAS Status
Fabiana Perrone, Italy
- EP.11.21** Efficacy of Immunotherapy in EGFR-Mutant NSCLC After Tyrosine Kinase Inhibitors: Real World Analysis at a Tertiary Oncology Center in Hong Kong
Gin Wai Gerry Kwok, Hong Kong
- EP.11.22** Efficacy and Safety of Atezolizumab Plus Bevacizumab-Based Therapy in Non-small Cell Lung Cancer: A Meta-Analysis of Clinical Trials
Dipesh Rohita, USA
- EP.11.23** Sex-Based Differences in Immune Toxicity Without Survival Trade-Off in Atezolizumab-Based Therapy for Lung Cancer
Amanda Tufman, Germany
- EP.11.24** A CT Based Tumor Microenvironment Specific Radiomics Signature for Predicting the Efficacy of Checkpoint Inhibitor Therapy in Advanced NSCLC
Haiyu Zhou, China

TRACK 12: METASTATIC NON-SMALL CELL LUNG CANCER – TARGETED THERAPY

- EP.12.01** Real-World Data of ROS-1 Positive NSCLCs- Mutational Heterogeneity, Clinical Characteristics and Its Outcomes
Kunal Jobanputra, India
- EP.12.02** Efficacy and Safety of Firmonertinib for EGFR Exon 21 L858R Mutation-Positive NSCLC Patients with Brain Metastases
Haichuan Su, China
- EP.12.03** Study on the Effects of Anlotinib Combined with PD-1 Antibody in Lung Cancer Rats and Its Impact on the PLGF/Flt-1 and TGF- β 1 Pathways
Shugeng Tang, China
- EP.12.04** Efficacy of EGFR TKIs of a Rare but Sensitive Subtype of EGFR L833V/H835L Mutation in Advanced NSCLC
Yue-Li Sun, China
- EP.12.05** The Effect of a Dutch Breakfast on the Exposure of Alectinib Using a Microtracer Approach: A Proof-Of-Concept Study
Ma Ida Mohmaed Ali, Netherlands
- EP.12.06** Brilliant First Analysis: A Real-World Study of Characteristics and Safety About Brigatinib as First-Line for Chinese Patients With ALK+ NSCLC
Lei Wang, China
- EP.12.07** Using Online Continuing Medical Education to Identify Ongoing Gaps in Global Clinicians' Understanding of HER2-Altered NSCLC
Michelle Worst, USA
- EP.12.08** A Real-World Study of the Efficacy and Safety of Firmonertinib for Patients with Non-small Cell Lung Cancer with EGFR Uncommon Mutations
Min Li, China

- EP.12.09** Third-Generation EGFR-TKIs in T790M-Negative NSCLC After First/Second-Generation EGFR-TKI Failure: A Retrospective Study
Xiaobi Huang, China
- EP.12.10** Clinical Investigators' (CIs) Preferences for First-Line Therapy of ALK-Positive Metastatic Non-small Cell Lung Cancer
Neil Love, USA
- EP.12.11** Prognostic Impact of Metastatic Tumor Burden in Patients with EGFR-Mutated Lung Cancer: Real-World Data from a Single Center
Silvia Sequero López, Spain
- EP.12.12** Efficacy of Lazertinib in Treatment-Naive Patients for EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases
Hyun Seok Kwak, Republic of Korea
- EP.12.13** Gradually or Locally Progressed NSCLC Patients Benefit from Aumolertinib in Post-1L Dose-Escalation Treatment
Jun Li, China
- EP.12.15** Predictive Value of Gastrin for the Absorption of pH-Dependent Small-Molecule Inhibitors in Patients With NSCLC
Niels Heersche, Netherlands
- EP.12.16** Prolonged Survival in Oligometastatic ALK-Positive NSCLC: Impact of Local Ablative Therapy in a Multimodal Treatment Approach
Caroline Kamali, Sweden
- EP.12.17** NNMT as a Therapeutic Target in EMT-Associated Osimertinib Acquired Resistance in EGFR-Mutant Lung Adenocarcinoma
Wei Wang, China
- EP.12.18** Osimertinib-Associated Asymptomatic Depigmented Skin Macules in a Mexican Cohort
Saul Campos-Gomez, Mexico
- EP.12.19** Efficacy of Aumolertinib in Patients with Advanced NSCLC for Uncommon EGFR Exon 19 Deletion Mutations
Yifan Yang, China
- EP.12.20** A Realworld Study: Clinical Molecular Characteristics and Prognostic Factors of NSCLC with MET Alteration
Xiao Fu, China
- EP.12.21** The Impact of Afatinib and Osimertinib Plasma Concentrations on Treatment Toxicities, Quality of Life, and Effectiveness in Patients With NSCLC
Sheng-Kai Liang, Taiwan
- EP.12.22** Clinical Treatment Outcomes of Erlotinib in Metastatic Non-small Cell Cancer Harboring Uncommon EGFR Mutations
Chalita Lagampam, Thailand
- EP.12.23** Disease Burden and rwPFS as a Surrogate Endpoint for rwOS in NTRK+ NSCLC and Other Advanced/Metastatic Solid Tumors
Carlos Flores Avile, USA
- EP.12.24** Common vs Uncommon EGFR Mutations in NSCLC and the Potential Prognostic Role of Neutrophil-To-Lymphocyte Ratio
Javier Baena Espinar, Spain
- EP.12.25** Demographic Influences on Treatment Preferences in Advanced EGFR+ mNSCLC: A Qualitative Analysis of Patient Perspectives on Osimertinib
Rena Seeger, Canada
- EP.12.26** Multi-Omics Decipher the Molecular Landscape of EGFR+ Non-small Cell Lung Cancer Patients Following Osimertinib Treatment
Per Hydbring, Sweden
- EP.12.27** Effect of PD-L1 Expression Level on Clinical Outcomes of Stage IV EGFR Mutant Lung Cancer Patients Treated with Osimertinib
Jonathan Lee, USA

- EP.12.28** Real-World Clinical Outcomes in Chinese Patients with Advanced EGFR-Mutated NSCLC on First-Line Third-Generation EGFR-TKIs Treatment
Xinlin Mu, China
- EP.12.29** Association Between Tepotinib-Induced Edema and Clinical Outcomes in Patients with MET Exon 14 Skipping NSCLC
Takayuki Kobayashi, Japan
- EP.12.30** Real-World Outcomes of Full and Reduced Dose Capmatinib and Tepotinib Treatment for MET Exon 14 Skipping Mutation NSCLC
Joseph Fuchs, USA
- EP.12.31** Dual Target Drug Discovery for EGFR and PIK3CA in Lung Adenocarcinoma Using Machine Learning and Molecular Simulation Techniques
Simiao Lu, China
- EP.12.32** Targeted Therapy Utilization in Patients with Stage IV Non-small Cell Lung Cancer Harboring Actionable Mutations
Edgardo S. Santos, MD, USA
- EP.12.33** Retrospective Analysis of Adenocarcinoma of Lungs from Medical Oncology Clinic in Eastern India
Kiran Yidagur Gangadharaiiah Lokesh, India
- EP.12.34** Long-Term Control of Leptomeningeal Disease in NSCLC With EGFR Mutations: A Case Series
Estelamari Rodriguez, USA
- EP.12.35** Insights on Treatment Experience from Patients With ALK+ NSCLC Treated With 1st-Line Brigatinib, Lorlatinib and Alectinib
Christopher Danes, USA
- EP.12.36** Data Visualization of Treatment Patterns in Adults with BRAFV600EMutant mNSCLC in Real-World Settings
David Planchard, France
- EP.12.37** Targeted Treatment of NSCLC With? BRAF Fusions: A Systematic Review
Saurav Verma, Canada
- EP.12.38** Firmonertinib(160Mg) Combined with Chemotherapy as First-Line Treatment for Advanced NSCLC Patients with EGFR Mutations and Cns Metastases
Lailing Li, China
- EP.12.39** Dynamic Evolution of Genomic and Microenvironment Landscape in ALK-Positive Non-small Cell Lung Cancer
Jiani Wu, China
- EP.12.40** Clinical Efficacy and Safety Analysis of Osimertinib Versus Aumolertinib in Real-World Treatment of EGFRm Advanced NSCLC
Hui Qiao, China
- EP.12.41** FUTURE Trial: First-Stage Data of Initial Firmonertinib 160mg in EGFR+/PD-L1+ Locally Advanced or Metastatic NSCLC (Simon's Two-Stage Design)
Hui Yu, China
- EP.12.42** Durable Response to ROS1-Tkis in Metastatic Squamous NSCLC With EZR-ROS1 Fusion
Edyta Urbanska, Denmark
- EP.12.43** Long Progression-Free Survival with Sunvozertinib in EGFRm NSCLC Patients After Third-Generation EGFR TKI Failure: Case Series
Mengxing You, China
- EP.12.44** The Efficacy of Capmatinib in Treating NSCLC Patients with MET Amplification in a Multi-Center Real-World Setting
Ning Yan, China
- EP.12.45** Concurrent ROS1-Rearrangements of Brain Metastasis in EGFR-Mutation Lung Adenocarcinoma
Ching Min Tseng, Taiwan

- EP.12.46** Efficacy of Sunvozertinib in Advanced NSCLC With HER2 Exon 20 Insertion After Prior Treatment Failure: A Real-World Case Series
Dongying Liu, China
- EP.12.47** Persistent Response of Sunvozertinib in Lung Adenocarcinoma Patient with EGFR Exon 20 Insertion Mutation
Hui Han, China
- EP.12.48** Identifying Optimal First-Line Treatment Strategy for Advanced-Stage EGFR Mutant NSCLC: A Network Meta-Analysis
Du Feng, China
- EP.12.49** Osimertinib Distribution in Brain Metastases from Patients with Metastatic Non-small Cell Lung Cancer
Geerten Veerman, Netherlands
- EP.12.50** Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor as an Effective Subsequent Line: A Case Series from Kuwait
Abdulaziz AlJassim, Kuwait
- EP.12.51** Clinical Landscape and Future Perspectives of Targeted Protein Degradation Therapies in Lung Cancer
Man Sun, China
- EP.12.52** A High-Fat Meal Optimizes the Pharmacokinetic Profile of DO-2, a Novel MET-Kinase Inhibitor for NSCLC
Daan Lanser, Netherlands
- EP.12.53** Case Report Response to Treatment with Erdafitinib in a Patient with FGFR2 Mutation in Adenocarcinoma Lung Cancer
Grezia Siancas, Peru
- EP.12.54** Real-World Use of Targeted Therapy Combinations to Manage Secondary Oncogenic Addiction in Non-small Cell Cancer
Clara Morin, France
- EP.12.55** Aumolertinib Combined with Metronomic Oral Vinorelbine in Advanced EGFR-Mutant NSCLC
ZhenTian Liu, China
- EP.12.56** IPD Meta-Analysis of Intracranial Efficacy: Can CNS Data Refine First-Line Choices in EGFR-Mutant NSCLC?
Blerina Resuli, Germany
- EP.12.57** Ensartinib Exhibits Potential Synergistic Effects with Radiotherapy in ALK-Positive Non-small Cell Lung Cancer
Buhai Wang, China
- EP.12.58** Feasibility of Aumolertinib Followed by SRT in EGFR+ NSCLC Patients with Intracranial Oligo-Progression: A Phase II, Prospective Study
Jiayan Chen, China
- EP.12.59** Calcium Channel Blockers and Irreversible EGFR TKIS. Opportunities Missed?
Jo Monsen, Norway
- EP.12.60** Multiple Primary Lung Cancer with Driver Gene Mutations: Is Targeted Therapy Always the Optimal Choice?
Zi-Rui Ren, China
- EP.12.61** Prognostic-Predictive Modeling in Advanced Non-small Cell Lung Cancer: A Review of Biomarkers Using AI, ML and DL
Saqib Khan, Canada
- EP.12.62** Identification of Optimal Candidates for the FLAURA2 Regimen in EGFR-Mutated NSCLC Based on PFS2 Analysis
Yuya Murase, Japan
- EP.12.63** Combining Chemotherapy with Osimertinib Beyond Progression in EGFR-Mutant NSCLC: A Case-Based Experience Combining Chemotherapy and Osimertinib Beyond Progression in EGFR-Mutant NSCLC: A Case-Based Experience
Ana Cardeña-Gutiérrez, Spain

- EP.12.64** Real-World Effectiveness of First-Line Osimertinib in EGFR-Mutated NSCLC: Interim Results From the French POSITHES Study
Florian Guisier, France
- EP.12.65** Factors Impacting Targeted Therapy Use in Stage IV Non-Small Cell Lung Cancer Patients With Infrequent Actionable Mutations
Mike Gart, USA

TRACK 13: SMALL CELL LUNG CANCER AND NEUROENDOCRINE TUMORS

- EP.13.01** Survival Analysis of Malignant Pleural Effusion in Small Cell Lung Cancer: A Single-Center Retrospective Analysis
Ping Zhan, China
- EP.13.02** Incidence and Characteristics of Small Cell Lung Cancer at the National Respiratory Center of Persahabatan Hospital, Indonesia in 2023-2024
Kiki Widyastuti, Indonesia
- EP.13.03** A Single-Center Experience with Tarlatamab in Relapsed/Refractory Advanced Small Cell Lung Cancer and Neuroendocrine Carcinomas
Yunan Nie, USA
- EP.13.04** Patients with Limited Stage Small Cell Lung Cancer Detected Through Lung Cancer Screening May Have Improved Survival
Juhi Gor, USA
- EP.13.05** Twice Daily Hyperfractionated vs Once Daily Normofractionated Chemo-Radiotherapy in LS-SCLC: A Monocentric Experience
Anna Cappelli, Italy
- EP.13.06** Immunotherapy for ES-SCLC Comorbid with COPD: A Real-World Retrospective Study
Ping Zhan, China
- EP.13.07** Association of Gut Microbiota and Metabolites with Thalidomide-Induced Antiemetic Efficacy in Small Cell Lung Cancer Patients
Qiang-Guo Sun, China
- EP.13.08** Early Hospitalization During Chemoradiation for Limited-Stage Small Cell Cancer Is Associated with Inferior Survival
David Billing, USA
- EP.13.09** Neoadjuvant Chemoimmunotherapy Versus Chemotherapy for LS-SCLC
Liwei Yang, China
- EP.13.10** Superior Vena Cava Syndrome in Extensive Stage (ES)-SCLC: A Marker of Aggressive Disease but Also a Window for Achieving Prolonged Survival?
Matteo Fila, Italy
- EP.13.11** Real-World Survival Data Over 25 Years in Extensive-Stage Small-Cell Lung Cancer: The Impact of Immune Checkpoint Inhibitors
Ryo Ariyasu, Japan
- EP.13.12** A Retrospective Study of the Efficacy of Chemoimmunotherapy for Extended-Stage Small Cell Lung Cancer in Elderly Patients
Yoshihiro Taguchi, Japan
- EP.13.13** Treatment Outcome in Limited Stage Small Cell Lung Cancer: National Retrospective Study
Martina Vrankar, Slovenia
- EP.13.14** Real-World Data Analysis of Treatment Pattern and Prognosis of Patients with Limited-Stage Small Cell Lung Cancer in Japan
Seiji Niho, Japan
- EP.13.15** Outcome and Safety of Lurbinectedin as Compassionate Use in SCLC: A Retrospective Multicentric International Study
Daniela Scattolin, Italy
- EP.13.16** Safety and Efficacy of Chemoimmunotherapy in Stage IV Small Cell Lung Cancer: A Single-Center Retrospective Analysis
Arne Peeters, Belgium

- EP.13.17** Efficacy of First-Line Chemoimmunotherapy with Durvalumab or Atezolizumab in SCLC - Experiences from Practice of Two Polish Oncology Centers
Aleksandra Lomza-Laba, Poland
- EP.13.18** Retrospective Evaluation of the Prognostic Impact of Anti-PD-L1 Antibodies in ECOG-PS 2-3 Patients with Extensive-Stage SCLC
Kosuke Sakai, Japan
- EP.13.19** 30-Year Review of Real-World Outcomes in Small Cell Lung Cancer at Hospital Clinic of Barcelona
Luisa Delgado, Spain
- EP.13.20** Stereotactic Body Radiotherapy for Limited-Stage Small Cell Lung Cancer: Outcomes from a Single-Institution Retrospective Study
João Basílio, Portugal
- EP.13.21** Extended Follow-Up of First-Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: Real-World Multicenter Study
Yechan Song, Republic of Korea
- EP.13.22** Survival and Treatment Patterns in Limited Disease-SCLC: Real World Data from the Swedish National Lung Cancer Registry
Johan Isaksson, Sweden
- EP.13.23** Tiselimab Plus Sitravatinib or Anlotinib as Maintenance Therapy in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Yun Fan, China
- EP.13.24** ES-SCLC Outcomes Following SBRT and/or Thoracic Consolidation After Induction Systemic Therapy
Helen Gandler, USA
- EP.13.25** Real-World Treatment Patterns in ES-SCLC Highlight Continued Unmet Medical Need in the Era of New Therapies: ESSENCE Study
Helen Ross, USA
- EP.13.26** Gut Microbiota and Metabolites as Potential Biomarkers for Immunotherapy Efficacy in Patients with Extensive-Stage Small Cell Lung Cancer
Meixi Lin, China
- EP.13.27** Co-Targeting SFKs and DNA Damaging Chemotherapy Drugs as a Novel Therapeutic Strategy in SCLC
Nerea Otegui, Spain
- EP.13.28** Assessment of Clinical Characteristics and Outcomes of Brazilian ES-SCLC Patients on First Line Durvalumab + Chemotherapy
Mauro Zukin, Brazil
- EP.13.29** Safety and Efficacy of DLL3 CAR-T Cells Armored With dnTGFBR2 in a Patient with Recurrent Small Cell Lung Cancer
Zhonglin Hao, USA
- EP.13.30** Real-World Analysis of Treatment Patterns in Limited-Stage Small Cell Lung Cancer: Implications for Clinical Practice
Yan Xu, China
- EP.13.32** Multi-Institutional Real-World Experience of Early Tarlatamab-Related Toxicities for Extensive Stage Small Cell Lung Cancer
Estelamari Rodriguez, USA
- EP.13.33** Treatment Timeliness and Impact on Survival in Extensive Stage Small Cell Lung Cancer
Tom John, Australia
- EP.13.34** Meta-Analysis of First-Line Immunochemotherapy in ES-SCLC: Does ECOG PS =2 Affect Survival Outcomes
Xinmin Yu, China
- EP.13.35** Sequential Atezolizumab Regimens (Chemo Followed by Anlotinib) for ES-SCLC: Real-World Data
Xiaojun Qian, China

- EP.13.36** Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer
Letong Yang, China
- EP.13.37** Immunotherapy Plus Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials
Chia Ching Lee, Singapore
- EP.13.38** Real-World Comparison of Carboplatin-Etoposide vs Cisplatin-Etoposide in ES-SCLC
Deepro Chowdhury, Canada
- EP.13.39** Factors Associated with Refusal of Chemoradiotherapy in Stage I-III Small Cell Lung Cancer and Their Effect on Survival
Yagni Patel, USA
- EP.13.40** Trial of Chemotherapy in Patients with Relapsed Small Cell Lung Cancer Combined with Allopurinol and Mycophenolate (CLAMP)
Brendan Knapp, USA
- EP.13.41** Expression of PD-L1 and Alternative Immune Checkpoints (ICs) and Their Impact on Outcomes in Small Cell Lung Cancer (SCLC)
Mumtu Lalla, USA
- EP.13.42** Self-Oxygenating PROTAC Microneedles for Spatiotemporally-Tunable Protein Degradation and Enhanced Small Cell Lung Cancer Therapy
Meng Hou, China
- EP.13.43** The Prognostic Factors Related with the Organ Specific Metastasis on Survival in ES-SCLC; TROD 08-16 Study
Serap Akyurek, Turkey
- EP.13.44** Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Neuroendocrine Neoplasms of the Lung (NEN-L)
Haichuan Hu, USA
- EP.13.45** Efficacy and Prognostic Significance of Immunotherapy in Postoperative Recurrent and Advanced Large Cell Neuroendocrine Carcinoma
Hua Zhong, China
- EP.13.46** Novel Prognostic Markers in Pulmonary Neuroendocrine Tumors (Carcinoid Tumors)
Somagattu Sushmitha, India
- EP.13.47** The Subtle Signals of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): A Clinical Characterization
Catherine Meador, USA
- EP.13.48** Natural Killer (NK) Cell Heterogeneity in Small Cell Lung Cancer: Implications for Chemo-Immunotherapy Response
Caterina De Rosa, Italy
- EP.13.49** Prognosis of Perioperative Therapy in Primary Limited-Stage Small-Cell Lung Cancer
Geyun Chang, China

TRACK 14: MESOTHELIOMA, THYMOMA, AND OTHER THORACIC TUMORS

- EP.14.01** Chemotherapy Plus Bevacizumab and Immunotherapy Prolonged the Survival of Unresectable Malignant Mesothelioma Patients in First-Line
Yuyan Wang, China
- EP.14.02** Overall Survival and PD-L1 Expression Analysis of Patients with Pulmonary Mesothelioma
Yoko Yonemori, Japan
- EP.14.03** Glutamine Dependency of Pleural Mesothelioma
Silvia Plans Marin, Spain
- EP.14.04** Mapping the Pleural Mesothelioma: Incidence, Treatment Patterns and Outcomes from Endemic Pocket in Southern Rajasthan, India
Ashish Jakhetiya, India

- EP.14.05** Predictive Factors of Postoperative Long-Term Survival in Patient with Pleural Mesothelioma
Masaki Hashimoto, Japan
- EP.14.06** Survival Analysis in Malignant Pleural Mesothelioma
Heves Sürmeli, Turkey
- EP.14.07** Applying Multi Criteria Decision Analysis in Health Care Decision Making in Egypt
Ahmed Nagy, Egypt
- EP.14.08** Gender Difference as a Prognostic Factor in Non-Epithelioid Pleural Mesothelioma: Survival Analysis in the Retrospective SONET Study
Federica Grosso, Italy
- EP.14.09** Comparison Between Epithelioid Type and Biphasic Type in Pleurectomy/Decortication for Pleural Mesothelioma
Kazunori Okabe, Japan
- EP.14.10** Role of CT Assessed in the Evaluation of Sarcopenia in Patient with Malignant Pleural Mesothelioma. Results From an Observational Study
Federica Grosso, Italy
- EP.14.11** Comparison of Short Term Surgical Outcomes for Thymectomy with Various Minimally Invasive Approaches: A Single Center Experience
Yohan Bae, Republic of Korea
- EP.14.12** Immune Profiles and Clinicopathological Insights in Thymomas: A Comprehensive Analysis
Ashmita Sukla, India
- EP.14.13** Utility of Visual Assessment of PET/CT for Differentiating Malignancy in Thymic Epithelial Tumors
Momoko Asami, Japan
- EP.14.14** Cyclophosphamide/Pegylated Liposomal Doxorubicin/Cisplatin as First-Line Treatment for Patients with Advanced Thymic Epithelial Tumors
Ying Liang, China
- EP.14.15** Patterns of Failure and Long-Term Outcomes in Patients with Thymoma Treated with Surgery and Radiation Therapy
Oded Icht, Canada
- EP.14.16** Clinical Characteristics, Surgical Risks, and Long-Term Prognosis of Good's Syndrome: A Retrospective Analysis of 108 Thymoma Cases
Shinya Otsuka, Japan
- EP.14.17** Clinical Outcomes of Patients with Advanced Thymic Malignancies Treated with Carboplatin/Pemetrexed Vs. Pemetrexed Alone
Melina Marmarelis, USA
- EP.14.18** Post-Thymectomy Myasthenia Gravis: A Multicenter Retrospective Study on Clinical Characteristics and Outcomes
Francesco Guerrera, Italy
- EP.14.19** A Single Institution Retrospective Analysis of Mediastinal Tumor Resections Utilizing Robotic-Assisted Surgery
Yuichiro Ueda, Japan
- EP.14.20** Whole-Exome Sequencing Study of Thymic Epithelial Tumors
Wen Gao, China
- EP.14.21** Real-World Clinical Outcomes of Patients with Masaoka Stage Iv Thymic Carcinoma Treated with Carboplatin and Paclitaxel
Mikako Nakamura, Japan
- EP.14.22** Intrathoracic Radiotherapy in the Treatment of Human Papillomavirus-Associated Head and Neck Squamous Cell Carcinoma Metastases
Jennifer Ma, USA
- EP.14.23** Distinct Mechanical Responses in PSP Reveal AKT1 Mutation and Mechanical Tension Synergy in EMT
Xichun Qin, China

- EP.14.24** Report of Four Cases of Primary Pulmonary Sarcoma Experienced at Our Hospital
Yoshiyuki Mishina, Japan
- EP.14.25** The Initial Outcome of Single Port Robotic Surgery for Mediastinal Tumors With 16 Cases
Daisuke Ito, Japan
- EP.14.26** Novel Bioengineered Drugs with Immunotherapies for Malignant Pleural Effusion
Ping Zhan, China
- EP.14.27** mTOR Inhibitor as Treatment in Pulmonary Epithelioid Hemangioendothelioma, a Case Series
Rene Letelier Farias, Chile
- EP.14.28** Three-Dimensional Reconstruction of the Sternum: A Novel Approach for Improved Surgical Outcomes
Ashish Jakhetiya, India
- EP.14.29** A Case Study of Multiple Nodular Lesions in the Anterior Mediastinum Detected on Preoperative Imaging
Keisuke Fujimoto, Japan
- EP.14.30** Clinicopathological Features and Diagnostic Challenges of Pulmonary Lymphoma: A Retrospective Review of 21 Cases
Tae-Jung Kim, Republic of Korea
- EP.14.31** Incidence Trends and Survival Outcomes of Pulmonary Langerhans Cell Histiocytosis: A National Cancer Study Using SEER
Janani Arunachalam, USA

TRACK 15: MULTIDISCIPLINARY CARE: NURSING, ALLIED HEALTH AND PALLIATIVE CARE

- EP.15.01** Anorexia, an Underreported Adverse Event, Predicts Mortality in Lung Cancer Patients
Aline Barreto, Brazil
- EP.15.02** Therapeutic Efficacy of Traditional Chinese Medicine Heat Patch Therapy for People with Lung Cancer
Ya-Ning Chang, China
- EP.15.03** Why Are Patients with Non-small Cell Lung Cancer in Stage I-IIIa Considered Inoperable? A Registry Study from Denmark
Thomas Budolfson, Denmark
- EP.15.04** Lung Function Before and After Development of Checkpoint Inhibitor Pneumonitis: Insights for Risk Assessment and Recovery
Senthuran Shivakumar, Australia
- EP.15.05** Wearable Devices and ePROs for Perioperative Continuous Monitoring in Thoracic Surgery
Qui Zhong, China
- EP.15.06** Bridging the Gap: Co-Designing Tools to Improve Equity in Lung Cancer Screening Care Pathways
Ambreen Sayani, Canada
- EP.15.07** Living with Lung Cancer-A Qualitative Exploration of Its Psychosocial Impact
Tanvi Reddy, India
- EP.15.08** The Lived Experience of Dyspnea and Quality of Life Before and After Lung-Sparing Surgery
Melissa Culligan, USA
- EP.15.09** Clinical Decision Flowchart for Optimizing the Use of EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: Real-World Data
Gisele Fraga, Brazil
- EP.15.10** Do Enhanced Recovery After Lung Cancer Surgery Programs Risk Putting Primacy of Caring at Stake?
Malene Missel, Denmark

- EP.15.11** Patterns of Care and Outcomes in Patients with Advanced Lung Cancer in a Hospital Palliative Care Unit: A Single-Center Retrospective Study
Rita Leporati, Italy
- EP.15.12** Virtual Personalized Exercise Program for Subjects with Lung Cancer: A Feasibility Study
Melissa Neumann, USA
- EP.15.13** Pilot Study of Exercise Program and Monitoring by a Lung Cancer Patient Navigator During Chemoradiotherapy for Stage III Lung Cancer
Puey Ling Chia, Singapore
- EP.15.14** Empowering Lung Cancer Care: The Role of AI Chatbots to Promote Exercise Oncology
Tindara Franchina, Italy
- EP.15.15** Lived Experiences and Needs of People Living Long-Term with Metastatic Non-small Cell Cancer: A Qualitative Study
Robin Urquhart, Canada
- EP.15.16** Patient's Understanding of Follow-Up Post Curative Primary Lung Cancer Surgery
Peter Barton, UK
- EP.15.17** The Role of Pneumonia in Mortality Among Hospitalized Patients with Advanced Lung Cancer
Xiaofang Gao, China
- EP.15.18** Characteristics and Clinical Outcomes of Hispanic Patients with Thoracic Malignancies Requiring ICU Admission: A Single Center Experience
Stella Isabel Martinez Jaramillo, Colombia
- EP.15.19** Patients with Advanced-Stage Lung Cancer in Intensive Care Unit, a Retrospective Observational Study Assessing Their Prognosis
Sebahat Ocak, Belgium

TRACK 16: PATIENT ADVOCACY

- EP.16.01** Is Follow Up for Lung Cancer Surgery Evidence Based Within the UK - a Critical Review of Protocols
Peter Barton, UK
- EP.16.02** Lung Cancer Patients' Involvement and Support Preferences and Needs: Insights from a Global Patient Experience Survey
Karen Clayton, UK
- EP.16.03** Characterization of a Real-World Data Set of EGFR+ NSCLC Patients
Brittney Nichols, USA
- EP.16.04** Relationship Between Telomere Length and Pulmonary Toxicity in Patients with Locally Advanced Unresectable Lung Cancer
Alfredo Marín-Muñiz, Spain
- EP.16.05** Expectations and Quality of Life of Lung Cancer Patients During the Care Process
Erika Pataki, Hungary
- EP.16.06** Health Literacy Leads to Health Equity; a Best Practice Approach from a Lung Cancer Organization
Maureen Rigney, USA
- EP.16.07** Addressing Unmet Needs of the Lung Cancer Community: The Journey to Find and Implement Mind Over Matter
Maureen Rigney, USA
- EP.16.08** Preliminary Study of Culturally Adapted Approaches to Enhance Lung Cancer Education for Hispanic/Latino Populations
Matthew Reiss, USA

TRACK 17: GLOBAL HEALTH, HEALTH SERVICES, AND HEALTH ECONOMICS

- EP.17.01** Identifying Barriers to Timely Initiation of Oral Anti-Cancer Medication in Patients with Non-small Cell Lung Cancer
Courtney Granville, USA
- EP.17.02** Treatment and Survival Outcomes for Indigenous Australians Within the Victorian Lung Cancer Registry
Louis Irving, Australia
- EP.17.03** Disparities in Lung Cancer Treatment for Older Adults
Roshni Kailar, USA
- EP.17.04** Social Vulnerability as a Determinant of Disparities in Lung Cancer Management and Survival
Priscila Berenice Costa, Brazil
- EP.17.05** Association of Social Vulnerability with Prognosis of Lung Cancer in Japan
Yoshitaka Seki, Japan
- EP.17.06** Evolving Trends in Lung Cancer Epidemiology in India: A Shift in Patterns and Clinical Insights
Ulhas Batra, India
- EP.17.07** Using COM-B Behavioural Change Framework to Implement Lung Cancer Pathway for Primary Care Physicians
Zulfiquer Otty, Australia
- EP.17.08** Ready or Not: Assessing Provider and Facility Preparedness for Bispecific Therapy in Extensive Stage-Small Cell Lung Cancer
Joelle Fathi, USA
- EP.17.09** Pulmonary Nodule Burden in Melbourne: A Snapshot Pre-Australian Lung Cancer Screening Rollout
Chui Lyn Leong, Australia
- EP.17.10** Opportunities and Challenges of Lung Cancer Diagnosis, Care and Treatment in Western Kenya
Atundo Murunga, Kenya
- EP.17.11** Integrating Prevention and Screening of Tobacco-Related Diseases Including Lung Cancer Screening: Results of a Pilot Program
Maya Lemonnier, France
- EP.17.12** Utility of CT Scans & Blood Tests After Maintenance Durvalumab Post Chemort in Stage III NSCLC Patients
Amelia Muñoz-Lerma, Spain
- EP.17.13** Healthcare Professionals' Perceived Barriers and Facilitators of Risk-Stratified Follow-Up Care in Lung Cancer
Nadia Moss, Netherlands
- EP.17.14** Concordance Between Clinical and Radiological Diagnoses of Pneumonitis: Retrospective Cohort Review from Regional Health Service in Australia
Divyanshu Dua, Australia
- EP.17.15** Tackling the Lung Cancer Crisis in Canada: Co-Creating a National Strategy to Reduce Lung Cancer Mortality by 30% Action Plan?
Christian Finley, Canada
- EP.17.16** Improved Concordance to Clinical Practice Guideline: Analysis Of Multidisciplinary Team Discussed Patients with Stage III Lung Cancer
Xinghua Cheng, China
- EP.17.17** Availability of PD-L1 and NGS Results at Initial Medical Oncology Consultation in Patients with Non-small Cell Lung Cancer
Jacqueline Martin, Canada
- EP.17.18** Refining Lung Cancer Diagnosis Through Multidisciplinary Team Collaboration
Xiaojuan Zhang, China

- EP.17.19** Quality Control and Analysis of Standardized Diagnosis and Treatment of Lung Cancer
Zhen He, China
- EP.17.20** Natural Language Processing in Rapid Evaluation of Suspicious Lung Findings: Impact on Lung Cancer Outcomes
Elizabeth Dudnik, Israel
- EP.17.21** A Digital Health Solution for Monitoring Pulmonary Symptoms in Cancer Treatment
Garry Beran, UK
- EP.17.22** The Burden of Lung Cancer in Nigeria's Capital City: Findings from the Population Based Cancer Registry
Victoria Igbinomwanhia, Nigeria
- EP.17.23** Demographic Profile and Patient Journey of Early-Stage NSCLC Patients in a Brazilian Public Reference Center: A Real-World Study
Ricardo Terra, Brazil
- EP.17.24** Clinicopathological Features of Lung Cancer: A Study from a Tertiaryreferral Center in Georgia
Anna Geguchadze, Georgia
- EP.17.25** The Transition of Treatment Choice for First-Line Treatment for Advanced or Recurrent NSCLC and the Patients' Characteristics
Yuki Akazawa, Japan
- EP.17.26** Survival in Advanced NSCLC Patients With PD-L1 =50% Treated with ICIs: A Multicenter, Retrospective Real-World Study in Georgia
Ana Tsereteli, Georgia
- EP.17.27** Real-World Impact on Overall Survival of High-Cost Targeted and Immunotherapies in Lung Cancer Patients Under Chile's DAC Program
Rene Letelier Farias, Chile
- EP.17.28** Duration of Systemic Therapy in Patients with Metastatic EGFR-Mutated NSCLC and Brain Metastases: First vs Third Generation TKIs
Alex Louie, Canada
- EP.17.29** Real-World Effectiveness of Immunotherapy for Advanced Non-small Cell Lung Cancer (NSCLC) Without Oncogenic Driver Alteration
Chulamas Horugsa, Thailand
- EP.17.30** Rising Incidence of Early Onset Thoracic Malignant Tumors: Real-World Data from Two Hospitals in Brazil
Beatriz Miyamura, Brazil
- EP.17.31** Temporal Trends and Prognostic Factors in Lung Cancer Patients: Analysis Of a 25-Year Cohort of 2,488 Cases
Bruna Rezende, Brazil
- EP.17.32** Real-World Disease Impact in First-Line Treated Patients with Advanced Non-small Cell Lung Cancer With PD-L1 Expression =50%
Dwight H. Owen, USA
- EP.17.33** Evolving Treatment Patterns in Early-Stage Non-small Cell Lung Cancer in the USA
Jhanelle Gray, USA
- EP.17.34** Real-World Survival Outcomes in Non-small Cell Lung Cancer: Insights from UK Ehr-Derived Data
Amit Samani, UK
- EP.17.35** Treatment-Associated Interstitial Lung Disease in Extensive-Stage Small Cell Lung Cancer
Gregory Calip, USA
- EP.17.36** Disparities in Survival Outcomes of Primary Pulmonary Diffuse Large B-Cell Lymphoma: A SEER Database Analysis
Janani Arunachalam, USA
- EP.17.37** Assessing the Hidden Risk From 1990-2021: Radon-Attributable TBL Cancer Burden Across the European Union
Joy Doshi, UK

- EP.17.38** Intersecting Determinants of NSCLC Outcomes in Brazil: The Roles of Histology, Socioeconomic Status, and Healthcare Sector Disparities
Fabio Ynoe de Moraes, Canada
- EP.17.39** Carbon Footprint of Lung Cancer Management and Impact of Lung Cancer Screening Implementation
Valentin Héluain, France

IT'S NOT A RACE. IT'S A CAUSE.

The Backyard Steps Experience


A charitable initiative from The Ricky Rubio Foundation during the IASLC World Conference on Lung Cancer.



LET'S CLIMB THE STAIRS OF
MONTJUÏC TOGETHER!

Where?
Montjuïc Main Stairs
Barcelona

When?
September 7, 2025
18:00 – 20:30



Bus transfers will be provided at **18:00** from the following pick up points:

18:00 **FIRA Gran Via, North Entrance, Hall 8**

(Meeting Point: Wellness Challenge Counter, Registration Area, Ground Floor)

18:00 **Hotel Porta Fira**

18:00 **Hotel Melia Sarria**


18:00 **Hotel Nobu**

18:00 **INNSIDE Barcelona Apolo**

Return transfers to above listed points will be provided (except FIRA Gran Via).

For more information, please visit: therickyrubiofoundation.org/reto-backyard/#K18

DOWNLOAD THE
**IASLC WELLNESS
CHALLENGE APP**
TO PARTICIPATE



07

GENERAL INFORMATION

IASLC 2025 WORLD CONFERENCE ON LUNG CANCER
CONQUERING LUNG AND OTHER THORACIC CANCERS WORLDWIDE IN THE 21ST CENTURY.

The Exhibit Hall is located at Hall 8.1 on the first floor.

EXHIBIT HALL FEATURES

- ✓ Delegate Lounges
- ✓ IASLC Lounges & Booth
- ✓ Podcast Studio
- ✓ Meeting Pods
- ✓ Exhibitor Lounge
- ✓ Food & Beverage (F&B)
- ✓ Poster Tours and ePoster Lounge



Exhibitors By Name

1Cell.Ai	421	British Thoracic Oncology Group (BTOG)	Tabletop #6
AbbVie Oncology	103	Caris Life Sciences	107
Accord Healthcare	419	Catalyst Pharmaceuticals, Inc.	408
AEACaP Asociación Española de Afectados de Cáncer de Pulmón	Tabletop #2	Daiichi Sankyo, Inc.	102
ALCMI	Tabletop #1	Eli Lilly and Company	402
American Association For Cancer Research (AACR)	108	Genmab	304
Amgen	403	Gilead Oncology	305
Annalise.ai	210	Global Lung Cancer Coalition	Tabletop #5
AstraZeneca	303	Gradient Bioconvergence (GBCC)	411
Bayer	203	IASLC	101
BioNTech	106	ImmunityBio	209
Boehringer Ingelheim	301	Japan Lung Cancer Society (JLCS)	Tabletop #3
Bristol Myers Squibb	409		

Johnson & Johnson	302	Pfizer Oncology	202
KRAS Kickers	Tabletop #3	PharmaMar	406
Median Technologies	420	Predicine	105
Miconvey	412	Qure.ai	206
MSD	401	Regeneron	425
Natera	207	Revolution Medicines	104
National Comprehensive Cancer Network (NCCN)	Tabletop #4	Roche	404
Nuvalent, Inc.	413	Scanlan International	423
Nuvation Bio	201	Summit Therapeutics	204
Oncology Frontier 肿瘤瞭望	211	Takeda	405
Oncoscope-AI	407	The Ricky Rubio Foundation	Tabletop #7
Personalis, Inc.	424	The White Ribbon Project	Tabletop #8
PExA AB	212	Thermo Fisher Scientific	205

Exhibitors By Booth Number

IASLC	101	Roche	404
Daiichi Sankyo, Inc.	102	Takeda	405
AbbVie Oncology	103	PharmaMar	406
Revolution Medicines	104	Oncoscope-AI	407
Predicine	105	Catalyst Pharmaceuticals, Inc.	408
BioNTech	106	Bristol Myers Squibb	409
Caris Life Sciences	107	Gradient Bioconvergence (GBCC)	411
American Association For Cancer Research (AACR)	108	Miconvey	412
Nuvation Bio	201	Nuvalent, Inc.	413
Pfizer Oncology	202	Accord Healthcare	419
Bayer	203	Median Technologies	420
Summit Therapeutics	204	1Cell.Ai	421
Thermo Fisher Scientific	205	Scanlan International	423
Qure.ai	206	Personalis, Inc.	424
Natera	207	Regeneron	425
ImmunityBio	209	ALCMI	Tabletop #1
Annalise.ai	210	AEACaP Asociación Española de Afectados de Cáncer de Pulmón	Tabletop #2
Oncology Frontier 肿瘤瞭望	211	KRAS Kickers	Tabletop #3
PExA AB	212	National Comprehensive Cancer Network (NCCN)	Tabletop #4
Boehringer Ingelheim	301	Global Lung Cancer Coalition	Tabletop #5
Johnson & Johnson	302	British Thoracic Oncology Group (BTOG)	Tabletop #6
AstraZeneca	303	The Ricky Rubio Foundation	Tabletop #7
Genmab	304	The White Ribbon Project	Tabletop #8
Gilead Oncology	305	Japan Lung Cancer Society (JLCS)	Tabletop #9
MSD	401		
Eli Lilly and Company	402		
Amgen	403		

Thank You TO ALL WCLC 2025 CONFERENCE SUPPORTERS

DIAMOND LEVEL



Johnson & Johnson

GOLD LEVEL



SILVER LEVEL



REGENERON®



BRONZE LEVEL



Conference App Supporter – Nuvalent

Connecting Changemakers Lounge – Merck Healthcare

Driving Discovery Lounge – Roche

Patient Advocacy Lounge Supporter – Johnson & Johnson

Podcast Onsite Studio Supporter – Merck Healthcare

Poster Session Supporter – Johnson & Johnson

BOOTH 421



1Cell.Ai, based in Foster City, California, is at the forefront of precision oncology, driving personalized cancer therapy with its innovative single cell multi-omics platform combining cutting-edge molecular science with advanced AI technology. This platform delivers real-time information allowing for the comprehensive analysis of individual cancer cells across multiple molecular levels, including genomics, transcriptomics, proteomics, and epigenomics. This technology provides deep insights into tumor heterogeneity, enabling the identification of rare cell populations that may drive metastasis or resistance to therapy, and tailoring treatments to improve patient outcomes.

1cell.ai

BOOTH 103



At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various targeted treatment modalities including Antibody Drug Conjugates (ADCs), Immuno-Oncology, bi-specific/multi-specific antibody, and CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

abbvie.com/oncology

BOOTH 419



Headquartered in the United Kingdom, Accord Healthcare is a fast-growing global pharmaceutical company that develops, manufactures and distributes medicines in over 85 countries worldwide, helping to improve access for patients to vital pharmaceutical care. Our approach is agile and inventive, we're driven to think differently by continuing to explore and deliver high quality medicines designed to benefit patients' lives worldwide.

accord-healthcare.com

TABLETOP #2



The Spanish Association of Lung Cancer Patients (Asociación Española de Afectados de Cáncer de Pulmón AEACaP) is a non-profit organization established in December 2008 to support individuals diagnosed with lung cancer. As Spain's sole association dedicated exclusively to this disease, AEACaP offers free psychological support, legal advice, and guidance on medical consultations to patients and their families. The organization also promotes research to improve treatment options and quality of life, conducts informational activities to raise awareness, and advocates for equal access to healthcare services across all regions.

afectadoscancerdepulmon.com

TABLETOP #1



ALCMI is a nonprofit international consortium comprised of 25 of the world's premier oncology research institutions. We partner with the top minds from the most respected medical facilities, providing financial support and access to a team of experts and staff to assist in launching and managing investigator-initiated trials. We bridge the gap between clinical research organizations (CROs) and site management organizations (SMOs), resulting in a streamlined, agile process for quickly funding and initiating lung cancer research projects.

alcmi.org

BOOTH 108



The mission of the American Association for Cancer Research (AACR) is to prevent and cure cancer through: Research, Education, Communication, Collaboration, Science Policy and Advocacy, and Funding for Cancer Research. Through its programs and services, the AACR fosters research in cancer and related biomedical science, accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer, promotes science education and training, and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

aacr.org

BOOTH 403



Amgen harnesses the best of biology and technology to make people's lives easier, fuller and longer. We draw upon our deep knowledge of science to push beyond what's known today. With roots in the biotech revolution, we are one of the world's leading independent biotech companies.

amgen.com

BOOTH 210



Annalise.ai, Harrison.ai's radiology AI solution, empowers clinicians to deliver more accurate and efficient radiology results throughout the imaging workflow. The comprehensive AI solutions detect up to 124 findings on chest X-rays and up to 130 findings on non-contrast head CT scans and can be customised for a wide range of care settings. The solutions are clinically available in 40+ countries and deployed at 1,000+ sites in Australia, APAC, US, UK, EU and the Middle-East. Their CT Chest solution will be launching in Europe in 2026.

annalise.ai

BOOTH 303



AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to deliver life-changing medicines to patients. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

astrazeneca.co.uk

BOOTH 203



Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. The oncology franchise includes both marketed products and clinical development compounds, which reflect the company's approach to research: prioritizing targets and pathways with the potential to impact the way that cancer is treated.

bayer.com

BOOTH 106



BioNTech is a global immunotherapy company pioneering novel therapies for cancer. Its diversified oncology portfolio consists of complementary therapeutic modalities, including mRNA immunotherapies, next-gen immunomodulators and targeted therapies.

biontech.com/int/en/home.html

BOOTH 301



We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research.

boehringer-ingelheim.com

BOOTH 409



Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients' lives through science.

bms.com

TABLETOP #6



The British Thoracic Oncology Group (BTOG) is the multi-disciplinary group for healthcare professionals involved with thoracic malignancies throughout the UK. BTOG's mission is to support and educate thoracic oncology healthcare professionals, creating a professional community to exchange ideas, information, and innovation and to foster the development of research. The overall aim is to represent the needs of people with thoracic malignancies in the UK and ensure they have equitable access to optimal care. The vision is to contribute to achieving survival rates equal to the best in the world.

btog.org

BOOTH 107



Caris Life Sciences® is a leading next-generation AI TechBio company and precision medicine pioneer actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (DNA, RNA and proteins) and the application of AI and machine learning algorithms, Caris has created the large-scale, multi-modal database and computing capability needed to analyze and unravel the molecular complexity of disease.

carislifesciences.com

BOOTH 408



Catalyst is committed to developing and commercializing novel medicines for patients living with rare and difficult to treat neurological diseases.

catalystpharma.com

BOOTH 102



With more than 120 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 17,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.

daiichisankyo.com

BOOTH 402



Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.

lilly.com

BOOTH 304



Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer and other serious diseases. Genmab's proprietary pipeline includes bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

genmab.com

BOOTH 305



Gilead Oncology is working to transform how cancer is treated. We are innovating with next generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody drug conjugates and small molecules to cell therapy based approaches, we are creating new possibilities for people with cancer.

global.askgileadmedical.com

TABLETOP #5



The Global Lung Cancer Coalition promotes global understanding of the burden of lung cancer and the right of patients to effective early detection, better treatment and supportive care. Serving as the international voice of lung cancer patients, the Global Lung Cancer Coalition is committed to improving disease outcomes for all.

lungcancercoalition.org

BOOTH 411



Gradient Bioconvergence (GBCC) is an organization developing patient-derived cancer organoids (PDOs) in a global scale. We have built Asia's largest repository of PDOs with next-generation sequencing of over 700 models from patients with lung, gastric, colorectal, pancreas, and ovarian cancer. In addition, we are developing co-culture systems with autologous immune cells. Our PDO models are available for drug evaluation services. Based on our genomic and drug response data, we are discovering and validating novel oncology targets through our AI-driven target discovery and CRISPR-based PDO platform. Beyond cancer, GBCC has established brain organoids from hiPSCs for drug evaluation and disease modeling.

gradientbio.com

BOOTH 209



ImmunityBio develops therapies and vaccines to defeat cancers and infectious diseases, going beyond checkpoint inhibitors to bolster the immune system to deliver durable, safe protection. ANKTIVA® is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer, T- and memory T cells for long-duration response.

anktiva.com

TABLETOP #9



Founded in 1960, the Japan Lung Cancer Society (JLCS) is the largest professional organization in Japan devoted to lung cancer research, prevention, diagnosis, treatment, and advocacy. With more than 7,500 members, including physicians, researchers, and allied health professionals, the JLCS promotes multidisciplinary collaboration and advances science through annual meetings, educational programs, and publications. The society actively fosters international exchange—particularly with the IASLC and other global partners—to share knowledge and improve patient outcomes worldwide. The JLCS remains committed to reducing the burden of lung cancer and, ultimately, to realizing a world free from the disease.

haigan.gr.jp

BOOTH 302



At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

innovativemedicine.jnj.com/emea

TABLETOP #3



The KRAS Kickers mission is to connect people to current research, resources, and community to kick cancer's KRAS! KRAS kickers members engage with leading doctors, researchers, and advocates to learn about new developments and clinical trials, connect to resources, build community, and share their stories to give hope to all with a KRAS biomarker.

kraskickers.org

BOOTH 420



Pioneering innovative imaging services and Software as Medical Devices, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eYonis™, an AI/ML tech-based suite of software as medical devices (SaMD) for the early diagnosis of lung and liver cancers. Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies.

mediantechnologies.com

BOOTH 412



Miconvey Technologies Co., Ltd., guided by the mission of "All Efforts For Health", is a national high-tech enterprise specializing in minimally invasive surgical instruments. As a subsidiary of Hemony Pharmaceuticals Group, Miconvey has established a comprehensive system encompassing research & development, manufacturing, and sales. Its core products include ultrasonic scalpel systems, manual and powered staplers, and endoscopy. Miconvey's products have obtained multiple international certifications, including China NMPA, EU CE, U.S. FDA, and Korea KFDA, with a business footprint in over 50 countries and regions worldwide.

miconvey.com

BOOTH 401



At MSD, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, MSD is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.

msd.com

BOOTH 207



Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment response monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. Signatera is personalized and tumor-informed, providing each individual with a customized blood test, tailored to fit the unique signature of clonal mutations found in that individual's tumor. Signatera is intended to detect and quantify cancer left in the body, at levels down to a single tumor molecule in a tube of blood, to identify recurrence earlier and to help optimize treatment decisions.

natera.com/oncology

BOOTH 413



Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

nuvalent.com

BOOTH 201



Nuvation Bio is a late clinical-stage, global biopharmaceutical company focused on treating patients with the most difficult-to-treat cancers for which conventional therapies have failed.

nuvationbio.com

BOOTH 211



Oncology Frontier is a leading Chinese medical media platform dedicated to delivering timely, cutting-edge oncology updates worldwide. Covering around 100 international and domestic academic conferences annually, we conduct over 3,000 interviews with key opinion leaders. Our mission is to keep Chinese healthcare professionals informed of global advances in oncology by fostering academic exchange on latest research, innovative technology, and clinical practice between Chinese and international experts. At WCLC 2025, we will host MEET WCLC Daily Highlights Program to enhance awareness of Chinese research and engagement of Chinese oncologists in IASLC and the WCLC community.

ioncol.com

BOOTH 407



Oncoscope-AI is a comprehensive medical decision-support tool developed by a team of oncology scientists and AI experts. The software conducts daily Cochrane-level literature reviews supported by an agentic system of large language models, extracting 32 key variables from each relevant oncology publication into a structured database. 100% human reviewed and cross-checked, the results data are integrated with treatment paths from national guidelines and cross-linked with FDA and clinical trial registries. Designed for oncology professionals, the intuitive, interactive platform offers individual and institutional subscription options delivering real-time clinical data, empowering oncologists to make timely informed treatment decisions that improve patient outcomes.

oncoscope-ai.com

BOOTH 424



At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development.

personalis.com

BOOTH 212



PExA delivers a unique non-invasive sampling platform from the small airways, enabling biomarker discovery where lung diseases begin. Actively used by leading research groups in Lung Cancer studies, PEXA also offers strategic opportunities for pharma and diagnostic companies. Potential applications include early detection, screening, and supporting drug and diagnostic development.

pexa.se

BOOTH 202



Pfizer Oncology is at the forefront of a new era in cancer care. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives.

pfizer.com

BOOTH 406



PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

pharmamar.com

BOOTH 105



Predicine is a global molecular insights company committed to advancing precision medicine in oncology. Predicine is developing proprietary technologies for cfDNA and cfRNA liquid biopsy to enable minimally invasive molecular diagnoses for early cancer detection, treatment selection, therapy response, minimal residual disease monitoring, and disease progression. Predicine's portfolio includes blood, urine, tissue based NGS assays designed for globally harmonized use in clinical trial, companion diagnostic (CDx) development, and commercialization. Through its business operations in Silicon Valley, Houston, Chicago and Shanghai, Predicine is partnering and collaborating with leading biopharma companies, institutions, and governments to support personalized healthcare on a global scale.

predicine.com

BOOTH 206



Qure.ai is a health-tech company that uses Artificial Intelligence (AI) to make healthcare more accessible and equitable for patients worldwide. Our solutions power the efficient detection, measurement and tracking of Lung Cancer to support clinicians and hospital administrators. We empower healthcare by helping to diagnose conditions early, prioritize treatment planning and ultimately improve the quality of patient life.

qure.ai

BOOTH 425



Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and candidates in development. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, and through research initiatives such as the Regeneron Genetics Center.

regeneron.com

BOOTH 104



Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.

revmed.com

BOOTH 404



Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.

roche.com

BOOTH 423



Since 1921, the Scanlan family has been dedicated to hand-crafting the world's finest surgical instruments. Explore our Scanlan® LEGACY Needle Holders and Forceps, showcasing the revolutionary Scan-II™ handle design. Our comprehensive range includes Scanlan® VATS instruments such as D'Amico Clamps, Suctions, Biopsy Forceps, Gonzalez-Rivas Dissector, Rocco Nodule Clamps, and Khan Decortication Grasper. Join us on our continued journey of excellence in surgical solutions.

scanlaninternational.com

BOOTH 204



Summit is a biopharmaceutical oncology company focused on resolving serious unmet medical needs. Summit's compound, ivonescimab, is a novel, potential first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with anti-angiogenesis effects of anti-VEGF in a single molecule. Ivonescimab displays cooperative binding to these targets with increased avidity in the tumor microenvironment. Summit's Phase III NSCLC trials include HARMONi (enrolled: NCT06396065), HARMONi-3 (enrolling: NCT05899608), HARMONi-7 (enrolling: NCT06767514). Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China's NMPA.

smmttx.com

GENERAL INFORMATION Exhibitor Descriptions

BOOTH 405



At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. Our therapies for hematologic cancers and solid tumors have helped transform the treatment landscape for previously underserved patients. Building on this leadership, we are advancing a pipeline focused on the power of innate immunity. Our goal is to introduce new classes of immunotherapies that can lead to deep, durable responses so more patients can benefit from innovative medicines.

takedaoncology.com

TABLETOP #4



The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives.

nccn.org

TABLETOP #7



The Ricky Rubio Foundation is a non-profit organization dedicated to fighting lung cancer through awareness, research, and patient support. With 41/2002, we turn the law into a message: a clothing collection that raises awareness of every patient's right to molecular diagnosis. We also proudly join the Wellness Challenge to promote physical activity as a powerful ally in recovery and long-term wellbeing. Because personalized treatment starts with awareness—and movement.

therickyrubiofoundation.org

TABLETOP #8



The White Ribbon Project is a grassroots movement changing public perception of lung cancer by promoting the truth that anyone with lungs can get lung cancer. Founded by survivor Heidi Nafman-Onda and her husband Dr. Pierre Onda, it builds community, raises awareness, and advocates for issues important to the lung cancer community such as lung cancer screening, biomarker testing, and research funding. Thousands of handmade white ribbons have been shared worldwide to bring hope, connection, and urgency to this silent epidemic.

thewhiteribbonproject.org

BOOTH 205



Thermo Fisher Scientific is the world leader in serving science. We provide a comprehensive suite of solutions for precision oncology, spanning early development through commercial strategy, encompassing companion diagnostics. Our leading clinical research services enable customers to accelerate innovation and increase development productivity. Our advanced next-generation sequencing technology, OncoPrint™ Solutions, enables laboratories everywhere to deliver genomic profiling from solid tumors and hematological cancers in as little as one day.

thermofisher.com/oncoprint

IASLC



STEP IT UP FOR RESEARCH

IASLC WELLNESS CHALLENGE 2025

Barcelona

GREAT PRIZES AWAIT AND EVERY STEP COUNTS!

 Visit the Wellness Challenge Desk at Registration

DOWNLOAD THE IASLC
WELLNESS CHALLENGE
2025 APP



INDUSTRY SPONSORED SYMPOSIA

SATURDAY, SEPTEMBER 6, 2025

09:00 - 10:00 **IS01: INDUSTRY SPONSORED SYMPOSIUM BY ASTRAZENECA: PREPARING NSCLC FOR THE FUTURE OF DIAGNOSTIC BIOMARKER TESTING**

ROOM 04



LIVESTREAMED



SNACKS PROVIDED



NOT FOR CME CREDIT

Chair: Charu Aggarwal, USA

- 09:00** **Welcome and Introduction**
Charu Aggarwal, USA
- 09:05** **Where Are We Now? The Current State of Biomarker Testing in NSCLC**
Sandip Patel, USA
- 09:20** **Navigating the Emerging Biomarker Approaches in NSCLC**
Charu Aggarwal, USA
- 09:35** **Bridging the Gap: Multidisciplinary Strategies for Redefining Biomarker Testing**
Fernando Lopez-Rios, Spain
- 09:50** **Panel Discussion and Q&A**
All Faculty

09:00 - 10:00 **IS02: INDUSTRY SPONSORED SYMPOSIUM BY ELI LILLY AND COMPANY: PRECISION STARTS EARLY: THE EVOLVING ROLE OF BIOMARKER TESTING IN EARLY-STAGE NSCLC**

ROOM 05



LIVESTREAMED



SNACKS PROVIDED



NOT FOR CME CREDIT

Chair: Sonja Loges, Germany

- 09:00** **Welcome & Opening Remarks**
Sonja Loges, Germany
- 09:05** **The Clinical Impact of Comprehensive Biomarker Testing in Early-Stage NSCLC**
Sara Pilotto, Italy
- 09:20** **Implementing Comprehensive Biomarker Testing in Early-Stage NSCLC - Facing the Challenge**
Paul Hofman, France
- 09:35** **Panel Discussion and Q&A**
All Faculty
- 09:55** **Closing Remarks**
Sonja Loges, Germany

10:30 - 11:30 **ISO4: INDUSTRY SPONSORED SYMPOSIUM BY DAIICHI SANKYO AND MSD: EMPOWERING CLINICIANS IN SCLC MANAGEMENT: KEY INSIGHTS ON DIAGNOSIS, TREATMENT, AND EMERGING STRATEGIES**

ROOM 05



LIVESTREAMED



SNACKS PROVIDED



NOT FOR CME CREDIT

Chair: Antonio Calles, Spain

- 10:30** **Welcome and Introduction**
Antonio Calles, Spain
- 10:33** **Epidemiology, Risk Factors and Molecular Genetics of SCLC**
Antonio Calles, Spain
- 10:43** **Current Treatment Modalities and Challenges**
Alfredo Addeo, Switzerland
- 10:53** **Future Directions in SCLC Research**
Charles M Rudin, USA
- 11:03** **Open Discussions**
All Faculty
- 11:28** **Closing Remarks**
Antonio Calles, Spain

12:00 - 13:00 **IS05: INDUSTRY SPONSORED SYMPOSIUM BY ABBVIE: WHAT SEZ6 SAYS ABOUT SMALL CELL LUNG CANCER (SCLC) AND NEUROENDOCRINE NEOPLASMS (NENS)**

ROOM 04



LIVESTREAMED



LUNCH PROVIDED



NOT FOR CME CREDIT

Chair: Ernest Nadal, Spain

- 12:00** **Welcome and Introduction**
Ernest Nadal, Spain
- 12:05** **SEZ6 Lights the Way: A Lineage Marker in SCLC and NENS**
Daniel Morgensztern, USA
- 12:25** **Emerging Landscape of SEZ6-directed Therapeutics for SCLC and NENS**
Anne Chiang, USA
- 12:50** **Panel Discussion**
All Faculty

12:00 - 13:00 IS06: INDUSTRY SPONSORED SYMPOSIUM BY PFIZER:
SUSTAINED CLINICAL BENEFIT IN 1L ALK+ ANSCLC: HOW TO
OPTIMISE OUTCOMES FOR OUR PATIENTS

ROOM 05

Chair: Tony Mok, China

- 12:00** **Welcome and Introduction**
Tony Mok, China
- 12:03** **Achieving Sustained Clinical Benefit: Advances in the 1L ALK+ aNSCLC Treatment Landscape**
Tony Mok, China
- 12:19** **Patient Cases: Optimising Outcomes for Patients With ALK+ aNSCLC**
Justin Gainor, USA and Maria Rosario Campelo, Spain
- 12:49** **Patient Cases: Discussion and Q&A**
All Faculty
- 12:59** **Summary and Close**
Tony Mok, China

13:30 - 14:30 IS08: INDUSTRY SPONSORED SYMPOSIUM BY ACCORD
HEALTHCARE: RECENT DEVELOPMENTS IN THE FIRST-LINE
TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

ROOM 04

Chair: Simon Ekman, Sweden

- 13:30** **Introduction**
Simon Ekman, Sweden
- 13:38** **Existing Immune Checkpoint Inhibitors in ES-SCLC**
Silvia Novello, Italy
- 13:58** **New Immune Checkpoint Inhibitors in ES-SCLC**
Francesco Grossi, Italy
- 14:18** **Questions and Answers**
All Faculty
- 14:28** **Wrap-up**
Simon Ekman, Sweden

SATELLITE CME SYMPOSIA

SATURDAY, SEPTEMBER 6, 2025

10:30 - 11:30 IS03: SATELLITE EBAC/CME SYMPOSIUM BY ANSWERS IN CME
ON BEHALF OF DAIICHI SANKYO, INC.: RESHAPING THE
MANAGEMENT OF METASTATIC NSCLC: TACKLING HER2
OVEREXPRESSION TO ELEVATE OUTCOMES

ROOM 04

Panel: Raffaele Califano, UK, Nicolas Girard, France, Antonio Passaro, Italy

- 10:30** **Welcome and Introduction**
- 10:35** **STATE OF SCIENCE: Role of Biomarker Testing in NSCLC**
- 10:50** **FROM BENCH TO BEDSIDE: Efficacy of HER2-Directed ADCs for HER2-Overexpressing NSCLC**
- 11:05** **PRACTICAL CARE CONSIDERATIONS: Integrating HER2-Directed ADCs into Treatment Algorithms for HER2-Overexpressing NSCLC**
- 11:20** **Questions, Take-Home Learning and Evaluation**

13:30 - 14:30 IS07: SATELLITE EBAC/CME SYMPOSIUM BY PEERVOICE ON
BEHALF OF BAYER: PIONEERING PRECISION: A REAL-WORLD
ROADMAP TO OPTIMAL OUTCOMES IN NTRK FUSION-POSITIVE
AND HER2-MUTANT ADVANCED NSCLC

ROOM 05

Chair: Solange Peters, Switzerland

- 13:30** **Welcome and Introduction**
Solange Peters, Switzerland
- 13:35** **Patient Voices in Lung Cancer: Mapping Challenges, Unmet Needs, and the Path Forward**
Merel Hennink, Netherlands
- 13:45** **Precision Oncology Approaches in the Treatment of NTRK Fusion-Positive Advanced NSCLC to Optimize Clinical and Patient Outcomes**
Merel Hennink, Netherlands, Stephen Liu, USA
- 14:05** **Advancements in Clinical Research for HER2-Mutant Advanced NSCLC: Redefining Treatment Strategies with Targeted Therapy to Optimize Outcomes**
Merel Hennink, Netherlands, Stephen Liu, USA
- 14:25** **Closing Remarks & Conclusions**
Solange Peters, Switzerland

15:00 - 16:00 IS09: SATELLITE CME SYMPOSIUM BY PHYSICIANS' EDUCATION RESOURCE ON BEHALF OF SUMMIT THERAPEUTICS, INC.: A NEW ERA OF TARGETED THERAPY FOR ADVANCED NSCLC: EXPLORING FUTURE DIRECTIONS FOR BISPECIFIC ANTIBODIES AND ADCS

ROOM 04

LUNCH PROVIDED



ACCME ACCREDITED BY OTHER PROVIDER

Chair: Sandip Patel, USA

15:00 Program Introductions

Sandip Patel, USA

15:05 Unlocking the Potential of Biospecific Antibodies in Advanced NSCLC

Myung-Ju Ahn, Republic of Korea

15:40 Bracing for Impact: A New Wave of ADCs in NSCLC

Giannis Mountzios, Greece

15:55 Posttest Assessment and Concluding Remarks

Sandip Patel, USA

INDUSTRY SPONSORED SYMPOSIA

SUNDAY, SEPTEMBER 7, 2025

13:45 - 14:45 IS11: INDUSTRY SPONSORED SYMPOSIUM BY ASTRAZENECA: MAXIMISING A MULTIDISCIPLINARY APPROACH: SHAPING THE FUTURE OF LUNG CANCER CARE WITH IMMUNOTHERAPY

ROOM 04

LIVESTREAMED



LUNCH PROVIDED



NOT FOR CME CREDIT

Chair: Natasha Leighl, Canada

13:45 Welcome and Introductions

Natasha Leighl, Canada

13:48 Panel Discussion: Enhancing Outcomes in Early-Stage NSCLC and Limited-Stage SCLC Through MDT Collaboration

Natasha Leighl, Canada, Matthias Guckenberger, Switzerland, Erin Gillaspie, USA

14:25 Future Outlook for Metastatic NSCLC: Navigating the Evolving Treatment Landscape

Natasha Leighl, Canada

14:35 Q&A and Meeting Close

All Faculty

13:45 - 14:45 IS12: INDUSTRY SPONSORED SYMPOSIUM BY JOHNSON & JOHNSON: ADVANCING EGFR-MUTANT NSCLC CARE

ROOM 08

LIVESTREAMED



SNACKS PROVIDED



NOT FOR CME CREDIT

Chair: Luis Paz-Ares, Spain

13:45 Welcome and Introductions

Luis Paz-Ares, Spain

13:52 Treatment-Naïve Disease: Making the First Move

Sanjay Popat, UK

14:12 Overcoming Treatment Resistance: Key Strategies

Anne-Marie Dingemans, Netherlands

14:27 Panel Discussion

All Faculty

14:42 Closing Remarks

Luis Paz-Ares, Spain

13:45 - 14:45 **IS13: INDUSTRY SPONSORED SYMPOSIUM BY NUVENT BIO INC.: UNDER THE MICROSCOPE: FOCUSING ON ROS1+ NSCLC**

ROOM 01

LIVESTREAMED



LUNCH PROVIDED



NOT FOR CME CREDIT

Chair: Charu Aggarwal, USA

13:45 **Role of ROS1 Fusions in NSCLC**

Charu Aggarwal, USA

13:55 **Optimizing Outcomes Through Testing**

Jürgen Wolf, Germany

14:15 **Selecting an Optimal Treatment Approach for Patients**

Javier de Castro, Spain

13:45 - 14:45 **IS14: INDUSTRY SPONSORED SYMPOSIUM BY REGENERON: NSCLC REIMAGINED: NOVEL TREATMENT STRATEGIES IN ADVANCED NSCLC**

ROOM 05

LIVESTREAMED



LUNCH PROVIDED



NOT FOR CME CREDIT

Chair: Pilar Garrido, Spain

13:45 **Welcome and Introduction**

Pilar Garrido, Spain

13:50 **The First-Line Frontier: Reviewing ICI-based Treatment Combinations for Advanced NSCLC**

Pilar Garrido, Spain

14:05 **A Spotlight on Squamous Histology: Exploring the Evolving Treatment Landscape for Patients with Advanced Squamous NSCLC**

Biagio Ricciuti, USA

14:20 **Reshaping the Standard: Current and Future Post-progression Strategies for Advanced NSCLC**

Federico Cappuzzo, Italy

14:35 **Panel Discussion and Meeting Close**

18:30 - 19:30 **IS15: INDUSTRY SPONSORED SYMPOSIUM BY NATERA: SIGNATERA ULTRASENSITIVE MRD TESTING FOR LUNG CANCER**

ROOM 05

SNACKS PROVIDED



NOT FOR CME CREDIT

Presenter: Michael Krainock, USA

18:30 **Introduction to ctDNA and Natera MRD Portfolio**

18:40 **Unmet Needs in Lung Cancer and Potential Applications for MRD**

18:45 **Early-Stage Risk-Stratification Clinical Data**

18:55 **Early Recurrence Detection Clinical Data**

19:05 **ICI Treatment Response Monitoring Clinical Data**

19:15 **Real World Case Studies**

19:20 **Future Directions and Q&A**

SATELLITE CME SYMPOSIA

SUNDAY, SEPTEMBER 7, 2025

18:30 - 19:30 **IS10: SATELLITE CME SYMPOSIUM BY PHYSICIANS' EDUCATION RESOURCE ON BEHALF OF ASTRAZENECA: TUMOR BOARD: ADVANCES IN MANAGING EGFR-MUTANT NSCLC - APPLYING EVIDENCE ACROSS THE DISEASE CONTINUUM**

ROOM 04

SNACKS PROVIDED



ACCME ACCREDITED BY OTHER PROVIDER

Chair: Tina Cascone, USA

18:30 **Program Introductions**

Tina Cascone, USA

18:35 **Spotlight on the Management of Early-Stage EGFR-Mutant NSCLC**

Christina Baik, USA

18:45 **At the Frontline: Current and Emerging Therapeutic Approaches for EGFR-Mutant Metastatic NSCLC**

David Planchard, France

19:05 **Combating EGFR-TKI Resistance: Outlook for Metastatic NSCLC in the Second-Line Setting and Beyond**

Tina Cascone, USA

19:20 **Posttest Assessment & Audience Q&A**

Tina Cascone, USA

NON-PROFIT PRESENTATION

SUNDAY, SEPTEMBER 7, 2025

10:45 - 11:30 **NP01: NON-PROFIT PRESENTATION BY BRISTOL MYERS SQUIBB FOUNDATION: TRANSFORMATIVE INSIGHTS: IMPACT OF BMS FOUNDATION-FUNDED PROGRAMS IN LOW-AND MIDDLE-INCOME COUNTRIES**

ROOM 12

Chair: Ray Osarogiagbon, USA

Panel: Nestory Masalu, Tanzania, Ricardo Sales dos Santos, Brazil, Zixiao Ma, China

INDUSTRY SPONSORED SYMPOSIA

MONDAY, SEPTEMBER 8, 2025

13:45 - 14:45 **IS16: INDUSTRY SPONSORED SYMPOSIUM BY DAIICHI SANKYO, INC.: MULTIDISCIPLINARY CARE FOR PATIENTS WITH BRAIN METASTASES IN EGFRm NSCLC OR SCLC**

ROOM 01

Chair: Hossein Borghaei, USA

- 13:45** **Introduction and Housekeeping**
Hossein Borghaei, USA
- 13:50** **Brain Metastases in Lung Cancer**
Hossein Borghaei, USA, Seema Nagpal, USA
- 13:55** **Case Study A: Previously Treated EGFRm NSCLC**
Hossein Borghaei, USA, Seema Nagpal, USA, Kristin Higgins, USA
- 14:15** **Case Study B: Previously Treated SCLC**
Hossein Borghaei, USA, Seema Nagpal, USA, Kristin Higgins, USA
- 14:30** **Audience Q&A**
- 14:40** **Summary and Close**
Hossein Borghaei, USA

13:45 - 14:45 **IS17: INDUSTRY SPONSORED SYMPOSIUM BY BOEHRINGER INGELHEIM INTERNATIONAL GMBH: TARGETED THERAPIES, PERSONALIZED CARE: PATIENT-CENTERED ADVANCES FOR THE TREATMENT OF NSCLC AND SCLC**

ROOM 08

Chair: Christine Lovly, USA

- 13:45** **Chair's Welcome and Introductions**
Christine Lovly, USA
- 13:50** **Targeting HER2 in NSCLC: How Have Patients Responded to Emerging Therapies?**
Tatsuya Yoshida, Japan
- 14:10** **T-Cell Engagers and the Next Wave of Combination Therapies for Advanced SCLC**
Ticiana Leal, USA
- 14:30** **Panel Discussion: How Can These Approaches Benefit Patients in the Clinic?**
All Faculty

13:45 - 14:45 **IS18: INDUSTRY SPONSORED SYMPOSIUM BY MSD: A DECADE OF PROGRESS: ADVANCES IN IMMUNOTHERAPY FOR NSCLC?**

ROOM 05

Chair: Martin Reck, Germany

- 13:45** **Welcome & Introduction: 10 Years of IO in Metastatic NSCLC, What's Next?**
Martin Reck, Germany
- 14:00** **Early-Stage and Locally Advanced NSCLC**
Enriqueta Felip, Spain
- 14:12** **Patient Case(s)**
Mir Alireza Hoda, Austria
- 14:25** **Subcutaneous IO in Clinical Practice**
Enriqueta Felip, Spain
- 14:35** **Panel Discussion, Q&A and Closing**
All Faculty

13:45 - 14:45 **IS19: INDUSTRY SPONSORED SYMPOSIUM BY ASTRAZENECA: METASTATIC EGFRm NSCLC: ADAPTING TO PATIENTS, GROUNDED IN EVIDENCE**

ROOM 04

Chair: Helena Yu, USA

- 13:45** **Welcome and Introductions**
Helena Yu, USA
- 13:49** **EGFR-TKIs as Backbone Therapy for EGFRm NSCLC**
Patrick Forde, USA
- 13:59** **Novel Combinations Therapies in EGFRm mNSCLC: What Could and Should Be Done**
Stephanie Saw, Singapore
- 14:14** **Understanding Patient Preferences When Living with Lung Cancer**
Luca Ostacoli, Italy
- 14:27** **Panel Discussion and Closing Remarks**
All Faculty

Hours of Operation:

REGISTRATION DELEGATE HELP DESK MOBILE APP HELP DESK

Fira Gran Via (North Entrance)

Friday, September 5	15:00 - 19:00
Saturday, September 6	07:30 - 18:30
Sunday, September 7	07:30 - 17:00
Monday, September 8	08:00 - 17:00
Tuesday, September 9	08:00 - 14:00

SPEAKER LOUNGE

Hall 8.0 - Ground Floor

Friday, September 5	15:00 - 19:00
Saturday, September 6	07:30 - 18:30
Sunday, September 7	07:30 - 17:00
Monday, September 8	08:00 - 17:00
Tuesday, September 9	08:00 - 13:00

WELLNESS LOUNGE

Hall 8.0 - Ground Floor

Saturday, September 6	09:00 - 16:00
Sunday, September 7	09:00 - 17:00
Monday, September 8	09:00 - 17:00
Tuesday, September 9	09:00 - 14:00

AWARDS LUNCHEON

Hall 8.0 - Room 01-02, Ground Floor

Saturday, September 6	11:30 - 13:00
-----------------------	---------------

IASLC BUSINESS MEETING

Hall 8.0 - Room 09, Ground Floor

Monday, September 8	14:45 - 15:30
---------------------	---------------

PRESS & MEDIA WORK ROOM

Press & Media Center, First Floor

Saturday, September 6	07:00 - 18:00
Sunday, September 7	08:00 - 18:00
Monday, September 8	08:00 - 18:00
Tuesday, September 9	08:00 - 14:00

PRESS CONFERENCE SCHEDULE

CC7 AB - Press Conference Room

Saturday, September 6	17:45 - 18:45
Sunday, September 7	10:45 - 11:45
Monday, September 8	10:45 - 11:45
Tuesday, September 9	10:15 - 11:15

EXHIBIT HALL

Hall 8.1 - First Floor

Saturday, September 6	17:45 - 19:15
Sunday, September 7	10:00 - 15:30
Monday, September 8	10:00 - 15:30
Tuesday, September 9	10:00 - 13:00

POSTER DISPLAY

Hall 8.1 - Exhibit Hall, First Floor

P1:	
Sunday, September 7:	10:00 - 15:30
Presenters in Attendance:	10:30 - 12:00
P2:	
Monday, September 8:	10:00 - 15:30
Presenters in Attendance:	10:30 - 12:00
P3:	
Tuesday, September 9:	10:00 - 13:00
Presenters in Attendance:	10:00 - 11:30

Poster Session supported by

Johnson&Johnson

POSTER TOURS

Hall 8.1 - Exhibit Hall, First Floor

CONTINUING MEDICAL EDUCATION (CME) AND CERTIFICATE OF ATTENDANCE

Credits can be claimed in the IASLC Lung Cancer 360 starting September 9 through December 31, 2025. Log in using your Lung Cancer 360 Username and Password, select the sessions you attended, and download your certificate. If you are new to Lung Cancer 360 or forgot your password, click the Reset Password link. For assistance, please email education@iaslc.org.

A Conference evaluation will be sent via email at the conclusion of the Conference.

 For more information on CME please visit:
wclcl.iaslc.org/cme-information

ONSITE SERVICES



NURSING MOTHER'S LOUNGE

A reserved area for nursing mothers is available in Hall 8.0, located just beyond Room 10.



PRAYER ROOM

A designated multifaith prayer room is located directly at the entrance to Hall 8.0.



FIRST AID ROOM

The First Aid Room is located in Hall 8.0, at the rear of Room 07.



LUGGAGE DROP

Luggage drop will be available in the registration area on Tuesday, September 9.



SPEAKER LOUNGE

Designated area in Hall 8.0 for all oral presenters to upload and review their slides. Coffee and refreshments will be available.



EXHIBITOR LOUNGE

A dedicated space, located in Hall 8.1 - Exhibit Hall, for exhibitor staff to relax and recharge away from the busy show floor.

 For more information on presenter resources please visit:
wclcl.iaslc.org/presenter-resources



EMERGENCY INFORMATION

In case of an emergency within the Fira Gran Via venue, please call **+34 93 233 41 00**. This number activates all onsite emergency protocols and enables incident tracking.

EXPLORE. ENGAGE. RECHARGE.

Make the most of your time at WCLC 2025 with curated experiences that add depth and dimension to your conference experience.

From exclusive lounges and wellness retreats to hands-on exhibits and share-worthy social moments, this year's event is filled with opportunities to learn, connect, and recharge.



VISIT THE IASLC BOOTH (#101)

📍 Hall 8.1 - Exhibit Hall, First Floor 🕒 Open during Exhibit Hall Hours

Don't miss the chance to connect with the IASLC team and learn about all the exciting activities and initiatives we have planned! At the demo kiosks, be the first to navigate through the new IASLC Thoracic Circle or explore all online educational material IASLC Members can enjoy through Lung Cancer 360.

Enjoy a dedicated lounge for IASLC members, where you can also have your professional photo taken. Not a member yet? No problem! You can join anytime—even right at the booth—and start enjoying exclusive benefits. Stop by the Committee Corner—a dedicated space for connection, collaboration, and celebration! Throughout the meeting, committee members and attendees are welcome to gather, network, and share ideas in an informal setting. The space will also feature special recognition of our outgoing chairs and a warm welcome for the new ones. Come by and be part of the ongoing conversations that help shape our community!

There's also a **fun activity** waiting for you, with the chance to win fantastic prizes.

IASLC PATIENT ADVOCACY LOUNGE

📍 Hall 8.1 - Exhibit Hall, First Floor 🕒 Open during Exhibit Hall Hours

A valued feature at WCLC, we warmly welcome all all patients/survivors, caregivers/partners, and advocates, to enjoy exclusive access to this lounge. It's designed as a space to relax, connect, and recharge, with comfortable seating options and charging points for your devices.

Supported by: **Johnson&Johnson**



IASLC PODCAST STUDIO

📍 Hall 8.1 - Exhibit Hall, First Floor

Check out Lung Cancer Considered in action at the IASLC podcast studio! Hosts Dr. Narjust Florez and Dr. Stephen Liu will lead meaningful conversations with researchers, healthcare professionals, patients, and advocates who are making a difference in thoracic cancer treatment.

Do you want to listen to previous episodes?

Tune in here! www.iaslc.org/LungCancerConsidered

Supported by: **MERCK**



WCLC 2025 PHOTOBOOTH & SOCIAL MEDIA ACTIVATION ZONE

📍 Hall 8 - Ground Floor

Whether you are a social media user or simply want to capture a special moment from WCLC 2025, be sure to stop by for a photo—solo or with fellow attendees! Our team is ready to help you snap the perfect shot. Choose your country's flag or favorite tag, flash your biggest smile, and strike a pose! If you would like, share your photos using **#WCLC25** and connect with us across major social media platforms!



IASLC WELLNESS CHALLENGE

Join us for the IASLC Wellness Challenge, a four-day event held alongside WCLC 2025! Using the IASLC Wellness Challenge 2025 app, your step count will be converted into points, giving you the chance to win prizes and enjoy some friendly competition with your peers. Each participant will be assigned to a regional team, celebrating our global community. Earn bonus points by engaging in various activities and working towards your wellness goals.

Learn more at: hekahealth.com/iaslc25



MEETING PODS

📍 Hall 8.1 - Exhibit Hall, First Floor 🕒 Open during Exhibit Hall Hours

We recognize the value of meaningful discussions that happen when you connect with fellow experts from around the world. The meeting pods are designed to provide attendees with the opportunity to hold spontaneous meetings while at WCLC 2025. No prior reservations are needed - meeting pods are available on a first-come, first-served basis. If others are waiting, we kindly ask that you limit your meeting to a maximum of one hour. While not fully soundproof, the meeting pods are conveniently set up with meeting tables and can accommodate 4 to 8 people.





IASLC ACADEMY AMAZING CASE RACE

This activity will take learners through five interactive, thoracic oncology case-based simulations. Each simulation provides a real-world scenario to exercise your decision-making skills with immediate results and feedback.



IASLC VOICES IN ACTION

Be part of something bigger, share your voice! We invite IASLC members to visit our video station and record a short message. Whether it's your story, your work, or why the IASLC community matters to you, this is your chance to connect and inspire others. These videos will help amplify the power of our global community.

DELEGATE LOUNGES AND CHARGING AREA

Supported by:



- 📍 Hall 8.1 - Exhibit Hall, First Floor ⌚ Open during Exhibit Hall Hours

Enjoy access to multiple lounges across the exhibit floor—perfect for taking a break, catching up with fellow attendees, or using the power points to recharge your devices.

All WCLC 2025 attendees are welcome to use these lounges.

EXHIBITOR LOUNGE

- 📍 Hall 8.1 - Exhibit Hall, First Floor ⌚ Open during Exhibit Hall Hours

GARDEN LOUNGES

- 📍 Hall 8.1 - Exhibit Hall, First Floor ⌚ Open during Exhibit Hall Hours

Take a break, enjoy some fresh air, and treat yourself to a refreshing ice cream or freshly squeezed smoothie in the outdoor garden lounges, conveniently located at the entrance of Exhibit Hall 8.1, leading to Plenary Hall 6

WELLNESS LOUNGE

- 📍 Hall 8.0 - Ground Floor ⌚ Saturday, September 6 09:00 - 16:00
 Sunday, September 7 09:00 - 17:00
 Monday, September 8 09:00 - 17:00
 Tuesday, September 9 09:00 - 14:00

Launched for the first time in San Diego, the Wellness Lounge returns to Barcelona following the incredible positive feedback received. Designed as a quiet retreat, the lounge offers delegates a space to decompress, relax, and take a break from the bustling session rooms and common areas. It also serves as a safe space for our international attendees battling jet lag, providing a comfortable spot to take a power nap and recharge.

Stay Energized and Hydrated!

CATERING SERVICES AT WCLC 2025

You won't go hungry at WCLC 2025! We invite you to take advantage of the complimentary catering services available to all registered delegates. Enjoy a variety of refreshments and meals throughout the Conference.

Complimentary coffee, tea, soft drinks, and a selection of snacks will be available in Exhibit Hall 8.1 as well as in the Hall 8 Cafe.

COFFEE BREAKS

- 📍 Hall 8.1 - Exhibit Hall, First Floor
 ⌚ Sunday, September 7 10:30 - 12:00
 Monday, September 8 10:30 - 12:00
 Tuesday, September 9 10:00 - 11:30

WELCOME RECEPTION

The Welcome Reception offers an opportunity to network in a relaxed setting. Enjoy regional canapés and drinks while connecting with fellow delegates and exhibitors.

- 📍 Hall 8.1 - Exhibit Hall, First Floor
 ⌚ Saturday, September 6 17:45 - 19:15

CONFERENCE LUNCHES

Standing working lunches will be available in the Exhibit Hall, offering a variety of hot and cold items. Additionally, Industry Symposia Organizers often provide packed lunches for delegates attending their sessions.

- 📍 Hall 8.1 - Exhibit Hall, First Floor
 ⌚ Saturday, September 6:
 See 'Special Lunches'
 Sunday, September 7:
 13:15 - 15:15
 Monday, September 8:
 13:15 - 15:15
 Tuesday, September 9:
 See 'Special Lunches'

SPECIAL LUNCHES AT WCLC 2025

All delegates are welcome to attend these special sessions, which include lunch. Access is available on a first-come, first-served basis until maximum capacity is reached.

AWARDS LUNCHEON

- 📍 Hall 8.0 - Room 01-02, Ground Floor
 ⌚ Saturday, September 6 11:30 - 13:00

WORK-LIFE HARMONY: REDEFINING BALANCE IN THE DEMANDING FIELD OF ONCOLOGY

- 📍 Hall 8.0 - Room 12, Ground Floor
 ⌚ Sunday, September 7 13:45 - 14:45

INCLUSION IN ACTION: ADDRESSING HIDDEN AND EMERGING INEQUITIES IN THORACIC ONCOLOGY

- 📍 Hall 8.0 - Room 10, Ground Floor
 ⌚ Monday, September 8 13:30 - 14:45

Supported by: **Johnson&Johnson**

NAVIGATING GENDER EQUITY IN THE DAILY LIFE OF A THORACIC ONCOLOGIST

- 📍 Hall 8.0 - Room 03, Ground Floor
 ⌚ Monday, September 8 13:45 - 14:45

Supported by: **Johnson&Johnson**

CLOSING LUNCH - NOT SO TRIVIAL: A WCLC INTERDISCIPLINARY QUIZ CHALLENGE

- 📍 Plenary, Hall 6
 ⌚ Tuesday, September 9 14:15 - 15:45

Download Now! WCLC 2025 MOBILE APP

All sessions will be audio recorded and made available on the Mobile App - along with the presentation slides - within 24 hours after each session. Abstracts and all posters are also accessible via the Mobile App. Log-in details have been sent to your registered email.

If you need assistance, please visit the WCLC 2025 Help Desk in the registration area or contact us at:
wclc2025-registration@icsevents.com.


Mobile App Supported by:




Mobile App Features:

- ✓ Full Scientific Schedule
- ✓ Abstract Book, Program Book
- ✓ Venue and Exhibit Floor Plan
- ✓ Presentation Slides and Recordings (Within 24 Hours)
- ✓ Opportunity to Create Personalized Schedule
- ✓ Networking Features to Connect with Delegates and Faculty
- ✓ Notification Alerts
- ✓ Livestream of Plenary Sessions, IASLC Award Luncheon and IASLC Business Meeting

Download the WCLC 2025 App:



HALL 8.0 - GROUND FLOOR





2026 World Conference on Lung Cancer

SEPTEMBER 12 – 15, 2026 | SEOUL, REPUBLIC OF KOREA

Save the Date!


SEPTEMBER 12 - 15, 2026

SEOUL, REPUBLIC OF KOREA

wclc.iaslc.org



#WCLC26



AKT1, BRAF, PTEN, RET are tumor profiling biomarkers

NGS biomarker reports in 24 hours

Visit us at Booth #205

Make treatment decisions without waiting weeks for next-generation sequencing (NGS) results. With the Oncomine™ Dx Express Test, your lab can deliver NGS reports in as little as 24 hours.*

- **Turnaround time of as little as 24 hours**, from tissue sample to report
- **Minimal DNA and RNA input requirements**, capable of analyzing small and challenging samples such as core-needle biopsies and fine-needle aspirates

Request the Oncomine Dx Express Test from your lab to make the best-informed treatment decisions and minimize delays in patient care.

* Timing varies by number of samples and type of run.

Learn more at thermofisher.com/oncomine-express-test

For In Vitro Diagnostic Use. © 2025 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. **FLY-11063969 0725**



Advancing precision oncology & Reshaping cancer care

We are committed to **redefining healthcare** and are **working tirelessly to get in front of cancer**. By connecting the best of Health&Care, we're striving to **transform the lives** of people with **lung cancer**. Our goal is to change the devastating course of lung cancer and adapt those learnings to **transform outcomes** in other cancers.

Scan to learn more at
<https://innovativemedicine.jnj.com/emea/>



CP-525095 | June 2025
©Janssen Pharmaceutica NV

Johnson&Johnson
The Health & Care Company